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Abstract 
Introduction: Idiopathic Parkinson’s disease (PD) is a chronic and 
progressive neurodegenerative disorder that is characterised by motor symptoms.  
However, there is increasing awareness that a range of neuropsychiatric and cognitive 
problems also accompanys PD.  The objective of this thesis was to examine the 
profile of neuropsychiatric and cognitive problems for patients with PD without 
dementia.  Parkinson’s disease patients who could be identified at the time of this 
study were invited to participate.  Each patient was individually matched to a healthy 
control in terms of age, premorbid intelligence, and years of education.  Results: 
Neuropsychiatric symptoms were common for this patient group, over 40% self-
reported symptoms consistent with depression, 40% with physical fatigue, 38% with 
mental fatigue, 38% with apathy and 32% with sleep problems.  More than 77% of 
patients with PD reported symptoms associated with at least one problem and over 
46% with 3 or more problems.  Increased symptoms consistent with depression and 
anxiety and the presence of hallucinations also predicted poorer quality of life after 
controlling for motor symptoms.  However, the of level agreement between patient 
report and that of a person who know them well was low: 40.9% for apathy, 28% for 
hallucinations, 39% for depression, 25% for sleep problems and only 7.7% agreement 
for the presence of anxiety.  To obtain an accurate profile of cognitive impairments 
patients were assessed on measures of higher order language ability and a broad range 
of commonly used cognitive tests.  Overall, PD patients were impaired on aspects of 
higher-order language.  However, results indicated that these deficits were not a 
primary effect of PD, but could be explained in terms of deficits in speed of 
information processing associated with the disease.  Compared to healthy controls, 
PD patients also showed deficits on measures of executive function, working 
2  
memory, problem solving, and visuospatial skills.  However, they were unimpaired on 
measures of planning, attention and memory/learning.  Deficits in problem solving 
were only evident for tasks with a high visuospatial content and were no longer 
significant when visuospatial skills were controlled for.  Further investigation 
indicated that planning in PD patients was not impaired in general and was dependent 
on the sensitivity of tests used.  To further examine cognitive deficits, patients were 
divided into groups according to their cognitive performance.  Three sub-groups of 
patients were identified that formed a continuum of cognitive impairment from 
none/mild to severe.  Compared to controls, one subgroup showed no or minimal 
impairment (PD-NCI), a second group showed a more variable pattern of severe and 
mild impairments (PD-UCI), and a third group had evidence of severe impairment 
across most of the cognitive domains tested.  This latter group was labelled PD-Mild 
Cognitive Impairment (PD-MCI). The PD-UCI and PD-MCI groups were also 
significantly different from their controls with respect to their ability to carry out 
functional activities of everyday living.  The PD-MCI group had evidence of global 
cognitive decline, possibly reflecting a stage of pre-clinical dementia.  The severity of 
cognitive deficits was not associated with other clinical and demographic 
characteristics such as motor impairments, age or disease duration.  These results 
were confirmed when patients were retested one year later.  Conclusions: Comorbid 
neuropsychiatric and cognitive problems are common for patients with PD prior to 
any overt signs of dementia.  However, PD patients are heterogeneous with regard to 
their presentation and different subgroups of patients are identifiable based on 
cognitive performance.  This information has both theoretical and clinical relevance.   
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Chapter 1 - Introduction   
Abbreviations used in the text Chapter One 
1) AD = Alzheimer’s disease; 2) GPi = Globus pallidus interna; 3) GPe = external 
segment of the globus pallidus; 4) MCI = Mild Cognitive Impairment; 5) PD = 
Parkinson’s disease; 6) PDD = Parkinson’s disease with dementia; 7) PD-MCI = 
Parkinson’s disease with Mild Cognitive Impairment; 8) PD-UCI = Parkinson’s 
disease Uncertain Cognitive Impairment; 9) PD-NCI = Parkinson’s disease 
No/Minimal Cognitive Impairment; 10) PFC = Pre frontal cortex; 11) WM = 
Working Memory; 12) SAS = Supervisory Attention System;13) SN = Substantia 
nigra ; 14) SNc = Substantia nigra pars compacta ; 15) SNr = Substantia nigra pars 
retculata; 16) STN = Subthalamic nucleus; 17) WCST = Wisconsin Card Sorting 
Test. 
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1.1 Overview   
Idiopathic Parkinson’s disease (PD) is a chronic and progressive 
neurodegenerative disorder that affects around 1/1000 individuals (Twelves, Perkins, 
& Counsell, 2003).  The pathology of this disorder is focused on the substantia nigra 
and nigrostriatal tract, resulting in the motor symptoms that characterise this disorder 
(Braak & Braak, 2000).  Onset occurs most commonly after the age of 50 and its 
incidence increases with advancing age (de Rijk et al., 1997).  While PD is primarily 
characterised by motor dysfunction, signs of early cognitive disturbances are also a 
feature of the disease process (Brown & Marsden, 1990; Marsh, 2000; Shulman, 
Taback, Bean, & Weiner, 2001).  The end consequence of this cognitive decline may 
be frank dementia.  Indeed, research indicates that a substantial number of individuals 
with PD will progress to a diagnosis of dementia (see Emre, 2003 for review).  
However, there is also a substantial body of research that suggests that individuals 
with PD without overt signs of dementia, may be impaired on a number of cognitive 
tasks, with executive function deficits being prominent (see Brown & Marsden, 1990; 
Pillon, Boller, Levy, & Dubois, 2001 for reviews).  Deficits in these facets of 
cognition, particularly in combination with other psychiatric symptoms, are especially 
important as it is likely that they will impact on other areas of cognitive ability, and 
affect the individual’s functioning in everyday situations. 
Although there has been abundant research regarding the cognitive and 
psychiatric outcomes, the precise nature of the decline in these areas of functioning in 
relation to PD, and hence their relationship to deficits in everyday living skills, are 
poorly defined.  The proposed research was designed to generate novel information 
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on the cognitive and psychiatric profile of non-dementing PD patients, and the 
relationship between these deficits and everyday living skills. 
A particular focus of the research was to identify a discrete battery of 
cognitive and psychiatric measures that would be able to detect people with PD who 
were experiencing clinically significant problems who could be at risk of later 
dementia.  The ability to identify this particular group of people with PD will provide 
an opportunity for intervention.  Intervention strategies could be aimed at reducing the 
impact of cognitive and psychiatric deficits which are a significant cause of caregiver 
distress and frequently lead to premature placement in care units (Aarsland, Larsen, 
Karlsen, Lim, & Tandberg, 1999; Aarsland, Larsen, Tandberg, & Laake, 2000).  In 
addition, more recent research has indicated that cognitive decline may be delayed by 
the use of drug and behavioural interventions (Aarsland, Larsen, Karlsen, Lim, & 
Tandberg, 1999; Aarsland, Larsen, Tandberg, & Laake, 2000).  Therefore, early 
detection of cognitive and psychiatric deficits that may signal the early decline to 
dementia could have personal, social and economic value.   
As mentioned previously, the research regarding the non-motor deficits in PD 
is voluminous.  However, to provide sufficient background for the current research, 
this literature review will first provide general background information including 
epidemiology and characteristic motor symptoms.  The focus of the review will be an 
examination of the major theories used to account for the deficits associated with this 
disorder, and an overview of the cognitive and psychiatric outcomes that have been 
reported.  The difficulties connected with research in this area will also be covered as 
they have important implications in terms of explaining the inconsistencies inherent in 
the current literature.  Further, this information will be used to inform appropriate 
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methodologies for this project which will endeavour to overcome many of the 
shortcomings of previous research.  Each of these perspectives is important as their 
synthesis is required to adequately inform the current research hypothesis.   
1.2 Epidemiology   
Epidemiology has been intensively investigated in an effort to identify patterns 
that may provide information regarding the cause of PD and lead to appropriate 
interventions (Di Monte, Lavasani, & Manning-Bog, 2002).  A number of causes have 
been suggested, e.g. environmental and genetic influences (see Di Monte, Lavasani & 
Manning-Bog, 2002 for review).  However, the slow and insidious onset that is 
characteristic of this disorder makes the identification of any causal links extremely 
difficult.  Further, differences in study design and diagnostic criteria make any 
comparisons across studies problematic (Marion, 2001; Twelves, Perkins, & 
Counsell, 2003).  Thus, despite considerable research interest, the etiology of PD 
remains unknown.  Nonetheless, PD is a relatively common disease with significant 
health costs associated with its management, and it is therefore important to have 
accurate information regarding its incidence and prevalence rates.   
Incidence and prevalence rates have been investigated in a number of 
countries.  While many studies rely on a review of medical records, door to door 
surveys suggest that over 20% of cases remain undetected in the community (de Rijk 
et al., 1997).  It is therefore not surprising that estimates of incidence and prevalence 
vary widely depending on the case ascertainment method used (de Rijk et al., 1997; 
Guttman, Slaughter, Theriault, DeBoer, & Naylor, 2003; Twelves, Perkins, & 
Counsell, 2003).  In a recent review, von Campenhausen et al., (2005) stated that 
higher quality studies, (i.e., those that used an established diagnostic criteria, included 
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the entire age range of the population, and used screening by an experienced 
neurologist) reported prevalence rates of 108 to 257/100,000 and incident rates of 11-
19/100,000.  However, even when the most rigorous design is used, a significant 
number of cases may be misdiagnosed (Schrag, Ben-Shlomo, & Quinn, 2002). 
Despite variations in the reported incidence and prevalence of this disorder, it 
has been consistently reported that rates steadily increase with age and that disease 
symptoms usually appear after 50 years of age (Bower, Maraganore, McDonnell, & 
Rocca, 2000; de Rijk et al., 1997; MacDonald, Cockerell, Sander, & Shorvon, 2000; 
Mayeux et al., 1995).  Further, while PD is thought to affect all races equally (with 
any discrepancy between races generally thought to be associated with case 
ascertainment methods), there is a preponderance of males to females, with males 
having a 1.5-2 times increased likelihood of being diagnosed with PD (Guttman, 
Slaughter, Theriault, DeBoer, & Naylor, 2003; Mayeux et al., 1995; Wooten, Currie, 
Bovbjerg, Lee, & Patrie, 2004). 
1.3 Motor Symptoms   
Tremor, rigidity, bradykinesia and postural instability are considered to be the 
cardinal features of PD (see 1.3.1 for description of motor symptoms).  However, 
presenting motor symptoms vary considerably for each individual and may have 
particular importance for the identification of PD subtypes (See Table 1 for common 
motor features associated with PD).  Initial diagnosis is based on the evaluation of 
presenting physical symptoms and their history but a definitive diagnosis of PD can 
only be made on the basis of autopsy evidence which includes the degeneration and 
loss of pigmented cells in substantia nigra pars compacta (SNc) and the presence of 
Lewy bodies (Kang et al., 2005).  Clinical symptoms of PD only manifest when 
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nigrostriatal dopamine depletion is at around 80%, and approximately 60% of the 
dopaminergic neurons in SNc have been lost (Gibb, 1997).   
Table 1: Common motor symptoms associated with Parkinson’s disease (Jankovic, 
2003).   
Tremor 
Rigidity 
Bradykinesia 
Postural instability 
Masked facies 
Hypophonia 
Dysphagia 
Sialorrhea (excessive salivation) 
Respiratory difficulties 
Festination 
Freezing 
Micrographia 
Decreased blink rate 
Levodopa induced dyskinesias 
 
A number of neurodegenerative diseases can be mistaken for PD. These are 
generally referred to as Parkinson plus syndromes and include: progressive 
supranuclear palsy, cortical-basal degeneration, multiple system atrophy, dementia 
with Lewy body and vascular Parkinsonism.  However, research indicates that the 
degree of clinical diagnostic accuracy is higher when more stringent criteria are 
applied such as the United Kingdom Parkinson's Disease Society Brain Bank 
Diagnostic Criteria for Parkinson's disease (see Table 2) (Jankovic, 2003).   
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Table 2: United Kingdom Parkinson’s Disease Society Brain Bank Clinical 
Diagnostic Criteria  (Reproduced from Hughes, Daniel, Kilford, & Lees, 1992).   
Inclusion Criteria 
• Bradykinesia 
• Plus at least one of the following 
o Muscular rigidity 
o 4-6 Hz rest tremor 
o Postural instability not caused by primary visual, vestibular, cerebellar or 
proprioceptive dysfunction 
Exclusion Criteria 
• History of repeated head injury 
• History of repeated stroke 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia 
• Babinski sign 
• Cerebral tumour or communicating hyrocephalus on CT scan 
• Negative response to large doses of levodopa 
• MPTP exposure 
Supportive Criteria 
Three or more of the following for diagnosis of definite PD: 
• Unilateral onset 
• Resting tremor 
• Progressive disorder 
• Responsive to levodopa  
• Severe levodopa-induced chorea 
• Levodopa reponse for ≥ 5 years 
• Clinical course ≥ 10 years 
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1.3.1 Description of Characteristic Motor Symptoms   
Tremor and bradykinesia are the two most common initial symptoms (Uitti, 
Baba, Wszolek, & Putzke, 2005).  Tremors occur predominantly at rest, with a 
frequency of 4-6Hz, and diminish on action (Jankovic, 2003).  However, not all 
patients with PD manifest a resting tremor as the presenting symptom, and 15% will 
never manifest a tremor during the entire course of the disease (Jankovic, 2003; Kang 
et al., 2005).  The etiology of the resting tremor remains unknown (Carr, 2002).  
Patients with PD may also develop a postural tremor, 5-8Hz, that occurs during 
activity (Jankovic, 2003).   
Bradykinesia is defined as a slowness of movement.  It is often used 
interchangeably with hypokinesia, which refers to slowed movements, but with the 
addition that the movements performed are smaller than intended (e.g. micrographia), 
and with akinesia, referring to a lack of spontaneous movement (e.g. lack of 
spontaneous arm swing when walking) (Berardelli, Rothwell, Thompson, & Hallett, 
2001).  Bradykinesia is thought to result from deficient output from the Basal Ganglia 
to the cortex (Berardelli, Rothwell, Thompson, & Hallett, 2001).   
Rigidity, also a prominent feature of PD, refers to the increased tone or 
stiffness in the muscles that are resistant to passive movement, and may result in a 
subjective feeling of tightness and pain in the muscles.  The fourth cardinal feature is 
postural instability, a tendency to lose balance with propulsion and retropulsion.  
Postural instability is more common in the later stages of the disease and is generally 
accompanied by festination (i.e. short shuffling steps).   
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The cause of postural instability is not known, but has been attributed to the 
degeneration of the globus pallidum, reduced or absent vestibular responses, or 
abnormal postural reflexes (Jankovic, 2003).   
As stated at the beginning of this section, individuals vary greatly in their 
presentation of motor symptoms and it has been suggested that differences in motor 
presentation may be indicative of differences in disease progression (Kang et al., 
2005).  Indeed, two recent studies have suggested that different subgroups of patients 
with PD can be identified by a combination of motor and cognitive symptoms 
(Graham & Sagar, 1999; Lewis et al., 2005).   
1.4 Theory of Deficits Associated with Parkinson’s disease   
1.4.1 The Structure of the Basal Ganglia   
Dysfunction of the basal ganglia system is considered key to the motor, 
cognitive, and psychiatric deficits associated with Parkinson’s disease.  Therefore, a 
brief description of the basal ganglia, its structure and changes that occur with PD is 
important in terms of understanding the possible deficits that are associated with this 
disorder.   
The basal ganglia are a group of interconnected subcortical structures in the 
forebrain.  Although the structures that are considered to be part of the basal ganglia 
vary, there is general agreement that they include the caudate nucleus, putamen (these 
two structures are often referred to as the striatum), globus pallidus (globus pallidus 
and putamen are sometimes referred to as the lenticular nucleus) and the nucleus 
accumbens (Ring & Serra-Mestres, 2002).  Many authorities also include the 
substantia nigra, subthalamic nucleus and the amygdala as structures of the basal 
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ganglia (Haber, 2003; Herrero, Barcia, & Navarro, 2002; Ring & Serra-Mestres, 
2002; Yelnik, 2002).  The ventral striatum, comprising the ventromedial caudate, 
ventral putamen, nucleus accumbens and olfactory tubercle, is a term more recently 
used to describe parts of basal ganglia that are closer to limbic structures (Haber, 
2003).  Traditionally, the basal ganglia have been considered to be involved primarily 
in movement, but it is now recognised that they also play a vital role in cognitive, 
behavioural, and psychiatric functions (Ring & Serra-Mestres, 2002).   
1.4.2 Deficits Associated with Basal Ganglia Dysfunction   
Dysfunctions within the basal ganglia are implicated in a range of movement, 
psychiatric, and cognitive problems, often resembling deficits usually associated with 
lesions of the prefrontal cortex (Aarsland et al., 1999; Adler, 2005; Bhatia & 
Marsden, 1994; Burn, 2002b; Cummings, 1992; Eslinger & Grattan, 1993; Friedman 
& Chou, 2004; Pillon, Boller, Levy, & Dubois, 2001).  Recent reviews suggest 
different regions of the basal ganglia are associated with diverse range of functions.  
For example, the ventral regions of the basal ganglia are key in reward and 
reinforcement, the central regions with cognitive functions that include procedural 
learning, and working memory, while dorsolateral portions of the striatum control 
movement (Haber, 2003).   
This general topography has been supported to some extent by clinical cases.  
Bhatia and Marsden (1994) reviewed available literature and reported outcomes for 
240 patients who had experienced focal lesions to different basal ganglia structures.  
Of the 240 patients, 111 had behavioural problems, including abulia (defined by the 
authors as apathy with loss of initiative and spontaneous thought and emotional 
responses), disinhibition, obsessive compulsive disorder, speech disorder and 
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depression.  Abulia was the most common behaviour disturbance, and 13% of the 240 
patients had symptoms consistent with this disorder.  The most frequent motor 
disorders included dyskinesia, Parkinsonism, changes in muscle tone (muscular 
rigidity) and resting tremor.  Deficits varied depending on the position of the lesions 
experienced by the patients.   
From clinical cases such as those described, it is possible to make some 
general assumptions about lesions in the basal ganglia.  For example, the authors 
reported that lesions confined to the caudate rarely caused motor problems and were 
more likely to cause problems with behaviour, whereas lesions in the lenticular nuclei 
rarely caused behavioural problems, but were highly likely to cause motor problems.   
1.4.3 Contemporary Model of the Basal Ganglia   
Because early theorists emphasised the role of the basal ganglia in motor 
functioning, its function was originally conceptualised as receiving information from 
diverse areas of the sensory and association cortices, and funnelling this information 
to the motor cortex.  However, this view has been substantially revised over the past 
20 years.  One of the most influential models has been that suggested by Alexander 
and colleagues (1986; 1990).  These authors propose that the basal ganglia are 
involved in at least 5 parallel loops with the cerebral cortex.  Two of these loops are 
associated with the control of movement, and involve areas of the cerebral cortex 
associated with motor and oculomotor functioning.  The remaining three loops are 
involved in cognition and behaviour, and include dorsolateral prefrontal, lateral 
orbitofrontal and the anterior cingulate regions of the cerebral cortex (Alexander & 
Crutcher, 1990; Alexander, DeLong, & Strick, 1986).  Each basal ganglia-
thalamocortical loop receives input from multiple functionally-related cortical areas 
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and have been described as being closed, in that each receives input from and projects 
output to a specific cortical area (Alexander, DeLong, & Strick, 1986; Middleton & 
Strick, 2000a).  However, while each of the loops was conceptualised as segregated, 
they also receive inputs from, and output to, other structures (Alexander, DeLong, & 
Strick, 1986; Haber, 2003; Middleton & Strick, 2000a).  Since its original inception, 
the model has been developed to include both direct and indirect pathways (Albin, 
Young, & Penney, 1989).   
The motor circuit is most commonly used to facilitate an understanding of 
how the basal ganglia function (see Figure 1).  The direct pathway, which comprises 
mainly D1-type receptors, projects to the main output nuclei of the basal ganglia, the 
globus pallidus interna (GPi) and the substantia nigra pars reticulata (SNr).  The 
GPi/SNr inhibits targets in thalamus and brain stem, with an excitatory effect on 
thalamo-cortical projection (Yelnik, 2002).  The indirect pathway, which comprises 
mainly D2- type receptors, projects primarily to the external segment of the globus 
pallidus (GPe), which outputs to the subthalamic nucleus (STN).  Output from the 
STN to the GPi/SNr is excitatory, with an inhibitory effect on the thalamo-cortical 
projection (Lewis, Caldwell, & Barker, 2003; Yelnik, 2002).  When functioning 
effectively, the two pathways work in unison to create a balanced system.  More 
recently, a number of deviations to the classic basal ganglia model have been 
suggested, including projections to the pendunculo-pontine nucleus and the spinal 
cord (Delwaide, Pepin, De Pasqua, & de Noordhout, 2000).   
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Figure 1: A schematic representation of the basal ganglia using the motor circuit.   
The direct pathway, represented by the blue lines, projects to the globus pallidus 
interna (GPi) and the substantia nigra pars reticulata (SNr). The GPi/SNr inhibits 
targets in thalamus and brain stem with an excitatory effect on thalamo-cortical 
projection. The indirect pathway represented by the red lines, projects primarily to the 
external segment of the globus pallidus (GPe) which outputs to the subthalamic 
nucleus (STN). Output from the STN to the GPi/SNr is excitatory, with an inhibitory 
effect on the thalamo-cortical projection (Adapted from Lewis, Caldwell, & Barker, 
2003; and Obeso et al., 2000).   
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1.4.5 Limitations of the Model   
While this model has provided a useful framework from which to 
conceptualise the basal ganglia and associated disorders, it is important to be aware of 
some of the model’s limitations (see Hauber, 1998 and Saint-Cyr, 2003 for 
comprehensive reviews).  For example, it is clear that a degree of information 
integration occurs within the basal ganglia, given that the multiple related cortical 
areas project to a given sub-region of the striatum, and input structures (striatum) 
comprise of approximately 30 times more neurons than the output structures (SNr, 
and the GPi, Hauber, (1998)).  However, the current model lacks explanatory value in 
terms of how this information is integrated (Saint-Cyr, 2003).   
Further, a number of more recent findings are not easily explained by the 
model.  For example, D1 and D2 neurons have been found to “co-localize” on striatal 
neurons and all striatal neurons that project to the GPi also project to the GPe.  
Therefore, the conceptualisation of the D1 /D2 neurons in the basal ganglia as being 
either excitatory or inhibitory is considered to be an over-simplification (Bar-Gad & 
Bergman, 2001).   
Other aspects of the original model remain a matter of debate, including the 
extent to which the loops are segregated, whether there is functional overlap, and 
whether there are additional basal ganglia-thalamocortical loops (Chesselet & Delfs, 
1996; Levy et al., 1997; Saint-Cyr, 2003; Wichmann & DeLong, 2003).  Major 
regions of the cortex project to overlapping areas of the striatum, suggesting that the 
circuits are not totally segregated on the basis of cortical input (Saint-Cyr, 2003).  
Also, there are projections back to the cortex from the GPe and projections from the 
basal ganglia to the brain stem.  However, the role of these open circuits is not 
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adequately explained by the model (Bergman & Deuschl, 2002; Delwaide, Pepin, De 
Pasqua, & de Noordhout, 2000).  Despite the limitations covered above, anatomical 
observations and clinical studies have provided wide support for the model suggested 
by Alexander and colleagues, and it has been used to inform both research and 
surgical interventions (Middleton & Strick, 2000a, , 2000b).   
1.5 Parkinson’s disease and the basal ganglia   
1.5.1 The Dopamine Theory   
Parkinson’s disease is characterised by the depletion of dopamine due to the 
degeneration of dopaminergic neurons in the SN (see Figure 2), and not surprisingly, 
the dopamine theory is used to account for the deficits reported with this disorder.  It 
is therefore essential to understand how this theory has been used to explain both the 
motor and non-motor aspects of this disorder.   
Motor deficits are characteristic of PD and the dopamine theory explains this 
in the following way.  It is suggested that the direct and indirect pathways, described 
earlier, operate on the GPi/SNr.  The nigrostriatal denervation leads to over-activity of 
GPi/SNr (Lewis, Caldwell, & Barker, 2003; Yelnik, 2002), with an overall inhibitory 
effect on the thalamus.  This in turn leads to an under-activation of the motor cortex 
and a reduction or absence of movement as seen by the presence of bradykinesia or 
akinesia associated with PD (Lewis, Caldwell, & Barker, 2003; Obeso et al., 2000).   
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Figure 2: A schematic representation of the basal ganglia using the motor circuit, for a 
patient with Parkinson’s disease.   
A depletion of nigorstriatal dopaminergic neurons in the substantia nigra pars 
compacta (SNc) is represented by the thin lines. The direct and indirect pathways 
operate on the GPi/SNr.  The nigrostriatal denervation leads to over-activity of 
GPi/SNr with an overall inhibitory effect on the thalamus leading to an under-
activation of the motor cortex (Adapted from Lewis, Caldwell, & Barker, 2003; and 
Obeso et al., 2000).   
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The cell bodies of the nigrostriatal dopaminergic neurons are located in the 
SNc and project primarily to the putamen, but also to the caudate.  Research suggests 
that Parkinson’s disease first affects the posterior putamen, then the anterior putamen 
and the caudate nucleus (Bruck, Aalto, Nurmi, Bergman, & Rinne, 2005; Jellinger, 
1999).  This explains why motor symptoms are often the first signs for people with 
PD (Middleton & Strick, 2000b).  In contrast, dopamine depletion associated with 
Huntington’s disease begins in the anterior caudate and initial problems are usually 
cognitive in nature (Lawrence et al., 1998; Lawrence et al., 1996).   
Interestingly, it has been reported that neuronal loss in the SN in people with 
PD is not evenly distributed.  Neurons in the ventrolateral part of the SN degenerate to 
a greater extent than those in the medial part.  This has important implications in 
terms of the projections from the SN.  Research indicates that different types of PD, 
(e.g., akinetic-rigid type and tremor-dominate type) show different patterns of 
neuronal loss in the SN, and it is has been suggested that these different patterns of 
neuronal loss could explain the heterogeneity of motor symptoms (Damier, Hirsch, 
Agid, & Graybiel, 1999; Rinne, 1993).   
Consistent with the dopamine theory, most medications used to control the 
motor symptoms that characterise PD are based on dopamine replacement therapy.  
These treatments, at least in the early stages of the disease, ameliorate many of the 
motor symptoms, with symptoms only re-appearing at the “end of dose”.  Further, 
surgical procedures based on the dopamine model have been reported to be highly 
successful for some patients.  Neurotoxic models have also supported the role of 
dopamine in the motor symptoms associated with PD (Dauer & Przedborski, 2003).   
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1.5.2 Dopamine Theory, Cognition and Behaviour   
Dopamine depletion has also been associated with deficits in cognition and 
behaviour seen in PD.  It is therefore essential to be aware of the current theories used 
to explain this link.  As mentioned previously, the dorsolateral, orbitofrontal and 
anterior cingulate circuits, outlined by Alexander, DeLong, and Strick (1986), have 
been associated with behavioural and cognitive disorders (see Table 3).  Each of these 
circuits share the same features as the motor circuit described earlier, with direct and 
indirect pathways, each loop being segregated, and arising from and projecting to the 
same area of the cortex (see Figure 3 for a diagrammatic representation of the closed 
circuit for each pathway.  Only the direct circuit is shown).  A large body of research 
supports the role of these circuits in cognitive and behavioural functioning (see Owen, 
2004a for review).  Also, lesions to the cortical areas and at other points of the circuits 
have been reported as having similar effects.  Indeed, people with PD exhibit many of 
the deficits associated with dysfunction of the basal thalamo-cortical loops outlined 
here (deficits are covered in detail in section 1.4).  Given the clear association 
between motor dysfunction in PD and dopamine depletion, it would be expected that 
an equally clear relationship would be evident for cognitive and behavioural deficits, 
however, this is not the case (see Table 4).  Indeed this inconsistent association has 
led researchers to suggest that dopamine plays an indirect or moderating role in the 
cognitive and behavioural deficits associated with PD (Mattay et al., 2002).   
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Table 3: Cognitive and behavioural problems associated with dysfunction in the three 
frontal-sub-cortical circuits (Chow & Cummings, 1999).   
 
Circuit Dysfunction Impairments 
Dorsolateral 
Prefrontal circuit 
  
 Executive functions  
  • Poor organisational strategies 
• Poor memory search strategies 
• Stimulus bound behaviour/Environmental 
dependency 
• Impaired set shifting and maintenance 
• Poor working memory 
 
Anterior Cingulate  
circuit 
  
 Socially appropriate behaviour 
  • Personality change 
• Emotional incontinence 
• Impulsivity 
• Irritability 
• Mood disorders 
LateralOrbitofrontal 
 circuit 
 
 Motivated behaviour  
  • Apathy 
• Poverty of spontaneous speech 
• Poor response inhibition 
• Reduced creative thought 
• Akinetic mutism 
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1.5.3 Effects of Medications on Cognitive and Behavioural Symptoms   
In contrast to the ameliorating effects of dopamine replacement on motor 
symptoms, a more complex pattern is seen for cognitive and behavioural deficits.  
Indeed, L-dopa medications (L-Dopa is a precursor to dopamine which, unlike 
dopamine itself, easily crosses the blood brain barrier) have been reported as helping, 
hindering or having no effect on non-motor symptoms (see Table 4) (Cools, 2006; 
Kulisevsky et al., 1996; Pillon, Czernecki, & Dubois, 2003).   
Table 4: Effect of L-dopa on cognition and behaviour (Adapted from Pillon, 
Czernecki, & Dubois, 2003).   
Status  Reference 
Improvement “on” state 
 
 Apathy (Czernecki et al., 2002) 
 Cognitive Flexibility (Cools, Barker, Sahakian, & Robbins, 2001a, , 
2003) 
 Memory (Cooper et al., 1992) 
 Tower of London (Cooper et al., 1992) 
 Working memory (Cooper et al., 1992; Costa et al., 2003; Fern-
Pollak, Whone, Brooks, & Mehta, 2004; 
Mattay et al., 2002) 
Deterioration “on” state  
 Decision making  (Cools, Barker, Sahakian, & Robbins, 2003) 
 Memory (Poewe, Berger, Benke, & Schelosky, 1991) 
 Errors on choice reaction time (Schubert et al., 2002) 
 Probabilistic reversal learning (Cools, Barker, Sahakian, & Robbins, 2001a) 
 Wisconsin Card Sorting Test (Kulisevsky et al., 1996) 
No change “on” state  
 Cognitive slowing (Press, Mechanic, Tarsy, & Manoach, 2002) 
 Memory (Kulisevsky et al., 1996; Lange et al., 1992) 
 Reward association learning (Czernecki et al., 2002) 
 Visual Learning Discrimination Task (Lewis, Slabosz, Robbins, Barker, & Owen, 
2005) 
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It is clear then that the dopamine theory alone is insufficient to explain the 
non-motor deficits associated with PD.  Therefore, a brief overview of the theories 
used to explain the cognitive and psychiatric deficits associated with this disorder is 
provided.   
1.5.4 “Overdose” Hypothesis   
While a number of explanations have been offered regarding the inconsistent 
effects of dopamine on cognitive and behavioural symptoms associated with PD, one 
of the most compelling is the “overdose” hypothesis.  It has been suggested that the 
variable outcomes in terms of cognitive and behavioural deficits is related to the 
pattern of depletion of dopaminergic neurons within the substantia nigra (SN).  As 
stated earlier, the neuronal loss in the SN is not evenly distributed (Damier, Hirsch, 
Agid, & Graybiel, 1999; Haber, 2003; Rinne, 1993).  Each of the circuits shown in 
Figure 3 receive projections from different regions of the SN. This observation has 
given rise to the “overdose” hypothesis.  This hypothesis suggests that levels of 
dopamine required to remedy deficits will change throughout the course of the disease 
(Cools, 2006; Kulisevsky, 2000).  For example, motor symptoms appear first, but 
levels of dopamine required to remedy the depletion of dopamine in the motor circuits 
may result in an “overdosing” of the cognitive circuits, with a resultant deleterious 
effect on cognitive performance.  As stated earlier, projections to the putamen 
(associated with the motor circuits) have been found to deteriorate prior to the 
projections to the caudate (associated with cognitive functioning).  Further, within the 
caudate there is a progression of loss of dopamine projections that are more severe in 
the ventrolateral part of the caudate nucleus that projects to the dorsolateral pre-
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frontal cortex.  Less affected are the cells in the ventral striatum that project to the 
anterior cingulate (Cools, 2006).   
 
 
Figure 4: Schematic of the neurochemical pathology in Parkinson’s disease.   
Parkinson’s disease is characterised by motor deficits and depletion of dopamine 
beginning in the pre and supplementary motor areas. The blue shading represents the 
progression of dopamine depletion in the basal ganglia-thalamocortical loops 
(reproduced from Cools, 2006). (Abbreviations: Ach=acetylcholine; ACC=anterior 
cingulate nucleus; DA=dopamine; dl-PFC= dorsolateral prefrontal cortex; DL-
Put=dorsolateral putamen; Gpi=internal segment of the globus pallidus; LC=locus 
coeruleus; NA=noradrenaline; OFC=orbitofrontal cortex; PFC=prefrontal 
cortex;PMC= premotor cortex; SMA= supplementary motor area; SI=substantia 
innominata; Snr= substantia nigra pars reticulate;Tail-CAUD=tail of the caudate 
nucleus; V-Put=ventral putamen; va=ventral anterior nucleus; md=dorsomedial 
nucleus; vl=ventrolateral nucleus; vl-PFC=ventrolateral prefrontal cortex; vm-
CAUD=ventromedial caudate nucleus; VTA=ventral tegmental area.   
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In addition to a progressive loss of dopamine in the associated frontal circuits, 
as shown in the above schematic, it has been proposed that other neurotransmitters are 
also depleted with progressive stages of the disease (Cools, 2006).  However, other 
authors have suggested that the depletion of neurotransmitters other than dopamine 
(e.g. serotonin) may occur early in the disease process, and this may explain why 
symptoms associated with neurotransmitters other than dopamine (e.g., depression) 
may, in some cases, predate the onset of motor symptoms (Leentjens, 2004; Shiba et 
al., 2000).   
1.5.5 Abnormalities of Other Structures and Systems   
In addition to the main closed circuits, the frontal lobes are reciprocally 
connected to functionally similar areas of the brain via a number of open afferent and 
efferent connections (see Table 5. For a full account of the major and minor afferent 
and efferent connections of the frontal-subcortical circuits see Chow & Cummings, 
1999).  While the degeneration of the dopaminergic neurons are considered to be a 
hallmark feature of PD, the characterisation of this disorder as being isolated to the 
dopamine system is considered to be misleading (Braak & Braak, 2000).  Evidence of 
abnormalities in other subcortical structures (including the loss of noradrenergic 
neurons in locus coeruleus, serotonergic neurons in the dorsal raphé nucleus, and 
cholinergic neurons in the nucleus basalis of Meynert), are evident from the early 
stages of the disease process (Braak & Braak, 2000; Jellinger, 1999; Murai et al., 
2001; Slaughter, Slaughter, Nichols, Holmes, & Martens, 2001).  Furthermore, there 
is strong evidence that the mesocortical dopaminergic system also contributes to 
deficits in cognitive and behavioural functioning (Mattay et al., 2002).  The 
mesocortical dopaminergic system arises from the ventral tegmental area with direct 
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projections to the frontal cortex.  Depletion of these projections has also been found in 
people with PD (Marsden, 2006).  This diverse pattern of degeneration is thought to 
underlie heterogeneous, cognitive and psychiatric features of PD (Jellinger, 1999; 
Marsh, 2000).   
Table 5: Major open afferent and efferent connections of the frontal-subcortical 
circuits, using Brodmann’s area classification (Chow & Cummings, 1999).   
 
 Dorsolateral 
Circuit 
Orbitofrontal 
Circuit 
Anterior cingulate 
Circuit 
Major open 
afferent 
connections 
Dorsofrontal area 46 Superior temporal area 
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Hippocampus 
 Parietal area 7a Orbitofrontal area 12 Entorhinal area 28 
   Perirhinal area 35 
    
Major open 
efferent 
connections 
Dorsofrontal area 46 Orbitofrontal area 12 Substantial nigra (pars 
compacta) 
 Anterior frontal area 8 Mediofrontal area 25 Medical subthalamic 
nucleus 
  Mediofrontal area 32 Lateral Hypothalamus 
    
 
1.6 Cognitive Deficits associated with Parkinson’s disease   
1.6.1 Overview   
A major focus of this thesis is the development of a cognitive and 
neuropsychiatric profile of PD patients.  It is therefore pertinent at this point to review 
the major literature regarding deficits in these areas of functioning.  There are a 
number of difficulties associated with research in this area, and it is important to 
review the literature in light of these.   
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1.6.2 Difficulties with the research in this area   
Over the past 20 years there has been considerable interest in identifying the 
cognitive and behavioural consequences of PD (Taylor & Saint-Cyr, 1995).  
However, there is a great deal of inconsistency in the literature regarding the precise 
nature and extent of these deficits (Taylor & Saint-Cyr, 1995).  Brown and Marsden 
(1990) suggest that the inconsistency in the literature most likely reflects the 
heterogeneity of tasks employed in testing PD patients, and the varying levels of 
complexity and processing demands of the different tasks.  Moreover, tasks that are 
traditionally used to assess cognitive functions (executive functions, language and 
memory) rely on multiple aspects of mentation, but many studies have relied on single 
tests to either prove or disprove a deficit in a particular area of functioning.  
Furthermore, there is a lack of consistency regarding the way in which different 
cognitive skills have been operationalised (Taylor & Saint-Cyr, 1995).   
Another potential cause of inconsistency in findings is that studies vary in 
terms of inclusion criteria, and groups are often heterogeneous in presentation.  Also, 
the effects that different medications used to treat PD may have on cognition are often 
not considered (Taylor & Saint-Cyr, 1995).  Moreover, much of what is known about 
the range of neuropsychological deficits associated with PD relies on a compilation of 
outcomes for different groups of patients.  These groups differ with respect to a 
number of characteristics including level of motor impairment, age, and stage of 
disease.  A much more consistent understanding of cognitive problems may emerge if 
a single group was used to examine all potential domains of impairment.   
Despite the limitations in the literature, a general pattern of cognitive domains 
that are more likely to be impaired in patients with PD has been identified.  These 
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include visuoperception/visuospatial ability, speed of mental processing, memory, 
learning, and executive functions (including, planning, working memory, verbal 
fluency and attention).  Impairments in some areas of functioning are evident even 
from the early stages of the disease (Levin & Katzen, 1995).  It has been suggested, 
given the consistency with which deficits in executive functions have been reported 
for patients with PD, that problems with areas such as memory and language may be 
secondary to these (Bondi, Kaszniak, Bayles, & Vance, 1993b).  However, the nature 
of any core cognitive deficit in PD patients remains a matter of debate, with some 
researchers suggesting that deficits in attentional control represent the primary deficit 
while others propose working memory or inhibition.   
The literature in the area of cognitive outcomes in PD is extensive, and there 
are several recent comprehensive reviews (Levin & Katzen, 1995; Owen, 2004a; 
Pillon, Boller, Levy, & Dubois, 2001; Zgaljardic, Borod, Foldi, & Mattis, 2003).  
Therefore, this review will focus on providing an overview of the current 
understanding of cognitive deficits associated with PD without dementia, with 
reference to the major articles in the area.  A major purpose of this part of the review 
was to inform the test selection for the current project.   
1.7 Executive Functions 
1.7.1 Overview 
A number of executive-type skills have been assessed in patients with PD.  
However, deficits in planning, working memory, and attention have been suggested as 
core deficits in patients with PD, and there has been considerable research interest in 
these skills (these are reviewed in more detail here).   
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The prefrontal cortex, and more specifically the dorsolateral prefrontal cortex, 
is considered to have a pre-eminent role in the performance of executive functions 
(Fuster, 2000).  The prefrontal cortex is unique in that it is the only cortical area to 
receive information from all sensory, cortical, and motor systems, as well as sub-
cortical structures including the limbic system and basal ganglia (Fuster, 2000).  The 
effective processing of this information enables an individual to integrate cognitive 
and perceptual processes across time and space and update goals in the face of new 
information, in other words, an executive function (Roberts & Pennington, 1996).  
While there is no single agreed definition for executive functions (Salthouse, 2005), a 
wide range of skills and abilities including planning, working memory, decision 
making, and goal directed behaviour, flexibility, attention, self-monitoring, and 
control of ongoing behaviour are considered to be subsumed under this umbrella term 
(Samango-Sprouse, 1999).   
1.7.2 Working Memory   
Given the substantial number of connections between the prefrontal cortex and 
the basal ganglia, and the essential contribution of the prefrontal cortex to working 
memory (Bor, Duncan, Lee, Parr, & Owen, 2005), it is not surprising that there has 
been extensive research on the link between deficits in working memory (WM) and 
PD.  Working memory refers to the ability to temporarily store and manipulate 
multiple aspects of information required for higher order cognitive tasks (Baddeley, 
1992).  The term WM is generally considered to encompass and expand the concept 
of short term memory (Lezak, 1995) and is often considered pivotal to other 
“Executive Functions” as its contribution to the processes subsumed under this term is 
fundamental.  Experimental research and functional imaging confirm that the pre-
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frontal cortex (PFC) plays a strong role in the different components of WM 
(Romanski, 2004).   
1.7.2.1 Visual/Spatial Working Memory   
Different models have stimulated research into WM.  One of the most 
influential of these is that suggested by Baddeley and Hitch.  This model will be used 
in this review to aid the understanding of the deficits in WM that are commonly 
reported in PD.  According to the model of WM suggested by Baddeley and 
colleagues (Baddeley, 2003b; Baddeley & Della Sala, 1996; Baddeley & Hitch, 1974; 
Fuster, 2001), the visuo-spatial component may be conceptualised as the ability to 
temporarily store and manipulate visual (colour, shape) or spatial (location) 
characteristics of objects.  As can be seen in Table 6, a wide range of tests and 
experimental tasks have been employed to examine this area of functioning in PD.  
Tasks often vary in the complexity and processing demands required for their 
successful completion, and this may explain some of the inconsistent findings in this 
literature.   
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Table 6: Tasks used for assessing visual/spatial working memory deficits for 
individuals with Parkinson’s disease.   
Authors 
Test/Experimental  
task 
Task Requirement 
Impairment 
Found 
    
Boller et al., (1998) Corsi Cubes  Simple storage Yes a 
Bradley et al., (1989)study 1 
Bradley et al.,(1989)study 1 
Spatial span* 
Complex spatial span* 
Simple storage 
Manipulation/interference 
No 
Yes 
Costa et al., (2003) n-back Visual object * 
 Visual spatial* 
Distraction 
Distraction 
Yes c 
No c 
Fournet et al., (1996) Spatial span task* Delay/interference Yes 
Fornet et al., (2000) Spatial span task* Simple storage/ 
Delay/interference 
Yes c 
Kemps et al., (2005) Corsi Blocks Simple storage Yes 
Le Bras et al., (1999) Pattern span task* Manipulation  Yes 
Morris et al., (1988) Corsi Blocks * Simple storage No 
Owen et al., (1992) Corsi cubes* 
Self ordered search 
task/spatial* 
Simple storage 
Self directed search 
No/Yes b, c 
Yes b 
Owen et al., (1993) Self ordered search 
task/spatial* 
Self directed search Yes b 
Owen et al., (1997) Self ordered search 
task/spatial* 
Self ordered search 
task/visual* 
Self directed search 
Self directed search 
Yes b 
Yes b 
Postle et al., (1997) Spatial WM task* 
Object WM task* 
Delay 
Delay  
Yes 
No 
Stepanokava & Ruzicka (1998) Spatial WM task Recall/Recognition No 
Stofferes et al., (1997) Corsi Blocks* Simple storage Yes c 
Sullivan et al., (1993) Corsi Blocks 
Corsi Blocks 
Simple storage 
Distraction 
No  
No 
Tamura et al., (2003) Spatial span (WMS-R) 
Spatial span Backward 
(WMS-R) 
Simple storage 
Manipulation 
No 
No 
 
a Groups divided in terms of levels of depressive symptoms; b Groups divided in terms 
of severity of motor symptoms;c Groups tested on and off medication;* Computer 
generated task  
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1.7.2.2 Simple Storage/ Delay Tasks   
Simple storage of information requires fewer resources than active 
manipulation, therefore a relative preservation of this skill might be expected in the 
early stage of PD.  Simple storage for spatial WM has frequently been assessed using 
a variation of the Corsi blocks task (see Table 6).  Preserved simple storage of visuo-
spatial material for PD patients with mild to moderate symptoms relative to healthy 
controls, has been reported by a number of authors (Bradley, Welch, & Dick, 1989; 
Morris et al., 1988; Sullivan, Sagar, Cooper, & Jordan, 1993; Tamura, Kikuchi, 
Otsuki, Kitagawa, & Tashiro, 2003), regardless of depressive symptoms (Boller, 
Marcie, Starkstein, & Traykov, 1998).  However, while there are exceptions to this 
finding, it is considered that these inconsistencies are likely to reflect differences in 
task complexity or subject characteristics (Kemps, Szmalec, Vandierendonck, & 
Crevits, 2005; Stoffers, Berendse, Deijen, & Wolters, 2003).   
1.7.2.3 Complex Visuospatial Working Memory Tasks   
It might be expected that visuo-spatial impairments would be more 
pronounced if a task required active manipulation of material rather than simple 
maintenance, further, that any delays or distractions would produce a greater level of 
difficulty.  However, as with simple span tasks, deficits are consistently found for 
medicated patients with mild to moderate symptoms (Baddeley & Della Sala, 1996; 
Fournet, Moreaud, Roulin, Naegele, & Pellat, 1996, , 2000; Le Bras, Pillon, Damier, 
& Dubois, 1999), with no significant impairment in non-medicated patients at the 
early stage of PD (Owen et al., 1993a; Owen, Iddon, Hodges, Summers, & Robbins, 
1997; Owen et al., 1992).  One study has reported a finding contrary to this pattern.  
Owen et al., (1995) reported deficits in a spatial sequence generation task only in a 
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non-medicated group, and not in the medicated PD groups with mild or severe motor 
problems (Owen, Sahakian, Hodges, Summers, & et al., 1995).   
Surprisingly, the addition of interference or delay does not differentially affect 
PD patients relative to controls, with similar decrements in performance being evident 
as task difficulty increases (Fournet, Moreaud, Roulin, Naegele, & Pellat, 2000; Le 
Bras, Pillon, Damier, & Dubois, 1999; Sullivan, Sagar, Cooper, & Jordan, 1993).   
In an additional refinement, Postle et al. (1997) tested and confirmed their 
hypothesis that structures supporting WM may be differentially affected by the 
disease pathology associated with early PD.  Therefore, WM for features and objects, 
mediated by the ventrolateral prefrontal cortex, should remain relatively unimpaired, 
while visual spatial WM, mediated by the dorsolateral pre-frontal cortex, should be a 
more sensitive measure of impairment as this structure would deteriorate earlier in the 
disease process.  However, Costa et al. (2003) reported the opposite effect when 
comparing outcomes for an n-back1 visual object and visual spatial WM task.  While 
patients performed with normal accuracy in the visual-spatial WM task, they showed 
significant impairments for performance on the visual-object WM task.  These authors 
suggest that the visual object task used in their study may have been more difficult 
than that used in other studies, thereby creating longer latencies and reduced accuracy 
in response selection (Costa et al., 2003).   
Neither of these findings were supported by Owen, (1997b) who, using a self-
ordered search task, examined the effects of organisational strategy on spatial and 
object WM at different stages of PD.  Patients were divided into groups according to 
                                                
1 The n-back task is an experimental task where the participant is presented with a series of stimuli 
either visual or auditory and are required to indicate whether the current stimulus matches a stimulus 
presented n-back in the series where n= a number between 0-3.  
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disease severity, early course of the disease, medicated with mild-moderate physical 
symptoms, and medicated with severe physical symptoms.  Non-medicated patients in 
the early course of the disease were not significantly different from controls, while 
medicated patients with mild and severe motor symptoms made significantly more 
search errors for both visual object and spatial task (Owen et al., 1993a; Owen, Iddon, 
Hodges, Summers, & Robbins, 1997; Owen et al., 1992).   
Stepanokova and Ruzicka (1998) have suggested that many of the tests used to 
assess visuo-spatial WM are unusual or novel, creating greater task demands.  
Therefore, these authors used tasks that more closely resembled everyday problems 
and reported no deficits in visuo-spatial functioning for patients with PD compared to 
controls (Stepankova & Ruzicka, 1998).   
1.7.2.4 Summary   
Despite the different methodologies used in the studies reviewed, a consistent 
pattern emerged from the literature, with visuo-spatial WM deficits being apparent 
even in the early course of the disease process for medicated PD patients.  On the 
other hand, there appears to be consistent evidence of spared visuo-spatial WM for 
early stage non-medicated patients.  Furthermore, the addition of a delay or 
interference does not differentially impair the performance of PD patients.  There was 
no clear support for the assertion that visuo-spatial WM deficits are evident for tasks 
that require active manipulation while not evident with simple storage tasks, or for the 
assertion that spatial tasks are more likely to show deficits than object WM tasks.   
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1.7.2.5  Verbal Working Memory   
According to Baddeley’s model, the second subcomponent of the WM system 
is the phonological loop which holds verbal information in a phonological code, 
whether presented visually or verbally.  The phonological loop can be further divided 
into a temporary store that can only hold the memory trace for a few seconds if the 
information is not rehearsed, and the sub-vocal rehearsal system (Baddeley, 2003b).  
The subvocal rehearsal system not only enables information to be maintained, it is 
also the process by which information entering the system in a non-verbal form is 
coded.  The memory span for verbal information is defined as the amount of material 
that can be actively stored in the rehearsal loop and subsequently articulated.  Two 
phenomena that are known to reliably influence the verbal span are the word length 
effect (word spans decrease as the length of the words to be recalled increases) and 
the phonological similarity effect (i.e. words that are phonologically similar are more 
difficult to remember Baddeley, (2003b)).  
1.7.2.6 Simple Storage and Delay   
For patients with PD, it has been suggested that verbal WM may be less 
vulnerable to impairment at the earlier stages of the disease process than visuospatial 
WM (Lewis et al., 2003).  Indeed, as noted by Lewis et al. (2005), spatial WM deficits 
may occur while verbal WM remains unimpaired within the same patient group 
(Bradley, Welch, & Dick, 1989; Owen, Iddon, Hodges, Summers, & Robbins, 1997).  
While this observation adds weight to the suggestion that spatial WM may be more 
vulnerable than Verbal WM, it is not unequivocal as the opposite pattern has also 
been reported (Tamaru, 1997).   
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However, as can be seen in Table 7, at least in terms of simple storage, the 
performance of PD patients relative to controls has consistently been found to be 
unimpaired.  Intact verbal WM has been a robust finding, regardless of depressive 
symptoms (Boller, Marcie, Starkstein, & Traykov, 1998), or disease severity 
(Graceffa, Carlesimo, Peppe, & Caltagirone, 1999; Sullivan, Sagar, Cooper, & Jordan, 
1993).   
One notable exception to these findings is a study by Press et al. (2002).  In 
this study, participants were presented with a Sternberg item recognition paradigm 
with memory sets of one, three, or five digits.  Following this, they were presented 
with a probe and asked to indicate (by pressing a key) whether or not it was part of the 
memory set.  While there was no effect for accuracy or reaction time as a result of 
dopaminergic state, patients with PD showed evidence of impaired reaction time and 
accuracy in higher WM load conditions relative to controls.  Interestingly, these 
impairments were only evident on the first session and patients with PD were as 
accurate as controls by the second session.  The authors suggest that a procedural 
learning deficit may explain impairments in WM performance for PD patients.  A 
unique feature of this study was that it required recognition rather than recall, which is 
generally regarded as less memorially demanding.  However, while no specific delay 
is imposed, the Sternberg item recognition paradigm automatically imposes a delay.  
Therefore, the characteristics of this test may be more complex than those required by 
a simple storage paradigm, and may explain the apparent discrepancy.   
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Table 7: Tasks used for assessing verbal working memory deficits in individuals with 
Parkinson’s disease.   
Authors Test/Experimental task Task Requirement Impairment 
Boller et al. (1998) Digit span  Simple storage No a  
Bradley et al. (1989) 
study 1 
Digit span * Simple storage No 
Bradley et al.,(1989) 
study 2 
Memorising short phases * Decision making/ 
interference 
No 
No 
Bublak et al.. (2002) Digit span  
Digit Backward 
Digit Ordering 
Reading span task  
Number reordering* 
Simple storage 
Manipulation 
Manipulation 
Distraction 
Manipulation 
No 
No  
Yes 
Yes 
Yes 
Cooper et al. (1991) 
 
Digits forward 
Digits Backward 
Digit ordering  
Simple storage 
Manipulation 
Manipulation 
No 
Yes 
Yes 
Cox (2002) Counting task  Distraction Yes 
Dalrymple-Alford et al. 
(1996) 
Digit span  Simple storage No 
Fournet et al. (1996) Word span * Delay Yes 
Fournet et al. (2000) Word span* Delay Yes c 
Gabrieli et al. (1996) 
 
Reading span 
Arithmetic span 
Distraction 
Distraction 
Yes 
Yes 
Gilbert et al. (2005) Digit span 
Verbal span 
Simple storage 
Manipulation 
No 
Yes 
Graceffa et al. (1999) Word span  
Brown Peterson distracter 
task* 
Simple storage 
Delay 
No 
No 
Kensinger et al. (2003) Digit span 
Word span 
N-back task* 
Reading span 
Simple storage 
Simple storage 
Distraction 
Distraction  
No 
No 
Yes 
Yes 
Lewis et al. (2003) Number span 
Computer generated number 
re-ordering*  
Simple storage 
Manipulation 
No d 
Yes d 
Lewis et al. (2005) Number span* 
number re-ordering* 
Delay 
Manipulation 
No c 
No/Yes c 
Moreaud et al. (1997) Word span* Delay Yes 
Owen et al. (1997) Computerised verbal working 
memory* 
Organisational strategy No/Yes b 
Press et al. (2002) Item recognition*  Simple storage Yes c 
Skeel et al. (2001) Word span  
Word span 
Simple storage 
Delay/Interference 
No c 
No c 
Stebbins et al. (1999) Listening span test 
Digit ordering test 
Distraction 
Manipulation 
Yes 
Yes 
Sullivan et al. (1993) Letter recall 
 
Simple storage 
Distraction 
No 
Yes 
Tamura et al. (2003) Digit span 
Digit span/backwards 
Mental calculation 
Simple storage 
Manipulation 
Manipulation 
No 
Yes 
Yes 
a Groups divided in terms of levels of depressive symptoms; b Groups divided in terms of severity of 
motor symptoms;c Groups tested on and off medication; d Groups divided in terms of cognitive ability; 
* Computer generated task  
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The inclusion of a delay would be expected to add an additional load to the 
WM, and as can be seen from Table 7, with few exceptions the PD patients are 
impaired compared to controls when the WM task has a delay component (Bublak, 
Muller, Gron, Reuter, & von Cramon, 2002; Fournet, Moreaud, Roulin, Naegele, & 
Pellat, 1996, , 2000; Lewis et al., 2005).   
However, the imposition of a delay does not appear to simply reflect an 
inefficient processing skill.  If this were the case, an increase in the delay period 
would differentially affect PD patients compared with controls.  But both patients 
with PD and controls are equally affected by increases in the delay period (Fournet, 
Moreaud, Roulin, Naegele, & Pellat, 2000).  This has been found for patients both on 
and off medication (Cooper, Sagar, Jordan, Harvey, & Sullivan, 1991; Fournet, 
Moreaud, Roulin, Naegele, & Pellat, 2000).   
Furthermore, the introduction of simple distraction tasks do not differentially 
affect patients with PD (Cooper, Sagar, Jordan, Harvey, & Sullivan, 1991; Fournet, 
Moreaud, Roulin, Naegele, & Pellat, 1996).  Moreover, in both simple span tasks and 
tasks that introduce a delay, patients with PD have not been found to be differentially 
affected by the word length effect or phonological similarity effect when compared 
with controls (Graceffa, Carlesimo, Peppe, & Caltagirone, 1999; Moreaud, Fournet, 
Roulin, Naegele, & Pellat, 1997).   
1.7.2.7 Complex Verbal Working Memory Tasks   
As can be seen from Table 7, deficits are more likely when active 
manipulation of material is required, rather than simple maintenance.  In studies that 
used the same patient group to examine both tasks of simple storage and 
manipulation, a consistent pattern of spared simple storage and impaired manipulation 
 40 
was found (Bublak, Muller, Gron, Reuter, & von Cramon, 2002; Cooper, Sagar, 
Jordan, Harvey, & Sullivan, 1991; Gilbert, Belleville, Bherer, & Chouinard, 2005; 
Kensinger, Shearer, Locascio, Growdon, & Corkin, 2003; Lewis et al., 2003; 
Sullivan, Sagar, Cooper, & Jordan, 1993; Tamaru, 1997).  However, there were some 
exceptions to this pattern of deficits (Bradley, Welch, & Dick, 1989; Lewis, Slabosz, 
Robbins, Barker, & Owen, 2005).   
All the previously mentioned studies have combined patients with different 
levels of disease severity.  In contrast, using a task that required organisational 
strategy, Owen et al. (1997) reported that when patients were divided into groups 
according to disease severity, those in the early course of the disease (mean = 18 
months) and those medicated with mild-moderate physical symptoms demonstrated 
no verbal WM impairments.  However, the group of medicated patients with severe 
physical symptoms did show impairment.   
1.7.2.8 Summary   
The research reviewed here consistently found evidence of preserved simple 
storage for verbal WM in patients with PD.  Deficits were more likely to be reported 
for tasks that required a delay or active manipulation of the material presented.  
Neither word length effect, phonological similarities effect, nor the length of a delay 
differentially impaired patients with PD relative to controls.  Further, there was some 
evidence that even complex verbal WM tasks were preserved for early stage 
medicated and non-medicated patients with PD.  The literature reviewed here 
provides some tentative support for the assertion that the phonological loop is less 
vulnerable to impairments associated with PD than the visuo-spatial sketch pad.  The 
variation in performance over different task demands may be attributable to the 
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different regions of the brain that are activated during these tasks.  MRI studies have 
demonstrated that low load non-spatial WM task activate the left ventral lateral 
prefrontal cortex, while high load tasks activate the dorsolateral prefrontal cortex.   
1.7.3 Planning   
Planning refers to the ability to reach a desired goal through a number of 
intermediary steps, some of which may be counter-intuitive in that they do not lead 
directly to the end goal (Owen, 1997a).  The prefrontal cortex is thought to play a 
major role in planning ability (Owen, 1997a) and findings from patients with frontal 
lobe lesions (Carlin et al., 2000; Owen, Downes, Sahakian, Polkey, & Robbins, 1990) 
and imaging studies have supported this association (Baker et al., 1996; Cools, 
Stefanova, Barker, Robbins, & Owen, 2002; Owen et al., 1992).  Deficits attributed to 
planning ability have been reported in patients with PD using the Modified Six 
Elements Task (from the Behavioral Assessment of the Dysexecutive Syndrome test 
battery) (Uekermann et al., 2004), and variations of the Tower of London task (Cools, 
Stefanova, Barker, Robbins, & Owen, 2002; Culbertson, Moberg, Duda, Stern, & 
Weintraub, 2004; Morris et al., 1988; Owen et al., 1992).  Evidence of planning 
deficits have been found in the early stages of the disease process.  For example, in a 
study conducted by Owen et al.(1992) which used three groups, early non-medicated, 
mild to moderate stage medicated, and late stage medicated, patients with PD spent a 
longer time planning solutions, compared with controls.  Furthermore, increased 
errors in execution of solutions were evident for patients in the later stages of the 
disease.  However, goal-sub-goal conflicts which are attributed to a failure to inhibit a 
pre-potent response rather than planning deficits, has been offered as an alternative 
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explanation for the difficulties reported for patients with PD using the Tower tasks 
(Goel & Grafman, 1995).   
1.7.4 Attention   
There are conflicting findings in the literature as to whether patients with PD 
demonstrate deficits in attention.  This may be due to the variety of 
neuropsychological tests that have been used to assess this area, including digit span 
and the Wisconsin Card Sorting Test (WCST).  A major theory that has driven much 
of the research on this topic suggests that deficits in patients with PD are a result of 
reduced attentional resources.  Brown and Marsden (1991) have suggested a model 
(based on that proposed by Shallice), of a supervisory attention system (SAS).  In this 
model, attention must be consciously allocated in novel or demanding tasks that 
cannot be performed automatically.  The SAS is considered to have limited capacity 
and impairments in performance will be observed when this is exceeded.  Indeed, it 
has been repeatedly demonstrated that people with PD have greater difficulty when 
asked to perform two tasks simultaneously (dual task tests) that exceed their 
attentional capacity (Brown & Marsden, 1988; Dalrymple-Alford, Kalders, Jones, & 
Watson, 1994).  Therefore, deficits might not be apparent at easier stages of a given 
task and only become apparent as the task increases in difficulty (Brown & Marsden, 
1991).  Further, tasks that require internally generated cues will be more effortful 
(e.g., more complex aspects of the Stroop task and tests such as the WCST).  A 
number of studies have reported findings that support this theory (Cooper & Sagar, 
1993; Dujardin, Degreef, Rogelet, Defebvre, & Destee, 1999).   
Much of the research regarding attention has concentrated on attentional set 
shifting, namely, the ability to flexibly change behaviour in response to changing 
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contingencies of a task and requiring the ability to shift attention to relevant stimuli.  
Imaging studies suggest that efficient performance of attentional set-shifting is 
associated with both fronto-striatal functioning and the integrity of the frontal lobe 
(Marie et al., 1999; Monchi et al., 2004; Monchi, Petrides, Petre, Worsley, & Dagher, 
2001).  Attentional set-shifting difficulties have commonly been reported in patients 
with frontal lobe damage and patients with PD using a variety of tasks including the 
Odd Man Out Task (Flowers & Robertson, 1985; Richards, Cote, & Stern, 1993), 
intra-and-extra dimensional shift paradigms (Gauntlett-Gilbert, Roberts, & Brown, 
1999; Lewis, Slabosz, Robbins, Barker, & Owen, 2005; Owen et al., 1992; Owen et 
al., 1993b), verbal fluency (Zec et al., 1999), the Stroop test (Dujardin, Degreef, 
Rogelet, Defebvre, & Destee, 1999), the California Card Sorting Test (Dimitrov, 
Grafman, Soares, & Clark, 1999), and the Wisconsin Card Sorting test (Bondi, 
Kaszniak, Bayles, & Vance, 1993b; Canavan et al., 1989; Farina et al., 2000; 
Inzelberg et al., 2001).  However, Owen et al. (1993) suggest that the fundamental 
deficit in attentional set-shifting for the frontal lobe and PD patients may be due to 
different cognitive processes.  While PD patients have difficulty shifting attention to a 
new, previously irrelevant dimension (“learned irrelevance”), patients with frontal 
lobe damage tend to continue to attend to a previously relevant, but now irrelevant 
dimension (perseveration).  However, van Spaendonck et al., (1995) reported that 
deficits for patients with PD were only apparent when they were first required to shift 
set, with no difference for subsequent attentional set shifting.  Others have suggested 
that set-shifting deficits appear only when patients with PD are required to rely on 
internally-generated cues and are unimpaired when external cues are provided (Brown 
& Marsden, 1988; Hsieh, Lee, & Tai, 1995).  Deficits in set-shifting have been 
reported for patients during the early and late stage of the disease (Owen et al., 1992) 
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for both medicated (Canavan et al., 1989; Taylor, Saint-Cyr, & Lang, 1986) and non-
medicated patients with PD (Canavan et al., 1989).  Furthermore, deficits are not 
always ameliorated by dopamine, as shown by Lewis et al. (2005) who found no 
improvement in performance when patients were tested on L-dopa.   
While tasks such as the WCST have frequently been used to test for deficits in 
attentional set-shifting, it has been noted that multiple cognitive skills in addition to a 
set-shifting requirement are required for effective completion.  These include ability 
to stay on task, concept formation, and rule learning, making it difficult to analyse 
whether any reported deficits are indeed related to deficits in set-shifting or some 
other component (Rogers et al., 1998; Royall et al., 2002).  To date, deficits in 
performance for patients with PD using WCST have been attributed to difficulties 
with forming, holding or shifting attention between sets.  To more specifically 
investigate attentional set-shifting, tasks that deemphasised rule learning and concept 
formation have been used.  Using these tasks, patients with PD still exhibit attentional 
set-shifting deficits when compared with age matched controls, even in the early 
stages of the disease process (Cools, Barker, Sahakian, & Robbins, 2001b; Rogers et 
al., 1998).   
However, some aspects of attention appear to remain intact.  The digit span 
test is generally considered to be a test of sustained attention.  Patients with PD have 
consistently been reported as being unimpaired in this task (Boller, Marcie, Starkstein, 
& Traykov, 1998) regardless of disease severity (Graceffa, Carlesimo, Peppe, & 
Caltagirone, 1999; Sullivan, Sagar, Cooper, & Jordan, 1993).   
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1.7.5 Verbal Fluency   
Extensive research has been generated regarding fluency tasks and PD.  
Semantic and phonemic categories are generally used to test deficits in this skill.  
However, some research has focused on production of verbs (as opposed to nouns) as 
it has been suggested that the retrieval of action words relies more heavily on the 
prefrontal cortex (Piatt, Fields, Paolo, Koller, & Troster, 1999; Piatt, Fields, Paolo, & 
Troster, 1999; Woods, Carey, Troster, & Grant, 2005).  Nonetheless, outcomes using 
semantic and phonemic categories have been inconsistent with some researchers 
reporting deficits for verbal fluency tasks while others have reported no such deficits 
(see Table 8).   
 A number of explanations have been offered for these disparate findings.  For 
example, Hanley et al. (1990) indicated that group characteristics and suitable control 
groups were important, reporting that the semantic and letter deficit observed in their 
study disappeared when age, current verbal ability, and depression were taken into 
account.  The sensitivity of the word-fluency measure used may affect the outcomes.  
Generating words from a semantic category may be more effortful than from a 
phonemic category, and therefore provide a more sensitive measure (Auriacombe et 
al., 1993).  Indeed, deficits in semantic fluency have been reported in groups where 
phonemic fluency has been preserved (Auriacombe et al., 1993; Raskin, Sliwinski, & 
Borod, 1992; Zec et al., 1999).   
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Table 8: Examples of studies that have found contradictory findings for Phonemic and 
Semantic Verbal Fluency Tasks.   
 
Type of Deficit 
 
Authors 
 
Present  
Phonemic (Azuma, Cruz, Bayles, Tomoeda, & Montgomery, 2003; Bayles, 
Trosset, Tomoeda, Montgomery, & Wilson, 1993; Gurd & Ward, 
1989) 
Semantic (Auriacombe et al., 1993; Azuma, Cruz, Bayles, Tomoeda, & 
Montgomery, 2003; Bayles, Trosset, Tomoeda, Montgomery, & 
Wilson, 1993; Gurd & Ward, 1989; Randolph, Braun, Goldberg, & 
Chase, 1993; Raskin, Sliwinski, & Borod, 1992) 
Absent  
Phonemic (Azuma et al., 1997; Downes, Sharp, Costall, Sagar, & Howe, 1993; 
Gotham, Brown, & Marsden, 1988; Hanley, Dewick, Davies, 
Playfer, & Turnbull, 1990; Piatt, Fields, Paolo, & Troster, 1999; 
Raskin, Sliwinski, & Borod, 1992; Troster et al., 1998; Van 
Spaendonck, Berger, Horstink, Buytenhuijs, & Cools, 1996) 
Semantic (Azuma et al., 1997; Downes, Sharp, Costall, Sagar, & Howe, 1993; 
Gotham, Brown, & Marsden, 1988; Hanley, Dewick, Davies, 
Playfer, & Turnbull, 1990; Troster et al., 1998; Zec et al., 1999) 
 
In the study conducted by Auriacombe et al. (1993), semantic deficits were 
found in the absence of letter fluency deficits.  These authors suggest that the letter 
provided in letter fluency tasks provided a stronger prompt than a semantic category, 
which would therefore rely more heavily on the individual’s spontaneous ability to 
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retrieve the information.  This hypothesis was further examined by Randolph et al. 
(1993), who tested patients with Alzheimer’s disease (AD) and PD using a cued and 
uncued semantic fluency task.  In the uncued task, participants were asked to provide 
as many different exemplars from a semantic category in the standard way.  However, 
for the cued task, participants were provided with a cue every 15 seconds, (e.g., if the 
semantic category was “animals” a cue at 15 seconds might be animals you find in the 
home).  Patients with PD performed significantly worse than healthy elderly controls 
only in uncued conditions.  On the other hand, patients with AD did not benefit from 
cues, indicating reduced semantic stores.  However, Azuma et al. (1997) proposed 
that not all semantic and letter categories were equivalent, and that differential 
performance on these two tasks was also likely to be influenced by the relative 
difficulty of individual categories used by different researchers.   
Alternating word categories have been used to increase the sensitivity of 
verbal fluency tasks.  Zec et al. (1999) reported preserved phonemic word fluency 
with impaired semantic and alternating word fluency.  However, Gotham, Brown and 
Marsden (1988) reported evidence of deficits with alternate word fluency tasks only 
when the patients with PD were tested when off L-Dopa.  Moreover, Downes et al. 
(1993) reported that the deficits in verbal fluency tasks were not attributable to basic 
fluency or switching deficits, as patients with PD were able to shift between probes 
for the same domain (e.g. phonemic-phonemic, semantic-semantic), and that deficits 
only appeared when the participants had to switch between domains (e.g phonemic – 
semantic).   
In a recent meta-analysis of 68 studies of verbal fluency deficits, Henry et al. 
(2004) found that both phonemic and semantic fluency were impaired for PD patients.  
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However, sematic fluency tasks were relatively more impaired than phonemic fluency 
tasks.  Moreover, tests that required switching were differentially impaired.  This 
meta analysis lends support to the assertion that not all verbal fluency tasks are 
equally sensitive, and some care needs to be exercised when selecting which task to 
use (Henry & Crawford, 2004).   
1.8 Language and Verbal Functions   
The most noticeable communication deficits in patients with PD are those 
associated with motor dysfunctions, and include hypophonia and hyperkinetic 
dysarthria (difficulty with speech mechanisms, Murdoch, 2001).  However, there is 
increasing evidence that basal ganglia are also implicated in complex language 
processes and verbal function (Murdoch, 2001).  Given this association, it is not 
surprising that deficits in complex language and verbal functions have been reported 
in patients with PD (Azuma et al., 1997; Gotham, Brown, & Marsden, 1988; 
Grossman et al., 1991; Grossman, Carvell, Stern, Gollomp, & Hurtig, 1992; 
Natsopoulos et al., 1991).   
1.8.1 Complex Language   
Impairments in many different aspects of complex language have been 
associated with PD, including sentence comprehension and pragmatics of speech 
(rules for appropriate social language), difficulties with interpreting ambiguity, 
figurative language, and confrontational naming (Godbout & Doyon, 2000; 
Grossman, 1999; Grossman et al., 1991; Grossman, Carvell, Stern, Gollomp, & 
Hurtig, 1992; Lewis, Lapointe, Murdoch, & Chenery, 1998; Murdoch, 2001).  
Deficits in complex language have been attributed to grammatical difficulties 
(Natsopoulos et al., 1991), slowed information processing speed (Grossman et al., 
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2002), and working memory deficits associated with PD (Baddeley, 2003a; Howard, 
Binks, Moore, & Playfer, 2000).  There is also evidence that pragmatic social 
communication skills such as topic maintaince and appropriate interpretation of 
information are impaired for individuals with PD (McNamara & Durso, 2003).  
Pragmatic and social deficits are overtly evident in patients with PD in terms of their 
physical presentation e.g., flat affect and lack of body language.   
1.9 Visuoperception/Visuospatial Functions   
Deficits in visuoperceptual/visuospatial functions have commonly been 
reported for patients with PD even in the earliest stages of the disease process, even 
when the task requires no motor components (Hovestadt, de Jong, & Meerwaldt, 
1987).  These deficits have been associated with lesions in the right posterior cortex 
(Lezak, 1995; Treccani, Torri, & Cubelli, 2005).  Impairments in patients with PD 
have been reported using a variety of tasks (for a full listing and review of tests used 
with PD patients see Waterfall & Crowe, 1995).  Some of the more common tests 
used are: Judgement of Line Orientation (Montse, Pere, Carme, Francesc, & Eduardo, 
2001), mental rotation tests (Crucian et al., 2003; Lee, Harris, & Calvert, 1998), the 
Rey Osterrieth Complex Figure Test (Freeman et al., 2000; Grossman et al., 1993), 
Bicycle Drawing Test (Sandyk, 1994), and Cube Copying task (Maeshima, Itakura, 
Nakagawa, Nakai, & Komai, 1997).   
Performance on visuoperceptual/visuospatial tasks has been reported as 
showing a pattern of deterioration over time that is not significantly related to motor 
deficits (Katsarou et al., 1998), but that is correlated with the onset of symptoms 
associated with dementia (Levin et al., 1991; Raskin et al., 1990).   
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However, some authors have argued against the proposition that PD is 
associated with a generalised visuoperceptual/visuospatial deficit, suggesting instead 
that differences result from methodological issues such as task requirements.  For 
example, many earlier studies used timed tasks (Brown & Marsden, 1986; Waterfall 
& Crowe, 1995).  Furthermore, as has been pointed out by Crucian and Okun (2003), 
visuoperceptual/visuospatial tasks require multiple cognitive processes such as 
attentional resources and working memory, and these factors may underlie any 
observed deficits.  This suggestion has been supported by Waterfall and Crowe 
(1995), who in a recent meta-analysis showed that visuoperceptual/visuospatial tasks 
vary greatly in their requirements and can be further reduced to a number of different 
categories.  These authors reported that deficits are more likely to be seen in complex, 
higher order tasks that require attention, problem solving and internal control of 
behaviour, and not in lower order tasks with externally generated cues.   
Deficits in executive skills have been particularly implicated in 
visuoperceptual/visuospatial functioning (Bondi, Kaszniak, Bayles, & Vance, 1993a; 
Crucian et al., 2003; Crucian & Okun, 2003).  However, this finding is not conclusive 
as other authors have reported no association (Cronin-Golomb & Braun, 1997).  
These conflicting results indicate that the relationship between executive and 
visuoperceptual/visuospatial functions is complex and multifactorial.   
1.10 Memory and Learning   
Deficits in memory have been frequently reported for patients with PD 
(Stefanova et al., 2001).  It has generally been accepted that while cued and 
recognition memory appear to be unimpaired (suggesting intact coding ability), 
patients with PD have difficulty with the more effortful task of free recall, thereby 
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indicating a deficit in retrieval of the information. (Brown & Marsden, 1988, , 1991; 
Buytenhuijs et al., 1994; Crucian et al., 2003; Crucian & Okun, 2003; Hsieh & Lee, 
1999; Knoke, Taylor, & Saint-Cyr, 1998; Sagar, Sullivan, Gabrieli, Corkin, & 
Growdon, 1988).  However, a recent review of the literature has challenged the view 
that recognition memory remains intact for patients with PD (Whittington, Podd, & 
Kan, 2000).  Whittington et al. (2000) conducted a meta analytical review of the 
literature and found that while recognition memory remained unimpaired in de novo 
patients, there was a small recognition deficit for medicated patients with PD 
(Whittington, Podd, & Kan, 2000).  Further, greater deficits in recognition memory 
were found with increased task difficulty (Whittington, Podd, & Kan, 2000).  Also, it 
has been reported that while patients with PD show deficits in recognition over short 
delays, this is ameliorated after a longer delay (Cooper, Sagar, & Sullivan, 1993).  Of 
the executive function measures, working memory has been reported as most 
predictive of deficits, with a strong relationship between working memory and recall 
of information (Gabrieli, Singh, Stebbins, & Goetz, 1996; Higginson et al., 2003).  
While patients with PD spontaneously recall less information, their ability to learn 
new information and their rate of forgetting is not significantly different to that of 
healthy controls (Buytenhuijs et al., 1994; Stefanova, Kostic, Ziropadja, Ocic, & 
Markovic, 2001).   
1.11 Psychiatric and Behavioural Symptoms   
1.11.1 Overview   
There are a number of psychiatric and behavioural symptoms associated with 
PD that may be as debilitating as the cognitive and motor symptoms, and are often 
associated with reduced quality of life and caregiver distress (Caap-Ahlgren & 
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Dehlin, 2001; Marsh, 2000).  The most common non-motor symptoms are listed in 
Table 9.  It is likely that psychiatric symptoms may interact to exacerbate cognitive 
and motor problems associated with PD, making them an important consideration 
when assessing cognitive deficits.  Therefore, a brief overview of the commonly co-
morbid non-motor symptoms is provided here.   
Table 9: Common psychiatric and other non-motor symptoms that are associated with 
Parkinson’s disease (Dewey, 2003).   
Depression 
Anxiety 
Psychosis 
Fatigue 
Apathy 
Dementia 
Sleep disorders 
Olfactory dysfunction 
Pain and sensory disturbance 
Seborrhea 
Autonomic dysfunction 
Visual disturbance 
 
While hallucinations and psychosis are considered to be common side effects 
of medications used to control motor symptoms (Marsh, 2000), other non motor 
symptoms (e.g., depression, anxiety, apathy and fatigue) are reported by over 80% of 
patients with PD (Marsh, 2000; Shulman, Taback, Bean, & Weiner, 2001).  Accurate 
identification of these disorders may be difficult as many symptoms associated with 
depression, anxiety, apathy and fatigue overlap with PD symptoms.  However, it has 
been consistently demonstrated that psychiatric disorders are more common in PD 
patients than in age-matched controls.   
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1.11.2 Depression   
Depression refers to a state of low mood characterised by feelings of 
inadequacy, inactivity, and pessimism about the future.  Depression is one of the most 
common non motor symptoms associated with PD, with reported prevalence ranging 
from 7-76% (Slaughter, Slaughter, Nichols, Holmes, & Martens, 2001; Veazey, Aki, 
Cook, Lai, & Kunik, 2005).  The reported variation is due mostly to differences in 
sampling methods, type of assessment scales used, variations in cut-off points for 
scales, and how depression is actually defined (Slaughter, Slaughter, Nichols, 
Holmes, & Martens, 2001; Veazey, Aki, Cook, Lai, & Kunik, 2005).  It has been 
suggested that a true rate of around 31% would be found in community samples of 
patients with PD (Slaughter, Slaughter, Nichols, Holmes, & Martens, 2001; Veazey, 
Aki, Cook, Lai, & Kunik, 2005).  However, it is likely that depression associated with 
PD is under-diagnosed as many of the symptoms associated with PD are similar to 
those of low mood (e.g. difficulties sleeping, psychomotor retardation and apathy) and 
may be overlooked (McDonald, Richard, & DeLong, 2003; Shulman, Taback, 
Rabinstein, & Weiner, 2002).   
There is some debate in the literature as to whether depressive symptoms are 
secondary, resulting from being diagnosed with a debilitating disorder, or are 
associated with neuropathological changes that accompany the disorder.  The 
occurrence of depression in PD is reported as having a bimodal distribution, being 
more frequent in early and late stages of the disease, consistent with the assertion that 
it is a reactive depression.  However, changes in mood often predate the diagnosis of 
PD, and are ameliorated with medication (Leentjens, 2004; Shiba et al., 2000).  
Furthermore, as indicated previously, the noradrenaline and serotonergic pathways 
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implicated in depression in the general population are compromised in patients with 
PD (McDonald, Richard, & DeLong, 2003; Murai et al., 2001).  It is likely that a 
diagnosis of PD and neuropathological changes interact together with the individual’s 
personality to increase the risk of low mood, which may sometimes be severe enough 
to warrant a diagnosis of major depressive episode.  Regardless of the exact etiology, 
mood disorders are commonly co-morbid in patients with PD, and are associated with 
difficulties in concentration and attention, and impact on an individual’s performance 
on a range of cognitive tasks and everyday activities (Kuzis, Sabe, Tiberti, Leiguarda, 
& Starkstein, 1997).   
1.11.3 Anxiety   
Anxiety refers to feelings of fear, apprehension and dread about the future 
without a specific cause.  Anxiety disorders occur in up to 40% of patients with PD, a 
rate which is higher than that found in other disease populations (Richard, Schiffer, & 
Kurlan, 1996; Walsh & Bennett, 2001).  While a range of anxiety disorders have been 
reported as associated with PD symptoms, they are more commonly clustered in the 
generalized anxiety, panic and phobic disorder spectrum (Walsh & Bennett, 2001).  
Anxiety commonly occurs co-morbidly with depression, but may occur as an isolated 
cluster of symptoms (Walsh & Bennett, 2001).   
As with depression, there is some debate as to whether the symptoms 
associated with anxiety that occur in patients with PD represent a psychological 
reaction to the disease, or are directly linked to neuropathalogical changes associated 
with the disease process.  It has been suggested that anxiety could be a side effect of 
the L-dopa.  However, at least in terms of panic attacks, symptoms occur almost 
exclusively in the “OFF” phase of fluctuations and are relieved by the administration 
 55 
of Levodopa or dopaminergic agonists (Vazquez, Jimenez-Jimenez, Garcia-Ruiz, & 
Garcia-Urra, 1993).  Furthermore, as with depressive symptoms, there is an increased 
occurrence of anxiety disorders that predates the diagnosis of PD (Shiba et al., 2000).  
Recent research suggests that the severity of anxiety symptoms is related to depletion 
of dopamine and noradrenaline in the locus coeruleus and areas of the limbic system 
(Remy, Doder, Lees, Turjanski, & Brooks, 2005).   
1.11.4 Apathy   
Apathy is defined as a lack of motivation, interest or concern, which manifests 
itself as a decrease in goal directed behaviour (Marin, 1990).  Between 30-45% of 
patients with PD report symptoms consistent with this syndrome (Isella et al., 2002; 
Starkstein et al., 1992).  Apathy is often co-morbid with depression (Starkstein et al., 
1992), and may be mistaken for depression as a number of the symptoms overlap.  
However, apathy is considered a separate neuropsychiatric syndrome differentiated by 
the fact that, unlike depression, there is no low mood or feelings of hopelessness 
(Levy et al., 1998).  Symptoms of bradyphrenia and bradykinesia are similar to those 
associated with apathy, and it has been suggested they result from neuropathological 
changes in the same subcortical structures (Marsh, 2000).  It has been suggested that 
apathy results from dopaminergic nigro-striatal denervation (Levy & Dubois, 2005), 
and this is supported by the dopamine-dependent differences in severity that have 
been reported when patients are in the “on or off” state.  With or without depression, 
apathy is significantly correlated with deficits on cognitive tasks, e.g., planning, 
initiation and monitoring of goal-directed behaviours (Levy et al., 1998; Schrag, 
2004).   
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1.11.5 Fatigue   
Fatigue is described as the sense of being overly tired, lacking energy and 
feelings of exhaustion, and is listed as a feature of anxiety and depression by the 
Diagnostic and statistical manual of mental disorders- Fourth edition (DSM-IV).  
Given symptom overlap with depression and anxiety, fatigue is often undiagnosed by 
physicians (Friedman & Chou, 2004).  However, symptoms of fatigue, not explained 
by depression, have been reported in over 40% of individuals with PD.  This contrasts 
with 4.5%-18% of the normal elderly reporting the same problems (Friedman & 
Chou, 2004; Karlsen, Larsen, Tandberg, & Jorgensen, 1999).  Fatigue has been 
reported as the presenting symptom in 2% of patients with PD (Hoehn & Yahr, 1967), 
and many patients with PD rate fatigue as their most disabling symptom (Friedman & 
Friedman, 1993).   
The neuropathological changes associated with fatigue are not well 
understood, but it is suggested that the symptoms may be related to dysfunction of the 
frontal lobes (Friedman & Chou, 2004).  However, mental and physical symptoms 
may represent separate syndromes with different etiologies (Lou, Kearns, Oken, 
Sexton, & Nutt, 2001; Zenzola et al., 2003).  This suggestion is supported by the 
finding that while other aspects of fatigue are influenced by depression, physical 
fatigue is not (Zenzola et al., 2003).  Also, patients with PD report experiencing more 
physical fatigue than mental fatigue, and the severity of physical fatigue does not 
correlate with mental fatigue (Lou, Kearns, Oken, Sexton, & Nutt, 2001).  
Furthermore, while Levodopa has been helpful in treating physical fatigue associated 
with reduced activity, it does not ameliorate the symptoms of mental fatigue 
associated with reduced motivation.   
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1.11.6 Psychosis   
Precise prevalence rates for psychosis are difficult to establish because of 
varying definitions used in the literature.  However, hallucinations and delusions are 
relatively common in patients with PD, with prevalence rates of approximately 30% 
and 3% respectively (Ismail & Richard, 2004).  The presentation of symptoms 
generally fall into two categories: patients who experience hallucinations but retain 
insight  (“benign hallucinations”), and patients who experience hallucinations 
(typically without insight), and persecutory delusions in the context of dementia 
(Weintraub & Stern, 2005).  The precise etiology of psychosis remains unclear, but it 
is generally accepted that they are related to an excess of dopaminergic medication 
(Ismail & Richard, 2004).  While in some cases symptoms may predate medication, 
psychosis occurs at much lower rates in untreated patients with PD (Weintraub & 
Stern, 2005).   
1.11.7 Sleep Disturbance   
Sleep patterns change with age, and older individuals commonly have 
difficulty sleeping or require less sleep (Shochat, Loredo, & Ancoli-Israel, 2001).  
However, sleep disturbances are significantly more common in patients with PD than 
age-matched controls (Friedman & Chou, 2004).  While sleep problems are varied, 
sleep fragmentation due to difficulties with sleep maintenance is the most common 
type of sleep disorder in PD (Friedman & Chou, 2004).  Sleep disorders may be 
primary (i.e, directly related to PD) or secondary (i.e related to the side effects of 
medications, depression or anxiety).  Primary problems that may interfere with sleep 
maintenance include difficulty turning in bed, respiratory problems, depression, 
anxiety and tremors.  Secondary problems, related to the side effects of commonly 
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used medications, include the need for frequent urination and daytime sleepiness 
(Sanjiv et al., 2001).   
1.11.8 Emotional Expression   
Deficits in the ability to recognise emotional expression have been reported 
early in the disease process and PD patients have been reported as significantly 
impaired in their ability to decode primary facial expressions such as sadness, fear and 
disgust (Dujardin et al., 2004a; Kan, Kawamura, Hasegawa, Mochizuki, & Nakamura, 
2002; Sprengelmeyer et al., 2003; Troisi et al., 2002; Yip, Lee, Ho, Tsang, & Li, 
2003).  These deficits do not appear to be influenced by clinical variables such as 
duration of illness, motor symptoms, or depression (Dujardin et al., 2004a; Yip, Lee, 
Ho, Tsang, & Li, 2003).  Patients with PD also demonstrate emotional dysposity, the 
inability to vocally express feelings like anger, sadness, and verbal humour, and tend 
to produce monotonous flat speech (Benke, Bosch, & Andree, 1998).   
However, impairments in the recognition or expression of emotions are not 
found with written or verbal stimuli (Kan, Kawamura, Hasegawa, Mochizuki, & 
Nakamura, 2002).  The basal ganglia have been associated with the recognition of 
emotion (Cancelliere & Kertesz, 1990; Heilman & Gilmore, 1998; Weniger & Irle, 
2002), and impairments have also been found following sub-thalamic nucleus 
stimulation (Dujardin et al., 2004b).  As discussed previously, both these areas are 
implicated in PD, and their deterioration may explain difficulties with emotion 
recognition.   
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1.11.9 Dementia   
Dementia is arguably the most severe psychiatric outcome associated with PD, 
representing multiple cognitive and /or behavioural deficits which result in a 
significant decline in the person’s level of social or occupational functioning (using 
DSM-IV criteria).  The reported prevalence for Parkinson’s disease with dementia 
(PDD) varies greatly, largely due to methodological inconsistencies i.e., the way in 
which dementia is defined (Aarsland, Zaccai, & Brayne, 2005; Biggins et al., 1992; 
Mindham, 1999).  However, it is generally accepted that prevalence rates of dementia 
among people with PD are much higher than in the general population i.e., 
approximately four to five times that of elderly individuals without PD (Aarsland, 
Andersen, Larsen, Lolk, & Kragh-Sorensen, 2003; Emre, 2003; Hobson & Meara, 
2004; Mahieux et al., 1998).  While the exact neurophysiological basis of PDD 
remains undetermined, progression to dementia has been found to be more likely in 
patients with longer disease duration, of older age, and with more severe motor 
symptoms (Biggins et al., 1992; Caparros-Lefebvre, Pecheux, Petit, Duhamel, & Petit, 
1995; Hughes et al., 2000; Mahieux et al., 1998).   
Research indicates that cognitive deficits characteristic of PDD differ from 
those associated with Alzheimer’s disease (AD) (Mahieux et al., 1998; Stern et al., 
1998).  For example, while the initial symptom and essential characteristic of AD is 
impaired episodic memory, early executive function and visuospatial deficits are 
characteristic of PDD, with only mild impairments in memory retrieval being evident 
(Levy et al., 2002; Mahieux et al., 1998).   
The focus of more recent research has been to determine the exact nature of 
baseline tests that are predictive of later PDD.  Deficits in executive functions have 
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been reported by a number of authors (Azuma, Cruz, Bayles, Tomoeda, & 
Montgomery, 2003; Jacobs et al., 1995; Janvin, Aarsland, & Larsen, 2005; Mahieux 
et al., 1998; Woods & Troster, 2003).  However, it is difficult to compare these 
studies because definitions of executive function vary (Salthouse, 2005).  
Nonetheless, from the research to date, it seems evident that PDD differs from AD, 
with a hallmark feature being executive dysfunction rather than a deficit in episodic 
memory.  Moreover, executive dysfunctions appear to be an early indicator of later 
PDD.   
1.11.10 Conclusions   
It is clear that many patients with PD experience non-motor symptoms.  
Evidence of clinically significant mood, anxiety, and sleep disorders, along with 
fatigue, psychosis and apathy are frequently reported, and many patients with PD 
experience multiple symptoms.  Perhaps the most debilitating of the psychiatric 
disorders associated with PD is dementia, which is characterised by a cluster of both 
cognitive and behavioural deficits.   
1.12 Interim Summary   
Parkinson’s disease is a chronic progressive neurological disorder that affects 
approximately 100/100 000 individuals.  Onset generally occurs after 50 years of age 
and its incidence increases as the population grows older.  While PD has historically 
been considered as a motor disorder with hallmark features that include resting 
tremor, rigidity, bradykinesia and postural instability, it is now accepted that the 
disorder also includes a decline in behavioural and cognitive functioning that begins 
with subtle impairments, and for many results in dementia.  Moreover, it is becoming 
evident that the cognitive and behavioural symptoms associated with PD may be as 
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debilitating as the motor symptoms, and are associated with reduced quality of life 
and caregiver distress.   
Loss of dopamine-containing neurons in the substantia nigra and its 
projections to the basal ganglia is considered the focus of neuropathology in PD.  
Contemporary models of how the basal ganglia function suggest that the basal ganglia 
are involved in at least 5 parallel loops with the cerebral cortex, two of which are 
involved in motor functioning, with the remaining three implicated in cognition and 
behaviour.  Deficits associated with PD are thought to result from dysfunction in these 
loops, secondary to the depletion of dopamine-containing neurons in the substantia 
nigra that project to the basal ganglia.   
Consistent with the dopamine theory, many of the motor symptoms associated 
with PD are substantially ameliorated with dopamine replacement.  However, a more 
complex pattern of improvement has been reported for cognitive and behavioural 
deficits.  A number of explanations have been offered for this, including the “over 
dose hypothesis” which suggests that the levels of dopamine that are required to 
ameliorate the motor complications of PD “over dose” more intact structures that are 
implicated in cognitive and behavioural functions.  Alternatively, the other structures 
and systems that have been shown to degenerate in PD may contribute to the 
cognitive and behavioural dysfunction associated with this disorder.  For example, in 
addition to the main closed circuits suggested by Alexander et al. (1986), the frontal 
lobes are reciprocally connected to functionally similar areas of the brain via a 
number of open afferent and efferent connections that also deteriorate as part of the 
PD process.  Moreover, there has been evidence of abnormalities in other subcortical 
structures, evident from the early stages of the disease process.  This diverse pattern 
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of degeneration is thought to underlie the heterogeneous cognitive and behavioural 
features of PD.   
While there has been considerable interest in identifying the cognitive and 
behavioural features associated with PD, there has been inconsistency in the literature 
regarding what functions are impaired.  Much of this inconsistency has resulted from 
the application of different methodologies and diverse patient group characteristics.  
Despite the limitations in the literature, a general pattern of cognitive domains that are 
more likely to be impaired in people with PD has been identified including: 
visuoperception/visuospatial, speed of mental processing, memory and learning, and 
executive functions (including, planning, working memory, attention, verbal function 
and decision making).  Much of the more recent research regarding cognitive deficits 
in PD has focused on deficits in executive functions.  These facets of cognition are of 
particular importance because it is likely that they will impact on other areas of 
cognitive ability.  A number of neuropsychiatric symptoms have also been reported in 
PD, the most common of these being depression, anxiety, apathy, and fatigue, which 
are reported in up to 80% of people suffering from this disorder.   
1.13 Direction of Current Research   
As is evident in this review, cognitive and behavioural disorders associated 
with PD have generated considerable research interest with disparate results.  
However, one consistent finding is that people with PD represent a heterogeneous 
group with a variety of cognitive, behavioural, and motor symptoms.  In an effort to 
identify which people with PD will have cognitive difficulties, researchers have 
examined outcomes using a number of different groupings ie., frontal versus non-
frontal symptoms (Berry, Nicolson, Foster, Behrmann, & Sagar, 1999), sporadic 
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versus familial PD (Dujardin, Defebvre, Grunberg, Becquet, & Destee, 2001), motor 
symptoms (Dujardin, Defebvre, Grunberg, Becquet, & Destee, 2001; Lewis et al., 
2005), executive dysfunction (Lewis et al., 2003), and age at onset (Katzen, Levin, & 
Llabre, 1998).  A relatively common classification system has been motor 
symptomology, which is intuitively appealing given the neuropathology of PD.  
However, motor symptoms do not consistently correlate with cognitive or behavioural 
symptoms (Graham & Sagar, 1999).  As Graham and Sagar (1999) point out, 
classification systems have frequently been based on intuition, with little consensus 
regarding how different factors interact to disrupt cognitive and behavioural 
functions.   
This current research aims to use a data-driven method of identifying different 
sub-categories of people with PD, using the general concept of Mild Cognitive 
Impairment.  Mild cognitive impairment (MCI) is a term used in the dementia 
literature to describe cognitive impairments that exceed the level of impairment 
usually evident with normal aging, but not sufficiently severe to warrant a diagnosis 
of dementia (Petersen, 2000; Petersen, 2004; Petersen et al., 2001).  There has been 
some debate regarding how MCI should be defined, but more recently it has been 
recognised that multiple clinical subtypes exist: MCI amnestic type (typical of AD), 
MCI with cognitive deficits in multiple cognitive domains (language, executive 
function, visuospatial skills) with or without memory deficits, and MCI single 
cognitive domain with no memory impairment (Petersen, 2004).  The second subtype 
is considered more characteristic of people with PD and MCI (PD-MCI).   
The concept of MCI has only recently been formally investigated in relation to 
PD (Caviness et al., 2007; Woods & Troster, 2003) and it has been suggested that the 
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cognitive impairments in people with PD form a continuum from mild and subtle, to 
severe and overt (Stern et al., 1998).  Therefore, PDD could be viewed as the most 
severe end of the spectrum in terms of cognitive impairments, with PD-MCI forming 
a clinical entity that may represent those with preclinical PDD.  This line of research 
may provide an important avenue for understanding cognitive deficits in PD.   
The concept of PD-MCI presents an opportunity to intervene and delay the 
onset of more severe cognitive problems that may result in later dementia.  
Techniques such as functional imaging and eye movements have been proposed as 
useful in identifying early markers of PDD.  However, these methods are costly and 
not widely available, whereas a brief cognitive assessment provides a less invasive 
and cost effective method of identification that can be administered by a range of 
health professionals.  Moreover, research indicates that, as with AD, the impairments 
associated with PDD may be improved with cholinesterase inhibitors without 
worsening motor symptoms (see Burn & McKeith, 2003 for review).  Therefore, early 
identification of individuals likely to develop PDD could be the basis for intervention 
that could slow its development.  This is extremely important given the reduced 
quality of life associated with dementia, increased caregiver distress, and the resultant 
premature rest home placement.   
1.14 Objectives of the Current Research   
The general aim of this thesis is to contribute to the understanding of cognitive 
and behavioural deficits pertinent to everyday functioning in people with PD by 
specifying some of the relationships between these measures.  A central theme of this 
research is to explore whether sub-groups of people with PD can be identified based 
on their cognitive profile, specifically, to identify people with PD who could be 
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considered as suffering from MCI.  This is important as currently there is no agreed 
single set of tests that can be used to identify patients with PD who might be 
experiencing cognitive impairments that are not severe enough to warrant a diagnosis 
of dementia, but are of clinical relevance in that they affect aspects of everyday 
functioning.  Furthermore, identification of these subgroups may enhance our 
understanding of cognitive impairments in PD.  Moreover, timely identification of 
individuals with clinically significant levels of impairment is essential as it provides 
an opportunity to introduce appropriate treatment strategies, reduce personal and 
caregiver distress, and thus avoid premature rest home placement.  In line with this 
central theme, this thesis has a number of objectives:   
1.14.1 Objective 1: Develop a Cognitive and Behavioural Profile   
An initial objective of the project is to identify some of the pertinent cognitive, 
behavioural, and psychiatric deficits in PD patients compared with the normal elderly.  
This overlap is of particular importance as PD is primarily a disorder of the elderly, 
therefore observed deficits must be contrasted with the cognitive and behavioural 
effects of normal aging (Bennett et al., 2002; Dubois, Pillon, Sternic, Lhermitte, & 
Agid, 1990).  Given the association between PD and the frontal-striatal circuits, it is 
expected that executive functions are particularly vulnerable in individuals with PD.  
There is extensive literature regarding cognitive and behavioural outcomes and PD, 
however, the exact nature and extent of these deficits remains a matter of debate 
(Kulisevsky et al., 1996).  This objective will enable us to more fully define the extent 
of these deficits in PD compared with normal aging.   
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1.14.2 Objective 2: Determine Functional Deficits Associated with 
Parkinson’s Disease -  
As characteristic motor dysfunctions are often the focus of treatment 
intervention for PD, the more subtle deficits that result in an individual’s inability to 
function efficiently in their environment may be overlooked.  Therefore, the second 
objective will be the identification of functional deficits that may be associated with 
PD, using measures of cognitive, behavioural and psychiatric deficits and everyday 
living tasks.   
1.14.3 Objective 3: Identification of Sub groupings   
The central focus of this thesis is to explore whether subgroups of patients can 
be identified based on their cognitive profile.  Identification of these different sub 
categories of people with PD will use the general concept of Mild Cognitive 
Impairment to develop a unique method of classifying cognitive impairments for 
people with PD but without dementia (PD-MCI).  It is intended that a brief battery of 
tests (using information gained from objective 1 and 2) will be identified to 
distinguish different groups using a data-driven exploratory method involving cluster 
analysis.   
1.14.4 Objective 4: Confirmation of Groupings   
A follow-up study will examine the stability of cognitive groupings that 
emerge from the initial main study.  Individuals who are involved in the initial study 
will be invited to participate in a follow up study that will use the tests identified in 
phase one of this research to examine if they are indeed useful in terms of determining 
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sub-categories.  It would be expected that individuals would either remain in their 
original groupings, or show a decline in functioning.   
It is intended that a discrete group of non-invasive tests may be identified that 
will have clinical application.  A related goal of this objective will be to define which 
tests, from a number of conceptually related tests, are most sensitive or appropriate 
for use with PD patients.   
1.14.5 Objective 5: Complex Language and Parkinson’s Disease   
Deficits in complex language have been associated with PD, with speed of 
processing and working memory being suggested as mediating any deficits.  
However, there is considerable debate as to the exact nature of the relationship 
between complex language and these variables.  Therefore, as the fifth objective, the 
identification of the relative contribution of working memory and speed of processing 
on complex language skills, will be undertaken.  In addition, this project will look at 
the association between complex language skills and social functioning.   
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Chapter 2 – Method   
Abbreviations used in the text Chapter Two 
1) AD = Alzheimer’s disease; 2) BADS = Behavioral Assessment of the Dysexecutive 
Syndrome; 3) BADLS = Bristol Activities of Daily Living Scale; 4) BDI-II = Beck 
Depression Inventory; 5) CANTAB = Cambridge Neuropsychological Test Automated 
Battery; 6) CPT = Continuous Performance Task; 7) DEX = The Dysexecutive 
Questionnaire; 8) D-KEFS = Delis Kaplan Executive Function System; 9) DOT-A = 
The Adaptive Digit Ordering Task; 10) DRS-II = Dementia Rating Scale-II; 11) DSM-
IV = Diagnostic and Statistical Manual Fourth Edition; 12) ED = Extra Dimensional 
shift; 13) EXIT = The Executive Interview; 14) FAQ = Functional Activities 
Questionnaire; 15) FrSBE = Frontal Systems Behaviour Scale; 16) GDS = Geriatric 
Depression Scale; 17) HADS = Hospital Anxiety Depression Scale; 18) H&Y = Hoehn 
and Yahr Staging Scale; 19) ID/ED = Inter Dimensional/Extra Dimensional Shift; 20) 
IQCODE = The Informant Questionnaire on Cognitive Decline in the Elderly; 21) 
JOL = Judgement of Line Orientation test; 22) MMSE = Mini Mental Status Exam; 
23) 3MS = Modified Mini Mental Status Exam; 24) NART = National Adult Reading 
test; 25) NPI = Neuropsychiatric Inventory; 26); PD = Parkinson’s disease; 27) PDD = 
Parkinson’s disease with dementia; 28) PDQ-39 = The Parkinson’s Disease 
Questionnaire; 29) ROF = Rey-Osterrieth Complex Figure Test; 30) SN = Substantia 
nigra; 31) TEA = Test of Everyday Attention; 32) TOL = Tower of London; 33) TLC-
E = Test of Language Competence Expanded Edition- Level 2; 34) UPDRS = Unified 
Parkinson’s disease Rating Scale; 35) VAT = Visual Association Test; 36) VOSP = 
The Visual Object and Space Perception Battery; 37) WASI = Wechsler Abbreviated 
Scale of Intelligence; 38) WAIS-III = Wechsler Adult Intelligence Scale 3rd edition; 
39) WMS-III = Wechsler Memory Scale-3rd Edition. 
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2.1 Justification of Tests Selected   
In keeping with the main objective of this study, namely the development of a 
cognitive and behavioural profile of people with PD without dementia, a wide range 
of tests were administered over five testing sessions (three of these were conducted 
for study one and two during the follow-up study).  The selection of tests was 
determinded by theoretical and empirical findings, and subject characteristics (see 
Table 9 for outline of tests selected).   
2.1.1. Theoretical Basis   
The major theory in PD research is the dopamine theory.  To briefly recap, this 
theory proposes that Parkinson’s disease is associated with a decrease in dopamine in 
the basal ganglia secondary to degeneration of dopamine neurons in the substantia 
nigra.  A major consequence of the depletion of dopaminergic neurons is a disruption 
of the basal ganglia-thalamocortical circuits which are implicated in both motor and 
non-motor functions.  Of specific relevance to this study are the dorsolateral, 
orbitofrontal and anterior cingulate circuits, outlined by (Alexander, DeLong, & 
Strick, 1986), which have been associated with a range of behavioural and cognitive 
disorders.  Disorders associated with each of the circuits are briefly outlined below.  
Each circuit is proposed as having a pre-eminent, if not exclusive, role in the 
performance of different functions.   
A) Dorsolateral prefrontal circuit: The integrity of this circuit is 
associated with the effective performance of executive functions, the ability to 
integrate cognitive and perceptual processes across time and space and update goals in 
the face of new information.  Executive functions include working memory, decision 
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making, flexibility, set maintenance, self monitoring and control of ongoing 
behaviour (Roberts & Pennington, 1996; Salthouse, 2005; Samango-Sprouse, 1999).   
B) The Orbitofrontal circuit mediates socially appropriate behaviours.  
Personality changes are most commonly seen after disruption of this circuit and may 
include irritability and changes in mood (Mah, Arnold, & Grafman, 2005).  Patients 
with lesions in this area may behave inappropriately in social situations, often failing 
to respond to environmental and social cues (Chow & Cummings, 1999; Mah, 
Arnold, & Grafman, 2005).   
C) The Anterior cingulate: This circuit is involved in motivated 
behaviour (Tekin & Cummings, 2002).  Patients with lesions in the structures of the 
anterior cingulate are reported to be apathetic with impaired motivation along with 
poor response inhibition and may show a reduction in creative thought (Chow & 
Cummings, 1999).   
Measures selected for use in this study focused on assessing deficits 
considered likely with dysfunction of the dorsolateral, orbito-frontal and anterior 
cingulate circuits, to provide a theoretically relevant range of measures.   
2.1.2 Empirical Basis   
A general pattern of cognitive domains that are more likely to be impaired in 
patients with PD has emerged from the extensive literature in this area, as has been 
reviewed in section one.  These include deficits in verbal function, visuoperception, 
visuospatial skills, speed of mental processing, memory, learning and executive 
functions (including, planning, working memory and attention).  Moreover, 
impairments in executive functioning and working memory have consistently been 
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reported, even from the early stages of the disease process (Bondi, Kaszniak, Bayles, 
& Vance, 1993b; Levin & Katzen, 1995).  Therefore, we selected tests that had been 
demonstrated in the literature to detect deficits in PD, with a particular focus on 
executive functions and working memory.   
A number of screening tests for dementia were included in our battery.  This 
was of particular importance as this study aims to identify different sub-categories of 
people with PD without dementia, with an emphasis on generating criteria for PD-
MCI.  Therefore, it was critical that the screening tests identified people who 
suffering from dementia in order to exclude them from this study.   
There is no generally agreed on battery of tests that are used to assess 
cognitive and behavioural deficits associated with PD.  Indeed different tests which 
theoretically assess the same function are used interchangeably by researchers and 
may lead to some of the disparate findings in the literature.  Therefore some of the 
tests were selected to assess whether they were indeed interchangeable or whether 
some were more sensitive to problems associated PD than others.  For example, three 
different measures of depression were selected, the Geriatric Depression Scale, the 
Beck Depression Scale-II and the Hamilton Anxiety and Depression Scale.   
2.1.3 Subject Characteristics   
Another major consideration in the selection of tests was the likely subject 
characteristics that may affect optimal performance.  Specifically we wanted to ensure 
that deficits in performance were not due to the motor problems associated with PD.  
Individuals with motor symptoms ranging from mild to severe were included in in this 
research.  Therefore, tests were selected that involved a minimal motor component.  
Where motor skills were required, tests with minimal speed component were used.   
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The literature also suggests that fatigue may be a major problem for some 
people with PD and sessions were expected to last approximately three hours (most 
lasted between 3-4 hours) depending on the individual.  Therefore, tests that were of 
short duration (the majority took under 15 minutes to complete) were chosen so that 
frequent breaks could be provided as required (these tests are listed on Table 10 
numbers indicate where each test may be found in list of test descriptions).   
Table 10: Test selected to assess cognitive and behavioural functions in people with 
Parkinson’s Disease versus healthy controls.   
Initial Screening /Background tests 
 Beck Depression Inventory (BDI-II) 3 
Dementia Rating Scale-II (DRS-II) 10 
Ethnicity Data (see Appendix I for a copy) 
General Health and demographic screen (see Appendix II for copy) 16 
Geriatric Depression Scale (GDS) 17  
Hospital Anxiety and Depression Scale (HADS)18 
Mini Mental Status Exam (MMSE) 22 
Modified Hoehn and Yahr 23 
National Adult Reading Scale-II (NART-II) 25  
The Executive Interview (Exit) 33 
The Modified MMSE (3MS) 22  
Unified Parkinson’s disease Rating Scale (UPDRS) 38 
Vocabulary- Subtest from the Wechsler Abbreviated Scale of Intelligence (WASI) 41 
  
Tests of Executive Function /Planning 
 Category Fluency -Subtest from the Delis Kaplan Executive Function System (D-
KEFS) 9 
Category Fluency-switching (D-KEFS) 9 
CLOX- I 6 
Design Fluency-Filled dots (D-KEFS) 9 
Design Fluency-Switching (D-KEFS) 9  
Intra dimensional/ Extra dimensional Shift -Subtest from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) 
5 
Key Search -Subtest from Behavioural Assessment of the Dysexecutive Syndrome 
(BADS) 4  
Letter Fluency (D-KEFS) 9  
Stroop (Switching- D-KEFS) 9 
Stockings of Cambridge (CANTAB) 5 
Theory of Mind Test 30 
Tower of Hanoi (D-KEFS) 9 
Zoo Map - (BADS) 4 
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Table 10: Continued.   
General Memory 
 Auditory Recall - Subtest from the Wechsler Memory Scale -3rd edition (WMS-III) 42 
Logical Memory I&II (WMS-III) 42 
Paired Associates I&II (WMS-III) 42 
Rey-Osterrieth Complex Figure Test II&III (ROF) 27 
Visual Association Test (VAT) 39 
Problem Solving 
 Matrix Reasoning (WASI) 41 
Card Sort (Free) (D-KEFS) 9  
Tower of London Revised (TOL-R) 37 (see Appendix III for instructions) 
Gambling Task 15(See Appendix IV for instructions)  
Speed of Processing 
 Digit symbol coding -Wechsler Adult Intelligence Scale 3rd edition (WAIS-III) 11 
Motor copying (WAIS-III) 24 
Stroop (word naming – D-KEFS) 9 
Stroop (color naming- D-KEFS) 9 
Tests of Working Memory/Attention 
 Continuous Performance Task (CPT) 7(See Appendix V for instructions) 
Daneman and Carpenter Reading Span Test 8 (See Appendix VI for list of words and 
instructions for Study One.  Appendix VII shows words and instructions for Study 
Two) 
Digits Forward (WMS-III) 42 
Digits Backward (WMS-III) 42 
Letter Number Sequencing (WMS-III) 42 
Spatial Span (CANTAB) 5 
Spatial Working Memory (CANTAB) 5 
Memory for Temporal Order (Word sequencing test) 20 (See Appendix VIII for list of 
words used)  
Memory for Temporal Order Revised 21(See Appendix IX for list of words used 
Map Search – Subtest from Test of Everyday Attention (TEA) 28 
The Digit Ordering Task (DOT)32 
Visuoperceptual/Visuoconstruction 
 CLOX-II 6 
Incomplete letters- Subtest from The Visual Object and Space Perception Battery 
(VOSP) 40 
Judgement of Line Orientation 19 
Object Decision Task (VOSP) 40  
ROF-I 27 
Language 
 Test of Language Competence Expanded Edition-Level 2 (TLC-E) 29 
NOTE: Numbers indicate where the description of the test may be found in the list at the end 
of the method section.   
Another unique feature of this study was to examine the relationship between 
cognitive and behavioural deficits and aspects of everyday living.  As patients 
sometimes underestimate or minimise the extent of any deficits due to lack of insight 
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or problems with memory, tests were also selected for use with a person who knew 
the participant well (see Table 11).   
Table 11: Tests selected to assess Activities of Daily Living in People with 
Parkinson’s Disease versus Controls.   
Activities of Daily Living (completed by significant other) 
 Bristol Activities of Daily Living Scale (BADLS) 2 
 Frontal Systems Behaviour Scale (FrSBe) 13 
 Functional Activities Questionnaire 14 
 Neuropsychiatric Inventory (PD patients only) 26 
 The Clinical Assessment of Fluctuation 31(PD patients only) 
 The Dysexecutive Questionnaire (DEX) 3 
 The Informant Questionnaire on Cognitive Decline in the elderly (IQCODE)34 
 The One Day Fluctuation Assessment Scale 35 (PD patients only) 
Activities of Daily Living (completed by participant) 
 Apathy Scale 1 
 DEX (self report) 4 
 Fatigue Severity Scale 12 (See Appendix X for instructions) 
 FrSBe (self report) 13 
 Parkinson’s Symptom and Sleep Diary (PD Patients only) (See Appendix XI)  
 The Parkinson’s Disease Questionnaire (PDQ-39) 36 (PD patients only) 
 
2.2 Study One - Thinking and Language Skills in Parkinson’s Disease   
2.2.1 Participants   
Parkinson’s disease group   
Parkinson’s patients in the Canterbury region, who had not been diagnosed 
with dementia, were invited by letter to participate in the study by two consulting 
neurologists employed by Christchurch Hospital.  Included with the letter of invitation 
were an information sheet and a reply slip.  The reply slip was to be returned if the 
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patient consented to volunteer for the study (see Appendix XII, XIII, and XIV for 
copies of letter, information sheet and reply slip respectively).  The study received 
approval from the Canterbury Ethic Committee (see Appendix XV for a copy of 
ethics approval).   
Participants were required to meet the following inclusion/exclusion criteria:   
Inclusion Criteria:  
• A diagnosis of idiopathic Parkinson’s disease, confirmed by a neurologist using 
the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria (see 
Section One, Table 2).   
• Assessed at the Hoehn & Yahr stage 1-IV.   
• Aged between 50 and 80 years old.   
• Sufficient motor control to participate in testing, with no uncontrolled dyskinesia.   
• Adequate or corrected hearing and vision (self report checked by examiner).   
Exclusion Criteria:  
• Involved in current therapeutic trial.   
• History of:  
o Moderate or severe head injury.   
o Stroke or other neurological impairment.   
o Major medical illness (e.g. severe cardiovascular problems, type II 
diabetes).   
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o Significant psychiatric illness requiring hospitalisation.   
• Overt dementia (MMSE <25).   
• Hallucinations.   
• Alcohol or substance abuse.   
• Diagnosis of, or special education for, a learning disability.   
• Major depression in the previous 6 months.   
• Pre-morbid IQ estimated at <85 using National Adult Reading Test (NART).   
• Currently taking medications known to have a significant effect on Central 
Nervous system (other than medications prescribed for the control of PD 
symptoms).   
• Beck Depression Inventory –II score of >17.   
Of the total 115 letters that were posted out, 6/115 (5.2%) of individuals with 
PD were too unwell to participate, 6/115 (5.2%) were deceased, 8/115 (6.9%) 
declined, and 34/115 (29.6%) did not respond.  In total, 61/115 (53%) individuals 
with PD completed at least one of the testing sessions.  For the initial manuscripts that 
covered frequency of psychiatric problems, and sensitivity of depression measures, 
(see section 3) the inclusion criterion was a diagnosis of PD and the exclusion 
criterion was evidence of dementia.  For this aspect of the study, 59 patients were 
used.  Two of the 61 patients had to be excluded as they had evidence of dementia.  
No controls were required for these analyses.   
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However, for all other analyses and manuscripts, it was essential to have 
stringent inclusion/exclusion criteria so that accurate conclusions could be drawn 
regarding the impact on cognition for patients with PD, without dementia, compared 
to healthy older people.  For the main study, twenty one of the 61 PD participants did 
not meet the inclusion/exclusion criteria listed above, leaving 40 participants with PD 
who were available for inclusion in the main study (the main study is covered in 
Sections 4,5, and 6, and examines aspects of cognition and language for PD patients 
versus healthy older people).   
Controls   
Controls were recruited from a number of sources including a previously 
established data base, and by advertisements at local clubs (bowling, tramping and 
table tennis clubs) and businesses (see Appendix XVI for a copy of the 
advertisement).  Controls that were part of the established data base were initially 
contacted by phone.  All controls were given a brief outline of the study on first phone 
contact.  If they were willing to participate they were then sent an information sheet 
(see Appendix XVII for copy of the information sheet).   
In addition to adequate or corrected hearing and vision (self report, checked by 
the examiner) and being aged between 50 to 80 years of age, the same exclusion 
criteria listed above also applied to the control group.  A total of 65 controls 
completed at least one of the testing sessions.  Group and demographic characteristics 
are shown in Table 12 and Table 13 respectively.  Each of the 40 PD patients included 
in the main study were matched as closely as possible to healthy controls in terms of 
age (± 5 years of the matched control age, mean = 2.91 years) and pre-morbid IQ 
using the NART (± 5 points of the matched control score, mean = 2.29 points).  Such 
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a close match was not possible in 7/40 cases for age and 6/40 cases for ratings of pre-
morbid IQ.  In these cases, matching was within ± 5-9 years for age and ± 5-8 points 
for NART scores.  Matching was confirmed by t-statistics (IQ: t = 0.94, df =78, p > 
0.30; and age: t = 0.31 df = 78, p > 0.75).  There were significantly more males in the 
PD group (PD 26 /40 [65%] v Control 13/40 [32.5%]) (χ 2(df, 1) = 8.46, p = <0.01).   
 
Table 12: Group characteristics of Parkinson’s disease patients versus controls.   
Parkinson's disease (n=40) Control Group (n=40) 
 Mean SD Range  Mean SD Range t-vlaue p-level 
NART
1
 109.05 [10.13] 87-131  111.20 [10.30] 90-128 0.94 >0.30 
Education
2
 13.94 [2.56] 11-22  13.76 [2.57] 8-20 0.30 >0.75 
Age 66.15 [6.65] 52-77  66.58 [5.47] 52-76 0.31 >0.75 
MMSE
3
 28.65 [1.42] 25-30  29.58 [0.71] 28-30 3.67 <0.001* 
BDI-II
4
 7.59
 [4.34] 0-16  4.13 [3.39] 0-15 -3.96 <0.001* 
 
1
National Adult Reading Test, 
2
Total number of years formal education, 
3
Mini Mental Status 
Exam, 
4
Beck Depression Inventory, * significant at p<0.05 
 
 
Table 13: Group characterstics for Parkinson’s disease patients.   
 Mean SD Range    
PD onset
1
 6.49 [4.35] 0.25-23    
UPDRS
2
 28.46 [9.49] 13-49    
H&Y
3
 Level 1 Level 1.5 Level 2 Level 2.5 Level 3 Level 4 
 (n=8) (n=6) (n=7) (n=10) (n=7) (n=2) 
 1
Number of years since onset of Parkinson’s disease symptoms, 
2
Unified Parkinson’s disease Rating 
Scale (motor score component), 
3
Hohen & Yahr stage 
 
 79 
2.2.2 Procedure  
All participants were asked to attend three testing sessions, each lasting an 
average of three hours.  Testing sessions were scheduled one week apart.  However, 
due to other commitments of the participants on some occasions this was not possible 
and in these cases sessions were scheduled at slightly longer or shorter intervals.   
Session 1:  
At the beginning of the first visit, the study objectives were explained to the 
participant and consent forms were signed (See Appendix XVIII).  During this session 
general background information was collected, this included demographic details, 
educational history, alcohol and drug use, medications that were being taken and 
ethnicity data.  Information regarding current mental status and general past and 
present cognitive functioning was also collected.  For PD patients only, information 
regarding severity of illness was assessed (using the unified Parkinson’s disease 
Rating Scale, The Modified Schwab and England Activities of Daily Living Scale and 
the Modified Hoehn and Yahr scale).   
During this session participants completed self report questionnaires regarding 
their mood.  If any participant scored ≥ 14 BDI-II or ≥ 9 on the GDS they were given 
an information sheet regarding the implications of low mood.  They were also asked 
to consent to the researcher contacting their general practitioner so that the participant 
could be provided with further advice (see Appendix XIX and XX for these 
information sheets).  If any participant indicated that they had suicidal ideation or if 
they scored ≥ 19 on the BDI-II or ≥ 15 on the GDS then, as a further safety measure a 
full depression screen was conducted by a registered clinical psychologist.   
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At the end of the first session, participants were asked to take home a selection 
of standard self-report questionnaires to fill in and return at the next visit.  Also, if the 
participant consented, collateral information regarding the participants daily 
functioning was collected from an individual, volunteered by the participant, who 
knew the participant well (See Appendix XXI for consent form).  For individuals with 
PD, interviews with the significant other person were conducted by a trained research 
assistant and took place in an adjoining room while the participant was engaged in the 
second or third testing session.  For individuals acting as controls, information for 
significant others to complete was sent home with the participant and bought back at 
the next session.  See Table 14 for order of test presentation, and Table 15 for a list of 
tests conducted with significant others and tests completed by participants at home.   
Sessions 2 & 3:  
Sessions two and three included more specific memory, language and 
planning measures.  At the end of session two, participants were again asked to take 
home a selection of standard self report questionnaires to fill in and return at the next 
session.  At the end of session three participants were asked if they would consent to 
being contacted for a follow up study.  See Table 14 for the order of test presentation 
for sessions two and three.   
To minimise fatigue, testing in each session was arranged to enable 
unscheduled breaks to be taken as required.  To enable this flexibility, tests were also 
selected with brevity in mind and were a maximum of 20 minutes in duration, with 
the majority taking between 10-15 minutes to complete.  There was also one 
compulsory 20 minute break in each session during which the participants were 
provided either a morning or afternoon tea.  All participants were reimbursed $20 
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towards transport costs for each visit, or if required, the cost of a taxi within the 
Christchurch region.  Approximately six months following the completion of the main 
study, a brief outline of information regarding the outcomes were sent to participants 
(see Appendix XXII for copy).  
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Table 15: Tests completed by significant others and additional questionnaires 
completed by participants at home.   
Completed by significant other 
 Functional Activities Questionnaire 
 The Dysexecutive Questionnaire (DEX) 
 Frontal Systems Behaviour Scale (FrSBe) 
 Neuropsychiatric Inventory (PD patients only) 
 The Clinician Assessment of Fluctuation and the One Day Fluctuation 
Assessment Scale (PD patients only) 
Completed by participant for homework 
 DEX (self report) 
 HADS 
 Apathy Scale 
 Fatigue Questionnaire Scale 
 The Parkinson’s Disease Questionnaire (PDQ-39) 
(PD patients only) 
 
2.3 Study Two - Developing Cognitive Measures for Parkinson’s Disease   
2.3.1 Participants   
Participants were approached for retesting on average one year following the 
main study (The minimum period of follow up was 9 months and the maximum of 16 
months).  Participants who had given consent (39/40 people with PD and 40/40 of the 
healthy controls had consented at the end of first phase of testing) were first contacted 
by phone to ascertain whether they were still willing to participate in the second study, 
and if willing, given details of the studies objectives.  Participants were then sent an 
information sheet (see Appendix XXIII for copies of the information sheet used for 
both PD patients and controls).  The study received approval from the Canterbury Ethic 
Committee (see Appendix XXIV for copy of ethics approval).   
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Of the 39 patients who consented to being re-contacted, 33 were available for 
testing at follow-up.  Of the six subjects that were unavailable; one was deceased; two 
had been hospitalised; one was out of the city during the testing period; one declined; 
and one was unable to be contacted.  Controls that were matches for the patients with 
PD were also contacted.  Of the people with PD that were not available for follow-up 2 
came from group 1, 1 came from group 2 and 4 came from group 3.  Parkinson’s 
patients who did not participate at time two tended to be older (mean 72.1 v 64.9, t=-
2.86, df=38, p<0.01) and had lower scores on the MMSE (mean 27.4 v 28.9, t=2.69, 
df=38, p<0.02).   
Demographic characteristics of the available participants and their matches are 
shown on Table 16 and 17.  Patients and controls were required to meet the original 
inclusion/exclusion criteria outlined in the main study with the exception that 
individuals with low mood were included in the analyses.  There were significantly 
more males in the PD group (PD 23 /32 [72.0%] v Control 10/32 [31.3%]) (χ2 (df,1) = 
10.57, p <0.01).   
Table 16: Group characteristics, Parkinson’s disease patients versus controls.   
 
 Parkinson's disease (n=32) Control Group (n=32) 
 
 Mean [SD] Range Mean [SD] Range  t-value  p-level  
 
NART
1
 109.13 [10.63] 87-131 111.00 [10.79] 90-127 0.70 >0.45 
Education (yrs)
2
 13.90 [2.88] 11-22 13.76 [2.57] 8-20 -0.31 >0.75 
Age 64.90 [6.66] 52-77 65.38 [5.09] 52-76 0.31 >0.75 
MMSE
3
 28.84 [1.2] 26-30 29.68 [0.59] 28-30 -3.46 <0.001* 
BDI-II
4
 9.06 [4.29] 0-21 4.47 [5.05] 0-24 -3.92 <0.001* 
 
1
National Adult Reading Test, 
2
Total number of years formal education, 
3
Mini Mental Status 
Exam,
4
Beck Depression Inventory. 
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Table 17: Group characteristics for Parkinson’s disease patients.   
 
 Mean SD Range 
PD onset
1
 6.38 [4.61] 0.25-23 
UPDRS
2
 27.84 [8.00] 14-46 
H&Y
3
 Level 1 Level 1.5 Level 2 Level 2.5 Level 3 Level 4 
 (n=3) (n=6) (n=6) (n=6) (n=10) (n=1) 
 
 
1
Number of years since onset of Parkinson’s disease symptoms, 
2
Unified Parkinson’s disease Rating Scale 
(motor score component), 
3
Hohen & Yahr stage 
 
2.3.2 Procedure   
Each participant was required to attend two testing sessions, each lasting an 
average of three hours.  Testing sessions were scheduled one week apart.  However, 
occasionally, due to other commitments of the participants it was not possible to 
organise sessions in this way and in these cases sessions were scheduled at slightly 
longer or shorter intervals (see Table 17 for the order of test presentation for sessions 
one and two).   
Session 1:  
At the beginning of the first visit, the study objectives were explained to the 
participant and consent forms were signed (See Appendix XXV, the same consent form 
was used for both PD patients and controls).  During this session general background 
information was collected including, alcohol and drug use and medications that were 
being taken, and information regarding medical history for the intervening period of 
time between the two study phases.  Also, additional information regarding 
hallucinations was collected (See Appendix XXVI for health check list used for both 
PD patients and Control participants and hallucination screening questions).  
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Information regarding current mental status was collected for all patients and for PD 
patients only; information regarding severity of illness was reassessed (using the 
Unified Parkinson’s disease Rating Scale, The Modified Schwab and England 
Activities of Daily Living Scale and the Modified Hoehn and Yahr scale).   
At the end of the first session, participants were asked to take home a selection 
of standard self-report questionnaires to fill in and return at the next visit.  Also, if the 
participant consented (See Appendix XXVII for consent form used for both PD and 
Control participants), collateral information regarding daily functioning was collected 
from an individual, who knew the participant well.  For individuals with PD, interviews 
with the significant other person were conducted by a trained research assistant and 
took place in an adjoining room while the participant was engaged in the second testing 
session.  For individuals acting as controls, information for significant others to 
complete was sent home with the participant and bought back at the next session.  See 
Table 18 for order of test presentation and Table 19 for a list of tests conducted with 
significant others and tests completed by participants at home.   
Session 2  
The tests used in session two were selected from the tests shown in the main 
study to identify the different groupings of PD patients and included measures of 
general memory and cognition and executive functioning.  Specific measures of 
decision making and planning were also included in this session.  At the end of session 
two, participants were asked if they would consent to being contacted by the principle 
researcher (A.M) for a follow up study (it was intended to follow the patients over time 
to determine the cognitive and psychiatric problems that were predicative of decline 
into dementia).   
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To minimise fatigue, testing in each session was arranged to enable unscheduled 
breaks to be taken as required.  To enable this flexibility, tests were also selected with 
brevity in mind, and were a maximum of 15 minutes in duration, with the majority 
taking less than 10 minutes to complete.  There was also one compulsory 15 minute 
break in each session during which the participants were provided either a morning or 
afternoon tea.  All participants were reimbursed $20 for each visit towards transport 
costs, or if required, the cost of a taxi within the Christchurch region.   
Table 18: Order of test presentation for each of the two testing sessions.   
Session One Session Two 
 Signing of consent forms  Digit span (WMS-III) 
 General Health questionnaire  * The Adaptive Digit ordering test 
 Mini Mental Status Exam  Daneman & Carpenter 
* Fragmented letters –Visual Object Space and 
Perception Battery (VOSP) 
* Memory for Temporal Word Ordering  
      Test Revised 
* Object decision (VOSP)  
 Matrix reasoning (WASI subtest)  Letter Fluency Test (D-KEFS) 
 FrSBe  Category Fluency Test (D-KEFS) 
 Tower of London Revised (TOL-R)  
BREAK BREAK 
 CLOX 1 & II  Paired Associates-I (WMS-III) 
* Continuous performance test  ROF-1 (copy only) 
* Gambling Task   Distraction task 2.5 mins 
 DRS-2  ROF-2 
 BDI-II * Planning task 
Patients with PD only  Line Orientation Test 
 UPDRS * Map Search (Test of everyday attention) 
 Modified Hohen & Yarh  Paired Associates-II (WMS-III) 
 Schwab and England Activities of Daily 
       Living Scale 
 
*Tests that were unique to phase two of the study.  
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Table 19: Tests completed by significant others and additional questionnaires 
completed by participants at home.   
Completed by significant other 
 Functional Activities Questionnaire 
 Frontal Systems Behaviour Scale (FrSBe) 
 Neuropsychiatric Inventory (PD patients only) 
 The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale 
(PD patients only) 
 Bristol Activities of Daily Living Scale (BADLS) 
 Short IQCODE 
Completed by participant for homework 
 Sleep Diary 
 The Parkinson’s Disease Questionnaire (PDQ-39) (PD patients only) 
 
2.3.3 Test Description  
Following is a brief description of tests that were used in the various testing 
sessions, significant other interviews and homework.  Tests are listed below in 
alphabetical order:   
1. Apathy scale (Starkstein et al., 1992): The Apathy scale is a 14 item self-report 
measure.  Participants were asked to indicate the extent to which each of 14 
statements would apply to them, over the last month, using a 4 point scale (not at 
all=0, slightly=1, some=2, a lot=3).  Low scores were indicative of higher levels 
of apathy.   
2. Bristol Activities of Daily Living Scale: (BADLS) (Bucks, Ashworth, Wilcock, & 
Siegfried, 1996): Completed by a care giver, the BADLS is designed to assess the 
everyday ability of people who have memory difficulties.  The caregiver was 
required to assess the “significant other” on their ability in 20 different areas of 
daily living including food preparation, dressing ability or ability to perform tasks 
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of daily hygiene.  Each activity is rated 1-3 with higher scores indicating greater 
impairment.  If the caregiver had difficulty with any of the questions they were 
asked to rate the person using the level of ability which was most indicative of 
their average performance over the previous 2 weeks.  The scale also has a “not 
applicable” option, rated as 0.  For the purposes of this study an additional option 
was added of “due to Parkinson’s symptoms”, also rated as 0.   
3. Beck Depression Inventory-Second Edition (BDI-II) (Beck, Steer, & Brown, 1996): 
The BDI-II is a brief 21 item self report questionnaire that assesses an 
individual’s mood over the previous two week period.  Each item was rated on a 
4 point scale from 0-3.  Higher scores indicated the presence of a greater number 
of depressive symptoms.  Suggested cut offs are 0-13 for normal/minimal 
depressive symptoms, 14-19 mild, 20-28 moderate and 29-69 severe depression 
(Beck, Steer, & Brown, 1996).  A cut score of 16/17 has been suggested as most 
appropriate for identifying individuals with PD who have depression (Leentjens, 
Verhey, Luijckx, & Troost, 2000), and a score of >16 was adopted in this study 
as part of the exclusion criteria.   
4. Behavioural Assessment of the Dysexecutive Syndrome (BADS): Two subtests from 
this battery were used, the Zoo Map and Key Search.  Specific details regarding 
scoring are provided in the test manual (Wilson, Alderman, Burgess, Emslie, & 
Evan, 1996).  A self report questionnaire was also used from this test battery.   
• Zoo Map: This subtest is made up of two tasks.  In task A, the “high demand 
trial”, participants were presented with an A4 piece of paper on which there was 
a map of a zoo.  Twelve different locations were shown on the map, with the 
participants being required to visit six designated locations.  However, the task 
had a number of rules that the participant had to consider when planning their 
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route.  Participants were required to plan and then show how they would visit 
each of designated places without breaking any of the rules.  Instructions were 
provided verbally by the examiner, with a visual reminder of the locations that 
were required to be visited and the rules for the task, available at the top of the 
page above the map.  In task B, the “low demand trial”, participants were 
presented with a map of the zoo identical to, and using the same rules, as task 
A.  However, in task B participants were not required to plan their route around 
the zoo; they were only required to follow the instructions provided verbally 
and visually at the top of the page.  Points were deducted for rule violations, 
incorrect sequences for visiting the designated locations and time spent 
planning.  Scores for each version range from 0-16, with higher scores 
indicating better performance.  Scores for task A and B were combined and 
converted to a profile score that ranged from 0-4, with higher scores indicating 
better performance.   
• Key Search Test: Participants were presented with an A4 piece of paper on which 
there was a 10cm square and a black dot 5 cm below the square.  Participants 
were told to imagine that the square was a field in which they had lost their 
keys.  Starting at the black dot, they were to draw a line to show how they 
would search the field to make absolutely certain that they would find their 
keys.  The test was scored according to different components of the task and 
included: where the participant entered the field, where the participant finished 
the search, whether the line was continuous or broken and the type of search 
pattern (templates of possible search patterns are provided in the manual).  Raw 
scores range from 0-16, with higher scores indicating better performance.  Raw 
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scores were converted to a profile score that ranges from 0-4 with higher scores 
indicating better performance.   
• Dysexecutive Questionnaire (DEX): The DEX is a 20 item self report 
questionnaire that assesses symptoms associated with executive impairment.  
Questionnaire items cover three domains of functioning: behaviour, cognition, 
and emotion.  There are two forms of the DEX.  The first was completed by the 
participant and a second form was completed by a person who knew the 
participant well.  The DEX contains 20 items rated on a 5 point scale (0 = never 
and 5 = very often) with higher scores indicating greater impairment.   
5. Cambridge Neuropsychological Test Automated Battery (CANTAB): The CANTAB 
provides a computerised series of tasks using a touch screen.  The measures 
described here have formed the basis of numerous publications and further details 
regarding the different tasks and procedures used may be gained from these 
publications (Morris et al., 1988; Owen, Downes, Sahakian, Polkey, & Robbins, 
1990; Owen, Doyon, Dagher, Sadikot, & Evans, 1998; Owen et al., 1993b).   
• Motor screen: This task was used prior to the presentation of the CANTAB tasks 
to familiarise participants with the touch screen.  In this task a series of crosses 
were presented in different locations on the screen.  The participant was required 
to touch each cross when they appeared as quickly as they could.   
• Stockings of Cambridge (SOC’s ): Based on the Tower of Hanoi (Shallice, 1982), 
the SOC’s is considered to be a spatial planning task, requiring the formulation 
and execution of a series of sub-goals to complete simple problems.  In this task 
the participant was shown two displays of three coloured balls, one in the top 
half of the screen and the other in the bottom half of the screen.   
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 The balls were held in pockets or stockings, suspended from a line.  Each pocket 
was a different size, one could hold only 1 ball, another a maximum of 2 balls 
and the third held a maximum of 3 balls (see above diagram which is an example 
from the CANTAB program).  The participant was required to rearrange the 
balls in the bottom half of the screen to match the arrangement of the colored 
balls in the top half of the screen.  A touch sensitive screen enabled the balls to 
be moved by the participant who selected the desired ball by touching the image 
of the ball on the screen and then touching an empty pocket space where they 
wanted to place the ball.  The task started with a number of practice problems to 
familiarise the participant with the task (four 1 move problems and two 2 move 
problems).  Individual problems were discontinued if the participant was unable 
to reach the solution in double the minimum number of moves plus one.  There 
were a total of 12 problems that varied from two to five moves for a solution.  If 
a participant was unable to solve three consecutive problems in the minimum 
number of moves, the task was discontinued.  To gain a measure of movement 
speed, the computer replayed the solutions made by participant one move at a 
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time, and the participant was required to copy the replayed moves.  This 
occurred after the first six problems, and again at the end of the task.  Correctly 
completed solutions were measured in terms of problems completed in the 
minimum number of moves, the number of moves required to complete a 
problem, time taken to plan the solution and time taken to execute the solution.   
• Spatial Span: The CANTAB spatial span task is a computerised version of the 
Corsi Block tapping task (Milner, 1971).  In this task a pattern of white boxes 
appeared on the screen.  Some of the boxes changed colour for a brief period to 
indicate a sequence.  The participant was required to remember which boxes 
changed colour as well as the order in which they changed colour.  After a brief 
delay, the participant was required to touch the boxes in the same order that they 
changed colour.  Sequences varied in length from 2 to 9 boxes.  If the participant 
failed to remember the sequence correctly, another trial at that level was given.  
If the participant failed to remember the correct sequence on three trials at the 
same level, the task was discontinued.  Spatial span was determined by the 
longest sequence correctly remember by the participant.   
• Spatial Working Memory: Participants were required to find a blue token hidden 
in a group of boxes without looking in a box more than once.  Boxes were 
opened by touching each one so that it revealed its contents.  Once the token was 
found, the participant used it to fill an empty column on the side of the screen.  
Then a new token was hidden in a different box and the participant searched 
again.  The process was repeated until all the boxes had been used to hide the 
token and the column at the side of the screen was filled.  There were 4 practice 
trials, each with 3 boxes, and then the test trials that included four trials each 
with 4, 6, and 8 boxes.  An overall score was reported for each trial set, and the 
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total number of empty boxes visited before the blue token was found.  In 
addition, two types of search errors were reported: if the participant returned to a 
box that had already been used to hide the blue token (a between search error), 
or if a participant returned to a box that had already been shown to be empty in 
the same search sequence (a within search error).   
• Inter Dimensional/ Extra Dimensional Shift (ID/ED): This task was 
completed in two phases.  During Inter Dimentional phase the participant 
was required to attend to specific attributes of a dimension presented on the 
screen and to shift attention to different attributes of the stimuli when 
required.  Two dimensions were used, filled colored shapes and white lines 
(see picture below).   
 
To begin with, two stimuli were presented on the screen, and the participant 
had to determine which was correct and which was incorrect and respond by 
touching the computer screen.  After each response, the participant was given 
feedback to tell them whether their response was correct or incorrect.  After 
six correct responses the stimulus and/or rules were changed.  The term 
interdimensional was used to indicate that during this stage of the task the 
color filled shapes were the only relevant dimension.  During the Extra 
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Dimensional phase (ED), the participant was required to stop attending to the 
previously correct dimension and respond to a dimension that was previously 
irrelevant.  Therefore, instead of the color filled shapes being relevant, the 
white lines now become the dimension that needed to be attended to.  The test 
was discontinued if the participant failed to meet the stage criterion after 50 
trials.  There were nine stages in total, and the ID/ED was scored according to 
stages completed and the number of trials taken to complete a stage, with 
higher scores indicating greater impairment.   
6. CLOX (Royall, Cordes, & Polk, 1998): The CLOX is a brief drawing task that 
assesses visuospatial/executive skills and is frequently used to screen for 
dementia (Royall, Cordes, & Polk, 1998).  The test was administered in two 
stages, an unprompted stage and a copy stage.  In the unprompted stage, the 
participant was given a blank piece of paper and instructed: “Draw me a clock 
that indicates 1:45.  Set the hands and numbers on the face so that a child 
could read them.” The copy stage required the participant to reproduce a clock 
that was first drawn by the examiner.  Each stage of CLOX was scored from 
0-15, with lower scores reflecting greater impairment (Royall, Cordes, & 
Polk, 1998).  A cut off of 10 was used to distinguish normal elderly from 
those suffering from Alzheimer’s disease (Royall, Mulroy, Chiodo, & Polk, 
1999).  A recent review of studies using the CLOX reported a high inter-rater 
reliability and sensitivity and specificity, and has also been reported as 
correlating highly with the MMSE (Shulman, 2000).   
7. Continuous Performance Test adapted from (Adapted from Conner, 1995): This task 
was used to assess sustained attention.  Stimuli for this test were computer 
generated.  The participant was presented with a random series of letters on a 
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screen at varying inter-stimulus intervals of 2, 3 or 4 seconds.  Each letter was 
displayed for 2 seconds.  Participants were required to respond to each letter as 
quickly as possible by pushing the space bar.  However, there was an exception to 
this rule; participants were told not to push the space bar when letter X appeared.  
The task was 4 minutes in duration.  Two scores were generated using this task, 
the number of correct responses and the number of incorrect responses generated 
within each 1 minute period.   
8. Daneman Carpenter Reading Span Test (Daneman & Carpenter, 1980): This test was 
used to assess the participant’s verbal working memory (Waters & Caplan, 
1996b) and involved the presentation of sets of 2 - 6 sentences, each consisting of 
8 to 13 words.  Testing began with sequences of two sentences, with there being 
60 sentences in total.  Participants were asked to read each sentence out loud, 
judge the veracity of the statement, and remember the last word in each sentence.  
At the end of each set the participant was asked to recall as many of the last 
words as possible.  The reading span was the maximum sentence set remembered 
with over 66% accuracy (two out of three trials correctly recalled).  The test is 
discontinued if the participant was unable to remember the last word from any of 
the sentences in a given trial.   
9. Delis Kaplan Executive Functioning System (D-KEFS) (Delis, Kaplan, & Kramer, 
2001): The D-KEFS provides a battery of standardised tests designed to measure 
verbal and non-verbal executive functions.  Five of the nine sub-tests were 
selected for use in this study.  All sub-tests were administered according to 
standardised procedures outlined in the administration manual.  For each subtest, 
raw scores were converted to age corrected scaled scores (mean = 10 and SD=3).   
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• Card Sort: This was used to assess the participants problem solving ability and 
consisted of two conditions: a free sorting condition and sort recognition.  In the 
first phase, the free sorting condition, participants were required to sort a set of 
6 cards that had both perceptual features and printed words, into two groups, 
with three cards per group.  Participants were required to generate as many 
different groups as possible using a different rule or concept for each sort.  
There were eight possible sorts.  However, no feedback was given as to whether 
the sort was correct or incorrect.  In the second phase, sorting recognition, the 
examiner arranged the cards into two groups, with three cards in each group, 
using the eight correct sorts from phase one.  At the end of each sort the 
participant was required to describe the sorting rules that the examiner had 
used.   
• Verbal Fluency: Designed to test an individuals’ speed and ease of verbal 
speech, this test consists of three conditions, Letter Fluency, Category Fluency, 
and Category Switching.  Letter Fluency required the participant to generate as 
many different words beginning with a given letter, excluding proper nouns, 
numbers and repetitions.  Participants were given 60 seconds for each of three 
letters, F, A and S.  In Category Fluency the participant was required to produce 
as many words as possible associated with a particular semantic category 
(animals and boys names were used in this study).  The participant was given 
60 seconds for each category.  The third condition, category switching, required 
the participant to switch between two semantic categories (Fruits and furniture 
were used in this study).  Production of words for each condition was measured 
in 15 second intervals in terms of the number of words correctly generated, 
preservations, and the ability to stay with the required category.   
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• Design Fluency: This test was originally developed as a non verbal equivalent to 
verbal fluency tasks.  For this task the participant was presented with an array 
of boxes each containing 5 dots that they were required to connect, using only 
four lines, while making a different design each time.  Each line had to be 
connected to at least one other line at a dot.  For each of three conditions, Filled 
dots, Empty dots only and Switching, the participant was required to generate 
as many different designs as possible in a 60 second period.  For the filled dots 
condition, each of the response boxes contains just 5 dots.  The participant was 
asked to make as many different designs using just four lines to connect the 
dots.  In the Empty dot condition, each response box had five filled dots and 
five empty dots, and the participant was asked to make as many different 
designs as possible using only four lines and only connecting the empty dots 
while ignoring the filled dots.  In the final condition, Switching, each response 
box has five filled dots and five empty dots, and the participant was asked to 
make as many different designs as possible using just four lines and switching 
between an empty dot and a filled dot.   
• Tower Test: This test has traditionally been used to assess problem solving skills 
associated with frontal deficits (Shallice, 1982).  The D-KEFS tower test 
consists of five disks which vary in size from large to small, and a board with 
three vertical pegs of equal size (see picture below).  For each of the nine 
problems, the participant was presented with an example of the tower to be built 
and two to five disks on the board in a predetermined starting position, 
depending on the level of difficulty of the tower.  Participants were then told to 
move the disks on the board to look exactly like the tower in the picture.  
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They were asked to plan their moves prior to starting while observing two rules; 
never place a larger disk on top of a smaller disk and only move one disk at a 
time.  Each problem was scored in terms of whether the participant was able to 
complete the tower, the number of moves made to complete the tower and time 
taken (bonus points were given for faster completion times).  The task was 
discontinued after failure to complete three consecutive towers in the allotted 
time.   
• Color-Word Interference Test: This test measured the individuals’ ability to 
inhibit automatic verbal responses.  Participants were required to respond to 
four separate conditions.  In the first condition, the participant was presented 
with a page that had rows of coloured patches that they were required to name, 
and in the second condition they are presented with a page with rows of words 
that they were required to read.  The third condition is the traditional “stroop 
effect” where the participants’ were presented with a page of words printed in 
dissonant ink colours.  Participants were asked to name the colour of the ink 
that the letters are printed in rather than reading the word.  In the fourth and 
final condition, participants were presented with a page with rows of words, 
again printed in dissonant ink colours, but in this condition some of the words 
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are in boxes.  The participant was required to name the colour of the ink for the 
words that are not in boxes, and read the word if the word is inside a box.  For 
each condition participants were required to name the colours or read the words 
as quickly as possible without skipping any or making any mistakes.   
10. Dementia Rating Scale-2 (DRS-2) (Jurica, 2001): The DRS-2 is brief screen of 
impaired cognitive functioning, consisting of 36 tasks and five subscales.  The 
five subscales provide information on specific abilities and include: 1. Attention; 
2. Initiation/Perseveration; 3. Construction ability; 4. Conceptualisation; and 5. 
Memory.  Based on normative data, raw scores from each subscale were summed 
to provide an over all score (scaled scores for each sub-scale range from 2-18, 
with higher scores indicating better performance).  A combined scaled score was 
then generated adjusted for age and education using a regression formula 
provided in the administration manual (Jurica, 2001).  This scale has been shown 
to differentiate between cognitive deficits in PD patients and healthy controls 
(Brown et al., 1999).   
11. Digit Symbol Coding/Motor Copying (WAIS-III) (Wechsler, 1997): In this task 
participants were given an A4 sheet of paper.  At the top of the page was a key 
consisting of nine boxes with a digit at the top of each box and a symbol at the 
bottom.  Below these were lines of boxes with a digit at the top and an empty 
space at the bottom.  Participants were given 180 seconds to accurately fill in as 
many empty spaces as possible by drawing the symbol in the bottom of the box 
that was associated with number at the top of the box using the examples from the 
top of the page.  There were 133 boxes in the test.  Each correct response was 
scored 1, and one point is deducted for every incorrect response.  Raw scores 
  101 
were converted to T-scores for all subtests, and are converted to age adjusted 
scores (mean=100; SD=15).   
12. Fatigue Severity Scale (Krupp, LaRocca, Muir-Nash, & Steinberg, 1989): Based on 
the fatigue severity scale suggested by (Krupp, LaRocca, Muir-Nash, & 
Steinberg, 1989), this self-report questionnaire consists of 9 items relating to 
fatigue.  Participants answer each of the items using a 7 point scale where 1 
indicates strongly disagree and 7 strongly agree.  For this study, participants were 
required to answer the nine questions, firstly in relation to mental fatigue, and 
then answer the same nine questions in relation to physical fatigue.  Scores from 
the two scales were combined and ranged from 18-126, with higher scores 
indicating that the participant experienced higher levels of fatigue.   
13. Frontal Systems Behaviour Scale (FrSBe) (Grace & Malloy, 2001): The FrSBe 
provides a measure of three areas of behavioural functioning: apathy, 
disinhibition and executive functioning.  The test was a self report measure 
consisting of 46 questions describing possible behaviours, with each question 
being answered using a 5 point scale (1 = almost never and 5 = almost always).  
There was also a family rating form that enabled collateral information to be 
gathered from a person who knew the participant well.  Each question was 
answered in terms of how the participant was “at the present time” and how they 
were “before illness or injury”.  Participants with PD were required to fill in both 
parts of the form, whereas controls were only required to fill in the questions 
relating to their current functioning.  Raw scores were converted to age, gender 
and education adjusted T-scores (mean =50; SD=10).  Detailed scoring is 
provided in the administration manual (Grace & Malloy, 2001).  The 
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questionnaire has been reported to have good construct validity (Stout, Ready, 
Grace, Malloy, & Paulsen, 2003).   
14. Functional Activities Questionnaire (FAQ) (Pfeffer, Kurosaki, Harrah, Chance, & 
Filos, 1982): The FAQ was designed to assess older adults on a set of complex 
higher order functional abilities.  The questionnaire was completed by someone 
who knew the individual well.  The informant was required to rate the 
participants ability to do each of the 10 tasks listed by ticking the box for the 
word or phrase that applies best using a 4 point scale (dependent = 3, requires 
assistance = 2, has difficulty but does by self = 1, no difficulty = 0).  A total score 
for the FAQ was obtained by summing the scores across the 10 items.  A score of 
3 or “dependent” on three or more items is recommended as a cut-off for 
dementia (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982).  The scale has high 
sensitivity (0.85) and specificity (0.81) for distinguishing between demented and 
non-demented individuals (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982).   
15. Gambling Task (Bechara, Damasio, Damasio, & Anderson, 1994; Bechara, 
Damasio, Tranel, & Damasio, 1997): The Gambling task is considered to 
simulate real-life decision making.  In this computer generated task 
participants were presented with four decks of cards, labelled A, B, C, and D.  
The order of cards was predetermined and each deck had a different schedule 
of rewards and punishment.  Participants were required to select a card, from 
any deck, by clicking on it to reveal either a reward (increase in money) or 
punishment (decrease in money) with the instruction to win as much money as 
possible, or to avoid losing as much as possible.  A green bar at the top of the 
screen indicated how much the participant had won.  Participants began the 
game with a $2000.00 credit.  Overall, decks A and B were disadvantageous 
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(large gains but bigger losses) and decks C and D were advantageous (small 
gains but smaller losses).  Most people learn this pattern of wins and losses 
after approximantely 40-50 selections.  However, research indicates that 
patients with orbito frontal cortex lesions (also implicated in PD) tend to 
perseverate with bad decks (Bechara, Damasio, Damasio, & Anderson, 1994).  
There were 60 cards in each deck, and participants were required to continue 
playing until a total of 100 cards had been used.  Scores were calculated by 
the number of advantageous choices (C+D) minus disadvantageous choices 
(A+B) over the 5 blocks of 20 cards, and for the total 100 cards.   
16. General Health and Demographic screen: In addition to demographic data, 
specific questions regarding the particpants’ health history were gathered.  
The general health questionnaire included questions related to the 
inclusion/exclusion criteria, years of education, caffeine use and alcohol and 
drug use.   
17. Geriatric Depression Scale (GDS) (Yesavage et al., 1982): The GDS is a self report 
scale used to screen for possible depression in a normal older population.  This 
scale is considered as more appropriate for use with older populations as it does 
not contain questions pertaining to somatic symptoms.  The scale consists of 30 
yes/no items that assess an individual’s mood over the previous one week period.  
Items are scored as present or absent (0 = absent; 1= present) with total scores 
ranging from 0-30.  A score of 0-9 is considered normal, 11-20 mild to moderate 
depression and over 20 indicative of severe depression (Brink & et al., 1982).  
This scale has been validated for use with PD patients (Ertan, Ertan, Kizilatan, & 
Uygucgil, 2005).   
  104 
18. Hospital Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983): The 
HADS is a brief 14 item self report measure of anxiety (7 items) and depression 
(7 items).  It was developed for use with medical patients and is sensitive to mild 
disturbances in mood, without relying on somatic symptoms (Herrmann, 1997).  
Participants were asked to rate how they had been feeling in the past week using a 
4 point scale (0-3) for both anxiety, and depression scales.  The following 
recommended cut-offs were used, mild = 8-10, moderate = 11-15, and severe = 
16 or above.   
19. Judgement of Line Orientation (JOL) (Benton, Varney, & Hamsher, 1978): 
Judgement of Line Orientation test is frequently used to assess visuospatial 
function.  Participants were presented with a booklet containing a series of card 
pairs.  One of the card pairs, the response card, was displayed on the bottom of 
the page and contained an array of 11 numbered lines (3.8cm in length) each 
separated by an angle of 18 degrees (see picture below).  
 
The stimulus card was on the top page and displayed two lines at different angles 
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(3.8cm for practice items and 1.9cm in length for test items).  The participant was 
asked to identify the orientation of two lines on the bottom card by identifying the 
two lines with the same orientation from the 11 line array (see above drawings 
(A) and (B) for examples).  Each participant was presented with 5 practice items 
and 30 test items.  Responses for each line pair are scored 0 for an incorrect 
response and 1 for a correct response.   
20. Memory for Temporal Word Order-Time One (Shimamura, Janowsky, & Squire, 
1990): This test consisted of 15 single syllable words printed individually on 
cards (5.5cm x 12.5cm).  The participant was instructed to read aloud each word, 
presented to them by the examiner at the rate of 1 per second, and remember the 
sequence in which they occurred.  After a 10 second delay, using a duplicate set 
of cards, the participants were presented with an array of the same words in a 
different order and asked to place the words in the same order as the first list.  
The ability to remember the sequence in which the cards originally appeared is 
scored for each participant using Spearman rank order correlation (Shimamura, 
Janowsky, & Squire, 1990).  A higher correlation indicates greater accuracy in 
remembering the word order (100% accuracy = +1.0).   
21. Memory for Temporal Word Order Revised (Shimamura, Janowsky, & Squire, 1990): 
This test is identical to the Memory for Temporal Word Order test administered 
at time one.  However, the number of test stimuli was reduced to eight words to 
over come the floor effects that were evident for older individuals during the first 
testing session.   
22. Mini Mental Status Exam (MMSE)/Modified MMSE (3MS) (Folstein, Folstein, & 
McHugh, 1975; Tombaugh, McDowell, Kristjansson, & Hubley, 1996):  The 
MMSE is a brief objective screening instrument for the assessment of current 
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cognitive status, consisting of items that test an individual’s orientation to time 
and place (10 points), registration, attention and short-term memory (11 points) 
and language (9 points).  Items were scored as correct or incorrect.  Scores ranged 
from 0-30, with lower scores indicating greater impairment.  A variety of cut offs 
have been suggested for this instrument, but scores below 23-24 have been 
reported as having high sensitivity and specificity in identifying individuals with 
dementia (O'Connor et al., 1989).  For this study, a score of ≥ 25 was defined as 
“no signs of overt dementia” as part of the initial exclusion criteria.  The 
additional 4 categories (date and place of birth, word fluency, similarities, 
delayed recall of words) used in the 3MS were also administered and scored 
according to standard guidelines (Teng & Chui, 1987).  Scores for the 3MS range 
from 0-100 with lower scores indicating greater deficits.  A cut off score of <78 is 
considered sensitive for detecting early signs of Alzheimer’s disease (Tombaugh, 
2005).   
23. Modified Hoehn and Yahr (Hoehn & Yahr, 1967):  The modified Hoehn and Yahr 
scale is a widely used descriptive staging scale for PD patients.  This scale 
requires direct examination of the patient.  A numeric rating of 0-5 is used to 
represent increasing severity of symptoms, where 0 represents no sign of the 
disease and 5 represents wheel chair bound or bedridden unless aided.  In this 
study, the modified version of this scale which uses increments of 0.5 in the 
midranges was used.  It has been reported that the progression on the Hoehn and 
Yahr scale correlates well with motor decline, making it a useful measure for 
defining inclusion/exclusion, and has been reported as having good validity and 
reliability (Ramaker, Marinus, Stiggelbout, & Van Hilten, 2002).   
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24. Motor Copying (WAIS-III) (Wechsler, 1997): This task is used in conjunction with the 
Digit Symbol Coding task (see test 11) and follows a similar format.  Participants 
were presented with an array of boxes on a page.  In the top of each box was a 
symbol which the participant was required to copy in the empty space at the 
bottom of the box.  Each correct response was scored 1, and 1 point is deducted 
for every incorrect response.  The total score was then be subtracted from the 
Digit Symbol Coding score to provide an overall score for processing speed that 
was corrected for motor speed.   
25. National Adult Reading Test (NART): This test provides a brief estimate of full-scale 
IQ and comprises of a list of 50 “irregular” words (e.g Psalm) printed in order of 
increasing difficulty.  The words are “irregular” in terms of their pronunciation to 
minimise the possibility of reading by phonemic decoding rather than word 
recognition.  Words are scored 0 for incorrect pronunciation and 1 for correct 
pronunciation.  Raw scores are then converted to estimated premorbid IQ scores 
(instruction on how to calculate these transformations are contained in the 
instruction manual) (Nelson & Willison, 1991).  Correlations between NART IQ 
scores and more comprehensive batteries used to assess intelligence such as the 
WAIS and WAIS-R, are between 0.72 -0.81 (Lezak, 1995).   
26. Neuropsychiatric Inventory (NPI) (Cummings et al., 1994): The NPI is based on a 
structured interview with a caregiver who knows the patient well, and is designed 
to assess psychopathology associated with dementia.  The interview covers 12 
different areas of behavioural functioning: 1. delusions, 2. hallucinations, 
3.Agitation, 4. depression, 5. anxiety, 6. euphoria, 7. apathy, 8. irritability, 9. 
disinhibition, 10. aberrant motor behaviour, 11. night-time behaviour and 12. 
appetite/eating change.  Each question addresses changes in the person’s 
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behaviour since the onset of the illness.  The caregiver is first asked whether the 
behavioural change is present or absent.  If it is absent the interviewer continues 
to the next question.  If the behaviour change is present, the interviewer asks 
about the frequency (1 = occasionally - less than once per week, 2 = often-about 
once per week, 3 = frequently-several times per week but less than everyday, 4 = 
very frequently – daily or essentially continuously present) and severity (1 = mild 
– produces little distress in the patient, 2 = moderate – more disturbing to the 
patient but can be redirected by the caregiver, 3 = severe – very disturbing to the 
patient and difficult to redirect) of the behaviour.  Each domain is also scored in 
terms of how emotionally distressing the caregiver finds the behaviour (0 = no 
distress, 1 = minimal, 2 = mild, 3 = moderate, 4 = moderately severe, 5 = very 
severe or extreme).  Four scores were generated for each domain, frequency, 
severity, total (frequency x severity) and caregiver distress.  The scale has been 
reported to have good content and concurrent validity and inter-rater reliability 
(Cummings, 1997).   
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27. Rey Osterrieth Complex Figure Test (ROF) (Lezak, 1995): This test assesses a 
number of skills including planning, organisation and visuoconstructional ability 
and memory.  The participant was first asked to copy a complex figure (the Rey 
figure was used in this study, see above drawing) as carefully as possible.  Then 
after a 2½ minute delay and again after a 30 minute delay, without prior warning, 
participants were asked to reproduce the figure from memory.  Each of the three 
figures produced is scored separately on 18 different scoring units.  Each unit 
receives a score between 0-2 and is considered both in terms of accuracy and 
position relative to the whole design.  Total scores range from 0-36.  This test has 
previously been reported as sensitive to deficits in PD (Freeman et al., 2000).   
28. Test of Everyday Attention (TEA) Map Search (Robertson, Ward, Ridgeway, & al., 
1994): The map search is one sub-test of the TEA and is a visual search task 
which assesses visual selective attention.  Participants were presented with a map 
that had a number of different symbols (target symbols and distracter symbols) 
and were required to ring as many target symbols as possible in a two minute 
period.  On the desk beside the participant was a cue to remind them which 
symbol they were searching for.  After one minute participants were required to 
switch pens to enable a score for one minute to be obtained as well as a total 
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score.  Each correctly circled symbol was scored with a 1 and raw scores were 
then converted to age adjusted percentile score as outlined in the test manual 
(Robertson, Ward, Ridgeway, & al., 1994).   
29. Test of Language Competence- Expanded Edition (TLC-E): The TLC-E level two 
assesses higher order language functioning.  Explicit scoring instructions for this 
test are provided in the test manual (Wig & Secord, 1989).  Four areas of 
language competence were assessed and included:   
• Ambiguous Sentences: Participants were first read an ambiguous sentence that 
was then displayed in print.  For example “I saw the girl take his picture”.  They 
were then asked to provide two correct meanings for the sentence.  A total of 15 
sentences are presented, two trial sentences and 13 test sentences.  A score of 0 
was given for no correct responses, 1 for one correct response, and 3 when the 
participant identified both correct responses.   
• Listening Comprehension (making inferences): For the second sub-test 
participants were first read a scenario that is displayed in print.  For example, 
“Eric had wanted a moped for the longest time.  He sure was grateful for his 
Uncle Fred.  Eric was grateful for Uncle Fred because…”.  Participants were 
then read four statements, provided in print at the bottom of the page, and asked 
to select two plausible inferences for the scenario.  A total of 13 sentences were 
presented in this manner (one trial sentence and 12 test sentences).  A score of 0 
was given for no correct responses, 1 for one correct response, and 3 if the 
participant identified both correct responses.   
• Oral Expression (recreating sentences): For the third sub-test participants were 
presented a picture of a scene and read a sentence.  At the top of the picture were 
three words.  The participant was required to create an appropriate sentence that 
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could be used in the situation using all three words.  Two trial sentences and 13 
test sentences were presented.  All responses were recorded verbatim and were 
scored for inclusion of target words, 0 for one or no target word, 1 for any two 
words, and 3 points for all three words.  Sentences were also scored in terms 
being semantically, syntactically and pragmatically correct.  Intact sentences 
were given a score of 3 points, sentences with minor deviations 1 point, and 0 
points allocated for major deviations that result in nonsensical, “bizarre” or 
fragmented sentences.   
• Figurative Language: This sub-test is made up of two tasks.  In task A 
participants were verbally presented a situation and a figurative expression 
related to the situation.  Both the description of the situation and the figurative 
expression were also presented in print.  They were then asked to provide an 
interpretation for the figurative expression, which was recorded verbatim.  In 
task B participants were asked to match the figurative expression to one of four 
choices.  The situation description, figurative expression and the four choices 
were all presented in print.  The test consisted of one trial and 12 test items.  A 
score of 0 was given if the participant was unable to give an accurate 
interpretation or select the correct matching expression.  A score of 1 was given 
if the participant could give either an accurate interpretation or select the correct 
matching expression, and a score of 3 if they complete both tasks A and B 
correctly.  For each of the sub-tests the discontinue rule of failure to respond to 
three consecutive items was used.   
30. Theory of mind test: Based on a test that was devised to assess how well the 
participant was able to interpret the complex mental states of others (Baron-
Cohen, Wheelwright, Hill, Raste, & Plumb, 2001).  Participants were presented 
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with a partial picture of a face showing only the eye-region, and at each corner of 
the picture was a word.  They were then asked to make a judgement about which 
of four words most closely matched what the person in the picture might be 
thinking or feeling.  On an adjacent page was a description for each word.  
Participants were shown one practice item, to ensure they understood the task, 
and 36 test items.  Items were scored 0 for incorrect choices and 1 for correct 
choices.   
31. The Clinical Assessment of Fluctuation (Walker et al., 2000):  This scale is a brief 
screening instrument to assess whether an individual is experiencing episodes of 
confusion or impaired consciousness.  Episodes of confusion or impaired 
consciousness are infrequent in the normal population and may indicate the onset 
of dementia (Walker et al., 2000).  An informant, who knew the participant well, 
was asked a series of questions regarding episodes of confusion or impaired 
consciousness that had occurred in the month prior to assessment.  If there had 
been any episodes of confusion or impaired consciousness, the informant was 
asked to rate these using a 4 point scale.  For periods of confusion the informant 
was asked about frequency (1 = one per month, 2 = monthly-weekly, 3 = weekly-
daily and 4 ≥ daily), and for impaired consciousness the informant was asked 
about duration (0 = seconds, 1 ≤ 5 minutes, 2 = 5 minutes-1 hour, 3 ≥ 1 hour and 
4 ≥ 1 day).  These two scores were then multiplied together to produce a severity 
score that ranged between 0-12, with 0 representing no fluctuation or confusion 
and 12 being indicative of severe fluctuating confusion (Walker et al., 2000).  The 
authors of this test indicate that a score of 16, although possible, would indicate a 
state of continuous confusions and therefore would not be indicative of 
fluctuation (Walker et al., 2000).   
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32. The Adaptive Digit Ordering Task (DOT-A) (Werheid et al., 2002).The DOT-A is 
working memory task that is conceptually and structurally similar to traditional 
digit span tasks.  However, the DOT-A has been reported as having greater 
sensitivity to deficits associated with PD (Werheid et al., 2002).  Participants 
were verbally presented a random string of numbers and required to repeat them 
back in ascending order.  Each number was presented at the rate of one per 
second and strings varied in length from 3 to 8 items.  There were six different 
span lengths and two trials were given for each span.  The test was discontinued if 
the participant failed both trials of any item.  Each trial was scored 1 for correct 
and 0 for incorrect. The maximum number of digits and letters ordered correctly 
was reported.   
33. The Executive Interview (EXIT 25) (Royall, Mahurin, & Gray, 1992): The EXIT25 
consists of 25 test items to assess frontal systems impairment, and includes tests 
of perseveration, imitation, intrusions, frontal release signs, spontaneity, 
disinhibition and utilization behaviour.  Scores range from 0-50, with higher 
scores indicating greater impairment.  A cut off of 9 ± 3 is recommended as 
discriminating non-demented community dwelling elderly, with a cut off of 15 as 
discriminating normal elderly from those with dementia (Royall, Mahurin, & 
Gray, 1992).   
34. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) (Jorm, 
2004): The IQCODE assesses both positive and negative changes in memory over 
a 10 year period.  Informants are asked to rate the “significant other on 16 
statements compared with how they were 10 years ago using a 5 point scale 
where 1 = much improved and 5 = much worse.  Scores ranged from 16 to 80 
with higher scores being indicative of greater impairment.  However, this scale is 
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unique as it is possible for an individual to have improved over the 10 year period 
and scores under 48 indicated that there had been a general improvement in 
memory.  A systematic review of research using this measure indicated that it had 
high reliability for measuring cognitive decline (Jorm, 2004).   
35. The One Day Fluctuation Assessment Scale (Walker et al., 2000): This scale was used 
in conjunction with The Clinical Assessment of Fluctuation and was only 
administered if the informant had indicated that the individual they were rating 
had experienced periods of confusion or impaired consciousness.  Using this 
scale, the informant was asked to rate the “significant other” over the previous 24 
hours on seven items consistent with confused behaviour (falls, fluctuation, 
drowsiness, attention, disorganised thinking, altered level of consciousness, 
communication difficulties).  Scores range from 0-21 with higher scores being 
indicative of greater impairment (Walker et al., 2000).   
36. The Parkinson’s Disease Questionnaire (PDQ-39) (Jenkinson, Fitzpatrick, & Peto, 
1998):  The PDQ-39 is a 39 item self-report questionnaire developed to assess the 
impact of PD on an individual’s daily life.  The questionnaire is comprised of 
eight scales: 1. Mobility (10 items), 2. Activities of daily living (6 items), 3. 
Emotional well-being (6 items), 4. Stigma (4 items), 5. Social support (3 items), 
6. Cognitions (4 items), 7. Communications (3 items), 8. Bodily discomfort (3 
items).  Participants were asked to indicate the extent to which each of the 39 
questions had applied to them over the previous month, using one of five 
response categories: never, occasionally, sometimes, often, and always or cannot 
do at all.  Using the formula supplied in the manual, each scale was calculated to 
range from 0, no problem at all, to 100, maximum level of problems.  A single 
index score was calculated by summing the eight scales and dividing by 8.  The 
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PDQ is reported to have good test-retest reliability and good content and 
construct validity (Marinus, Ramaker, van Hilten, & Stiggelbout, 2002).   
37. The Tower of London Task Revised (TOL-R): The TOL-R is a computerized Tower 
of London task used to assess planning ability and consisted of a custom designed 
computer program on a Macintosh G4 running OS9 with an ELO 17 inch touch 
sensitive monitor having a screen resolution of 1280 by 1024 pixels.  The screen 
comprised two Tower of London images, one in the top half of the screen, the 
model or finish state, and one in the bottom half, the start state.  Only balls in the 
bottom half of the screen could be moved and the background of the top half of 
the screen was colored to remind participants of this rule (see picture below for an 
example of the customised TOL-R (McKinlay et al., In Press).   
 
 
At the side of the screen a number indicated how many moves were required to solve 
the problem.  Participants interacted with the computer task by touching an on-screen 
ball to select it.  When selected, the ball’s circumference flashed and the computer 
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emitted a sound, the participant could then place the ball onto another tower by 
touching the tower, or unselect the ball by touching it again.  Three primary measures 
were obtained using this task, pre-planning time, time to complete the task and number 
of moves to complete the task.  A total of forty one problems were administered 
divided into 2 phases.  Phase one of the computerized task consisted of 16 practice 
problems (2x1 move problems, 2x2 move problems and 12x3move problems).  Each 
problem in this section had a time limit of 60 seconds.  Participants were required to 
complete 92% (11) of the problems in this phase in order to progress to phase two.  
Phase two was divided into two parts.  Part A consisted of 9 problems (3x3 move 
problems, 3x4 move problems and 3x5 move problems).  Problems in this part of phase 
two had a time limit of 120 seconds.  This phase was discontinued if the participant 
failed three consecutive tower problems.  Phase two part B consisted of 16 problems 
(8x5 move problems and 8x6 move problems).  Problems in this part of phase two had 
a time limit of 180 seconds.  This phase was discontinued if the participant failed three 
consecutive tower problems.  For failed problems (either timed out or over the 
maximum number of moves) or problems that were not attempted, participants were 
assigned the maximum number of moves plus 1 and the maximum allowable time.   
38. Unified Parkinson’s Disease Rating scale (UPDRS): Developed by Fahn & Elton 
(1987), the UPDRS is a 42 item clinical test designed to provide a measure of the 
signs and symptoms associated with PD.  The UPDRS is structured according to 
four sections; 1. Mentation, behaviour and mood (e.g., cognition and motivation); 
2. Activities of daily living (e.g., speech, dressing and hygiene); 3. Motor 
examination; 4. Complications of therapy (e.g., presence of dyskinesias, and 
fluctuations in medication effectiveness).  Sections one, two and four are gathered 
by interview and section three by direct examination.  The first three sections are 
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rated on a 4 point scale (0 = normal and 4 = severe presentation of symptom).  
The final section, complications of therapy, only 4 of the 11 items are rated on a 4 
point scale with the remaining 7 being rated as present or absent (absent = 0 and 
present = 1).  The UPDRS is reported as having high convergent validity 
(Martinez-Martin et al., 1994) and good interrater reliability (Fahn & Elton, 1987; 
Goetz et al., 1995; Ramaker, Marinus, Stiggelbout, & Van Hilten, 2002).   
39. Visual Association Test (VAT) (Lindeboom, Schmand, Tulner, Walstra, & Jonker, 
2002):  The VAT is a test of incidental learning that consists of two sets of 6 line 
drawings.  The participant was first presented with 6 line drawings of objects or 
cues (e.g., a chair) and was asked to name them; they were not told that the 
objects must be remembered.  On the second presentation participants were 
presented with the same line drawings at a rate of 1 every 4 seconds, but this time 
the target was added in the form of an interacting object or animal (e.g. a 
hedgehog on the chair).  As with the first presentation, there was no explicit 
instruction to memorise the drawings.  On the third presentation participants were 
shown the original objects (cues) and asked to name the object that was missing 
(targets).  If less than 6 items were recalled, the second and third steps were 
repeated.  Items were scored 0 for incorrect and 1 for correct.  If a participant 
recalled all 6 items on the first recall trial, they were given a score of 12.  The 
VAT has been reported as have high specificity and sensitivity in distinguishing 
between dementia of the Alzheimer type (AD) and individuals without dementia 
using a cut off <4 for the first recall presentation (Lindeboom, Schmand, Tulner, 
Walstra, & Jonker, 2002).   
40. Visual Object and Space Perception Battery (VOSP): (Warrington & James, 1991). 
The VOSP is a test of visual perception.  Two sub-tests were used from this 
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battery, incomplete letters and the object decision test.  Sub-tests were 
administered according to standard procedures.  Prior to administration of the 
subtests participants completed a screening test to ensure adequate visual sensory 
capacities.   
• Incomplete letters: Stimuli consisted of 2 practice letters degraded by 30% and 20 
test letters degraded by 70%.  Participants were presented with pictures of 
incomplete letters one at a time and asked to name them.  Each answer was 
scored 1 correct, or 0 for incorrect, giving a maximum score of 20.  The sub-test 
was marked pass/fail.  Participants were considered to have failed if they score 
below the 5th percentile for their age range (<16 for individuals over 50).   
• Object decision: This sub-test used silhouette drawings of objects.  Participants 
were presented with 20 arrays of 4 silhouettes, in each array only 1 of the 4 
objects was a silhouette of a real object, the other three were distractor items 
constructed from similar but imaginary shapes.  Participants were required to 
identify the real object.  Each answer was scored 1 correct, or 0 for incorrect, 
giving a maximum score of 20.  The sub-test was marked pass/fail.  Participants 
were considered to have failed if they score below the 5th percentile for their age 
range (<14 for individuals over 50).   
41. Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler, 1999): Two sub-
tests were used from this battery, Vocabulary and Matrix Reasoning.  These 
two sub-tests provided an estimate of current Full Scale IQ.  Sub-tests were 
administered according to standard procedures and raw scores were converted 
to age corrected T-scores (mean of 50 and standard deviation of 10).   
• Vocabulary:  This sub-test assessed the individual’s expressive language skills.  
The test consisted of a total of 42 orally presented items for which the participant 
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provided a verbal description.  Items were scored either 0 for an incorrect 
description, 1 for a partially correct description, or 2 for a correct description.  The 
test was discontinued after 5 consecutive scores of 0.   
• Matrix Reasoning: The Matrix Reasoning sub-test consists of a total of 35 
incomplete patterns of increasing complexity.  The participant was required to 
complete each pattern by selecting the correct response from 1 of 5 choices.  Each 
item was score 0 for a fail and 1 for a correct response.  The test was discontinued 
after 4 consecutive scores of 0, or 4 scores of 0 on 5 consecutive items.   
42. Wechsler Memory Scale 3rd edition (WMS-III) (Wechsler, 1997): A number of sub-
tests were used from the WMS-III to assess the participants ability to learn and retain 
orally presented information.  Raw scores for all sub-tests were converted to age 
adjusted scores (mean =100; SD=15).  Detailed scoring is provided in the manual for 
these sub-tests (Wechsler, 1997).  Each sub-test was administered according to 
standard procedures.   
• Auditory Recall. This task is a test of delayed auditory recognition.  Performance 
is based on the composite of the Logical Memory II and Paired Associates II 
delayed recall phase which are described in detail below.  Raw scores vary 
between 0-30 and 0-24 for Logical Memory II and Paired Associates II 
respectively with higher scores indicating more complete recall.   
• Logical Memory I & II: Required both immediate and delayed recall of a 
narrative story.  In the immediate recall phase the participant was orally 
presented two narrative stories.  At the end of each story the participant was 
required to repeat back everything they heard.  The second story was repeated 
twice.  The delayed recall phase occured after an interval of between 25-30 
minutes.  The participant was once again required to recall everything they could 
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remember about the two stories.  For this study, scores from Logical Memory I 
& II were summed to provide an overall score.  Directly after completing the 
delayed recall phase, participants were asked 15 yes / no questions about each 
story.   
• Paired Associates I & II: This involved learning pairs of unrelated words so that 
the second word may be recalled when the first is presented.  Participants were 
read a list of eight word pairs.  After a delay of five seconds the first word in 
each pair was read and the participant was required to provide the second word.  
This sequence of presentation and recall was repeated over four trials.  At the 
end of the final recall phase, participants were told to remember as many of the 
words as possible as they would be tested again.  After an interval of between 
25-30 minutes the participant was orally presented the first word in the pair and 
asked to recall the second word.  For this study scores from Paired Associates I 
& II were summed to provide an overall score.  Directly after completing the 
delayed recall phase, participants were read 24 word pairs and asked to identify, 
by answering yes/no, which word pairs were included in the list they had learnt.   
• Letter-Number Sequencing test: Participants were verbally presented a string of 
numbers and letters (e.g., 3-Y-7-G) that they were required to re-order starting 
with the numbers, from lowest to highest, and then the letters in alphabetical 
order (e.g., 3-7-G-Y).  Strings varied in length from 2 to 8 items.  The maximum 
number of digits and letters ordered correctly was reported.   
• Digit Span: There were two components to this sub-test, digits forward and digits 
backwards.  In digits forward, participants were required to repeat back an 
increasing string of verbally presented digits (2-9 items).  In digits backwards, 
the participant was required to repeat back in reverse order an increasing string 
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of verbally presented digits (2-8 items).  Maximum number of digits repeated 
correctly was reported.   
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Chapter 3 - Neuropsychiatric Problems Associated With Parkinson’s Disease   
Abbreviations used in the text Chapter 3 
1) AUC = Average Under the Curve; 2) BDI-II = Beck Depression Inventory; 3) 
DSM-IV = Diagnostic and Statistical Manual Fourth Edition; 4) FrSBE = Frontal 
Systems Behaviour Scale; 5) GDS = Geriatric Depression Scale ; 6) HADS = 
Hospital Anxiety Depression Scale; 7) H&Y = Hoehn and Yahr Staging Scale; 8) 
MMSE = Mini Mental Status Exam; 9) NART = National Adult Reading test; 10) 
NPI = Neuropsychiatric Inventory; 11) PD = Parkinson’s disease; 12) PDQ-39 = 
The Parkinson’s Disease Questionnaire; 13) S&E = Modified Schwab and England 
Activities of Daily Living Scale; 14) UPDRS = Unified Parkinson’s disease Rating 
Scale; 15) ROC = Receiver Operating Characteristics. 
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3.1 Overview   
Defining the range and frequency of neuropsychiatric problems in patients with 
Parkinson’s disease (PD) has generated a great deal of interest over the past decade 
(e.g., Schrag, 2004; Schrag, Hovris, Morley, Quinn, & Jahanshahi, 2006; Shulman, 
Taback, Bean, & Weiner, 2001; Shulman, Taback, Rabinstein, & Weiner, 2002).  This 
interest has partly been due to a rising awareness that PD patients frequently suffer 
from a range of neuropsychiatric problems which have frequently been overlooked by 
clinicians (Schrag, 2004; Shulman, Taback, Rabinstein, & Weiner, 2002).  But also 
because, these problems are increasingly recognised as having an impact on quality of 
life for PD patients perhaps more so than the motor problems that has traditionally been 
the focus of any interventions.  Moreover, neuropsychiatric problems have been found 
to impact on the caregivers’ ability to cope (Schrag, Hovris, Morley, Quinn, & 
Jahanshahi, 2006).  The latter point is extremely important as PD patients often require 
high levels of assistance especially as the disorder progresses and caregiver distress 
may result in premature rest home placement having personal, social and health care 
cost.   
3.1.1 Difficulty with Research in the Area   
Assessing functional deficits in PD patients that are related to neuropsychiatric 
problems poses a number of difficulties in addition to those discussed earlier in relation 
to cognitive deficits (see section 1.6.2).  There are few neuropsychiatric tests 
specifically designed for or even validated for use with PD patients.  Furthermore, the 
current literature uses self report and significant other report interchangeably despite 
the fact that there is currently no evidence to suggest that these represent 
interchangeable means of reporting neuropsychiatric problems.   
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3.2 Current Research   
The investigation of neuropsychiatric problems for patients with PD partially 
addresses the first two objectives of this thesis (see section 1.14 for full outline of 
objectives for the thesis).  An initial objective of the thesis was to identify some of the 
pertinent cognitive, behavioural and psychiatric deficits in PD patients compared to 
normal elderly.  As part of this first objective an examination of the relative sensitivity 
of different measures for use with PD patients was also undertaken.  The second 
objective was to assess the ability of PD patients to function efficiently in the 
environment when they had cognitive or neuropsychiatric problems.  As part of this 
objective the possibility that neuropsychiatric problems would manifest in reduced 
quality of life was also examined.   
3.2.1 Manuscript 1 – Quality of Life   
To partially address the first and second objective, the first manuscript in this 
chapter examines the range of neuropsychiatric problems present in PD patients without 
dementia compared to healthy older individuals.  Currently, there is little research that 
has examined the range of neuropsychiatric deficits associated with PD and much of 
what is known about these problems has come from studies which have focused on 
only a small number of possible problems (e.g., examining the frequency of single 
neuropsychiatric problems such as depression or anxiety).  In this manuscript the 
relationship between neuropsychiatric problems and patients perceptions of their own 
quality of life was also examined.  Outcomes from this part of the study indicated that 
neuropsychiatric problems were common for patients with PD.  Moreover the presence 
of these problems was related to diminished quality of life as measured by the 
Parkinson’s Disease Questionnaire (PDQ-39) (Jenkinson, Fitzpatrick, & Peto, 1998).   
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As a caveat to this first paper it is important to be aware that the general concept 
“Quality of Life” has been criticised as being poorly defined and somewhat subjective 
(McKevitt, Redfern, La-Placa, & Volfe, 2003).  Further, many Quality of Life scales 
been found to have questionable psychometric properties (McKevitt, Redfern, La-
Placa, & Volfe, 2003).  The PDQ-39 has been designed and validated specifically for 
use with PD (Hagell, Whalley, McKenna, & Lindvall, 2003). The PDQ-39 is comprised 
of 39 questions which provide scores on eight discrete scales.  These scales can also be 
combined to form a meaningful single summary score (Jenkinson, Fitzpatrick, & Peto, 
1998).  However, the eight scales are made up of varying numbers of items (e.g., 3 for 
Social support and 10 for Mobility) calling into question the validity of the eight 
separate scales.  Further, some of the response alternatives have been found to be 
ambiguous (Hagell, Whalley, McKenna, & Lindvall, 2003).  It has been suggested that 
this questionnaire, although promising for use with this population, still requires further 
refinement (Hagell, Whalley, McKenna, & Lindvall, 2003).  Therefore, the outcomes 
reported here should be viewed with some caution.   
3.2.2  Manuscript 2 – Self v Significant Other   
The second manuscript in this chapter focuses on the degree to which informant 
and self-report can be considered to be interchangeable.  This paper also examines the 
relationship between caregiver perceptions of neuropsychiatric problems for PD 
patients and their own level of distress.  Results indicated that there is a high level of 
disagreement between significant other and self report.  Furthermore, caregiver distress 
was correlated with caregiver perceptions of the neuropsychiatric problems.   
This paper did not address the issue of which reporter was most accurate.  This 
question would need to be addressed in a future study.  However, it did confirm that 
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these reporting methods provided different information.  One explanation for this could 
be that covert problems such as anxiety and depression are more identifiable by the 
person experiencing them whereas the frequency of overt behaviours associated with 
aggression maybe more accurately reported by an observer.  Alternatively, there may 
be bias and inaccuracy in both types of report.  For example, observer report may be 
seriously biased by their own levels of distress whereas patient report may be distorted 
by a lack of insight into their problems.  To answer these questions future research 
could use more objective means of collecting information i.e impartial observers.   
3.2.3 Manuscript 3 – Unified Parkinson’s Disease Rating Scale   
The third manuscript in this chapter compared the relative sensitivity of 3 
different measures of depression (Beck Depression Inventory-II (BDI), Geriatric 
Depression Scale (GDS) and the Hospital Anxiety Scale (HADS)) and the Unified 
Parkinson’s Disease Rating Scale (UPDRS).  Presence of low mood or depression is 
often overlooked in PD patients (Shulman, Taback, Rabinstein, & Weiner, 2002).  This 
aspect of the research was undertaken to examine how accurate the UPDRS, commonly 
used by clinicians, would be in identifying patients with symptoms consistent with at 
least low mood, and who might require further assessment.  Results indicated that the 
UPDRS was not accurate, especially when identifying patients with only mild 
symptoms.  It was therefore concluded that it would be appropriate for a brief scale 
such as the BDI-II or the GDS be used routinely to screen for depression.   
One potential criticism of this study might be that the cut-offs for the BDI-II 
were validated for use with young healthy adults (Beck, Steer, & Brown, 1996), also 
that the BDI-II contains a number of items that tap into somatic problems.  However, 
  127 
we found a high level of agreement between the BDI-II and GDS, the latter which has 
been validated for use with older populations.   
3.2.4 Summary   
Overall evidence for a variety of neuropsychiatric problems was found for PD 
patients.  This finding was consistent with other research in this area.  Moreover, 
neuropsychiatric problems were found to negatively impact on the quality of live for 
PD suffers.  While previous studies have gathered information regarding 
neuropsychiatric problems using self-report and significant other report interchangeably 
is important to be aware that the perspectives of these two informant source differ 
significantly.   
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3.3 A Profile of Neuropsychiatric Problems and Their Relationship to Quality of 
Life for Parkinson’s Disease Patients Without Dementia   
(In Press-Journal of Parkinsonism and Related Disorders. Avaliable online July 2007) 
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3.3.1 Abstract   
A substantial number of patients with Parkinson’s disease have symptoms 
consistent with a range of neuropsychiatric problems including, anxiety, apathy, 
fatigue and depression.  Although a number of studies have examined individual 
symptoms, there is little information on the profile of neuropsychiatric symptoms that 
are associated with PD and their impact on quality of life.  We examined the 
frequency of neuropsychiatric symptoms for 49 patients with PD and found that over 
40% had symptoms consistent with depression, 40% with physical fatigue, 38% with 
mental fatigue, 38% with apathy and 32% with sleep problems.  Overall, 
neuropsychiatric problems were common with more than 77% of the patients 
reporting symptoms associated with at least one problem and over 46% with 3 or 
more problems.  Increased symptoms consistent with depression and anxiety and the 
presence of hallucinations also predicted poorer quality of life after controlling for 
motor symptoms.  Given the high frequency of neuropsychiatric symptoms and their 
potential impact on an individuals’ quality of life, increased recognition by clinicians 
is important so that appropriate intervention strategies may be implemented.   
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3.3.2 Introduction   
Neuropsychiatric symptoms frequently accompany the motor problems that 
are characteristic of PD and are increasingly recognised as an important cause of 
disability even in the absence of dementia.  Neuropsychiatric symptoms have been 
associated with reduced independence and decreased quality of life for patients with 
PD (Cubo et al., 2002; Weintraub & Stern, 2005), and are important predictors of 
caregiver distress which may result in early rest home placement.  However, 
neuropsychiatric symptoms are often not recognized by treating physicians (Shulman, 
Taback, Rabinstein, & Weiner, 2002) and there is still a lack of available information 
regarding the typical profile associated with PD.   
Neuropsychiatric symptoms often accompany disorders of the basal ganglia 
and in PD are thought to result partly from the degeneration of the fronto-striatal 
circuits (Chow & Cummings, 1999).  However, other factors also contribute to their 
prevalence including complications of treatment therapy, the individual’s reaction to 
having a debilitating disorder and the level of pain associated with the symptoms of 
PD.  Varying prevalence rates have been reported for neuropsychiatric symptoms in 
PD patients depending on methodology, with up to 70% reported as having symptoms 
consistent with depression (Burn, 2002b), 40% for anxiety (Starkstein et al., 1992), 
30% for hallucinations (Fenelon, Mahieux, Huon, & Ziegler, 2000), 43% for apathy 
(Isella et al., 2002; Starkstein et al., 1992), 40% for fatigue (Shulman, Taback, Bean, 
& Weiner, 2001) and 80% for sleep problems (Factor, McAlarney, Sanchez-Ramos, 
& Weiner, 1990; Tandberg, Larsen, & Karlsen, 1999).   
Although the presence of individual non-motor symptoms has been well 
reported there is little information regarding a typical profile of non-motor symptoms 
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associated with PD without dementia.  Two recent studies have described a range of 
symptoms using a single group of patients.  Aarsland et al., (1999) examined the 
frequency of neuropsychiatric symptoms in a group of 139 PD patients (H&Y stage I-
IV) with the Neuropsychiatric Inventory (Cummings et al., 1994) and found 
depression (38%) and hallucinations (27%) to be the most common disorders, with 
61% of the sample reporting at least one symptom.  Psychiatric symptoms were more 
common among patients in rest homes and those with cognitive impairment.  
However, 42% of their sample either met the criteria for or had questionable 
dementia.  (Shulman, Taback, Bean, & Weiner, 2001) reported sleep disturbance 
(47%) and sensory symptoms (63%) as being the most common neuropsychiatric 
symptoms in a group of 99 PD patients (H&Y I-IV) without dementia.  High rates of 
fatigue (40%), depression (36%) and anxiety (33%) were also reported in this group.  
Shulman et al. (2001) also found comorbidity to be high, with 59% of the patients 
having two or more symptoms and 25% having four or more.   
Given the relatively high frequency of neuropsychiatric problems associated 
with PD, it is important to identify their impact on patients’ everyday lives.  Indeed, 
various neuropsychiatric problems have been found to contribute to the reduction in 
quality of life in PD patients, in addition to the motor symptoms associated with the 
disease (Cubo et al., 2002; Schrag, Jahanshahi, & Quinn, 2000).  However, to date 
there has been no systematic study of the contribution that different neuropsychiatric 
problems make to quality of life for patients with PD.   
Thus we had three goals in the present research.  First, we wanted to determine 
the profile of neuropsychiatric symptoms in a group of PD patients without dementia 
and to examine comorbidity.  Second, because many neuropsychiatric problems such 
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as apathy, fatigue, depression and sleep disturbance have a considerable degree of 
symptom overlap, we examined the relationships among the neuropsychiatric 
outcome measures.  Finally, we examined the relationship between neuropsychiatric 
problems, motor symptoms and quality of life.   
3.3.3 Statistical Analysis   
The percentage of individuals with neuropsychiatric problems was calculated 
using previously validated cut-offs.  Quantitative data are also reported in terms of 
means and standard deviations.  Pearson correlation was employed to assess the 
relationships among the different neuropsychiatric problems and also between clinical 
/demographic characteristics and neuropsychiatric problems.  Multiple regression 
analysis was used to assess the influence of motor impairment and neuropsychiatric 
problems on quality of life.   
3.3.4 Methods   
Approval for the study was granted by the Canterbury Ethics Committee and 
informed consent was obtained from patients.  Patients, with a confirmed diagnosis of 
idiopathic PD, were invited to take part in the study through a letter from their 
neurologist.  Inclusion criteria were as follows: no evidence of another major medical 
illness, no evidence of dementia (MMSE ≥25) and less than 80 years of age.  From 
the 115 patients contacted, 56 patients who met the inclusion criteria (31 males and 18 
females) volunteered to take part.  Of these patients, two withdrew due to illness and 
5 did not complete the take home tests, resulting in their exclusion.  The clinical and 
demographic characteristics of patients included in this study are displayed in Table 
20.   
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Table 20: Clinical and demographic characterstics of Parkinson’s disease patients.   
 
  Mean   (SD)          Range 
 
Age 66.5    (6.8)      52.0  -  77.0  
MMSE1 28.6    (1.3)      25.0  -  30.0  
PD onset2   6.0     (4.2)        0.3  -  23.0    
UPDRS3 29.6     (9.7)     13.0  -  53.0  
Tremor Score   0.6     (0.4)       0.0  -    1.9  
Non Tremor Score   1.2     (0.4)       0.5  -    2.6  
S&E4           81.5% (0.1)     30.0% - 100.0% 
H&Y5              Level 1    Level 1.5     Level 2    Level 2.5    Level 3    Level 4 
              (n=9)       (n=6)  (n=10)       (n=13) (n=8)       (n=3) 
 
1 Mini Mental Status Exam;2Number of years since onset of Parkinson’s disease symptoms; 3Unified 
Parkinson’s Disease Rating Scale (motor score component); 4 Modified Schwab and England Activities of 
Daily Living Scale; 5 Hoehn & Yahr stage.  
 
3.3.5 Procedure   
This study forms part of a broader project examining the cognitive outcomes 
for patients with PD that was conducted over three testing sessions.  Information 
regarding current cognitive status, motor symptoms, hallucinations, sleep problems 
and depression were all collected as part of the first session.  Patients were also asked 
to take home and complete questionnaire forms which assessed symptoms of apathy, 
fatigue, and anxiety.  Patients were specifically requested to complete the forms by 
themselves and not to discuss their answers with anyone else.  Details regarding how 
to complete the forms were first explained during the first testing session and patients 
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were asked to return them when they attended the second session.  Any questions or 
difficulties were addressed when the forms were returned.   
Instruments used to collect clinical characteristics 
1) A semi-structured interview was used to gather demographic and clinical 
details and included information about patient health history, drug use, age 
and duration of PD.   
2) The Mini Mental Status Exam (MMSE) provided information regarding current 
cognitive functioning (Folstein, Folstein, & McHugh, 1975).  A variety of cut-
offs have been suggested for this instrument, but scores below 23-24/30 have 
been reported as having high sensitivity and specificity in identifying individuals 
with dementia (O'Connor et al., 1989).  For this study a score of ≥ 25 was used as 
one of the inclusion criteria.   
3) Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn & Elton, 1987).  
Three scores were generated using this scale, a) The severity of motor 
symptoms was rated using the motor section; b) Tremor score (calculated as the 
average of items 16 and 20-26), and c) non tremor score (calculated as the 
average of items 5,7,12-15, 18, 19, and 27-44) (as outlined by Lewis et al., 
2003).   
4) The Hoehn and Yahr (H&Y) was used to rate the stage of the disease (Hoehn & 
Yahr, 1967).  In this study the modified version of this scale was used which 
uses increments of 0.5 in the midranges.   
5) A global measure of overall functional status was evaluated using the Modified 
Schwab and England Activities of Daily Living Scale (S&E), and provided a 
global measure of overall functioning in activities of daily living, including 
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ability to complete personal hygiene and daily chores without difficulty, 
slowness or impairment.  A scale of 0-100% was used where 0% represents a 
vegetative state and 100% represents total independence (Ramaker, Marinus, 
Stiggelbout, & Van Hilten, 2002).   
Instruments used to collect Neuropsychiatric information  
1) Sleep Disturbance: The frequency of sleep disturbance was assessed using a 
single screening item contained in the UPDRS (Fahn & Elton, 1987).  Patients 
were asked to respond with Yes/No to the question, “Do you have any problems 
with your sleep?”  
2) Hallucinations: presence of hallucinations were assessed using the UPDRS 
which uses a 5 point scale where 0=None, 1=Vivid dreaming, 2= “Benign” 
hallucinations with insight retained, 3= Occasional to frequent hallucinations 
or delusions without insight, 4= Persistent hallucinations, delusions or florid 
psychosis (Fahn & Elton, 1987).  For the purposes of this study, hallucinations 
were considered to be present if the patient scored greater than two.   
3) Symptoms of depression were assessed using the Beck Depression Inventory 
(BDI-II) (Beck, Steer, & Brown, 1996).  The BDI-II consists of 21 items, each 
rated from 0 to 3.  A threshold of 14 and above is recommended for detecting 
the presence of depression (probable depression), and 9 and above for 
screening purposes (possible depression).  For this study a score of ≥9 was 
taken as evidence of depression (Leentjens, Verhey, Luijckx, & Troost, 2000).   
4) Anxiety was assessed using the Hospital Anxiety and Depression Scale 
(HADS), which consists of 14 items.  Of these, seven relate to anxiety and are 
each rated on a four point scale (0-3) with a maximum score of 21.  A 
threshold of 10 has been recommended for detecting probable anxiety, with 
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above 8 for possible anxiety.  For this study score of ≥ 8 was taken as 
evidence of anxiety (Zigmond & Snaith, 1983).   
5) Fatigue was assessed using the Fatigue Severity Scale (FSS) (Krupp, LaRocca, 
Muir-Nash, & Steinberg, 1989).  This self-report questionnaire consists of 9 
items, each scored on a 7 point scale where 1 indicates “strongly disagree” and 
7 “strongly agree”.  For this study the questionnaire was modified so that 
mental fatigue and physical fatigue could be examined separately.  Patients 
were asked to answer each item in separately in terms of mental and physical 
fatigue providing two scores Average scores were then calculated.  A cut-off 
of >4, which has previously been used for patients with PD, was used for both 
scores to indicate presence of mental or physical fatigue (Shulman, Taback, 
Bean, & Weiner, 2001).   
6) Apathy was assessed using the Apathy scale (Starkstein et al., 1992) which is 
a 14 item self-report measure.  Participants are asked to indicated the extent to 
which each of the 14 statements applied to them over the last month using a 4 
point scale: not at all, slightly, some, a lot.  We used the recommended cut-off 
of >14 (Starkstein et al., 1992).   
Measure used to evaluate Quality of Life  
1) Quality of life was assessed using The Parkinson’s Disease Questionnaire 
(PDQ-39) (Jenkinson, Fitzpatrick, & Peto, 1998).  The PDQ-39 is a 39 item 
self-report questionnaire developed to assess the impact of PD on an 
individual’s daily life.  The questionnaire contains eight dimensions: a) 
Mobility (10 items); b) Activities of daily living (6 items); c) Emotional well-
being (6 items); d) Stigma (4 items); e) Social support (3 items); f) Cognitions 
(4 items); g) Communications (3 items); h) Bodily discomfort (3 items).  
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Participants were asked to indicated the extent to which each of the 39 items 
applied to them over the last month, using one of five response categories: 
never, occasionally, sometimes, often, always or cannot do at all.  Scale scores 
were then calculated from 0 (no problems at all) to 100 (maximum level of 
problems) using the formula supplied in the manual, which takes into account 
the different number of questions used in each dimension.  A single index 
score was calculated by averaging the eight scale scores.   
3.3.6 Results   
Table 21 displays the mean and standard deviation for the entire sample and 
also percentage of patients who exceeded the cut-offs for each of the 7 
neuropsychiatric outcomes.  Overall, neuropsychiatric problems were extremely 
common with over 77% of the patient sample reaching the cut-off for one or more 
problems (11/49=0; 6/49=1; 9/49=2; 14/49=3; 2/49=4 and 4/49=5).  Physical fatigue, 
mental fatigue, depression and apathy were the most frequent neuropsychiatric 
problems, and were reported by over 38% of the patients.  Sleeping problems were 
reported by 32% of the patients.  Anxiety and hallucinations were less frequent, with 
just over 16% and 12% respectively of the patients meeting the cut-off points.   
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Table 21: Means, standard deviations and percentages of patients with problems for 
each neuropsychiatric measure.   
 
 Mean (SD) 
for total group 
Percentage (n) 
with problems 
Range 
 
 
Physical Fatigue 
 
 3.9 (1.6) 
 
40.1% (20/49) 
 
1.0 -   6.9 
Mental Fatigue  3.7 (1.6) 38.8% (19/49) 1.0 -   7.0 
Depression  7.9 (5.0) 40.1% (20/49) 0.0 – 19.0 
Anxiety
2
  5.1 (3.6) 16.7% (  7/42) 0.0 – 17.0 
Apathy 11.9 (5.9) 38.8% (19/49) 0.0 – 25.0 
Hallucinations N/A1 10.2% (  5/49) N/A1 
Sleep Disturbance 
 
N/A1 32.7% (16/49) N/A1 
1N/A = not applicable these measures used a single yes/ no format. 2 The Hospital Anxiety and 
Depression scale (HADS) used to detect the presence of anxiety was only completed by 42 of the 49 
patients.  
 
A major goal was to assess the relationship between the different 
neuropsychiatric problems because there is considerable symptom overlap.  As can be 
seen on Table 22, there was a strong positive correlation between physical and mental 
fatigue.  There were also significant positive relationships between physical fatigue, 
apathy and depression and between physical fatigue, anxiety and depression.  By 
contrast, mental fatigue and hallucinations were only significantly correlated with 
depression, and there was no significant association between sleep and any of the 
other measures.   
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Table 22: Correlations between neuropsychiatric measures.   
 
 *p<0.05;**p<0.01;***p<0.001. 
 
We also examined the association between clinical/demographic 
characteristics and neuropsychiatric outcomes.  As can be seen from Table 23, fatigue 
and apathy scales and the presence of hallucinations were positively correlated with 
measures of motor impairment using the H&Y and tremor /non tremor scores derived 
from the UPDRS.  Sleep problems were positively correlated with disease duration.  
There was no association between scores of depression and anxiety on any of the 
clinical or demographic characteristics and no significant association with age for any 
neuropsychiatric outcome.   
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Physical Fatigue 
 
 ---- 
      
Mental Fatigue 0.80***  ----      
Depression 0.36* 0.30* ----     
Anxiety1 0.32* 0.24 0.67*** ----    
Apathy 0.30* 0.28 0.40** 0.24 ----   
Hallucinations 0.19 0.12 0.32* 0.29 0.18 ----  
Sleep Disturbance 0.09 0.11 0.10 0.26 0.19 0.11 ---- 
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Table 23: Correlations for clinical /demographic characteristics and neuropsychiatric 
problems.   
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Gender 
 
-0.08 
 
-0.22 
 
 0.04 
 
-0.26 
 
-0.79 
 
-0.02 
 
-0.15 
Age  0.12  0.05 -0.05 -0.13 -0.13 -0.17 -0.05 
Disease Duration
1
  0.10  0.26 -0.20 -0.07 0.37* -0.16  0.10 
H&Y
2
  0.43**  0.45**  0.49***  0.25  0.07  0.15  0.13 
UPDRS
3
  0.40**  0.33*  0.30*  0.31* -0.05  0.08  0.03 
Tremor Score  0.26  0.16  -0.00  0.15  0.01 -0.06  0.07 
Non Tremor score  0.42**  0.40**  0.46***  0.35* -0.01  0.20  0.07 
S&E
4
 -0.39** -0.39** -0.58*** -0.40** -0.02 -0.27 -0.07 
 
1Number of years since diagnosis of Parkinson’s disease; 2 Hoehn & Yahr stage 3Unified Parkinson’s 
disease Rating Scale (motor score component); 4 Modified Schwab and England Activities of Daily 
Living Scale. 
*p<0.05;**p<0.01;***p<0.001. 
 
Multiple regression analyses were used to examine the influence of motor 
impairment and neuropsychiatric problems on quality of life (PDQ-39).  Specifically, 
our goal was to test whether neuropsychiatric problems made an independent 
contribution to predicting quality of life, after controlling for the relationship between 
motor symptoms and quality of life.  To reduce collinearity, we used a single measure 
of fatigue (the average of scores for mental and physical fatigue), and only the tremor 
and non-tremor UPDRS scores were included as measures of motor symptoms.  
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Scores for each PDQ-39 domain, as well as the overall score, were used as dependent 
variables.  For each dependent variable, motor symptoms were entered on the first 
step, and each neuropsychiatric symptom was then entered separately on the second 
step.  Beta weights for tremor and non-tremor scores from the first step, and for each 
neuropsychiatric symptom on the second step, are listed in Table 24.  Also shown is 
the incremental variance accounted for PDQ-39 scores by the each neuropsychiatric 
symptom (R2 change).  Table 24 shows that non-tremor but not tremor scores were 
significantly related to overall quality of life (PDQ-Total).  Among neuropsychiatric 
problems, anxiety, depression and the presence of hallucinations explained significant 
amount of variance after controlling for motor symptoms.   
We also examined the effects of neuropsychiatric problems for each of the 
different quality of life domains measured by the PDQ-39.  Table 24 shows that 
whereas non-tremor scores were significantly related to quality of life for all domains 
except stigma, tremor scores were not.  Neuropsychiatric symptoms also explained 
significant variance in different aspects of quality of life.  Anxiety was significantly 
related to quality of life, after controlling for motor symptoms, for each of the PDQ-
39 domains.  A similar finding was evident for depression which also accounted for 
significant incremental variance in quality of life scores for all domains except for 
perception of social support.  Also presence of hallucinations accounted for 
significant variance in the domains of daily living, emotional well being, bodily 
discomfort and overall poorer quality of life.   
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Table 24: Beta weights for tremor, non-tremor and each neuropsychiatric symptom for 
regression analyses predicting Parkinson’s Disease Quality of Life Questionnaire.   
R2 change for each symptom is shown in parentheses.   
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  PDQ-Total 
  
 0.06 
 
0.61*** 
 
  
 0.69*** 
(0.46) 
  
 0.22 
(0.04) 
  
 0.22 
(0.04) 
  
 0.51** 
(0.23) 
  
 0.17 
(0.02) 
  
 0.39** 
(0.10) 
 
 
 Subscales 
 
        
 Mobility -0.10 0.71***  0.43** 
(0.18) 
-0.02 
(0.00) 
-0.01 
(0.03) 
 0.28* 
(0.07) 
-0.03 
(0.00) 
 0.20 
(0.03) 
 
 Activities of 
Daily Living 
 
 0.14 
 
0.60*** 
  
 0.36** 
(0.12) 
  
 0.30* 
(0.08) 
 
 0.28* 
(0.06) 
  
 0.25* 
(0.06) 
  
 0.21 
(0.04) 
  
 0.30* 
(0.07) 
    
 Emotion 
 
 0.03 
 
0.33* 
  
 0.78** 
(0.60) 
 
 0.21 
(0.04) 
 
 0.20 
(0.03) 
 
 0.66*** 
(0.41) 
  
0.13 
(0.02) 
  
 0.45** 
(0.16) 
    
 Stigma 
  
 0.14 
 
0.11 
  
 0.45** 
(0.20) 
 
 0.21 
(0.04) 
  
 0.04 
(0.00) 
  
 0.34* 
(0.11) 
  
 0.14 
(0.02) 
  
 0.24 
(0.05) 
    
 Social 
Support 
  
 0.15 
 
0.36* 
  
 0.40** 
(0.16) 
  
 0.14 
(0.02) 
  
 0.24 
(0.05) 
  
 0.26 
(0.06) 
  
 0.14 
(0.02) 
  
 0.10 
(0.00) 
 
 Cognitive 
Impairment 
  
 0.23 
 
0.48*** 
  
 0.57*** 
(0.32) 
  
 0.33** 
(0.09) 
 
 0.35** 
(0.09) 
 
 0.42*** 
(0.16) 
  
 0.03 
(0.00) 
 
 0.38** 
(0.11) 
 
 Communication 
difficulties 
  
 0.07 
 
0.49*** 
  
 0.37* 
(0.14) 
  
 0.40** 
(0.14) 
  
 0.09 
(0.00) 
  
 0.28* 
(0.08) 
  
 0.23 
(0.05) 
  
 0.28 
(0.06) 
 
 Bodily 
discomfort 
 
 0.03 
 
0.39** 
 
 0.47** 
(0.22) 
 
 0.05 
(0.00) 
 
 0.27 
(0.06) 
 
 0.28* 
(0.08) 
 
 0.20 
(0.04) 
 
 0.39** 
(0.12) 
         
 
 1Only 42 patients completed the anxiety scale.  
* p<0.05; **p<0.01; *** p<0.001  
 
By contrast, apathy was only significantly related to communication 
difficulties and the perception of cognitive impairment after controlling for motor 
symptoms.  Both sleep difficulties and increased fatigue were only significantly 
associated with cognitive impairment.  Overall, these results show that 
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neuropsychiatric problems are associated with significant variance in quality of life 
for PD patients after controlling for the effects of motor symptoms.   
3.3.7 Discussion   
The data presented here suggest that neuropsychiatric problems are common 
for patients with PD.  Over 77% of the patients reported symptoms consistent with at 
least one problem and more than 46% with 3 or more problems.  Over 40% of the 
sample had symptoms consistent with depression, 40% physical fatigue, 38% mental 
fatigue, 38% apathy and 32% reported having sleep problems.  Symptoms consistent 
with anxiety were reported by 16% of the patients and the presence of hallucinations 
by 10%.  Given the overlap between symptoms we also examined the relationship 
between these neuropsychiatric outcomes.  There were strong positive correlations 
between physical and mental fatigue, and between fatigue, apathy and depression.  By 
contrast, the presence of hallucinations was only significantly related to depression, 
and there was no significant correlation between sleep disturbance and any of the 
other measures.   
In terms of the association between clinical/demographic and neuropsychiatric 
problems, motor impairment but not age, gender or disease duration was associated 
with all of the neuropsychiatric problems except for anxiety and depression.  In terms 
of motor symptoms, non-tremor scores but not tremor scores were significantly 
related to neuropsychiatric problems.   
We also found that in addition to motor deficits, neuropsychatric problems 
contributed to reduced quality of life in patients with PD.  Anxiety, depression and the 
presence of hallucinations were significantly associated with an overall poorer quality 
of life, after controlling for the relationship between motor symptoms and quality of 
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life.  When aspects of quality of life were considered separately, anxiety and non 
tremor scores were always predictive of lower quality of life.  Similarly, depression 
was associated with lower quality of life for every domain apart from level of social 
support.  By contrast, fatigue and increased sleep problems were only associated with 
decreased self ratings of cognitive impairment and apathy with decreased self ratings 
of cognitive impairment and communication difficulties.   
Our results are consistent with other studies which have reported similar levels 
of depression, fatigue and sleep disturbance (Isella et al., 2002; Karlsen, Larsen, 
Tandberg, & Jorgensen, 1999; Rojo et al., 2003; Shulman, Taback, Bean, & Weiner, 
2001).  The prevalence of anxiety was somewhat lower here than in previous studies 
(Shulman, Taback, Bean, & Weiner, 2001).  However, our study used the HADS 
while Schulman et al., (2001) used the Beck Anxiety Scale, and there is currently no 
information regarding the relative sensitivity of these two measures with PD patients.   
Neuropsychiatric problems are increasingly recognized as contributing to 
poorer quality of life in patients with PD (Chapuis, Ouchchane, Metz, Gerbaud, & 
Durif, 2004; Cubo et al., 2002).  Fortunately many of the neuropsychiatric problems 
associated with this group may be ameliorated with appropriate intervention.  For 
example recent research has piloted patient education regarding information on 
problems associated with degenerative disease as being beneficial to patients with PD 
and their caregivers (Macht et al., 2007).  However, identification of individuals 
experiencing these problems may require screening of all patients because the 
association between disease duration and severity (as measured by motor symptoms) 
is inconsistent (see Shrag, 2006 for review).  Indeed, in the present study disease 
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duration was significantly correlated with only one of the seven neuropsychiatric 
problems that we examined.   
It is important to acknowledge some possible limitations of our study.  
Although it was attempted to recruit a representative sample, only patients who 
volunteered were included, and thus it is possible that they were healthier than those 
who did not respond.  Also, inclusion criteria were restricted to those patients who did 
not have another major health problem.  Arguably, both of these factors may have 
reduced the representativeness of the sample.  Nevertheless, these results still 
demonstrate that for many PD patients, neuropsychiatric problems as well as motor 
symptoms may contribute to reduced quality of life.   
The identification of neuropsychiatric problems in patients with PD is 
important because these problems are amenable to intervention, and a lack of timely 
intervention may needlessly reduce the individuals’ quality of life.  Given that 
neuropsychiatric problems are not consistently associated with other more overt signs 
of the disease, such as motor impairments, all patients should routinely be screened 
for commonly occurring problems such as anxiety, depression, and fatigue.   
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3.4 Neuropsychiatric problems in Parkinson’s Disease: Comparisons Between 
Self and Significant OtherReport   
(In review Journal of Aging and Mental Disorders.)  
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3.4.1 Abstract 
Neuropsychiatric problems occur frequently in patients with Parkinson’s 
disease without dementia, and may cause distress for both patients and their 
caregivers.  However, much of the relevant research has used reports from caregivers 
and patients interchangeably.  The main aim of this study was to determine the level 
of agreement between significant other and patient report of neuropsychiatric 
problems.  Forty-nine patients who met the inclusion criteria and 43 informants who 
knew the patient well (significant others) participated in the study.  Ratings of 
patients’ behavior by the significant others, and the stress they experienced, were 
obtained using the Neuropsychiatric Inventory (NPI).  Information from patients was 
obtained using commonly-used rating scales and previously validated cut-offs.  Both 
the patients and the significant others also completed the Frontal Systems Behavior 
Scale which assesses behaviors associated with apathy, disinhibition, and executive 
dysfunction.  Although the frequencies of neuropsychiatric problems reported by 
significant others and the patients were similar, the level of agreement was low: 
40.9% for apathy, 28% for hallucinations, 39% for depression, 25% for sleep 
problems and only 7.7% agreement for the presence of anxiety.  Agreement between 
significant other and self-report was still low when both completed the same rating 
scale in terms of apathy (r = 0.36), disinhibition (r = 0.16) and executive dysfunction 
(r = 0.00).  In addition, stress reported by significant others was associated with the 
perception of presence of neuropsychiatric problems in the patient, not just the 
presence of these problems.  Overall, results show that there is a low level of 
agreement between significant other and self-report of neuropsychiatric problems.  
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3.4.2 Introduction   
A significant proportion of patients with PD are reported to experience a range 
of neuropsychiatric problems including sleep disturbance, fatigue, depression and 
anxiety (Aarsland & Karlsen, 1999; Bronnick, Aarsland, & Larsen, 2005; McKinlay 
et al., 2007; Shulman, Taback, Bean, & Weiner, 2001).  These problems have been 
associated with reduced quality of life for the patient, increased caregiver distress, and 
early rest home placement (Aarsland, Larsen, Karlsen, Lim, & Tandberg, 1999; 
Aarsland, Larsen, Tandberg, & Laake, 2000; Fernandez, Tabamo, David, & 
Friedman, 2001).  Routine assessment for their presence should provide an 
opportunity for clinical interventions that will reduce caregiver distress and prolong 
independence for patients with PD.  However, there is no widely-accepted assessment 
methodology for these neuropsychiatric problems. Moreover, self-ratings and reports 
from significant others have often been used interchangeably (Aarsland & Karlsen, 
1999; Shulman, Taback, Bean, & Weiner, 2001) with the assumption that they are 
equally valid measures of the patients’ symptoms.  This assumption may not be 
correct.  Thus it is important to determine whether reports from patients and 
significant others provide equivalent information.   
The level of agreement between self versus significant-other reports of 
neuropsychiatric symptoms for patients with PD is yet undetermined.  These two 
means of reporting may provide very different information about the patient’s status.  
Whereas significant others’ reports are based on their observations, the patient is 
describing their own symptoms based on personal experience that may or may not be 
accompanied by overt behaviours and which they may not have communicated with 
anyone else.   
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Even in the context of the healthy elderly, self and significant-other report 
may not be interchangeable.  For example, McAvay et al (2004) examined the 
frequency of depression reported by the elderly compared to that of an informant and 
found that a number of elderly people who self-reported depressive symptoms were 
not identified by the informant and vice versa.  Overall, informants tended to 
underestimate the presence of depression, identifying these symptoms in only 11% of 
individuals compared to a self-reported frequency of 18% (McAvay, Bruce, Raue, & 
Brown, 2004).   
Both self and significant-other reports have potential problems.  For example, 
self-report from patients with PD may be problematic because cognitive deficits that 
are frequently associated with this disorder may impair their ability to accurately 
describe problems.  It is known that the agreement between significant-other and self-
report decreased with more severe cognitive problems in Huntington’s disease 
suggesting that as cognitive status becomes impaired, patient assessment is less 
accurate than that obtained from a caregiver (Chatterjee, Anderson, Moskowitz, 
Hauser, & Marder, 2005).  Conversely, the reports of significant others may be 
influenced by their own level of distress.  Mangone et al (1993) reported that the best 
predictor of feelings of burden for the caregivers of patients with probable Alzheimer 
disease was their report of perceived behaviour problems (Mangone et al., 1993).   
The primary objective was to examine the level of agreement between ratings 
of neuropsychiatric symptoms reported by PD patients and those reported by a 
significant-other.  Rating scales were used that are commonly found in the literature 
and which separately examine self or significant-other reports of neuropsychiatric 
symptoms in PD patients.  Secondly, the relationship between the significant other’s 
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own level of distress and his/her perception of neuropsychiatric symptoms in the 
patient was examined.  As discrepancies in many commonly used neuropsychiatric 
measures could be explained by the fact that they represent different psychometric 
instruments and lack common measures, the Frontal Systems Behaviour Scale 
(FrSBe) was also used, which is completed by both the patient and their significant 
other.  This scale provided a method to directly compare the level of agreement 
between the two methods of reporting.   
3.4.3 Methods   
Approval for the study was obtained from the Upper South B Canterbury 
Ethics Committee and informed consent was obtained from the patients.  Patients 
were also asked to nominate an informant (a “significant other” who knew them well) 
who would provide information regarding the patients’ everyday functioning and 
general behavior.  Informed consent was obtained independently from all nominated 
significant others.   
Participants  
Patients in the Canterbury region of New Zealand with a confirmed diagnosis 
of idiopathic PD, identified by two experienced neurologists, were invited to take 
part.  Inclusion criteria required no evidence of any other major medical illness, no 
evidence of dementia (MMSE ≥25), and being between 55 and 79 years of age.  Of 
the 115 letters that were mailed out, 11/115 (9.6%) could not participate due to illness 
or dementia, 8/115 (9.6%) were deceased, 8/115 (6.9%) declined, 34/115 (26.9%) did 
not respond.  A total of fifty-four patients who met the inclusion criteria volunteered 
to take part.  Five of these patients did not complete the take home tests and were 
excluded.  Forty-nine patients, of whom 43 were also able to provide a significant 
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other contact, took part in the study.  In the majority of cases (approximately 90%), 
the significant other was a spouse.  The clinical and demographic characteristics of 
patients who were included are listed in Table 25.   
Table 25: Clinical and demographic characteristics, Parkinson’s disease patients.   
 Mean Range 
Age 66.6 (6.8) 52.0  -  77.0 
MMSE1 28.5 (1.3) 25.0  -  30.0 
PD Duration 6.0 (4.2) 0.3  -  23.0 
UPDRS2 26.6 (9.7) 13.0  -  53.0 
 
1 Mini Mental Status Exam;2Parkinson’s Disease Rating Scale (motor score component). 
 
3.4.4 Procedure   
Patients were assessed while on PD medication.  Information regarding 
current cognitive status, motor symptoms, hallucinations, sleep problems and 
depression were all collected during the session.  Patients were also asked to complete 
self-report forms later at home regarding symptoms of apathy, and anxiety.  Details 
on how to complete these forms were explained during the session, and patients were 
asked to return these approximately seven days later.  Any questions or difficulties 
regarding the completion of the forms were addressed at this time.  Patients were 
specifically requested to complete the self-report forms independently, unless they 
required help with writing.  Information regarding the patients’ everyday activities 
and general behavior were collected during a face-to-face interview with the 
nominated significant other.  In the majority of cases, these were conducted by a 
second interviewer while the patients themselves were being assessed.   
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Clinical and demographic characteristics  
1) A semi-structured interview was used to gather demographic and clinical 
details including age, time since diagnosis of PD and current medications.   
2) The Mini Mental Status Exam (MMSE) provided information regarding 
current global cognitive status, with 30 being the maximum score that may be 
achieved (Folstein, Folstein, & McHugh, 1975).  A variety of cut offs have 
been suggested for this instrument, but scores below 23-24/30 have been 
reported as having high sensitivity and specificity in identifying individuals 
with dementia (O'Connor et al., 1989).  In this study, patients were included if 
they scored ≥25.   
3) The Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn & Elton, 1987) 
motor section (section III) was used to rate current motor impairment.  Scores 
on this scale range from 0-108, with higher scores indicating greater motor 
impairment.   
4) The Hoehn and Yahr (H&Y) was used to rate the stage of the disease (Hoehn 
& Yahr, 1967).  The modified version of this scale was used, which has 
increments of 0.5 in the midranges (stage 1, (n=9); 1.5,( n=6); 2, (n=10); stage, 
2.5, (n=13); 3, (n=8); 4,( n=3)). 
Neuropsychiatric information using self report only.   
1) Symptoms of depression were assessed using the Beck Depression Inventory 
(BDI-II) (Beck, Steer, & Brown, 1996).  The BDI-II consists of 21 items, each 
scored from 0 to 3.  A threshold of 14 and above is recommended for detecting 
the presence of depression (probable depression), and 9 and above for 
screening purposes (possible depression).  To be comparable with the 
Neuropsychiatric Inventory (NPI) which screens for both low mood 
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(dysphoria) and depression, we used a cutoff of ≥9 as evidence of depressive 
symptoms.   
2) Anxiety was assessed using the Hospital Anxiety and Depression Scale 
(HADS), which consists of 14 items (Zigmond & Snaith, 1983).  Of these, 
seven relate to anxiety and are each rated on a four point scale (0-3) with a 
maximum score of 21.  A threshold of 10 has been recommended for detecting 
probable anxiety, with above 8 for possible anxiety.  To aid comparison with 
the NPI, a score of ≥8 was taken as evidence of symptoms of anxiety 
(Zigmond & Snaith, 1983).   
3) Apathy was assessed using the Apathy scale (Starkstein et al., 1992) which is 
a 14 item self-report measure.  Participants are asked to indicated the extent to 
which each of the 14 statements applied to them over the last month using a 4 
point scale: not at all, slightly, some, a lot.  The recommended cut-off of >14 
was used for this study (Starkstein et al., 1992). 
4) Sleep Disturbance: The frequency of sleep disturbance was assessed using a 
single screening item contained in the UPDRS (Fahn & Elton, 1987).  Patients 
were asked to respond either Yes or No to the question, “Do you have any 
problems with your sleep?”  
5) Hallucinations: The presence of hallucinations was assessed by a single 
screening item from the UPDRS (Fahn & Elton, 1987).  A 5 point scale was 
used where 0=None, 1=Vivid dreaming, 2= “Benign” hallucinations with 
insight retained, 3= Occasional to frequent hallucinations or delusions without 
insight, 4= Persistent hallucinations, delusions or florid psychosis.  For the 
purposes of this study hallucinations were considered to be present if the 
patient scored two or higher on this scale. 
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Neuropsychiatric information from significant others only.   
Patients’ neuropsychiatric problems were assessed in a structured interview 
with the significant other using the Neuropsychiatric Inventory (NPI) (Cummings et 
al., 1994).  The NPI covers 12 different areas of behavioral functioning: Delusions, 
hallucinations, agitation, dysphoria/depression, anxiety, euphoria, apathy, irritability, 
disinhibition, aberrant motor behavior, night-time behavior and appetite/eating 
change.  Each question addresses changes in the person’s behavior since the onset of 
the illness.  The interviewee is first asked whether the behavioral change is present or 
absent.  If it is absent the interviewer continues to the next domain, otherwise the 
interviewer asks about the frequency of the problem (1=occasionally, 2=often, 
3=frequently, 4= very frequently) and severity (rated, 1=mild, 2=moderate, 3=severe) 
using the script provided in the manual.  Scores for each domain were generated by 
multiplying frequency by severity (maximum score = 12).  A total NPI score was 
generated by adding together the scores from each domain (for this study the 12 item 
score was used).  Each domain was also scored in terms of how emotionally 
distressing the significant other found the behavior (0=no distress, 1=minimal, 
2=mild, 3=moderate, 4=moderately severe, 5=very severe or extreme).  Information 
regarding significant others’ level of distress was also generated for each domain 
separately, and a total score was obtained by adding together the scores of the 
individual distress questions.   
Neuropsychiatric information from both patients with PD and significant others.   
Two versions of the The Frontal Systems Behaviour Scale (FrSBe) (Grace & 
Malloy, 2001) are available, one for self-report and another for the significant other to 
complete.  This scale provided a method to directly compare the level of agreement 
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between the two methods of reporting.  The FrSBe assesses three areas of behavioral 
functioning: apathy, disinhibition and executive functioning.  The scale consists of 46 
questions describing possible behaviors, with each question being answered using a 5 
point scale (1 = almost never and 5 = almost always).  Each question was answered in 
terms of how the patient was “at the present time”.  Raw scores were converted to 
age, gender and education adjusted T-scores (mean =50; SD=10), with higher scores 
indicating the presence of a greater number of problem behaviors.  A score of 60 – 64 
is considered borderline impairment, while >65 is considered to be clinically 
significant (Grace & Malloy, 2001).   
3.4.5 Statistical Analysis   
The percentage of individuals with neuropsychiatric problems was calculated 
using previously validated cut-offs as described in the methods section.  Data are also 
reported in terms of means and standard deviations.  Pearson correlation and t-tests 
were used to examine the relationship between significant other and self report.   
3.4.6 Results   
Table 26 shows the percentage of patients reported by significant others as 
having neuropsychiatric problems.  One or more problems were reported in over 80% 
of the patients.  Symptoms consistent with depression (42.2%) and difficulty sleeping 
(44.2%) were the most frequently reported problems.  Symptoms of agitation, anxiety, 
apathy and eating problems were each reported in over 20% of the patients.  Less 
frequently reported were symptoms of irritability, hallucinations, aberrant motor 
behavior, delusions and euphoria (< 12%).   
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Table 26: Significant others’ reports from the Neuropsychiatric Inventory, of the 
percentage of patients with symptoms and the sub-scale scores.   
 
Percentage with 
symptom (>zero) 
Mean (SD)1 for patients 
with symptom (>zero) 
Range 
 
Delusions 4.4%   (2/43) 8.0  (5.7) 1-12 
Hallucinations 8.9%   (4/43) 5.3  (5.0) 1-12 
Agitation 20.9%   (9/43) 2.6  (1.7) 1-6 
Depression 42.2% (19/43) 2.3  (2.0) 1-8 
Anxiety 23.3% (10/43) 3.0  (2.1) 1-8 
Euphoria 2.3%   (1/43) 1.0  (---) ---- 
Apathy 27.9% (12/43) 4.2  (3.6) 1-12 
Disinhibition 9.3%   (4/43) 3.3  (2.2) 1-6 
Irritability 11.6%   (5/43) 3.8  (2.3) 1-6 
Aberrant Motor 
Behavior2 
4.7%   (2/43) 2.5  (0.7) 1-3 
Difficulty Sleeping 44.2% (18/43) 6.2  (4.3) 1-12 
Eating Behavior3 30.2% (13/43) 4.2  (3.4) 1-12 
NPI total4 81.4% (35/43) 11.1 (12.8) 1-59 
 
1 Mean scores presented here are calculated in terms of frequency x severity according to standard 
Neuropsychiatric Inventory scoring instructions. 2 Aberrant motor behaviour refers to pacing or 
unusually repetitive behaviours e.g., opening closets or drawers; 3Eating behaviour refers to change in 
food types preferred or appetite; 4Total scores include night behavior and eating problems.  
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Table 27 displays the level of distress experienced by the significant other 
regarding each of the neuropsychiatric problems he/she reported as present in the 
patient.  Not all significant others found the presence of neuropsychiatric problems 
distressing.  Although over 80% of significant others reported at least one 
neuropsychiatric problem, only 48% reported finding any of these problems 
distressing.  However, for those who did, the presence of delusions, hallucinations, 
disinhibition and irritability were each reported as causing moderate to severe levels 
of distress.  By contrast, the reported presence of agitation, anxiety, apathy and 
difficulty sleeping, were associated with only mild to moderate distress in the 
significant other.  Least distressing were the presence of eating problems and 
depression, which were reported as causing only minimal to mild distress.   
Comparisons between the prevalence of neuropsychiatric problems using self 
(assessed using the BDI, HADS, Apathy Scale and the UPDRS) and significant-other 
reports (assessed using the NPI) were made for symptoms of apathy, anxiety, 
depression and the presence of hallucinations and sleep difficulties (see Table 28).  
Whereas reported frequency rates were similar for significant other and patient, the 
agreement between an individual patient’s report and that of their significant other 
was not high.  Indeed, there was a high of 40.9% agreement for the presence of apathy 
and a low of 7.7% agreement for the presence of anxiety.  Further, patients reported 
hallucinations that were not identified by the significant other in 3/5 (60%) of cases.  
However, higher levels of agreement were found for depression (9/20; 45%), apathy 
(10/19; 53%) and sleep difficulties (9/16; 56%).  But for anxiety, 6/7 (86%) of cases 
were identified by the patient and not by the significant other.   
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Table 27: The percentage of significant others reporting distress and the levels of 
distress associated with different symptoms they reported as present in the 
patient.   
Distress was assessed using the Neuropsychiatric Inventory. 
 
Percentage reporting 
distress  
(scores > zero) 
Mean (SD) for care-
givers with symptoms  
(scores >zero) 
Range 
 
 
Delusions 2.3%   (1/43) 5.0 (----) --- 
Hallucinations 7.0%   (3/43) 3.0 (2.0) 1-5 
Agitation 11.6%   (5/43) 2.2 (1.1) 1-3 
Depression 30.2% (13/43) 1.8 (0.7) 1-3 
Anxiety 14.0%   (6/43) 2.0 (0.9) 1-3 
Euphoria 0.0%   (0/43) --- --- 
Apathy 20.9%   (9/43) 2.1 (1.2) 1-4 
Disinhibition 2.3%   (2/43) 3.0 (1.4) 2-4 
Irritability 2.3 %   (2/43) 3.0 (0.0) --- 
Aberrant motor behavior 0.0%   (0/43) --- --- 
Difficulty Sleeping 23.3% (10/43) 2.6 (1.6) 1-5 
Eating Behavior 11.6%   (5/43) 1.5 (0.5) 1-2 
Caregiver distress total1 48.8% (21/43) 5.9 (4.6) 1-16 
 
1Total caregiver distress is the sum of the sub-scores 
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Table 28: Comparison between patient and significant other reports of 
neuropsychiatric problems.   
 
Frequency 
other report (n=43) 
Frequency 
Self report (n=49) 
Level of 
agreement 
Hallucinations 4 (9.3%) 5 (10.2%) 2 (28.6%) 
Depression 20 (46.5%) 20 (40.8%) 11 (39.3%) 
Anxiety 7 (16.3%) 7 (18.9%)1 1 (7.7%) 
Apathy 12 (27.9%) 19/49 (38.0%) 9 (40.9%) 
Sleep difficulties 18 (41.9%) 16/49 (32.7%) 7 (25.0%) 
 
1 Only 37 patients, who also were able to volunteer a significant other, completed self ratings for 
anxiety.  
 
Overall the correlations between significant other report versus self report and 
significant other distress versus self report were low for ratings of apathy, anxiety and 
sleep problems.  The only significant correlations were for the presence of 
hallucinations and depression (Table 29).  By contrast, there was a significant positive 
association between the report of neuropsychiatric symptoms by significant others and 
their distress (see Table 29).   
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Table 29: Correlations for significant other and self report of neuropsychiatric 
symptoms, significant other distress versus self report of symptoms and 
significant other report of neuropsychiatric symptoms and significant other 
distress.   
 
Significant other 
v self report 
 
 
Significant other 
distress v self 
report 
 
Significant other 
report v 
significant other 
distress 
Apathy 0.22 0.16 0.47** 
Anxiety1 -0.02 0.02 0.53*** 
Hallucinations 0.51*** 0.50** 0.99*** 
Sleep Problems 0.09 -0.02 0.63*** 
Symptoms of 
Depression 0.37* 
0.28 0.47** 
137 patients and their significant other completed the self ratings of anxiety, whilst correlations for all 
other measures are based on 43 patient and significant other pairs. 
*p<0.05;**p<0.01;***p<0.001. 
 
Ratings of sleep problems and hallucinations used a similar dichotomous scale 
for both self and significant-other reports.  However, self reports of depression, 
apathy and anxiety used continuous measures with set cut offs, while significant other 
report relied on a yes/no answer format.  Thus, it was possible that the lack of 
agreement between significant-other and self-report of neuropsychiatric problems was 
due to different measures used.   
To overcome the difficulty outlined above, patients and significant others also 
reported on the presence of neuropsychiatric problems using a rating scale that 
enabled both to report symptoms in the same manner so that direct comparisons could 
be made.  The Frontal System Behavior Rating Scale (FrSBe) includes many of the 
same problem behaviors as the NPI.  For this analysis we included only those patients 
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who were able to volunteer a significant other (n=43).  As shown on Table 30 even 
when the same rating scale was used, reported frequencies for significant other and 
patient differed.  Further, significant-other reports of neuropsychiatric problems did 
not correspond well with patient self-report, with a high of 53.1% agreement for the 
presence of apathy and a low of 13.6% agreement for the presence of disinhibition.   
Table 30: Comparison between patient and significant other reports for patients 
showing at least borderline impairment as rated by the Frontal System Behavior 
Rating Scale.   
 
Frequency 
other report 
Frequency 
Self report 
Level of 
agreement 
Apathy 21/43 (48.8%) 28/43 (65.1%) 17/32 (53.1%) 
Disinhibition 6/43 (14.0%) 19/43 (44.2%) 3/22 (13.6%) 
Executive function 15/43 (34.9%) 26/43 (60.5%) 9/32 (28.1%) 
Total Score 16/43 (37.2%) 27/43 (62.8%) 11/32 (34.4%) 
 
Figure 5 shows the mean self and significant other ratings using the FrSBe.  
For each of the sub-scales, ratings by significant others were lower than those by 
patients.  This difference was significant for ratings of disinhibition (t = 2.5, df = 84, p 
< 0.02), executive dysfunction (t = 2.1, df = 84, p < 0.05) and overall score (t = 2.2, df 
= 84, p < 0.05) but not for apathy (t=1.15, df=84, p>0.20).  On average, patient ratings 
indicated borderline impairment in terms of the total score and for the subscales 
apathy and executive dysfunction, but not for disinhibition.  However, significant 
other ratings for the patients were all in the average range (average range= T 50 +/- 
10).   
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Figure 5: Comparisons between self-rating and significant other rating using the 
Frontal Systems Behavioral Rating Scale.   
(Line indicates mean, T-score of 50 SD=10. Clinical range > 65). 
 
The level of agreement between the two groups was also compared using 
Pearson correlation.  The ratings of the two groups were significantly correlated (p < 
.05) for ratings of apathy (r = .36), but not disinhibition (r = .16), executive 
dysfunction (r = .00) or total score (r = 0.09) 
3.4.7 Discussion   
This study involved a comparison of significant other and self reports for 
neuropsychiatric symptoms experienced by PD patients, including anxiety, 
depression, apathy, hallucination and sleep problems.  Although similar rates of 
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symptoms overall were reported by patients and significant others, the level of 
agreement within individual dyads was low.  Thus our results show that reports of 
significant others and patients cannot be regarded as interchangeable.   
One possible reason for the lack of agreement may that significant others were 
asked to report on problems that could not be identified based on observable behavior, 
and thus relied on the patient having effectively communicated these problems to 
them.  Moreover, the format of the measures used for ratings of self and significant 
other reports differed.  For example, for anxiety, depression and apathy, patients were 
endorsing a range of symptoms and the resulting score was classified in terms of a 
predetermined cut-off as having or not having one of these disorders.  For the 
significant other reports (using the NPI), all disorders were identified by a yes/no 
response.  A yes/no format assumes that the informant has the relevant knowledge 
about indicative behaviors that are associated with the disorder, whereas for the 
patients, that knowledge is unnecessary because separate items on the scale are used 
for different behaviors.   
It could be argued that the difference detected in this study were a result of 
different scales being used to assess the different neuropsychiatric problems.  
However, when significant others and the patient were asked to report on the 
symptoms using the same scale (FsSBe), the relationship between the two reports was 
still low for ratings of disinhibition, executive dysfunction and in terms of the overall 
score.  The only area for which the scores between the two raters were significantly 
correlated was apathy.  On average patients perceived themselves has having more 
problems than did the significant other.   
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Previous research with Alzheimer’s patients suggests that significant others’ 
reports can be influenced by the burden they perceive that the patients’ behavior 
places on them (Mangone et al., 1993; Zanetti, Geroldi, Frisoni, Bianchetti, & 
Trabucchi, 1999).  Moreover, significant other reports may have been influenced by 
their own mental state.  Many caregivers of patients with PD are themselves 
depressed, and this may cause them to view the patient’s behavior more negatively 
and endorse more neuropsychiatric symptoms (Caap-Ahlgren & Dehlin, 2002; 
Fernandez, Tabamo, David, & Friedman, 2001).  Alternatively, patients might lack 
insight regarding their own behavior (Leritz, Loftis, Crucian, Friedman, & Bowers, 
2004).  However, neither of these explanations seems credible given that the patients 
tended to rate themselves as more impaired on the FrSBe than their significant other 
did.   
In this study it was found that the number of significant others who reported 
particular neuropsychiatric behaviors as being distressing was much less than the 
number reporting the presence of these behaviors.  One possible explanation for this is 
that caregivers reported levels of distress were influenced by their own sense of 
loyalty to the patient and therefore tended to under-report levels of stress.  Studies of 
patients with dementia have reported that caregivers are reluctant to be honest 
regarding a patient’s behavior because they did not want to upset them or they felt 
guilty doing so (Hughes, Hope, Reader, & Rice, 2002).  Alternatively, caregivers may 
not report distress as a means of coping with that distress.  Brandtstadter and Renner 
(1990) proposed that as individuals face the challenges of aging, they change their life 
expectations (update their goals) in an effort to preserve a sense of control.  In the 
case of individuals who assist in the care of a patient, updating of goals may include 
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an acceptance that PD may result in a number of neuropsychiatric problems and not 
allow this to cause distress.   
There were a number of limitations with this study.  First, comparisons would 
have been enhanced had the patients and significant others reports been obtained 
using similar scales throughout.  However, the measures we used are commonly used 
to assess either significant other report or self report of neuropsychiatric problems.  
Another potential shortcoming of the study is that we did not specifically collect 
information regarding the characteristics or mental state of the significant other 
reporters.  Therefore, we could not examine differences between significant others 
who found the presence of a particular disorder disturbing and those who did not.   
Overall, our results suggest that there may be a low level of agreement 
between significant other and self reports of neuropsychiatric problems.  Therefore, 
reports from these two sources cannot be considered interchangeable.  In addition, it 
appears that the perception of neuropsychiatric problems may influence the level of 
stress felt by the significant other as well as the actual presence of these problems.  
Many patients with PD rely on the support and assistance that is provided by a 
caregiver.  This assistance enables the patient to remain in their own homes.  
However, increased caregiver stress may lead to early rest home placement at both a 
personal and social cost.  Therefore, attention needs to be paid to the stress that 
caregivers experience in this role and the development of possible interventions to 
support them.   
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3.5 The Accuracy of the Unified Parkinson’s Disease Rating Scale (UPDRS-
Section 1) as a Screening Measure for Depression   
(In Press Journal of Parkinsonism and Related Disorders. Avaliable online May 2007) 
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3.5.1 Abstract   
The purpose of this study was to evaluate the accuracy of the UPDRS as a 
screening instrument for depression in Parkinson’s disease (PD).  Fifty nine patients 
with PD were screened for depression using the UPDRS.  Ratings were compared 
with scores on the Beck Depression Inventory (BDI-II), Geriatric Depression Scale 
(GDS) and the Hospital Anxiety Depression Scale (HADS).  A total of twenty nine 
patients were identified with possible depression by the BDI-II, GDS or HADS, with 
over one third of these (34%) assessed as having no depressive symptoms using the 
UPDRS.  The UPDRS lacks sensitivity as a screening instrument for possible 
depression.   
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3.5.2 Introduction   
Depression is a common feature in PD, with prevalence rates varying between 
7-70% depending on the method of assessment and criteria and used (Burn, 2002a).  
Because depression can have negative effects on an individuals’ cognitive functioning 
and quality of life, timely identification and intervention is extremely important.  
However, depression is often not recognized or is misdiagnosed by clinicians during 
routine assessment (Shulman, Taback, Rabinstein, & Weiner, 2002).  To assist in the 
recognition of non-motor symptoms such as depression, clinicians are often guided by 
standardized instruments such as the UPDRS (Fahn & Elton, 1987).  The UPDRS 
provides a comprehensive means of evaluating impairments associated with PD, and 
Section 1 of the assessment battery includes a question relating to the presence of 
depression.  Although the UPDRS lacks sufficient information for use as a diagnostic 
tool, it is commonly used as an initial screen.  Unfortunately, there is currently no 
information regarding the accuracy of the UPDRS as a screening tool for depression, 
and no guidelines for when a clinician should initiate a more detailed assessment.   
This study sought to assess whether the question in the UPDRS would 
accurately identify patients who required further screening by using the UPDRS in 
addition to three depression measures that have been validated for use in the PD 
population: the BDI-II, GDS and HADS (Ertan, Ertan, Kizilatan, & Uygucgil, 2005; 
Leentjens, Verhey, Luijckx, & Troost, 2000; Weintraub, Oehlberg, Katz, & Stern, 
2006).  The level of agreement among these scales was examined, using the optimal 
suggested cut-offs for this patient group.   
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3.5.3 Methods   
Approval for the study was obtained through the local ethics committee and 
patients were invited to take part through a letter from their neurologist.  From the 115 
patients contacted, 59 patients without evidence of dementia volunteered to take part.  
There were 40 males (67.8%) and 19 females (32.2%), with an average age of 66.7 
years (± 7.3) (age range 48 to 79 years old) and a mean UPDRS-subscale III score of 
31.0 ± 10.7.  All participants were administered the GDS, BDI-II, UPDRS and the 
Mini Mental Status Exam (MMSE, patients were included if they scored ≥25) 
(Folstein, Folstein, & McHugh, 1975).  A portion of the patients also completed the 
HADS.  The GDS is a 30 item self-rated depression measure with each item answered 
yes/no and rated 1/0.  The BDI-II consists of 21 items; each question is rated 0 to 3.  
Both the BDI-II and the GDS have been validated for use with PD patients, each with 
a threshold of 14 and above being recommended for detecting the presence of 
depression (probable depression), and 9 and above for screening purposes (possible 
depression) (Ertan, Ertan, Kizilatan, & Uygucgil, 2005; Weintraub, Oehlberg, Katz, & 
Stern, 2006).   
The HADS consists of 14 items.  Of these, seven relate to depression and are 
each rated on a four point scale (0-3) with a maximum score of 21.  A threshold of 10 
has been recommended for detecting probable depression, with above 8 for possible 
depression (Ertan, Ertan, Kizilatan, & Uygucgil, 2005; Weintraub, Oehlberg, Katz, & 
Stern, 2006; Zigmond & Snaith, 1983).  For each of these self report measures, higher 
scores are indicative of more depressive symptoms.   
The UPDRS has a single screening item for depression.  A score of zero 
indicates no symptoms, 1= periods of sadness or guilt greater than normal, but never 
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sustained for days or weeks, 2= sustained depression (one week or more), 3= 
sustained depression with vegetative symptoms (insomnia, anorexia, weight loss, loss 
of interest), 4= sustained depression with vegetative symptoms and suicidal thoughts 
or intent.  Patients with a score of 0 were considered to have no depressive symptoms, 
1-2 possible, and 3-4 probable depression.   
3.5.4 Statistical Analysis   
Pearson correlation was employed to assess the relationship between the 
different measures of depression.  We then examined how well the UPDRS predicted 
possible and probable depression, as defined by the BDI-II, GDS or HADS score 
exceeding the respective cut-off, through percentage agreement and Receiver 
Operating Characteristic (ROC) analyses.   
3.5.5 Results   
Significant positive correlations were obtained between all measures of 
depression.  Correlations were moderately strong between the UPDRS and BDI-II, r = 
.61, p < .001, GDS, r = .63, p < .001, and HADS, r = .42, p < .01.  The BDI-II and 
GDS were highly correlated, r = .77, p < .001, while the correlations between the 
HADS and BDI-II and GDS were also positive, r = .53, p < .001 and r = .66, p < 001.   
Table 31 shows cross tabulations between the UPDRS as diagnostic screen 
and those produced by applying the appropriate cut-offs for possible and probable 
depression for the BDI-II, GDS, and HADS.  Despite the positive correlation between 
the UPDRS and the three measures of depression, the UPDRS diagnostic screen 
agreed with the BDI-II in only 54.3% of total cases, and with the GDS and HADS in 
55.9 % and 56.5% of cases, respectively.  False negatives were unacceptably high:  Of 
 171 
 
the patients that had possible or probable depression according to the BDI-II and 
GDS, the UPDRS indicated no depression for 33% and 30% of cases, respectively.  
The proportion of cases identified by the HADS with possible or probable depression 
was significantly lower compared to the BDI, χ2 = 20.54, df = 1, p < 0.001, and the 
GDS, χ2 = 9.14, df = 1, p < 0.01).  Patients who completed the HADS did not differ 
significantly from those who did not, in terms of demographic variables or levels of 
depression on the other three scales used.   
A series of ROC analyses were conducted in which the UPDRS was used to 
predict possible/probable and probable depression, as defined by meeting the criteria 
for possible or probable depression on the BDI-II and GDS.  The HADS was not used 
as a criterion for this analysis because it identified only a small number of cases with 
possible and probable depression.  For sake of comparison, we also used the BDI-II 
and GDS to predict possible/probable depression according to the GDS and BDI-II 
respectively.   
The UPDRS achieved only moderate levels of accuracy in predicting possible 
depression:  AUC values for possible depression according to the BDI-II and GDS 
were .69 and .71, respectively.  Corresponding AUC values for the BDI-II predicting 
possible depression according to the GDS, and vice versa, were .85 and .84, which 
were significantly greater than UPDRS accuracy, z = -2.35, p < .01 and z = -1.64, p < 
.05 (Hanley & McNeil, 1983).  The UPDRS was more accurate in predicting probable 
depression according to the BDI-II and GDS, with AUC values of .85 and .85.  These 
values were less than those for the BDI-II and GDS predicting probable depression 
according to the GDS and BDI-II, AUC’s = .95 and .96, although the differences did 
not reach significance, z = -1.51 and z = -1.52, both ns.   
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Table 31: Cross tabulation of diagnostic screen classifications (“Not Depressed, 
“Possible Depression”, and “Probable Depression”) obtained with UPDRS and 
with three validated psychometric tests for depression (BDI-II, GDS, and 
HADS).   
Category Percentage indicates the proportion of cases in each diagnostic 
classification for the BDI-II, GDS, and HADS.  The percentage agreement 
column shows the percent of cases with a particular diagnostic classification for 
which the UPDRS gave the same classification; numbers in boldface indicate the 
overall percent agreement of UPDRS screen for each of the psychometric tests.   
  
UPDRS=0 
Not 
Depressed 
 
UPDRS=1-2 
Possible 
Depression 
 
UPDRS=3-4 
Probable 
Depression 
 
Category 
Percentage 
 
 
Percentage 
Agreement 
BDI-II 
1
      
 Not depressed  (<9) 22 13 0 59.3 62.9 
 Possible          (9-13) 7 6 0 22.0 46.2 
 Probable          (≥14) 1 6 4 18.6 36.4 
% UPDRS Categories 50.8 45.8 6.8   
Total Agreement     54.3 
GDS 
2
      
 Not Depressed (<9) 24 15 0 66.1 61.5 
 Possible           (9-13)   5 5 0 16.9 50.0 
 Probable           (≥14) 1 5 4 16.9  
% UPDRS Categories 50.8 42.4 6.8   
Total Agreement     55.4 
HADS 
3
      
 Not Depressed (<8) 24 17 2 93.5 55.8 
 Possible           (8- 9) 0 2 0 4.3       100.0 
 Probable          (≥ 10) 0 1 0 2.3   0.0  
% UPDRS Categories 52.2 43.5 4.3   
Total Agreement     56.5 
 
1Beck Depression Inventory-II; 2 Geriatric Depression Scale; 3Hospital Anxiety Depression Scale. Only 
a  portion of the participants completed the HADS (n=46/59).  
 
Overall 29 of the 59 patients (49%) had scores indicative of possible 
depression using the BDI-II, GDS or HADS.  There was no significant difference 
between patients who met the criterion for possible depression and those who did not 
in terms of years of education (t = 0.40, df =57, p > 0.65), age (t = 1.60, df = 57, p 
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>0.10), gender (t = -0.17, df = 57, p > 0.85) or disease duration (t = -0.18, df = 57 p > 
0.85).   
3.5.6 Discussion   
Although the UPDRS has been suggested as a suitable screen for depression in 
PD patients, there are no guidelines to indicate who should be referred for a more 
detailed assessment.  This study sought to evaluate the accuracy of the UPDRS as a 
screening instrument for depression.  Ratings on the UPDRS were compared to scores 
using three measures of depression validated for use with PD patients.  Overall, 29 of 
59 cases were identified as having possible depression by the BDI-II, GDS or HADS.  
The UPDRS failed to identify 34% of these cases as having any depressive symptoms 
whatsoever, which is an unacceptably high Type II error rate.  ROC analyses showed 
that the UPDRS had only moderate accuracy overall for predicting possible 
depression, as measured by BDI-II and GDS, with average AUC = .70.   
Apparently, individuals with milder symptoms were more likely to endorse 
“no depression” using the UPDRS.  This may result from how the question is 
currently structured with 0 being indicative of “not present,’ while a score of 1 refers 
to periods of sadness “greater than normal”.  Faced with this decision, individuals 
with mild symptoms may be more inclined to endorse no problems.  These issues 
have been recognized by the UPDRS task force who are currently revising the scale 
with the intention making it suitable for capturing mild impairments, and who also 
intend to provide more detailed guidelines for clinicians (Romano, 2005).   
Although there are notable differences in the structure of the BDI-II and GDS, 
overall there was a high level of agreement between the two measures.  By contrast 
the HADS identified significantly fewer of the patients as having possible or probable 
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depression compared to the BDI-II or the GDS.  It is possible that the traditional cut-
off scores for this measure are too conservative for use with PD patients.   
Conclusion 
Because a high level of sensitivity is desirable, the UPDRS in its present form 
has limited utility as a screening instrument for possible depression.  The routine 
administration of more comprehensive measures such as the BDI-II or GDS to screen 
for depression is therefore advisable.  Cut-off scores for the HADS may need to be 
revised for use with PD patients.   
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Chapter 4 - The Cognitive Profile of Patients with Parkinson’s disease   
Abbreviations in test chapter 4 
1) AD = Alzheimer’s disease; 2) ANCOVAs = Analyses of covariance; 3) ANOVA = 
analysis of variance; 4) BADS = Behavioral Assessment of the Dysexecutive 
Syndrome; 5) BDI-II = Beck Depression Inventory; 6) CANTAB = Cambridge 
Neuropsychological Test Automated Battery; 7) D-KEFS = Delis Kaplan Executive 
Function System; 8) DRS-II = Dementia Rating Scale-II; 9) DSM-IV = Diagnostic 
and Statistical Manual Fourth Edition; 10) FAQ = Functional Activities 
Questionnaire; 11) H&Y = Hoehn and Yahr Staging Scale; 12) ID/ED = Inter 
Dimensional/Extra Dimensional Shift; 13) JOL = Judgement of Line Orientation test; 
14) MCI = Mild Cognitive Impairment; 15) MMSE = Mini Mental Status Exam; 16) 
NART = National Adult Reading test; 17) PD = Parkinson’s disease; 18) PPD = 
Parkinson’s disease; 19) PD-MCI = Parkinson’s disease with Mild Cognitive 
Impairment; 20) PD-NCI = Parkinson’s disease No/minimal impairment; 21) PD-
UCI = Parkinson’s disease with Uncertain Impairment; 22) ROF = Rey-Osterrieth 
Complex Figure Test; 23) SOC’s = Stockings of Cambridge; 24) S&E = Modified 
Schwab and England Activities of Daily Living Scale; 25) TOL = Tower of London; 
26) UPDRS = Unified Parkinson’s disease Rating Scale; 27) WASI = Wechsler 
Abbreviated Scale of Intelligence; 28) WAIS-III = Wechsler Adult Intelligence Scale 
3rd edition; 29) WMS-III = Wechsler Memory Scale-3rd Edition. 
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4.1 Overview   
Cognitive deficits are a feature of PD, even in the absence of dementia.  A 
review of the existing literature indicates that deficits in the domains of memory, 
learning, visuoperception/visuospatial functioning, speed of mental processing and 
executive functions (including planning, working memory, verbal fluency, attention 
and set-shifting) are the most commonly affected domains of cognition that are 
associated with PD (see Pillon, Boller, Levy, & Dubois, 2001 for review).  However, 
there is still considerable controversy regarding the exact profile of cognitive deficits 
that are associated with this disorder.  It has been suggested that the lack of consensus 
is due to the heterogeneity of cognitive performance in PD patients that is unrelated to 
motor symptoms or disease duration (Lewis et al., 2003; Lewis et al., 2005).  This 
suggestion has led to a greater focus on identifying different sub-groups of patients 
based on their cognitive status (Lewis et al., 2005).  The identification of sub-groups 
of PD patients based on cognitive characteristics may be of some importance as 
particular groups could be at greater risk of cognitive decline and later dementia.  
Cognitive decline and dementia in PD have serious implications for the patient 
resulting in reduced quality of life, increased caregiver distress and resultant 
premature rest home placement (Schrag, Jahanshahi, & Quinn, 2000).   
4.1.1 Difficulty with research in this area   
Much of the inconsistency in results regarding cognitive deficits in PD has 
resulted from the application of different methodologies, diverse patient groups, 
heterogeneity of tasks employed and the varying levels of complexity and processing 
demands of the different tasks.  Assessing cognitive deficits in PD poses a number of 
difficulties in addition to those outlined in section 1.6.2.  For example, test selection is 
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constrained by the physical limitations of the patients.  There are few cognitive test 
batteries that have been developed specifically for individuals with physical 
limitations.  Further, any testing must be arranged in order to accommodate changes 
in physical functioning that can occur in a single session, e.g., fatigue, changes in 
medication effectiveness, and lack of motivation.  Another important consideration is 
the neuropsychiatric issues that frequently accompany PD.  Neuropsychiatric issues 
also raise the consideration of which patients to include or exclude while retaining the 
maximum generalisability of any data obtained.   
4.2 Current Research   
For this study a wide variety of tests were selected that would cover different 
aspects of cognition.  The purpose of this extensive testing was threefold.  Firstly, to 
identify the range and extent of cognitive problems in patients with PD compared to 
normal elderly.  Secondly, to use this information to develop a discrete set of tests 
capable of identifying which patients are experiencing cognitive impairments of 
sufficient severity to interfere with their daily lives.  Thirdly, to identify different sub-
groups of PD patients based on their cognitive performance.  Identification of sub-
groups may enhance our understanding of cognitive impairments in PD, and also 
might reveal patients who are at a stage of pre-clinical dementia or mild cognitive 
impairment.  The term mild cognitive impairment (MCI) has been used in research on 
Alzheimer’s disease to describe a stage of cognitive decline that is greater than that 
associated with normal aging.  Normal elderly who progress to a stage of mild 
cognitive impairment have been found to be more likely to develop AD.  It seems 
likely that a stage of MCI will also be identifiable for patients with PD (PD-MCI).  
The identification of cognitive test that signal PD-MCI presents an opportunity to 
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intervene and delay the onset of more severe cognitive problems that may result in PD 
with dementia (PDD).  This aspect of the research addresses objectives one to four 
briefly listed below (see section 1.14 for a full outline of the objectives for the thesis).   
1. Develop a cognitive and behavioural profile for PD compared to healthy 
elderly. 
2. To identify functional deficits that may be associated with PD. 
3. To identify sub-groups of patients based on their cognitive status. 
4. To develop a discrete group of non-invasive tests that will have clinical 
application. 
5. Follow-up study to examine the stability of the cognitive groupings that 
emerge from the initial main study.   
 
4.2.1 Manuscript 1 – Executive Function   
To partially address objective one, the first manuscript in this chapter provides 
a comprehensive assessment of cognitive characteristics in patients with PD without 
dementia, with particular emphasis on tests that were sensitive to executive 
dysfunction and its sub-components. While deficits in executive functions in PD have 
frequently been reported, there is little information regarding which aspects are 
impaired or spared.  In this study we found evidence of impaired performance across 
different aspects of executive functioning and visuospatial functioning.  Notably, 
some aspects of executive function were intact which may provide a focus for 
intervention strategies for those patients with cognitive impairments.  There was no 
evidence of deficits in the domains of memory/learning, or for measures of attention 
or planning. For this manuscript we assessed a single group of patients on tests that 
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covered a broad range of cognitive domains in order to identify a cognitive profile for 
PD patients.   
As a caveat to this first manuscript, it is important to be aware that a selected 
group of PD patients were tested. Patients were excluded based on a number of 
criteria (as outlined in 2.2.1 of this thesis). It could be argued that all PD patients 
could have been included and unwanted clinical characteristics could have been 
entered into subsequent analyses as covariates. This approach could have improved 
the generalisability of the study. However, after consideration of the number of 
medical issues that were likely to be present in an older population, and the impact 
that these might have on any cognitive outcomes, the exclusion criteria adopted here 
were considered to be most appropriate. Another issue relates to the number of 
comparisons that were run between the two groups and the decision regarding 
statistical significance. While some statisticians suggest that Bonferroni adjustments 
are appropriate when multiple tests are run in order to reduce the chance of a type one 
error, it was determined that the resultant increase in type two errors would be 
unacceptable. As a compromise,  the alpha level was set to p<0.01 and provided a full 
description of what was done to allow the reader to reach their own conclusion as 
suggested by Perneger (1998).   
4.2.2 Manuscript 2 – Mild Cognitive Impairment   
To address objectives two, three and four, outlined above, the second 
manuscript in this chapter used a data-driven method to identify sub-groups of PD 
patients that differed in terms of their cognitive functioning.  As a related aim, this 
manuscript also examined whether these sub-groups differed in terms of performance 
in activities of daily living.  Finally, from a practical point of view, it was intended to 
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identify, from the vast array of possibilities, a discrete set of tests that could be easily 
used by clinicians to determine which patients were experiencing cognitive problems 
that were likely to impact on their daily lives.  It was hypothesised that a specific 
subset of tests could be identified that would be most indicative of patients with PD 
with Mild Cognitive Impairment (PD-MCI).  Currently there is little research that has 
examined the range of cognitive deficits possible in PD patients or the impact that 
these deficits may have on daily functioning.  Further, much of the research to date 
has addressed the heterogeneity of cognitive problems by grouping patients based on 
their motor symptoms, age or disease duration.   
In this study three sub-groups were identified that formed a continuum of 
cognitive impairment from mild to severe.  Compared to controls, one group had little 
or no cognitive impairment (PD-NCI).  A second group showed a more variable 
pattern of mild –severe impairments (PD-UCI), while a third group had evidence of 
severe cognitive impairments across most of the cognitive domains tested (PD-MCI).  
The latter two groups were also significantly different from the control group in terms 
of their ability to carry out functional activities of everyday living.  The severity of 
cognitive deficits was not associated with other clinical and demographic 
characteristics (e.g. age, motor impairments or disease duration).  It was hypothesised 
that the third group represented patients who were more likely to develop frank 
dementia.  The organisation of PD patients based on cognitive characteristics can 
improve our understanding of PD and appropriate interventions can be better 
organised to meet their specific needs.   
It is important to be aware that statistical methods such as cluster analysis 
have associated advantages and disadvantages.  Cluster analysis are useful in 
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revealing hidden patterns in the larger data sets (Peck, 2005).  This is particularly true 
in the case where the population in question is heterogeneous.  The hierarchical 
clustering (k-means clustering) procedure used in this study assigns individuals into 
sub-groups to maximise homogeneity within groups and heterogeneity between 
groups (Peck, 2005).  However, there are also number possible problems with cluster 
analysis.  Firstly, the cluster analysis will produce as many clusters as requested 
(Cherry, 1993).  Further, as Cherry (1993) points out, it is difficult to know how many 
clusters exist in a given population.  Moreover, cluster solutions may lack stability 
and change depending on the variables entered into the analysis.  To address this 
issue, solutions were generated using 26 variables and 13 variables to test the stability 
of the resulting groups.   
4.2.3 Manuscript 3 – Pre-clinical Dementia   
The third manuscript in this chapter examined outcomes for the sub-groups 
one year after their initial assessment and addressed objectives four and five.  The aim 
of the follow-up study was to examine the performance of the three sub-groups 
identified in manuscript two using the tests that had been found to be sensitive to 
cognitive impairment in PD.  The groups at time two were also compared in relation 
to their performance at time one, it was expected that a trend for decline would be 
seen in the PD groups.  The results indicated that, consistent with their time one 
performance, the PD groups performed more poorly than controls on the domains of 
executive functions, problem solving, and working memory and visuospatial ability, 
with the greatest deficits being evident for the PD-MCI group.  There was no 
evidence of decline in cognitive functioning for any of the sub-groups between time 
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one and time two.  However, increased cognitive problems were associated with 
decreased functioning in activities of daily living.   
There were a number of issues that are pertinent to consider in relation to these 
findings.  While it appears that the PD patients were consistently impaired on the 
domains outlined above, to confirm that these deficits represent a cognitive profile for 
PD patients would require testing of an independent group of PD patients.  This 
would also enable the validity of the three clusters suggested here to be tested.  No 
trend for decline over time was found.  However, not all the patients were available 
for testing at time two.  Some of the original group of patients had either died or were 
hospitalised at the time of testing and too unwell to participate.  The majority of the 
patients that were unable to be tested at time two had been from the PD-MCI group 
and it is possible that the attrition of these patients influenced these results.   
4.2.4 Summary   
Overall we found evidence for a variety of cognitive deficits for PD patients.  This 
finding was consistent with other research in this area.  These data also added to the 
literature in a number of ways.  The cognitive profile of patients without dementia 
using a broad range of domains and tests was defined.  In addition, different 
subgroups of patients were identified based on their cognitive performance.  
Moreover this study extended the research in this area by examining how these 
problems impacted on the quality of live for individuals with PD.   
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4.3 Characteristics of Executive Function Impairment in Parkinson’s Disease 
Patients Without Dementia   
(In review: Journal of Neurology, Neurosurgery and Psychiatry) 
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4.3.1 Abstract   
Executive function impairments in PD are well documented.  However, 
information regarding the different aspects of executive functions that are impaired or 
spared is limited.  The goal of this study was to provide a comprehensive assessment 
of cognitive characteristics in patients with PD without dementia, with a particular 
emphasis on tests that are sensitive to executive dysfunction and its subcomponents.  
The relationship between different cognitive domains was also examined.  Forty 
Parkinson’s patients without dementia met the criteria for this study.  Each patient 
was individually matched in terms of age, sex and pre-morbid intelligence, to a 
healthy control.  Outcomes for patients were compared to controls using a 
comprehensive set of general executive function/attention tests, and measures for 
subcomponents of executive function including working memory, planning, and 
problem solving.  We also included measures of memory/learning and visuospatial 
skills to examine the relationship between aspects of executive function and other 
areas of cognition.  Patients with PD showed deficits on measures of executive 
function, working memory, problem solving, and visuospatial skills.  However, they 
were unimpaired on measures of planning, attention and memory/learning.  Deficits in 
problem solving were only evident for tasks with a high visuospatial content and were 
no longer significant when visuospatial skills were controlled for.  Overall, deficits in 
executive function, its subcomponents and visuospatial skills were apparent for PD 
patients compared to healthy controls.  However, some aspects of executive function 
were intact, which may provide a focus for intervention strategies for those patients 
with cognitive impairment.   
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4.3.2 Introduction   
It is well known that cognitive deficits are associated with Parkinson’s disease 
(PD), and are an important cause of functional impairment in many cases, with about 
30% of patients progressing to dementia (Aarsland, Zaccai, & Brayne, 2005).  
Cognitive deficits are associated with caregiver distress and premature rest home 
placement, and are therefore important in terms of both personal and social cost 
(Aarsland, Larsen, Tandberg, & Laake, 2000; Schrag, Jahanshahi, & Quinn, 2000).  
Given the relative importance of cognitive impairments, there has been considerable 
interest in identifying a specific cognitive profile for patients with PD to inform 
appropriate intervention strategies.   
Neuropathological changes associated with PD are focused on the basal 
ganglia and thalamocortical circuits, compromising the integrity of the prefrontal lobe 
which is considered to play a pre-eminent role in “higher order” or executive function 
(Duffy & Campbell, 1994; Fuster, 2000).  Executive function involves the ability to 
plan, initiate and monitor goal directed behaviour with the flexibility to update goals 
in the face of new information (Elliot, 2003).  Deficits in decision making, planning, 
initiation, working memory, self monitoring, problem solving and inhibition are all 
considered to reflect executive dysfunction (Salthouse, 2005).   
Given the neuropathology of PD, it has been suggested that the magnitude of 
cognitive deficit will reflect the degree to which the task relies on the integrity of the 
frontal lobe (Higginson et al., 2003; Taylor & Saint-Cyr, 1995).  Moreover, deficits 
observed with any tasks that do not rely predominantly on the frontal lobe, such as 
memory and visuospatial deficits, should be secondary and related to the higher 
 186 
 
cognitive demands that are mediated by the frontal lobes (Bondi, Kaszniak, Bayles, & 
Vance, 1993a).   
There is an abundance of research that supports the presence of deficits in 
executive functioning in PD (Dimitrov, Grafman, Soares, & Clark, 1999; Farina et al., 
2000; Muslimovic, Post, Speelman, & Schmand, 2005; Tamaru, 1997).  However, 
there is considerable uncertainty regarding the different dimensions of executive 
functioning that might be impaired or spared for PD patients, and the degree to which 
these impairments affect other cognitive functions (Weintraub & Stern, 2005).  Two 
recent publications have investigated the dimensions of executive function deficits in 
PD.  Uekermann et al., (Uekermann et al., 2004) examined the subcomponents of 
executive functions impaired in early stages of PD using a group of 20 patients and 
reported deficits in initiation, reasoning and planning.  Weintraub et al., (2005) 
identified planning and inhibitory control as two factors that were impaired in a group 
of 46 PD patients with mild to moderate symptoms.  Planning was associated with 
decreased motivation and inhibitory control deficits with motor slowing (Weintraub et 
al, 2005).  However, neither of these studies examined the relationship between the 
different subcomponents of executive function and other areas of cognitive 
functioning.   
There were three primary objectives in the present study.  First, to identify a 
pattern of deficits in executive function subcomponents and general cognitive deficits 
in PD patients without dementia, using a comprehensive set of commonly used 
neuropsychological tests.  These tests were specifically selected based on research 
that has found them to be sensitive to cognitive impairment in patients with PD, and 
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with the potential to be used by clinicians.  The second objective was to assess the 
relationship between cognitive deficits and the demographic and clinical features of 
the patient group.  Finally, it was planned to examine the relationship between 
different domains of executive function and other areas of more general cognitive 
function.   
4.3.3 Methods   
Approval for this study was granted by the Canterbury Ethics Committee and 
informed consent was obtained from patients.  Patients with a diagnosis of idiopathic 
PD confirmed by a specialist neurologist were invited to take part in the study.   
Participants  
Parkinson’s disease group  
Parkinson’s patients in the Canterbury region, who could be identified at the 
time of this study and had not been diagnosed with dementia, were invited by letter to 
participate.  Inclusion/exclusion criteria were as follows:   
Inclusion Criteria: 1) Assessed at the Hoehn & Yahr stage I-IV; 2) Aged 
between 50 and 80 years; 3) Adequate or corrected hearing and vision (self report 
checked by examiner); 4) Stable on PD medication; 5) English as the primary spoken 
language.  Exclusion criteria were: 1) Currently involved in a therapeutic trial; 2) 
History of: a) moderate or severe head injury; b) stroke or other neurological 
impairment; c) major medical illness; d)significant psychiatric illness requiring 
hospitalisation; e) suspicion of dementia symptoms (MMSE <25, DRS-II and DSM-
IV criteria); f) diagnosis of, or special education for, a learning disability; g) major 
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depressive episode in the previous 6 months; 3) Pre-morbid IQ estimated at <85 using 
National Adult Reading Test (NART); 4) Currently taking medications known to have 
a significant effect on Central Nervous system (other than medications prescribed for 
the control of PD symptoms); 5) Beck Depression Inventory –II score of >17.   
Of the 115 letters that were mailed, 6/115 (5.2%) of individuals with PD could 
not participate due to illness, 6/115 (5.2%) were deceased, 8/115 (6.9%) declined, 
34/115 (29.6%) did not respond, and 21/115 (18.3%) did not meet the 
inclusion/exclusion criteria.  After exclusions, 40 participants with PD were included 
in the analyses.  All patients were on antiparkinsonian medication and were tested 
while on optimal levels of medication.   
Controls  
Controls were recruited from a number of sources including a previously 
established data base, advertisements at local clubs (bowling, hiking and table tennis) 
and businesses.  All controls were given a brief outline of the study on first phone 
contact.  If they were still willing to participate they were then sent an information 
sheet.  In addition to adequate or corrected hearing and vision (self report, checked by 
the examiner) and being aged between 50 to 80 years of age, the same exclusion 
criteria listed above also applied to the control group.   
4.3.4 Procedure   
Assessments were carried out at the University of Canterbury over three 
testing sessions, each of three hours in duration.  Tests were presented in a fixed order 
with breaks taken as required.  Written consent was obtained from all participants at 
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the start of the first testing session after the study had been explained.  All patients 
with PD were tested while on optimal levels of medication.   
Background measures  
Prior to participating in the full cognitive assessment, all patients were 
assessed in terms of current and pre-morbid cognitive and mental status.  Additional 
information pertinent to the inclusion/exclusion criteria was elicited from all 
participants using a semi-structured interview.  PD patients also underwent a clinical 
assessment that included the Hoehn & Yahr staging and the Unified Parkinson’s 
Disease Rating scale to assess motor impairment.   
1) National Adult Reading Test (NART) was used to estimate pre-morbid IQ. 
This test comprised a list of 50 “irregular” words printed in order of increasing 
difficulty.  Words are scored 0 for incorrect and 1 for correct pronunciation (Lezak, 
1995).   
2) Beck Depression Inventory-II (BDI-II) consists of 21 items; each question 
is rated 0-3 with higher scores indicating greater intensity of symptoms (Beck, Steer, 
& Brown, 1996).  The BDI-II has been validated for use with PD patients, with a cut 
off of 17 being recommended for detecting the presence of depression (Leentjens, 
2004).   
3) The Mini Mental Status Exam (MMSE) provided information regarding 
current cognitive status.  Patients and healthy controls were included if they scored 
≥25 (Folstein, Folstein, & McHugh, 1975).   
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Three additional measures were used for patients with PD to provide 
information regarding motor impairment and global functioning in activities of daily 
living.   
4) Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn & Elton, 1987).  
Three scores were generated using this scale:  a) The severity of motor symptoms was 
rated using the motor section; b) a tremor score calculated as the average of items 16 
and 20-26 on the UPDRS; and c) a non tremor score calculated as the average of 
items 5,7,12-15, 18, 19, and 27-44 and divided by 26 (as outlined by Lewis, Dove, 
Robbins, Barker, & Owen, 2003).   
5) The Hoehn and Yahr (H&Y) was used to rate the stage of the disease 
(Hoehn & Yahr, 1967).  The modified version of this scale was used with increments 
of 0.5 in the midranges.   
6) The Modified Schwab and England Activities of Daily Living Scale (S&E), 
was used to provide a measure of overall functioning in activities of daily living, 
including ability to complete personal hygiene and daily chores without difficulty, 
slowness or impairment.  A scale of 0-100% was used where 0% represents a 
vegetative state and 100% represents total independence (Ramaker, Marinus, 
Stiggelbout, & Van Hilten, 2002).   
Neuropsychological assessment  
Neuropsychological assessment covered six cognitive domains: 1) General 
executive function/planning; 2) problem solving; 3) working memory/attention; 4) 
speed of processing; 5) memory/learning; 6) visuospatial ability.  Planning, problem 
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solving, and working memory are considered to be subcomponents of executive 
function, and were measured separately to provide an opportunity to examine the 
different aspects of executive function that might be impaired (Salthouse, 2005).  Also 
included were measures of attention and speed of processing.  Although not generally 
considered subcomponents of executive function, the integrity of these processes is 
directly linked with efficient processing of executive and general cognitive tasks.   
All tests were commonly used neuropsychological measures and scored 
according to standard procedures.  The majority of the measures used were from 
standardised batteries including the Wechsler Abbreviated Scale of Intelligence 
(WASI) [Mean 50, Standard deviation 10] (Wechsler, 1999), Delis Kaplan Executive 
Function System (D-KEFS)(Delis, Kaplan, & Kramer, 2001), and the Wechsler 
Memory Scale-III (WMS-III)(Wechsler, 1997) [both mean 10, standard deviation, 3] 
with age-adjusted norms.  Such norms were not available for tests from the 
Behavioural Assessment of the Dysexecutive Syndrome (BADS) [scores range from 
0-4] (Wilson, Alderman, Burgess, Emslie, & Evan, 1996), Cambridge 
Neuropsycholgical Test Automated Battery (CANTAB), Reading Span task, and tests 
of visuospatial functioning.  However, all patients were individually matched for age.   
Executive function/planning skills were evaluated using the following tests 
from the D-KEFS: Verbal Fluency test (with subtests for letter fluency, category 
fluency and category fluency switching) and Color-Word Interference test (with sub-
tests for Inhibition and Inhibition switching).  Also included in this domain were the 
Key Search and Zoo map from the BADS, the Intradimensional/Extradimensional 
Shift (ID/ED) from the CANTAB (number of stages completed, scores vary from 0-9) 
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and the CLOX-I (Royall, Cordes, & Polk, 1998).  The CLOX is an unstructured 
drawing test that has two parts; for both parts of the test a maximum score of 15 is 
possible indicating perfect performance.  In part one the participant is given the 
following instruction “Draw me a clock that says 1.45.  Set the hands on the face so a 
child could read them” (Royall, Cordes, & Polk, 1998).  Drawings are rated according 
to CLOX-1 directions.   
Problem solving was assessed using the Card Sorting subtests of free sorting 
and sorting recognition, and the Tower Task (number of towers completed in the 
minimum number of moves, maximum score possible 9).  Both of these tests were 
from the D-KEFS.  Problem solving was also assessed using the Matrix Reasoning 
subtest from the WASI the and the Stockings of Cambridge (SOC’s) from the 
CANTAB (number of towers completed in the minimum number of moves, maximum 
score possible 12), which is considered to be conceptually similar to D-KEFS Tower 
task.   
Working memory/ attention was assessed using Letter Number Sequencing, 
and Digits Forward and Backward, from the WMS-III, Spatial Span (maximum 
sequences correctly recalled 0-9) from the CANTAB and the Daneman and Carpenter 
Reading Span test (scores range from 1-6).   
Speed of processing was evaluated using Word Naming and Color Naming 
from the D-KEFS Color-Word interference test.   
Memory/learning was assessed using the WMS-III, Paired Associates 
(immediate and delayed), Logical Memory (immediate and delayed) and the Auditory 
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Recall Index.  The Rey Osterrieth Figure (ROF) recall after 3 and 30 minutes was also 
used as a measure of memory ability.  All three parts of the ROF are rated the same 
and can vary from 0-36, with higher scores indicating more accurate performance 
(Spreen & Strauss, 1998).   
Visuospatial/constructive skills were assessed using the Judgement of Line 
Orientation (JLO) (Benton, Varney, & Hamsher, 1978), the Rey Osterrieth Figure 
copy task and the CLOX part two.  Scores reported for the JLO are the number of 
correct line pairs, with possible scores ranging from 0-30.  For the CLOX-II, the 
examiner first draws a picture of a clock face with the hands on the clock face set at 
1.45.  The participant is then asked to copy the examiner’s drawing.   
4.3.5 Statistical Analyses   
Differences in demographic and clinical characteristics were examined using 
Student t tests and χ2 as appropriate.  To assess the magnitude of any differences 
between the two groups, effect sizes for cognitive impairments were generated using 
Cohen’s d.  To control for the effect of multiple comparisons, a stringent test of 
significance was applied (p < 0.01) for individual tests.  Pearson correlations were 
employed to assess the association between disease progression and cognitive 
outcomes and the association between different measures of executive function, 
visuospatial ability and memory/learning.  Z scores were then computed, using the 
control mean and standard deviation, so that comparisons could be made across tests.  
Analyses of covariance (ANCOVAs) were used to compare the difference between 
PD and control scores for a particular cognitive domain while using other domains as 
covariates. These were considered significant at p < 0.05.   
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4.3.6 Results   
Demographic and clinical characteristics  
Comparisons between patients with PD and their healthy controls on clinical 
and demographic characteristics are shown in Table 32.  Each of the 40 PD patients 
included in the main study, was matched as closely as possible to a healthy control in 
terms of age and pre-morbid IQ.  Matching was confirmed by t tests (IQ: t = 0.94, df 
=78, p > .30; and age: t = 0.31 df = 78, p > .75).  Patients with PD had significantly 
lower MMSE scores and were more likely to endorse symptoms associated with low 
mood. However, none of the PD patients showed any evidence of clinical depression 
or dementia.  Also, there were significantly more males in the PD group (PD 26/40 
[65%] v Control 13/40 [32.5%]) (χ2 (df = 1) = 8.46, p < .01).  Motor scores for 
patients with PD varied from mild to severe as measured by the H&Y.  However, the 
patients rated themselves as independent in daily activities as rated by the Modified 
Schwab and England Activities of Daily Living Scales.   
Cognitive outcomes: 
Table 33 shows means and standard deviations for patients versus healthy 
controls and results of t tests2.  Individual t tests between PD and healthy controls 
showed deficits on five out of the seven measures of executive function (Category 
Fluency, Category Switching, CLOX-I, and Stroop inhibition and inhibition 
switching).  However, there was no significant difference between the two groups in 
                                                
2 Due to motor impairments one patient was not able to complete the Key Search, ROF or the CLOX 
tasks. Due to error one control was not administered the Tower Task and two controls were not 
administered the Spatial Span task. Three PD patients were not able to return a completed FAQ. 
However, patients with missing data did not differ from the mean of the PD group in terms of their 
performance on the DRS-II, MMSE or in terms of years of education and ratings on the H&Y. 
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terms of planning ability as measured by the Zoo Map and Key search tasks.  Patients 
showed deficits on two of the six measures of problem solving (Matrix Reasoning and 
SOC’s) and two of the three measures of working memory (Reading Span Test, and 
Spatial Span task).  There was no evidence of impairment for either measure of 
attention (Digits Forward and Backwards).   
Table 32: Clinical and demographic characterstics, Parkinson’s disease patients versus 
controls.   
 
 Parkinson's disease (n=40) Control Group (n=40)   
  
 
 Mean SD Range Mean SD Range t-value p-level    
 
NART
1
 109.05 [10.13] 87-131 111.20 [10.30] 90-128 0.94 >0.30 
Education (yrs)
2
 13.94  [2.56] 11-22 13.76 [2.57] 8-20 -0.30 >0.75 
Age 66.15  [6.65] 52-77 66.58 [5.47] 52-76 0.31 >0.75 
MMSE
3
 28.65  [1.42] 25-30 29.58 [0.71] 28-30 3.67 <0.001* 
BDI-II
4
 7.59  [4.34] 0-16 4.13 [3.39] 0-15 -3.96 <0.001* 
PD onset
5
 6.49  [4.35]     0.25-23 
UPDRS
6
 28.46  [9.49] 13-49 
S&E
37                                         81.0%  [0.10]      
H&Y
8 Level 1 Level 1.5 Level 2 Level 2.5 Level 3 Level 4 
  (n=8) (n=6) (n=7) (n=10) (n=7) (n=2) 
         
   
1
National Adult Reading Test, 
2
Total number of years formal education, 
3
Mini Mental Status Exam, 
4
Beck Depression Inventory, * significant at p<0.001;
 5
Number of years since diagnosis of Parkinson’s 
disease, 
6
Unified Parkinson’s Disease Rating Scale (motor score component); 7Modified Schwab and 
England Activities of Daily Living Scale; 
8
Hoehn & Yahr stage.  
 
Consistent evidence of deficits was found for the patient group compared to 
healthy controls on measures of speed of processing.  Two out of the three measures 
of visuospatial ability were also impaired (ROF copy and CLOX-II).  However, there 
was no significant difference between the groups on measures of memory and 
learning.   
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The original analysis was re-run excluding the two patients who had an H&Y 
of 4 so that the group consisted of only patients with mild to moderate motor 
impairment.  The results remained substantially the same.  With these two patients 
excluded, significance levels for CLOX-I and two of the CANTAB tests, SOC’s and 
Spatial Span were now only significant at p < 0.05 (p’s <0.04, 0.02 and 0.02, 
respectively).  As the inclusion of these two participants did not change the pattern of 
impairments for the patients with PD compared to healthy controls, they were 
included in the analyses.   
In terms of effect sizes, for measures with a significant finding in the domain 
of executive function, these varied from medium to large (d = 0.57-0.88), with an 
average effect size of 0.77.  Significant effect sizes for problem solving (d = 0.63 & 
0.69), working memory (d = 1.23 & 0.65) and speed of processing (d = 0.67, 0.95 & 
0.76) were all large, with averages of 0.65, 0.94 and 0.79, respectively.   
Although some patients in this study were in the moderate to severe range in 
terms of disease progression, correlations revealed few associations between disease 
duration or motor symptoms (as measured by the H&Y stage), or mood (as measured 
by the BDI) and cognitive outcomes.  Disease duration was correlated with Paired 
Associates-II and Color Naming, H&Y stage with Spatial Span, Category Fluency 
with Color Naming, and mood with Letter Number Sequencing.  These associations 
remained significant after controlling for the effects of age, IQ and years of education.   
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Table 33: Cognitive Test Outcomes for Parkinson’s disease patients versus the 
healthy control group.   
 PD Controls   Cohen’s 
 (n=)  Mean [SD] (n=)  Mean [SD] t = p-level d  
Executive Functioning/Planning      
Verbal Fluency sub-tests: a      
• Letter Fluency  (40) 10.53 [3.8] (40) 12.50 [3.5]  2.44 <0.05  0.55 
• Category Fluency  (40)   9.38 [2.5] (40) 11.75 [3.4]  3.55 <0.001  0.80 
• Category Switching  (40)   9.90 [3.6] (40) 12.43 [3.3]  3.30 <0.01  0.72 
  CLOX-I (39) 12.49 [2.6] (40) 13.65 [1.5]  2.46 <0.01  0.57 
  Key Search b (39)   2.54 [1.4] (40)   2.33 [1.3] -0.70 >0.45 -0.15 
   Zoo Map b (40)   2.08 [1.9] (40)  1.90 [1.2] -0.65 >0.45 -0.17 
Color-Word Interference sub-tests:a      
• Inhibition  (40)   9.10 [3.3] (40) 11.58 [2.3]  3.87  <0.001  0.88 
• Switching  (40)   9.01 [3.7] (40) 11.83 [2.3]  3.99 <0.001  0.88 
  ID/ED- Phases completed c (40)   8.13 [1.6] (40)   8.48 [0.8] 1.20 >0.20  0.32 
Problem solving      
Sorting sub-tests: a      
• Card sorting  (40) 10.95 [2.6] (40) 11.83 [2.7] 1.47 >0.10  0.30 
• Card sortingdescription  (40) 10.83 [2.5] (40) 11.33 [2.8] 0.84 >0.40  0.19 
  Matrix Reasoning d (40) 53.13 [10.2] (40) 59.60 [8.5] 3.09 <0.01  0.69 
  Stockings of Cambridge c (1) (39)    6.6  [2.6] (39)   8.1  [2.1]  2.82 <0.01   0.63  
  Tower Test a (2) (39)    4.1  [1.1]  (39)   4.2  [1.2]  0.50 >0.60  0.09 
Working Memory/ Attention      
  Digits Forward e (40) 10.22 [2.1] (40) 10.95 [2.3]  1.48 >0.10  0.36 
  Digits Backwards e (40)   6.38 [2.2] (40)   7.25 [2.0]   1.86 <0.10  0.43 
  Letter Number Sequencing e (40) 10.38 [2.6] (40) 11.65 [2.7]  2.15 <0.05  0.45 
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Table 33: Continued.       
 PD Controls   Cohen’s 
 (n=)  Mean [SD] (n=)  Mean [SD] t = p-level d  
  Reading Span Test (40)   1.66 [0.6] (40)   2.46 [0.7]  5.73 <0.0001  1.23 
   Spatial Span c (40)   4.60 [0.7] (38)   5.18 [1.1]  2.78 <0.01  0.65 
Speed of Processing      
Verbal Fluency Test: a      
• Word Naming  (40) 10.13 [1.9] (40) 11.45 [1.8]  3.27 <0.01  0.95 
• Color Naming  (40)   9.20 [2.5] (40) 11.23 [1.6]  4.30 <0.0001  0.76 
Memory/Learning      
  Logical Memory immediate e (40)   7.85  [3.2] (40)   8.95 [3.4]  1.50 >0.10  0.30 
  Logical Memory delayed e (40)   8.63  [3.2] (40)   9.53 [3.4]  1.21 >0.20  0.27 
  Paired Associates immediate e (40)   8.00  [2.9] (40)   9.83 [3.6]  2.50 <0.02  0.55 
  Paired Associates delayed e (40)   8.40  [2.6] (40)   9.90 [3.2]  2.28 <0.03  0.51 
  Auditory Recall index e (40)   8.90  [3.3] (40) 10.33 [2.6]  2.13 <0.05  0.46 
  ROF-II&III (39) 14.65  [6.2] (40) 17.09 [7.5]  1.57 >0.10  0.35 
Visuospatial ability      
  ROF-I (39) 31.87 [4.2] (40) 34.90 [1.9]  4.14 <0.0001  0.92 
  Line Orientation (40) 23.13 [5.4] (40) 25.40 [3.4]  2.24 <0.05  0.51 
  CLOX-II (39) 14.18 [1.1] (40) 14.78 [0.7]  2.89 <0.01  0.65 
 
(1) Number of towers completed in minimum moves; aDelis Kaplan Executive Functioning System 
standardised scores; b Behavioural Assessment of the Dysexecutive Syndrome profile scores;c 
Cambridge Neuropsychological Test Automated Battery;d Wechsler Abbreviated Intelligence Scale 
standardised scores; e Wechsler Memory Scale- 3rd edition, standardised scores. 
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Correlations between cognitive measures are shown in Table 34.  All within-
domain correlations were significantly positive for problem solving, working 
memory/attention, speed of processing, memory and learning and visuospatial ability, 
and for 8 of 10 cases for executive function.  To further examine the relationship 
between each of the domains, scores for each of the measures in the matrix were 
transformed to z scores.  These z scores were generated using the mean and standard 
deviation of the control group.  Overall scores were then produced separately for each 
of the five domains by combining the z score of measures that differentiated PD 
patients from controls (p < 0.01) divided by the number of measures in each domain.  
The sixth domain, memory/learning, was included in the matrix for the purpose of 
comparisons.  Paired Associates I & II were combined and Logical Memory I & II 
were combined, giving a total of three measures that comprised the domain of 
memory/learning.  Correlations for the six domains using these composite scores are 
shown on Table 35.   
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Table 35: Correlations for between each of the six cognitive domains using scores for 
Parkinson’s disease patients.   
  
EF1 
 
 
PS2 
 
WM3 
 
SP4 
 
M&L5 
 
V6 
Executive Function 1.00      
Problem Solving 0.69*** 1.00     
Working Memory 0.61*** 0.46** 1.00    
Speed of Processing 0.71*** 0.55*** 0.32* 1.00   
Memory/Learning 0.37* 0.36* 0.29 0.05 1.00  
Visuospatial Ability 0.61*** 0.47** 0.40*** 0.56*** 0.06 1.00 
 
1Executive Function; 2 Problem Solving; 3 Working Memory; 4 Speed of Processing; 5 
Memory/Learning; 6 Visuospatial Ability;  significant *p<0.05;**p<0.01;***p<0.001. 
 
As shown in Table 35, executive function and problem solving domains were 
significantly correlated with all other domains.  Memory/learning was the only 
domain not significantly associated with working memory and visuospatial ability.  
The domain of memory/learning only showed significant correlations with the two 
domains of executive function and problem solving.   
Separate ANCOVAs were used to control for the effects of memory/learning 
and visuospatial ability, while assessing the difference between PD group and controls 
on the domains of executive function, problem solving, working memory, and speed 
of processing as shown on Table 36.   
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Table 36: Comparison between patients with Parkinson’s disease and healthy controls 
for the domains of Executive Function, Problem Solving, Working Memory and 
Speed of Processing after controlling separately for the effects of 
Memory/Learning and Visuospatial Ability.   
  
Memory/Learning 
Covariates 
 
 
Visuospatial Ability  
 F p F                               p 
Executive Function 13.16 <0.001*** 5.1 <0.05* 
Problem Solving  7.86 <0.01** 2.9 >0.10 
Working Memory 23.55 <0.0001*** 16.29 <0.001** 
Speed of Processing  7.43 <0.001** 7.20 <0.01* 
 
Although the differences remained significant for Working Memory and 
Speed of Processing (p < 0.01), Problem Solving and Executive function were no 
longer significant after controlling for visuospatial ability.  However, differences 
between the two groups remained significant (p < 0.01) for all domains after 
controlling for memory/learning.   
ANCOVA’s were used separately to control for the effects of executive 
function, problem solving, working memory and speed of processing (Table 37).  
There were no significant differences between the PD group and healthy control for 
the domain of memory/learning.  In terms of visuospatial ability, patients with PD 
remained significantly different from controls regardless of which covariate was 
entered into the analysis.   
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Table 37: Comparison between patients with Parkinson’s disease and healthy controls 
for the domains of Memory/Learning and Visuospatial Ability after controlling 
separately for the effects of Executive Function, Problem Solving, Working 
Memory and Speed of Processing.   
  
 
  
Executive 
Function 
 
 
Covariates 
 
Problem  
Solving 
 
 
 
Working 
Memory 
 
 
 
Speed of 
Processing 
 F    p F               P F   p F   p 
Memory/Learning 0.57 >0.40 2.35 >0.10 1.04 >0.30 3.25 <0.10 
Visuospatial Ability 5.36 <0.05* 9.34 <0.01** 6.09 <0.05* 7.34 <0.01* 
 
 
4.3.7 Discussion   
The purpose of this research was to identify a pattern of cognitive deficits in a 
group of PD patients without dementia compared to healthy controls.  We also 
examined the relationship between the different domains of cognitive functioning.  
Parkinson’s disease patients showed clear evidence of impaired performance across 
different aspects of executive functioning and its sub components (working memory, 
problem solving and speed of processing).  We also found evidence of a deficit in 
visuospatial ability which was independent of aspects of executive function.  
However, there was no evidence of deficits in measures related to memory/learning, 
attention, and planning.   
Of particular interest was the finding that patients with PD did not show global 
decline on measures on executive functioning, rather there was evidence of variable 
performance across the range of measures reflecting executive function abilities.  For 
example, while tests of mental flexibility and inhibition were consistently impaired, as 
reflected in category and letter fluency tasks and the Stroop tasks, tests that required a 
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degree of planning showed no impairment.  Also, patients with PD appeared to have 
little difficulty with many of problem solving tasks, with deficits only being observed 
in tasks that were strongly influenced by visuospatial ability.  Differences in the 
domain of problem solving were no longer significant when visuospatial ability was 
controlled for.  A more consistent pattern of deficits was evident in terms of working 
memory.  Whereas patients showed no deficits on attention-related tasks, they were 
impaired on three out of the four working memory tasks, with the fourth just failing to 
reach statistical significance.  Although two of the working memory measures 
required a degree of visuospatial ability (spatial working memory and spatial span), 
working memory impairment remained significant after visuospatial ability was 
controlled for.   
It has been suggested that any cognitive deficits associated with PD simply 
reflect the extent of executive function deficits (Taylor & Saint-Cyr, 1995).  
Therefore, the relationship between executive functions and its subcomponents and 
memory/learning and visuospatial ability, was also examined.  No significant deficits 
were found for memory/learning and this did not change when different aspects of 
executive function were controlled for.  However, the opposite was found for 
visuospatial ability.  Despite controlling separately for different aspects of executive 
function, the deficits in visuospatial ability remained significant.   
From the large body of literature regarding cognitive outcomes and PD 
(Pillon, Boller, Levy, & Dubois, 2001), relative to age matched controls, PD patients 
have been found to have deficits in executive function, inhibition, problem solving, 
planning, working memory, visuospatial skills and aspects of memory.  However, few 
researchers have specifically examined the different components of executive 
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function that might be impaired or spared.  Nonetheless, the performance across the 
range of measures reflecting executive function abilities found in this study is 
consistent with other research that has examined aspects of executive functions in PD 
patients (Marinus et al., 2003; Muslimovic, Post, Speelman, & Schmand, 2005; 
Uekermann et al., 2004; Weintraub & Stern, 2005).   
There is considerable evidence for deficits in visuospatial function in PD 
patients without dementia (see Waterfall & Crowe, 1995 for review).  However, this 
relationship has usually been considered to reflect the higher cognitive load generally 
associated with these tasks.  In this study we selected tests that had low cognitive 
demands and subsequently controlled separately for the effects of executive function 
and its subcomponents.  Bondi et al., (1993) found a result contrary to ours, but tests 
used in their study were heavily dependent on planning and organisation skills which 
are associated with executive functions.   
The majority of patients in this study were in the mild to moderate range in 
terms of disease symptoms.  However, two of our patients had more severe motor 
problems.  Despite this, correlations revealed few associations between cognitive 
performance and disease duration or motor symptoms.  Further, motor symptoms and 
disease duration have been reported by a number of groups as an unreliable means of 
identifying patients who have cognitive problems (Aarsland, Ballard, Larsen, & 
McKeith, 2001; Cooper, Sagar, Jordan, Harvey, & Sullivan, 1991; Graham & Sagar, 
1999; Janvin, Aarsland, Larsen, & Hugdahl, 2003; Lewis et al., 2005; Muslimovic, 
Post, Speelman, & Schmand, 2005).   
The profile of executive function, speed of processing and visuospatial deficits 
reported here is similar to other recent research regarding cognitive outcomes for PD 
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patients.  One of these recent studies reported outcomes for newly diagnosed patients 
while another examined patients with advanced PD.  Both these studies reported a 
similar range of cognitive deficits to those found here, even though this study consists 
of a sample of patients across a wide spectrum in terms of disease severity and 
duration (Green et al., 2002; Muslimovic, Post, Speelman, & Schmand, 2005).  
Deficits in executive function, speed of processing and visuospatial ability appear to 
constitute the core deficits for PD.  By comparison, deficits in general memory, 
planning and attention are much more variable and depend on the methodology of the 
study and inclusion criteria.   
One of the strengths of this study was that a range of measures were used to 
identify the profile of impaired and spared executive functions.  Also, medicated 
patients across the range of motor impairment who had the dexterity to engage in the 
testing were included to provide a more representative sample.  However, the findings 
presented here should also be considered in the context of several limitations.  
Although we endeavoured to recruit a representative sample, patients were self 
selected and tended to be relatively healthy.     
Cognitive impairments are common in PD.  A profile characterised by 
executive function, visuospatial and processing speed deficits has consistently been 
reported regardless of the disease duration.  A unique aspect of this study was the 
assessment of multiple aspects of executive function, providing evidence regarding 
intact and impaired executive functions.  Identifying the profile of cognitive deficits 
unique to PD is important as it provides information to clinicians regarding which 
measures are most appropriate to identify patients who may be experiencing cognitive 
decline.  However, information regarding intact skills is also useful because it may 
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provide an opportunity to develop appropriate intervention strategies, taking 
advantage of those aspects of cognitive functioning that have been spared, and that 
could prolong the independence of patients with PD who are experiencing cognitive 
decline.  
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4.3 The Identification of Mild Cognitive Impairment in Parkinson’s Disease   
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4.4.1 Abstract   
The goal of this study was to identify sub-groups of PD patients that differed 
in terms of their cognitive functioning.  Data from a broad range of 
neuropsychological tests and cognitive domains were used in a cluster analysis to 
identify different sub-groups of PD patients.  Resulting sub-groups were then assessed 
in terms of between-group differences and also compared to individually-matched 
healthy controls in cognitive functioning and ability to conduct activities of daily 
living.  Three sub-groups of patients were identified that formed a continuum of 
cognitive impairment from none/mild to severe.  Compared to controls, one subgroup 
showed no or minimal impairment (PD-NCI), a second group showed a more variable 
pattern of severe and mild impairments (PD-UCI), and a third group had evidence of 
severe impairment across most of the cognitive domains tested.  This latter group was 
labelled PD-Mild Cognitive Impairment (PD-MCI).  The PD-UCI and PD-MCI 
groups were also significantly different from their controls with respect to their ability 
to carry out functional activities of everyday living.  Results confirm that patients with 
PD are heterogeneous with regard to their cognitive presentation.  Further, the 
severity of cognitive deficits was not associated with other clinical and demographic 
characteristics such as motor impairments, age or disease duration.  This line of 
research has considerable clinical utility as it may enable the development of 
diagnostic criteria for preclinical dementia specific to PD patients (PD-MCI), 
providing a basis for early intervention that could slow the development of dementia.   
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4.4.2 Introduction   
Cognitive problems have been widely reported in patients with idiopathic 
Parkinson’s disease (PD) and include deficits in visuospatial abilities, speed of mental 
processing, memory, learning and executive functions (including planning, working 
memory, attention, verbal function, and decision making) (Pillon, Boller, Levy, & 
Dubois, 2001).  However, the research literature has mixed results regarding the 
constellation of cognitive deficits that characterize PD.  This inconsistency is thought 
to be due in part to methodological problems and diverse patient group characteristics.  
But even when these methodological concerns have been addressed, patients have 
been reported as heterogeneous with respect to their presentation of cognitive 
symptoms.  Thus, more recent research has focused on defining the characteristics of 
different subgroups of patients as defined by their motor and cognitive characteristics.  
The identification of these subgroups is important because cognitive deficits in PD 
have been linked to caregiver distress, reduced quality of life for the patient and early 
rest home placement (Aarsland, Larsen, Tandberg, & Laake, 2000; Schrag, 
Jahanshahi, & Quinn, 2000).  Furthermore, particular subgroups may be more 
vulnerable to severe cognitive decline which could signal the onset of dementia.  
Accurate identification of “at risk” patients would provide an opportunity for 
interventions that could ameliorate problems associated with cognitive deficits and 
reduce the associated personal and social costs.   
Researchers have examined cognitive outcomes using a number of methods to 
define subgroup patients, including frontal v non frontal symptoms (Turnbull, Berry, 
& Bowman, 2003); sporadic v familial PD (Dujardin, Defebvre, Grunberg, Becquet, 
& Destee, 2001); motor symptoms (Dujardin, Defebvre, Grunberg, Becquet, & 
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Destee, 2001; Lewis et al., 2005); levels of executive dysfunction (Lewis et al., 2003); 
and age of onset (Katzen, Levin, & Llabre, 1998).  Previous classification systems 
have frequently been based on intuition and there has been little consensus regarding 
how different factors interact to disrupt cognitive functions (Graham & Sagar, 1999).  
Thus more recent research has adopted a “data driven” approach to define subgroups 
of PD patients (Graham & Sagar, 1999; Lewis et al., 2005).  Methods such as cluster 
analysis, as used by these authors, have the advantages of avoiding arbitrary cut-offs 
and predetermined classification systems, and enabling discrete sub-groups to be 
identified so that all within a given group are maximally similar.   
Graham and Sagar (1999) used information regarding demographic, motor, 
mood and cognitive performance in a cluster analysis to identify different sub-groups 
in a convenience sample of 176 patients with PD.  Three separate clusters were 
identified:  1) a group with motor impairment only and no intellectual impairment; 2) 
a group with both motor and cognitive impairments; and 3) a group with rapidly 
progressing motor and cognitive symptoms.  The latter group tended to be older at 
disease onset.   
Lewis et al. (2005) obtained information regarding mood, motor and cognitive 
functioning from 120 patients in the early clinical stages of PD (Hoehn and Yahr 
stages I&II) and performed a cluster analysis.  Four separate sub-groups were 
identified with different characteristics: 1) younger age at disease onset; 2) tremor 
dominant with mood and cognitive impairment; 3) non-tremor dominant; and 4) a 
group with rapid disease progression but no cognitive impairment.  However, many of 
the variables studied by these researchers were based on motor impairment.  Because 
the relationship between motor impairment and cognitive symptoms is inconsistent 
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(Graham & Sagar, 1999; Janvin, Larsen, Aarsland, & Hugdahl, 2006; Lewis et al., 
2005; Mahieux et al., 1998) use of these variables may obscure the identification of 
sub-groups of patients with different cognitive characteristics including those at the 
stage of preclinical dementia or mild cognitive impairment.   
The term “mild cognitive impairment” (MCI) has been used in the dementia 
literature to describe cognitive deficits that are greater than those associated with 
normal aging, but not sufficiently severe to warrant a diagnosis of dementia (Petersen, 
2004; Petersen et al., 2001).  Individuals with MCI are more at risk of developing 
Alzheimer’s disease (AD).  Although the concept of MCI has not been widely studied 
in relation to PD, there are reasons to expect that it might be useful for identifying 
those patients that are more likely to progress to dementia.  For example, a recent 
study by Janvin et al. (2006) used the concept of MCI to examine progression of 
cognitive decline in 59 non-demented PD patients.  Two groups of patients were 
defined:  Those showing signs of MCI (n=29) according to the criteria suggested by 
Petersen, and those who were cognitively intact (n=30).  The MCI group was further 
divided into 3 subgroups according to their cognitive profile (MCI amnestic type, 
MCI single domain impaired non-memory and MCI multiple domains slightly 
impaired).  At the four-year follow-up, 62% of patients with MCI and 20% of 
cognitively intact patients were diagnosed as having dementia.  Single domain non-
memory and multiple domains slightly impaired were associated with the 
development of PDD, whereas MCI amnestic was not.  However, the range of 
cognitive domains assessed by Janvin et al. was limited, making it difficult to 
ascertain the specific impairments that might be associated with PD-MCI.   
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The question of whether Parkinson’s disease with MCI (PD-MCI) represents a 
distinct clinical entity that includes those patients who will progress to PDD requires 
further investigation.  The aim of the present study was to use a data-driven method to 
identify subgroups of patients with PD that differed in terms of cognitive functioning.  
Compared to previous studies (Graham & Sagar, 1999; Janvin, Larsen, Aarsland, & 
Hugdahl, 2006; Lewis et al., 2005), a broad range of neuropsychological tests were 
used, that assessed various domains of cognitive functioning.  We hypothesized that if 
PD-MCI represents a distinct subtype, then a cluster analysis should reveal not only 
those patients comprising the PD-MCI group, but the specific subset of tests that was 
most indicative of patients with PD-MCI.  To test this hypothesis, it was planned to 
determine whether the subset of tests that best differentiated among subgroups of PD 
patients was the same subset that differentiated the PD patients overall from healthy 
matched controls.  As secondary goals, it was planned to identify the clinical and 
demographic characteristics of any resulting subgroups, and to determine whether 
these differed in terms of impairments in daily living.  It would be expected that if a 
subgroup of patients with a pattern of cognitive impairment analogous to MCI 
associated with AD were found, that the resulting deficits would have begun to 
interfere with their ability to cope appropriately with activities of daily living.   
4.4.3 Methods   
Approval for this study was granted by the Canterbury Ethics Committee and 
informed consent was obtained from patients and control participants.   
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Participants  
Parkinson’s disease group  
Parkinson’s patients in the Canterbury region, with a diagnosis of idiopathic 
PD (diagnoses were confirmed by a neurologist who specialised in movement 
disorders), who could be identified at the time of this study and had not been 
diagnosed with dementia, were invited by letter to participate.  Inclusion/exclusion 
criteria were as follows: Inclusion criteria: 1) Assessed at the Hoehn & Yahr stage I-
IV; 2) Aged between 50 and 80 years; 3) Adequate or corrected hearing and vision 
(self report checked by examiner); 4) Stable on PD medication; 5) English as the 
primary spoken language.  Exclusion criteria were: 1) Currently involved in a 
therapeutic trial; 2) History of: a) moderate or severe head injury; b) stroke or other 
neurological impairment; c) major medical illness; d) significant psychiatric illness 
requiring hospitalisation; e) suspicion of dementia symptoms (MMSE <25); f) 
diagnosis of, or special education for, a learning disability; g) major depressive 
episode in the previous 6 months; 3) Pre-morbid IQ estimated at <85 using National 
Adult Reading Test (NART); 4) Currently taking medications known to have a 
significant effect on Central Nervous system (other than medications prescribed for 
the control of PD symptoms); 5) Beck Depression Inventory –II score of >17.   
Of the 115 letters that were mailed, 6/115 (5.2%) of individuals with PD could 
not participate due to illness, 6/115 (5.2%) were deceased, 8/115 (6.9%) declined, 
34/115 (29.6%) did not respond, and 21/115 (18.3%) did not meet the 
inclusion/exclusion criteria.  After exclusions, 40 participants with PD were included 
in the analyses.   
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Controls 
Controls were recruited from a number of sources including a previously 
established data base, advertisements at local clubs (bowling, hiking and table tennis) 
and businesses.  All controls were given a brief outline of the study on first phone 
contact.  If they were still willing to participate they were then sent an information 
sheet.  In addition to adequate or corrected hearing and vision (self report, checked by 
the examiner) and being aged between 50 to 80 years of age, the same exclusion 
criteria listed above also applied to the control group.   
4.4.4 Procedure   
Assessments were carried out at the University of Canterbury over three 
testing sessions, each of three hours duration.  Tests were presented in a fixed order 
with breaks taken as required.  Patients with PD were tested while on optimal levels 
of medication (based on patient report).  Information pertinent to the 
inclusion/exclusion criteria was elicited from all participants using a semi-structured 
interview.   
Participants were also asked to nominate a person who knew them well (a 
“significant other”) to provide collateral information regarding their daily living 
activities.  If the participants agreed, the significant other was contacted, the purpose 
of the study was explained, and consent obtained.  In most cases the significant other 
was a spouse or other family member.   
In the case of control participants, information for the significant others to 
complete was sent home with the participant and returned at the next testing session.  
For PD patients, information regarding everyday activities was collected during a 
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face-to-face interview with a significant other person.  In the majority of cases, these 
interviews were conducted by a second interviewer during the same time period that 
the patient was engaged in the second or third testing session.   
Clinical Assessment  
To ensure that none of the patients included in the study met the criteria for 
dementia, the Dementia Rating Scale (DRS-2) (Jurica, 2001) was used in addition to 
the MMSE.  This scale consists of 36 tasks and five subscales.  The five subscales 
provide information on specific abilities and include: 1. Attention; 2. Initiation/ 
Perserveration; 3. Construction ability; 4. Conceptualization; and 5. Memory.  Based 
on normative data, raw scores from each subscale were summed to provide an overall 
score (ranging from 0-144 with higher scores indicating better performance) A DRS-
II score of 130 has previously been validated as appropriate for PD patients (Brown et 
al., 1999).  However, as pointed out by Green et al (Green et al., 2002) this may 
exclude some patients due to motor deficits.  Therefore, patients with a total raw score 
of <120 were excluded and those with raw scores between 120 and 130 were further 
assessed for dementia by a registered clinical psychologist using the Diagnostic and 
Statistical Manual of Mental Disorders-IV (DSM-IV) criteria.  Two patients scored 
below 130 but neither patient met the DSM-IV criteria for dementia.  A combined 
scaled score adjusted for age and education was then generated using a regression 
formula provided in the administration manual (Jurica, 2001).   
Two scales were used to provide information regarding motor impairment: 1) 
The Hoehn and Yahr and 2) the Unified Parkinson’s Disease Rating Scale (UPDRS) 
(Goetz et al., 1995).  Three scores were generated using the UPDRS, a) The severity 
of motor symptoms was rated using the motor section; b) a tremor score calculated as 
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the average of items 16 and 20-26 on the UPDRS; and c) a non tremor score 
calculated as the average of items 5,7,12-15, 18, 19, and 27-44 and divided by 26 
(Lewis, Dove, Robbins, Barker, & Owen, 2003).  The Hoehn and Yahr (H&Y) scale 
was used to rate the stage of the disease (Hoehn & Yahr, 1967).   
Cognitive tests used in the cluster analysis  
Tests from six cognitive domains were included in the cluster analysis: 1) 
General executive function/planning; 2) problem solving; 3) working 
memory/attention; 4) speed of processing; 5) memory/learning; and 6) visuospatial 
ability.   
All tests were commonly used neuropsychological measures and scored 
according to standard procedures.  The majority of the measures used were from 
standardized batteries including the Wechsler Abbreviated Scale of Intelligence 
(WASI) [Mean 50, Standard deviation10], (Wechsler, 1997) the Delis Kaplan 
Executive Function System (D-KEFS),(Delis, Kaplan, & Kramer, 2001) and the 
Wechsler Memory Scale-III (WMS-III)(Wechsler, 1997) [both mean 10, standard 
deviation, 3] with age-adjusted norms.  Such norms were not available for tests from 
the Behavioral Assessment of the Dysexecutive Syndrome (BADS) [scores range 
from 0-4], (Wilson, Alderman, Burgess, Emslie, & Evans, 1996) Cambridge 
Neuropsychological Test Automated Battery (CANTAB),(Owen et al., 1992) Reading 
Span task, and tests of visuospatial functioning.   
Executive function and planning skills were evaluated using the following 
test from the D-KEFS: Verbal Fluency test (with subtests for letter fluency, category 
fluency and category fluency switching) and Color-Word Interference test (with sub-
tests for Inhibition and Inhibition switching).  Also included in this domain were the 
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Key Search and Zoo map from the BADS, the Intradimensional/Extradimensional 
Shift (ID/ED) from the CANTAB (Owen et al., 1992) (number of stages completed, 
scores vary from 0-9) and the CLOX-I (scores range from 0 to 15, with higher scores 
indicating better performance) .(Royall, Cordes, & Polk, 1998).   
Problem solving was assessed using the Card Sorting subtest sorting 
recognition, and the Tower Task (number of towers completed in the minimum 
number of moves, maximum score possible 9), both from the D-KEFS, Matrix 
Reasoning subtest from the WASI, and the Stockings of Cambridge (SOC’s) from the 
CANTAB (Owen et al., 1992) (number of towers completed in the minimum number 
of moves, maximum score possible 12).   
Working memory/attention was assessed using Letter Number Sequencing, 
and Digits Forward and Backward from the WMS-III, Spatial Span (maximum 
sequences correctly recalled 0-9) from the CANTAB and the Daneman and Carpenter 
Reading Span test (scores range from 1-6) (Daneman & Carpenter, 1980).  Speed of 
Processing was evaluated using Word Naming and Color Naming from the D-KEFS 
Color-Word interference test.   
Memory/learning was assessed with the WMS-III, Paired Associates 
(immediate and delayed), Logical Memory (immediate and delayed) and the Auditory 
Recall Index.  The Rey Osterrieth Figure (ROF) recall after 3 (ROF-I) and 30 minutes 
(ROF-II) was also used as a measure of memory ability.   
Visuospatial/constructive skills were assessed using the Judgement of Line 
Orientation (JLO); scores are number of correct line pairs, with possible scores 
ranging from 0-30 (Benton, Varney, & Hamsher, 1978).  Also included in this domain 
were the Rey Osterrieth Figure copy task and the CLOX part two.  All three parts of 
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the ROF are rated the same, scores range from 0-36, with higher scores indicating 
more accurate performance (Spreen & Strauss, 1998).   
Information regarding everyday living  
Functional Activities Questionnaire (FAQ) (Pfeffer, Kurosaki, Harrah, 
Chance, & Filos, 1982) was used to assess patients’ functional capacity and included 
items such as ability to prepare a balanced meal or remembering appointments.  The 
questionnaire was completed by a significant other who rated the patients on their 
ability to complete 10 higher-order tasks according to a 4 point scale (dependent = 3, 
requires assistance = 2, has difficulty but does by self = 1, no difficulty = 0).  A total 
score for the FAQ is obtained by summing the scores across the 10 items (Pfeffer, 
Kurosaki, Harrah, Chance, & Filos, 1982).   
4.4.5 Statistical Analysis   
Non-hierarchical (k-means) cluster analyses were performed on the 40 PD 
patients with two, three and four cluster solutions.  Analyses were conducted using 
the 26 tests covering all six cognitive domains (although patients were tested on a 
total of 29 tests, only 26 tests were completed by all patients and these were used in 
the cluster analysis3) and again using 13 cognitive tests that differentiated PD patients 
significantly from healthy controls (p< 0.01) Differences in demographic and clinical 
characteristics for the resulting subgroups were examined using analysis of variance 
(ANOVA).  Measures were then transformed to z-scores, using the control means and 
standard deviations, so that comparisons could be made across tests.  To control for 
                                                
3 Due to motor impairments one patient was not able to complete the Key Search, ROF or the CLOX 
tasks. Due to error one control was not administered the Tower Task and two controls were not 
administered the Spatial Span task. Three PD patients were not able to return a completed FAQ. 
However, patients with missing data did not differ from the mean of the PD group in terms of their 
performance on the DRS-II, MMSE or in terms of years of education and ratings on the H&Y. 
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the effect of multiple comparisons, p < 0.01 was considered significant for individual 
tests.  Finally, Student t-tests were used to compare each of the groups identified in 
the cluster analysis with their matched controls for cognitive outcomes and in terms of 
deficits in daily living.   
4.4.6 Results   
Figure 6 shows the results of the cluster analyses for 2, 3 and 4 cluster 
solutions using 26 and 13 variables.  Analysis of the 2, 3 and 4 cluster solutions for 
the 26 variables shows that groupings were consistent (Figure 6A).  Because the 
fourth group in the 4 cluster solution comprised only two patients, a final three cluster 
solution was forced by combining the yellow and red groups.  Table 38 displays the 
results of the ANOVAs for the resulting three groups for the full set of 29 variables.  
Numbers 1-13 on Table 38 indicate tests that are significant for PD patients versus 
matched control at p < 0.01.   
ANOVAs found significant differences (p < 0.01) across the PD subgroups for 
10 of these 13 measures (77%).  Of the remaining 16 variables which were not 
differentiated between PD patients and matched controls, significant ANOVA results 
were obtained in just 3 cases (18.8%).  This confirms that the variables which were 
most indicative of heterogeneity in cognitive functioning among PD patients were 
largely the same variables that differentiated PD patients from healthy controls, as 
predicted by the hypothesis that there is a subgroup of PD patients with cognitive 
impairment.  Because we were interested in identifying the most discriminating tests 
that could easily be used by clinicians to identify PD-MCI, we re-ran the analysis with 
just the 13 variables previously found to differentiate the PD patients and matched 
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controls.  This analysis yielded essentially the same clusters with 90% of cases 
remaining in their respective groups (see Figure 6B).   
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Different patient combinations for two, three and four cluster solutions 
using 26 variables (panel A) and then with the 13 variables (panel B) previously 
found to be differentially sensitive to impairments for Parkisons’ disease versus 
healthy controls.   
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Table 38: Comparison between the three Parkinson’s disease groups identified by the 
cluster for cognitive characteristics.   
 
 
 
∫ 
Green group 
N=19 
Mean [SD] 
Blue group 
N=9 
Mean [SD] 
Red group 
N=12 
Mean [SD] 
 
 
F 
 
 
p-level* 
Executive Functioning/Planning       
Verbal Fluency sub-tests: a       
• Letter Fluency     12.95  [3.0] 10.33  [2.8]   6.83  [2.1] 18.15 <0.001 
• Category Fluency   1 10.21  [2.5]   9.67  [2.3]   7.83  [2.3]   3.73 <0.05 
• Category Switching   2 11.42  [3.2] 10.89  [2.0]   6.75  [3.1]   9.70 <0.001 
  CLOX-I  3 13.89  [1.4] 10.89  [1.9] 11.36  [3.4]   7.48 <0.01 
  Key Search b    2.95  [1.1]    1.89 [1.5]   2.36  [1.6]   2.04 >0.10 
  Zoo Map b    2.47  [1.0]    1.89 [1.5]   1.58  [1.1]   2.38 >0.10 
Color-Word Interference subtesta       
• Inhibition   4 10.63  [2.3] 10.00  [1.9]   6.00  [3.5] 11.79 <0.001 
• Switching   5 10.90  [2.3] 10.11  [2.6]   5.42  [3.9] 13.84 <0.001 
  ID/ED- Phases completed c    8.58  [0.8]   8.44  [2.5]   7.17  [2.5]   3.31 <0.05 
Problem solving       
Card Sorting Description   12.32  [2.1] 10.89  [1.6]   8.42  [1.9] 15.00 <0.001 
  Matrix Reasoning d  6  60.16 [5.7] 49.00  [8.7] 45.08   [9.4] 15.89 <0.001 
  Stockings of Cambridge c (1)  7    7.42 [2.2]   7.67  [1.5]   4.58  [2.8]   7.01 <0.01 
  Tower Test a (2)     4.39 [1.1]   3.67  [0.7]   3.92  [1.2]   1.56 >0.20 
Working Memory/ Attention       
  Digits Forward e  11.00  [2.4]   9.56  [1.9]   9.50  [1.4]   2.59 <0.10 
  Digits Backwards e    7.58  [2.4]   5.22  [1.6]   5.33  [1.3]   6.80 <0.05 
  Letter Number Sequencing e    11.21  [2.8] 10.67  [0.7]   8.83  [2.7]   3.47 <0.05 
  Reading Span Test 8   1.79  [0.6]   1.78  [0.7]   1.38  [0.4]   2.32 >0.10 
  Spatial Span c 9   4.89  [0.5]   4.56  [0.5]   4.17  [0.8]   5.30 <0.01 
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Table 38 continued.   
 
 
 
∫ 
Green group 
N=19 
Mean [SD] 
Blue group 
N=9 
Mean [SD] 
Red group 
N=12 
Mean [SD] 
 
 
F 
 
p-
level* 
Speed of Processing       
Verbal Fluency Test: a       
• Word naming  10 10.95  [1.7]   9.78  [2.0]   9.08  [1.4] 4.56 <0.02 
• Color naming  11 10.58  [1.5]   8.78  [2.4]   7.33  [2.7] 8.71 <0.001 
Memory/Learning       
  Logical Memory immediate e    7.68  [3.0]   9.56  [1.9]   6.83  [4.0]  2.01 >0.10 
  Logical Memory delayed e    8.95  [3.1] 10.00  [2.7]   7.08  [3.3]  2.50 <0.10 
  Paired Associates immediate e    8.00  [3.1]   9.22  [3.4]   7.08  [3.0] 1.38 >0.20 
  Paired Associates delayed e    8.68  [2.8]   8.56  [2.1]   7.83  [2.9] 0.39 >0.60 
  Auditory Recall index e    9.42  [3.0] 10.56  [2.3]   6.83  [3.6] 4.30 <0.05 
  ROF-II&III  17.08  [6.4] 11.83  [4.5] 12.77  [5.9] 3.22 <0.10 
Visuospatial ability       
  ROF-I 12 34.58  [1.7] 29.28  [3.4] 29.32  [5.1] 12.04 <0.001 
  Line Orientation  27.00  [2.2] 20.00  [4.4] 19.33  [5.9] 16.86 <0.001 
  CLOX-II 13 14.74  [0.6] 12.89  [0.9] 14.27  [1.2] 14.12 <0.001 
∫ Bold numbers indicate tests that are significant at p < 0.01 for PD v Healthy controls, 1Number of 
towers completed in minimum moves; aDelis Kaplan Executive Functioning System standardized 
scores; b Behavioral Assessment of the Dysexecutive Syndrome profile scores;c Cambridge 
Neuropsychological Test Automated Battery;d Wechsler Abbreviated Intelligence Scale standardized 
scores; e Wechsler Memory Scale- 3rd edition, standardized scores. 
 
In terms of specific cognitive domains, significant differences among the PD 
subgroups were found for 5 out of 9 measures of executive function including verbal 
fluency ( category fluency, and category switching), the CLOX-I and measures of 
inhibition (see Table 38).  The groups also varied on 3 of 4 measures of problem 
solving (Card Sorting Description, Matrix Reasoning and Stockings of Cambridge), 1 
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of 4 working memory measures (Spatial Span), and all measures used to test speed of 
processing and visual spatial ability ( all p’s < 0.01).  None of the measures used to 
assess memory/learning showed evidence of deficit across all three groups.  There 
was no difference between the groups in terms of attention as measured by Digits 
Forward.   
ANOVAs were used to examine the clinical and demographic characteristics 
for the three PD groups (Table 39).  As might be expected, given their different levels 
of cognitive impairment, the groups showed significant differences in terms of current 
mental status as measured by the MMSE.  The only other significant differences 
between the groups were obtained for one measure of premorbid ability.  Patients in 
the PD-UCI and PD-MCI group had lower pre morbid intelligence, (F = 17.45, df = 
37, p < 0.001).   
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Table 39: Comparison between the three Parkinson’s disease groups identified by the 
cluster analysis for clinical and demographic characteristics.   
 
 
PD-NCI 
N=19 
Mean  [SD] 
PD-UCI 
N=9 
Mean  [SD] 
PD-MCI 
N=12 
Mean  [SD] 
 
 
F 
 
 
p-level 
MMSE1 29.32    [0.8] 28.77    [1.0] 27.50    [1.8] 8.27 <0.01 
DRS-II2 10.52    [2.1] 10.29    [1.6] 9.16    [3.7] 1.03 >0.30 
Years of Education 15.13    [0.1] 12.89    [1.8] 12.83    [1.0] 4.67 <0.05 
NART3 116.37  [7.3] 103.33    [7.9] 101.75    [7.4] 17.45 <0.001 
Age 64.37    [6.6] 66.00    [7.4] 69.08    [5.5] 1.94 >0.10 
UPDRS Total 4 26.68    [6.0] 28.11  [11.1] 31.82  [12.6] 1.03 >0.30 
UPDRS Tremor 0.57     [0.3] 0.42    [0.3] 0.66    [0.6] 0.96 >0.30 
UPDRS  Non Tremor 1.07     [0.3] 1.21    [0.5] 1.32    [0.5] 1.46 >0.20 
PD Onset5 5.79     [3.0] 6.33    [2.9] 7.84    [6.1] 0.77 >0.47 
H&Y6 2.03     [0.7] 2.05    [0.8] 2.33    [1.0] 0.54 >0.50 
BDI-II7 7.68     [4.5] 8.22    [5.2] 6.92    [3.5] 0.24 <0.79 
 
1 Mini Mental Status Exam; 2 Mattis Dementia Rating Scale adjusted for age and education; 3 
Premorbid intelligence estimate using the National Adult Reading Test; 4Unified Parkinson’s disease 
rating scale motor score; 5 Number of years since Parkinson’s disease was first diagnosed; 6 Hoehn & 
Yahr stage; 7 Beck Depression Inventory-II. 
 
Figure 7 displays the comparison between the three groups of PD patients 
identified in the cluster analysis using z-scores for the 13 measures that were found to 
be significantly different at p < 0.01 (see Table 38).  The graph shows that the three 
PD groups represent a continuum of overall cognitive impairment, from minimal/no 
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cognitive impairment (PD-NCI), uncertain cognitive impairment (PD-UCI), to mild 
cognitive impairment (PD-MCI), rather than impairments on different subsets of tests.   
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Figure 7: Comparison between the three groups of Parkinson’s disease patients 
identified in the cluster analysis using the 13 measures that showed significant 
differences (p<0.01) across groups.   
Table 40 shows the medications used by the patients according to their 
respective subgroups.  The only notable differences were that patients in the PD-UCI 
and PD-MCI groups were more likely to be using MAO-B Inhibitors and patients in 
the PD-NCI and PD-MCI group were more likely to be using anticholinergic 
medication.   
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Table 40: Medications used by each of the 3 sub-groups identified by the cluster 
analysis.   
 
PD-NCI 
% (n=19) 
PD-UCI 
% (n=9) 
PD-MCI 
% (n=12) 
L-Dopa 47.4 % (9/19) 66.7% (6/9) 66.7% (8/12) 
Anticholinergics 68.4% (13/19) 11.1% (1/9) 41.7% (5/12) 
Dopamine Agonists 52.6% (10/19) 44.4% (4/9) 50.0% (6/12) 
COMPT Inhibitor1 5.3%  (1/19) 11.1% (1/9) 8.3% (1/12) 
MAO-B Inhibitor2 15.8% (3/19) 44.4% (4/9) 66.7% (8/12) 
 
1 Catechol-O-methyl-tranferase Inhibitor; 2monoamine oxidase type-B Inhibitor 
 
Figure 8 shows a comparison of performances on the different cognitive tests 
for the three PD subgroups with healthy controls.  Each of the 40 PD patients was 
matched as closely as possible to a healthy control in terms of age and pre-morbid IQ 
(McKinlay, Grace, Dalrymple-Alford, & Roger in review).  Matching was confirmed 
by t tests (IQ: t = 0.94, df =78, p > 0.30; and age: t = 0.31 df = 78, p > 0.75).  As 
shown in Figure 8 (panel A), for the PD-NCI group, significant differences (p < .01) 
with their matched controls were found for 2 out of 29 measures, Reading Span 
(t=3.62, df, 36) and Paired Associates I (t=2.85 df = 36) in two separate domains, 
Working Memory and Memory/Learning.  The PD-UCI group, (panel B) had deficits 
over four domains, Working Memory, Executive function, Speed of Processing and 
Visuospatial skills (specific deficits included: CLOX-I ( t = 4.81, df = 16), Color 
Naming (t = 3.10, df = 16), ROF-I (t = 4.98, df = 16), and CLOX-II (t = 6.83, df = 
16)).   
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Figure 8: Comparison between Parkinson’s disease patients and matched controls on 
measures of cognitive functioning at time one. *= p<0.05; **= p<0.01; ***=p<0.001.   
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By contrast, the PD-MCI groups, (panel C) showed deficits across 5 of the 6 
domains compared to matched controls (the exception being Memory/Learning).  
Specific measures that showed a significant difference (p < .01) included  Letter 
Fluency (t = 5.27, df = 22), Category Switching (t = 5.08, df = 22), Inhibition (t = 
4.18, df = 22), Inhibition Switching(t = 3.77, df = 22), Matrix Reasoning (t = 4.00, df 
= 22), SOC’s (t = 2.97, df = 22), Reading Span (t = 4.80, df = 22), Word Reading (t = 
3.18, df = 22), Color Naming (t = 4.16, df = 22), ROF-I (t = 3.82, df = 22) and Line 
Orientation (t = 3.08, df = 22).   
Using a criterion that has been used in previous reports, mild cognitive 
impairment was defined as ≤ 1 SD and severe cognitive impairment ≤ 2 SD below the 
control group norm.  (Woods & Troster, 2003) Across the PD-NCI, PD-UCI, and PC-
MCI subgroups, there was a trend for an increasing number of patients to exhibit 
severe deficits on at least one cognitive domain (see Table 4).  Moreover, whereas the 
PD-NCI group showed evidence of deficits over two domains (working memory and 
memory/learning; see Figure 3) the deficit for one of the domains, memory/learning, 
was generated by a mild decline for the majority of the individuals in the groups as 
opposed to evidence of severe deficits (Table 4).  There was clear evidence of severe 
deficits in four domains for the PD-UCI group (executive function, speed of 
processing, working memory, and visuospatial ability) and five domains for the PD-
MCI group (executive function, speed of processing, problem solving, working 
memory, and visuospatial ability).   
All PD patients and 90% of the control group showed a mild and or severe 
deficit on at least one measure over one or more of the six cognitive domains. 
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However, PD patients were more likely to show increased evidence of severe deficits 
(see Table 41).   
Table 41: Number and percentage of Parkinson’s disease patients versus matched 
controls who exhibited deficits separately for each of the six domains.   
 Mild Deficits >1SD1 n (%)  Severe Deficits >2SD 1 n (%) 
 
NCI2 
n=19 
UCI3 
n=9 
MCI4 
n=12 
 
NCI 
n=19 
UCI 
n=9 
MCI 
n=12 
Executive function        
PD patients 12 (63.2) 5  (55.6) 0  (0.0)  4  (21.1) 4  (44.4) 12 (100.0) 
Matched controls 7 (36.8) 4  (44.4) 6 (50.0)  3  (15.8) 0   (0.0) 4  (33.3) 
Problem Solving        
PD patients 7  (36.8) 6  (66.7) 4  (33.3)  1   (5.3) 2  (22.2) 7  (58.3) 
Matched controls 5  (26.3) 4  (44.4) 7  (58.3)  1   (5.3) 0   (0.0) 0    (0.0) 
Working memory        
PD patients 8  (42.1) 3  (33.3) 5  (41.7)  5  (26.3) 4  (44.4) 7  (58.3) 
Matched controls 7  (36.8) 4  (44.4) 7  (58.3)  2  (10.5) 1  (11.1) 1    (8.3) 
Speed of processing        
PD patients 7  (36.8) 5  (55.6) 3  (25.0)  1  (5.3) 3  (33.3) 8  (66.7) 
Matched controls 5  (26.3) 1  (11.1) 2  (16.7)  1  (5.3) 0   (0.0) 0    (0.0) 
Memory/learning        
PD patients 10  (52.6) 4  (44.4) 8  (66.7)  2  (10.5) 0   (0.0) 3  (25.0) 
Matched controls 9  (47.4) 5  (55.6) 6  (50.0)  0  (0.0) 0   (0.0) 2   (16.7) 
Visuospatial ability        
PD patients 7  (36.8) 0   (0.0) 0  (0.0)  2  (10.5) 9 (100.0) 12 (100.0) 
Matched controls 4  (21.1) 1  (11.1) 4  (33.3)  5  (26.3) 0    (0.0) 2    (16.7) 
1If any patient or control had both a mild and severe deficit in a given domain they were counted as 
severe; 2 minimal cognitive impairments; 3 intermediate or uncertain cognitive impairment; 4 “Mild 
Cognitive Impairment” Bold numbers for severe deficits indicate the domains that were significantly 
impaired compared to controls (see Figure 3).  
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To provide a summary comparison, measures within each domain were 
averaged across participants and groups.  Results are shown in Figure 9.  There is 
evidence for increasing deficits across the three subgroups.   
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Figure 9: Comparisons between Parkinson’s disease patients and their matched 
controls for each of the six cognitive domains.   
(z-scores were generated by averaging all measures separately from each domain 
listed on Table 38, with the exception of Digits Forward which forms the domain of 
attention).   
Difficulties with daily living, as measured by the Functional Activities 
Questionnaire, are shown in Figure 10 for the PD subgroups and matched controls.  
The PD-UCI ( t = -2.59, p < 0.05) and PD-MCI (t = -3.05, p < 0.01), subgroups had 
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more difficulties with everyday tasks than matched controls.  By contrast, there was 
no significant difference between the PD-NCI group and their controls.   
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Figure 10: Comparison between the three groups of Parkinson’s disease patients and 
between each group of patients and their matched controls using the Functional 
Activities Questionnaire.   
(Only 37 Parkinson’s disease patients (PD-NCI n=18; PD-UCI n=8; PD-MCI n=11) and 33 
controls (15, 9 and 9 respectively) completed this questionnaire). * p<0.05; **p<0.01. 
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4.4.7 Discussion   
This study used a data-driven method to identify different sub-categories of 
cognitive impairment for patients with PD.  Twenty-nine commonly used 
neuropsychological tests, covering six cognitive domains, were administered to a 
group of PD patients.  We found that predominately the same variables that 
differentiated the PD patients overall from the healthy controls, were those that were 
associated with heterogeneity among PD subgroups.   
Differences among the PD subgroups were found for measures of executive 
function, problem solving, working memory, speed of processing, and visual spatial 
ability.  There was no difference between the groups in terms of memory/learning or 
attention.  Comparisons of these subgroups indicated that the groups represented a 
continuum of cognitive impairment (see Figures 7 and 9) ranging from none or 
minimal (which were labelled PD with No Cognitive Impairment (PD-NCI)) to PD 
patients with a more varied pattern of cognitive impairment which included areas of 
severe impairment (which were labelled as PD with Uncertain Cognitive Impairment 
(PD-UCI)) through to PD patients who were showing evidence of multiple domains 
with severe cognitive impairments but did not meet the criteria of dementia (PD-
MCI).  Taken together with the consistency of the tests which differentiated the PD 
patients from the healthy controls and were associated with heterogeneity across the 
PD subgroups, this suggests that MCI is an identifiable syndrome that affects a subset 
of PD patients.  Clinical and demographic characteristics were also examined and 
subgroups of patients were found to be similar in terms of medications used, motor 
impairments, age, and mood.   
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Because groups varied on some premorbid abilities, we also compared patients 
to matched controls.  Each of the 40 PD patients was matched as closely as possible to 
a healthy control in terms of age and pre-morbid IQ using the NART.  Compared to 
their controls, the PD-NCI group was impaired on a single measure in two domains: 
working memory and memory/learning.  The PD-UCI group was impaired on single 
measures from three different domains: executive function; speed of processing; and 
visuospatial ability.  However, the PD-MCI group was impaired on multiple measures 
over five domains: executive function; problem solving; working memory; speed of 
processing; and visuospatial ability.   
All patients, regardless of group, showed a mild deficit ( ≥ 1 SD below the 
control group norm) and/or severe deficit (≥ 2 SD below the control group norm) on 
at least one measure in one or more of the six cognitive domains.  When we assessed 
the number of patients from each group who showed impairment on at least one of the 
six domains, the PD-NCI group had little evidence of severe cognitive impairments 
(i.e., 84.2% of the patients in this group exhibited severe deficits in ≤ 1 of the six 
cognitive domains tested).  Only 21% (4/19) showed severe deficits in two or more 
domains.  By contrast, in the PD-UCI group 77.8% (7/9) of the patients had severe 
impairment in 2 or more domains, and all of the patients in the PD-MCI group had 
severe deficits in two or more domains.   
Differences for the groups of PD patients compared to their matched controls 
were also found in terms of functions of daily living.  Whereas the PD-NCI group 
were comparable to their matched controls in this regard, both the PD-UCI and PD-
MCI groups were considerably more impaired than their controls.   
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Consistent with previous research, our study found evidence for different sub-
groups of PD patients based on cognitive functioning (Lewis et al., 2005).  The 
importance of accurately defining different subgroups is amplified by the suggestion 
that some PD patients may be more at risk of progressing to PDD (Janvin, Larsen, 
Aarsland, & Hugdahl, 2006).  Prevalence rates of dementia among people with PD are 
much higher than in the general population, approximately four to five times that of 
elderly individuals without PD.(Aarsland, Andersen, Larsen, Lolk, & Kragh-
Sorensen, 2003).   
However, the cognitive symptoms associated with the preclinical phase of 
PDD have yet to be fully established.  Previous studies have found evidence for a 
range of different cognitive deficits that may best predict PDD, including attention, 
(Woods & Troster, 2003) inhibition(Mahieux et al., 1998), mental flexibility (Janvin, 
Aarsland, & Larsen, 2005), memory(Levy et al., 2002), language (Hobson & Meara, 
2004), and phonemic/semantic fluency (Jacobs et al., 1995).  While the range of 
measures previously suggested as predictive of PDD may seem diverse, the majority 
of them reflect what would generally be considered as executive functions, which 
have previously been suggested as the most common deficit in PD-MCI (Caviness et 
al., 2007).  In this study, all patients in the PD-UCI and PD-MCI subgroup had severe 
deficits of visuospatial ability and all but two patients in the PD-MCI group had 
severe deficits in executive functioning.  Many patients in the PD-MCI group also had 
deficits in other areas of cognitive functioning.  The only area that appeared to be 
spared was general memory/learning.   
Progression to dementia has been reported by some as being more likely in 
patients with longer disease duration, older age, and more severe motor symptoms 
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(Biggins et al., 1992; Caparros-Lefebvre, Pecheux, Petit, Duhamel, & Petit, 1995; 
Mahieux et al., 1998).  However, this finding was not supported in our study.  Indeed 
the subgroups were comparable on most of the demographic, clinical and motor 
characteristics assessed.  Moreover, other research suggests that clinical and motor 
characteristics by themselves are not sufficient to identify patients in the pre-clinical 
stages of PDD (Graham & Sagar, 1999) Furthermore, longer disease duration and 
severe motor problems are also more likely to be associated with older patients, and 
older people in general are more likely to progress to dementia.   
This study had a number of strengths as it used a wide range of tests across a 
broad range of possible domains, to determine cognitive deficits for the different 
groups.  Also, we used a data driven approach to examine the data to avoid the 
difficulties of predetermined cut offs.  However, a limitation of the study was the use 
of a cross-sectional design.  The groups identified here would have to be followed 
longitudinally to confirm whether the patients in the PD-MCI group were indeed more 
likely to progress to dementia.  Furthermore, the number of patients in two of the 
groups identified by the cluster analysis was relatively small.   
It is clear from these findings that patients with PD are heterogeneous with 
regard to their cognitive presentation.  Furthermore, the severity of cognitive deficits 
cannot be predicted by other clinical and demographic characteristics such as motor 
impairments, age, or disease duration.  We identified a group of patients with severe 
cognitive deficits over multiple domains and with evidence of problems in daily living 
that may be characteristic of PDD.  Longitudinal assessment of patients in this study 
is underway and will be essential to confirm the initial findings.   
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The identification of diagnostic criteria associated with PD-MCI would 
present an opportunity to intervene and delay the onset of more severe cognitive 
problems that may result in later dementia.  Preliminary research indicates that, as 
with AD, the cognitive impairments associated with PDD may be improved with 
cholinesterase inhibitors without worsening motor symptoms(2003).  Thus, early 
identification of individuals likely to develop PDD could be the basis for early 
intervention that could slow its development.   
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4.5 The Cognitive Characteristics of Pre-clinical Dementia in Parkinson’s 
Disease   
  239 
4.5.1 Abstract   
The aim of this study was to track the evolution of cognitive decline in PD 
patients order to identify a profile of pre-clinical dementia for this group.  Thirty three 
PD patients, divided into three sub-groups based on their initial cognitive 
performance, and their matched healthy controls were reassessed after a 1 year 
interval.  At initial assessment, one group of PD patients had no cognitive 
impairments (PD-NCI) and one had uncertain cognitive impairments (PD-UCI).  The 
third group had evidence severe cognitive impairments analogous to the state of pre-
clinical dementia found in early Alzheimer’s disease termed “Mild Cognitive 
Impairment”.  This latter group was labeled PD-MCI.  These PD groups were 
comparable with regard to motor impairments, age and education.  Patients were 
assessed over five domains:1) executive function; 2) problem solving; 3) working 
memory/attention; 4) memory, and 5) visuospatial ability.  The PD groups differed on 
the domains of executive function, problem solving and working memory with 
greatest deficits being evident for the PD-MCI group.  In terms of visuospatial ability, 
there was evidence of equivalent deficits for both the PD-UCI group and the PD-MCI 
group.  When compared to their matched controls the PD-NCI group differed on only 
1 of 15 measures tested and the PD-UCI on only two out of the 15.  But the PD-MCI 
group on was impaired on 6/15 measures over 3 domains (executive function, 
working memory and problem solving).  Increasing cognitive problems were also 
associated with decreased functioning in activities of daily living.  There was clear 
evidence of increasing cognitive decline across the three PD groups.  The PD-MCI 
group had evidence of global cognitive decline, possibly reflecting a stage of pre-
clinical dementia.   
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4.5.2 Introduction   
Cognitive deficits occur frequently in patients with Parkinson’s disease (PD) 
with about 40% of patients progressing to PD with dementia (PDD)(Cummings, 1988).  
Severe deficits in cognition and impairment in social functioning associated with PDD 
often result in reduced patient autonomy and may require early rest home care resulting 
in both social and personal cost.  Recent research suggests that cognitive decline may 
be effectively treated with medical interventions (Aarsland, Hutchinson, & Larsen, 
2003).  The possibility of delaying the onset of PDD has resulted in an increased 
interest in identifying the characteristics of PD patients that may be at risk for 
developing dementia.   
A number of clinical and demographic symptoms have been associated with 
PDD including older age, longer disease duration, hallucinations and more severe 
motor symptoms (Biggins et al., 1992; Caparros-Lefebvre, Pecheux, Petit, Duhamel, & 
Petit, 1995; Janvin, Aarsland, Larsen, & Hugdahl, 2003; Mahieux et al., 1998).  In 
terms of cognitive deficits, impairments in executive functions have been reported by a 
number of authors as a risk factor for later dementia (Azuma, Cruz, Bayles, Tomoeda, 
& Montgomery, 2003; Jacobs et al., 1995; Janvin, Aarsland, & Larsen, 2005; Mahieux 
et al., 1998; Woods & Troster, 2003).  However, deficits in executive function are 
common in PD patients and may lack specificity to be used as a predictor of later 
dementia.  Unfortunately, a clear cognitive profile associated with pre-clinical PDD has 
yet to be identified.   
Previously were assessed over a broad range of cognitive domains, including 
executive function, problem solving, working memory/attention, speed of processing 
and visuospatial ability, using common neuropsychological tests (McKinlay, Grace, 
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Dalrymple-Alford, & Roger - In review).  This information was then used in a cluster 
analysis to identify sub-groups of PD patients who were heterogeneous with regard to 
their cognitive presentation.  Three groups were identified.  One group of patients had 
no or minimal cognitive impairments (PD-NCI) on any of the domains measured.  
Another group had a variable pattern of mild, moderate and severe cognitive 
impairments and therefore labeled as uncertain cognitive impairment (PD-UCI).  
However, a third group was consistently impaired on most domains tested and 
resembled more closely the stage of Mild Cognitive Impairment (MCI) discussed in the 
Alzheimer’s disease (AD) literature.  This term has been used to describe cognitive 
impairments that exceed the level of impairment usually evident with normal aging, but 
not of sufficient severity to warrant a diagnosis of dementia.  Individuals with this level 
of cognitive decline are more at risk of developing AD (Petersen, 2004).  Therefore, the 
third group was labeled PD-MCI.  For all groups, executive function and visuospatial 
ability were the two domains most likely to be impaired, with attention and general 
memory being relatively unimpaired.  Severity of cognitive deficits was not associated 
motor impairments, age or disease duration (McKinlay, Grace, Dalrymple-Alford, & 
Roger- In review).   
The aim of this current study is to follow the evolution of these previously 
identified groups using a selection of tests that we had found to be sensitive to cognitive 
impairment in PD.  We also intended to compare the groups at time two in relation to 
their performance at time one.  We expected to see a trend for decline in our PD groups 
over the one year period.  More specifically we wanted to examine whether this trend 
was more noticeable in the PD-MCI group.  Thirdly, we wanted to examine the 
performance of the three groups in terms of their ability to perform activities of daily 
living.  According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-
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IV) a diagnosis of dementia requires that the deficits in cognitive performance cause 
significant impairment in social functioning.  Therefore, would expect to see a trend 
towards greater impairment in social functioning across the three PD groups compared 
to their healthy controls.   
4.5.3 Method   
Participants  
Participants were all recruited from a data base of PD patients and healthy 
controls who had agreed to participate in a longitudinal study examining cognitive 
deficits in PD.  Participants were approached approximately one year following the first 
study (the minimum period of follow up was 9 months and the maximum was 16 
months).  Participants who had given consent (39/40 people with PD and 40/40 of the 
healthy controls had consented to further follow-up at the end of first phase of testing) 
were first contacted by phone to ascertain whether they were still willing to participate 
in the second study, and if willing, given details of the studies objectives.  Of the 39 
patients who consented to being re-contacted, 33 were available for testing at follow-
up.  Of the six participants that were unavailable; one was deceased; two had been 
hospitalized; one was out of the city during the testing period; one declined; and one 
was unable to be contacted.  Of the people with PD that were not available for follow-
up 2 came from the PD-NCI group, 1 came from the PD-UCI group and 4 came from 
the PD-MCI group.  Parkinson’s disease patients who did not participate at time two 
tended to be older (mean 72.1 v 64.9, t=-2.86, df 38, p<0.01 and had lower score on the 
Mini Mental Status Exam (mean 27.4 v 28.9 , t=2.69, df 38, p<0.02).  Controls that 
were matches for the patients with PD, in terms of age and pre-morbid intelligence, 
were also contacted, two declined to participate in the second stage of the study.   
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Procedure  
This study received approval from the Upper South B Regional Ethics 
Committee.  Assessments were carried out at the University of Canterbury over two 
testing sessions, each of three hours in duration.  Tests were presented in a fixed order 
with breaks taken as required.  All patients were on antiparkinsonian medication and 
were tested while on optimal levels of medication.   
Inclusion criteria for patients were as follows, a diagnosis of idiopathic 
Parkinson’s disease, confirmed by a neurologist who specialised in movement 
disordeers, Hoehn and Yahr stage I-IV (Hoehn & Yahr, 1967); aged between 50 and 80 
years; adequate or corrected hearing and vision (self report checked by examiner) and 
stable on PD medication.  Exclusion Criteria included 1. currently involved in a 
therapeutic trial; 2. A history of: a) moderate or severe head injury b) stroke or other 
neurological impairment c) major medical illness, d) significant psychiatric illness 
requiring hospitalization ; e) diagnosis of a learning disability; 3) pre-morbid IQ 
estimated at <85 using National Adult Reading Test (NART) (Lezak, 1995);4) 
Currently taking medications known to have a significant effect on the Central Nervous 
system (other than medications prescribed for the control of PD symptoms).  In 
addition to adequate or corrected hearing and vision (self report, checked by the 
examiner) and being aged between 50 to 80 years of age, the same exclusion criteria 
listed above also applied to the control group.  Previously patients had been excluded it 
they had suspected dementia (Mini Mental Status Exam <25) (Folstein, Folstein, & 
McHugh, 1975) or signs of depression (Beck Depression Inventory-II>17 validated for 
detecting depression in patients with PD, (Leentjens, 2004).  However, as this study 
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was focused on the decline of cognitive functioning over time, these exclusion criteria 
were not used in the follow up assessment.   
Information pertinent to the inclusion/exclusion criteria used in the second 
phase of the study was elicited from all participants using a semi-structured interview.  
Written consent was obtained from participants at the start of the first testing session 
after the study had been explained.  Participants were also asked if a person who knew 
them well (a “significant other”) could be contacted to provide collateral information 
regarding their daily living activities.  If the participants agreed, the significant other 
was contacted, the purpose of the study was explained, and consent obtained.  In most 
cases the significant other was a spouse or other family member.  In the case of control 
participants, information for the significant others to complete was sent home with the 
participant and returned at the next testing session.  For PD patients, information 
regarding everyday activities was collected during a face-to-face interview with a 
significant other person.  In the majority of cases, these interviews were conducted by a 
second interviewer during the same time period that the patient was engaged in the 
second testing session.   
Cognitive Assessment: 
A selection of tests, for which impairments had been consistently found at time 
one, was used to check the stability of the groupings at time two.  All tests were 
commonly used neuropsychological measures and scored according to standard 
procedures.  The majority of the measures used were from standardised batteries with 
age-adjusted norms and included the Wechsler Abbreviated Scale of Intelligence 
(WASI) [Mean 50, Standard deviation10] (Wechsler, 1999), Delis Kaplan Executive 
Function System (D-KEFS)(Delis, Kaplan, & Kramer, 2001), and the Wechsler 
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Memory Scale-III (WMS-III)(Wechsler, 1997) [both mean 10, standard deviation, 3].  
Such norms were not available for the Reading Span task, or tests of visuospatial 
functioning.   
The following tests were used at time two: measures of executive functioning 
including the Verbal Fluency test (with subtests for letter fluency, category fluency and 
category fluency switching) from the D-KEFS and the CLOX-I (Royall, Cordes, & 
Polk, 1998).  The CLOX is an unstructured drawing test that has two parts; for both 
parts of the test a maximum score of 15 is possible indicating perfect performance.  In 
part one the participant is given the following instruction “Draw me a clock that says 
1.45.  Set the hands on the face so a child could read them” (Royall, Cordes, & Polk, 
1998).  Drawings are rated according to CLOX-1 directions.  Problem solving was 
assessed using the Matrix Reasoning subtest from the WASI.  Digits Forward and 
Backward, from the WMS-III and the Daneman and Carpenter Reading Span test 
(Daneman & Carpenter, 1980)(scores range from 1-6) were used to assess Working 
memory/attention.  Memory was assessed with using the Rey Osterrieth Figure recall 
after 3 minutes (ROF-II), Paired Associates (immediate and delayed) and the Auditory 
Recall Index (truncated) from the WMS-III.  The Auditory Recall Index would usually 
include Logical Memory I&II and Paired Associates I&II with scores ranging from 0-
54.  However, only Paired Associates were used at this assessment period therefore, 
scores varied from 0-24.  The truncated scores were not able to be converted into age 
adjusted scores.  Visuospatial ability was assessed using the Judgement of Line 
Orientation (JLO) (Benton, Varney, & Hamsher, 1978), scores reported for the JLO are 
the number of correct line pairs, with possible scores ranging from 0-30, The Rey 
Osterrieth Figure copy task and the CLOX part two.  Scoring for both parts of the Rey 
Osterrieth Figure as scored the same and can vary from 0-36, with higher scores 
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indicating more accurate performance (Spreen & Strauss, 1998).  For the CLOX-II, the 
examiner first draws a picture of a clock face with the hands on the clock face set at 
1.45.  The participant is then asked to copy the examiner’s drawing (Royall, Cordes, & 
Polk, 1998).  Although speed of processing, as measured by the Stroop task from the D-
KEFS, had significantly differentiated the three groups at time one, this domain was not 
included at time two due to the difficulty that more cognitively impaired patients had in 
understanding the instructions.  Also, as there was no evidence of a planning deficit at 
time one for PD patients v controls or for the different PD groups this domain was not 
included at time two.   
The Dementia Rating Scale (DRS-2) (Jurica 2001) was used to provide a global 
assessment of cognitive ability.  This scale consists of 36 tasks and five subscales.  The 
five subscales provide information on specific abilities and include: 1. Attention; 2. 
Initiation/Perseveration; 3. Construction ability; 4. Conceptualization; and 5. Memory.  
Based on normative data, raw scores from each subscale were summed to provide an 
overall score (ranging from 0-144 with higher scores indicating better performance).  A 
combined scaled score adjusted for age and education was then generated using a 
regression formula provided in the administration manual (Jurica, 2001).   
Assessment of Activities of Daily Living:  
The Functional Activities Questionnaire (FAQ)(Pfeffer, Kurosaki, Harrah, 
Chance, & Filos, 1982) was used to assess the patients functional capacity and includes 
items such as, ability to prepare a balanced meal or remembering appointments.  The 
questionnaire was completed by a significant other who rated the participants on their 
ability to do the 10 higher order tasks listed by ticking the box for the word or phrase 
that applied best using a 4 point scale (dependent = 3, requires assistance = 2, has 
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difficulty but does by self = 1, no difficulty = 0).  A total score for the FAQ is obtained 
by summing the scores across the 10 items.  Dependent on three or more items is 
recommended as a cut off indicating mild impairment in normal activities or 
independence (Pfeffer, Kurosaki, Harrah, Chance, & Filos, 1982).   
Assessment of Dementia:  
The DRS-II and the MMSE were used to screen for dementia.  Patients with a 
MMSE score of below 25 and or a total raw DRS-II score between 120 and 130 were 
further assessed for dementia by a registered clinical psychologist using the Diagnostic 
and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria.  This DRS-II score 
has previously been validated as appropriate for PD patients (Brown et al., 1999).  Two 
patients scored below 130, one from the PD-NCI group and the other from the PD-MCI 
group.  Only the patient from the PD-MCI group showed evidence of possible 
dementia.   
4.5.4 Statistical Analysis   
ANOVA’s were used to compare the three PD groups in terms of their clinical 
and demographic characteristics.  Scores were then converted to z-scores based on the 
control mean.  Student t-tests were used to compare each of the three PD groups with 
their matched controls on the 15 cognitive measures.  Descriptive measures were then 
used to examine severity and frequency of impairments within each group.  In order to 
make direct comparisons regarding performance at time one and time two, a repeated 
measures analysis of variance, with z-scores generated using control and SD from time 
one were using to generate z-scores for time one and time two.  Post hoc analyses were 
used to test whether any differences between time one and time two were significant.  
ANOVA’s and t-tests were also employed to test differences between the different PD 
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groups and their matched controls and between the three groups of PD patients on 
measures of daily living.   
4.5.5 Results   
As can be seen on Table 42, the groups were comparable on all demographic 
and clinical characteristics with the exception of current mental status and per-morbid 
intelligence.   
Table 42: Comparison between the three Parkinson’s disease groups identified by the 
cluster analysis for clinical and demographic characteristics at one year follow-up.   
 
 
 PD -NCI 
     N=17 
Mean  [SD] 
PD-UCI 
   N=8 
Mean [SD] 
PD-MCI 
    N=8 
Mean  [SD] 
 
 
F 
 
p-level 
MMSE1 29.24    [0.7]   29.13    [0.8]   27.50    [1.4]   7.77 <0.01 
Years of Education 15.09    [3.1]   12.88    [1.9]   12.75    [0.9]   3.31 <0.10 
NART2 115.88  [7.5] 103.38    [8.4] 100.00    [7.7] 14.11 <0.001 
Age3 63.65   [6.5]   65.38    [7.7]   67.00    [5.6]   0.73 >0.45 
UPDRS Total 4 26.00    [10.0]   26.38    [9.7]   31.25    [6.6]   0.33 >0.30 
PD Onset5  5.41     [3.5]     6.13    [3.0]     8.28    [7.2]   1.08 >0.35 
H&Y6  2.23     [0.6]     2.13    [0.8]     2.63    [0.7]   0.36 >0.30 
BDI-II7  9.41     [5.4]     9.38    [6.0]     7.62    [4.2]   0.51 <0.60 
 
1 Mini Mental Status Exam; 2 Premorbid intelligence estimate using the National Adult Reading Test; 3 
As at time one; 4Unified Parkinson’s disease rating scale motor score; 5 Number of years since 
Parkinson’s disease was first diagnosed as at time one; 6 Hoehn& Yahr stage; 7 Beck Depression 
Inventory-II. 
 
Each PD patient had been match as closely as possible to a healthy control in 
terms of age and pre-morbid intelligence.  Subject loss did not change the overall 
accuracy of the original matching in terms of age (PD-NCI v Control, t=0.69, df, 32, 
p>0.45; PD-UCI v Control, t=-0.24, df, 14, p>0.80; PD-MCI v Control, t=0.26, df,14, 
 249 
p>0.80) or pre-morbid intelligence (PD-NCI v Control, t=0.60, df, 32, p>0.50; PD-UCI 
v Control, t=-0.42, df, 14, p>0.65; PD-MCI v Control, t=0.68, df, 14, p>0.50).   
Comparisons between the three groups for the 15 measures are shown in Figure 
11 and Table 43.  Bolded p values in Table 43 indicate where significant group 
differences had been found at time one.  Analysis of variance (ANOVA’s) confirmed 
that there was a significant overall group difference for all measures of executive 
functioning and the measure of problem solving (all p<0.02).  Only one measure of 
working memory (Digits Backward), memory (Auditory Recall Index) and Visuospatial 
ability (Line Orientation) discriminated between the three PD groups.  Consistent with 
our previous findings, there was no significant difference between the groups in terms 
of attention as measured by digits Forward.   
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Table 43: Comparison between the three Parkinson’s disease groups identified by the 
cluster analysis on tests of cognition at the one year follow-up.   
    PD-NCI  
     N=17 
  PD-UCI  
      N=8 
  PD-MCI 
       N=8 
F p-level 
  Mean [SD] Mean[SD]  Mean [SD]   
Executive Functioning      
Verbal Fluency sub-tests: a      
• Letter Fluency  13.38  [3.8] 10.00  [3.0]   7.75  [1.6]   9.01 <0.001 
• Category Fluency  11.81  [2.8]   9.75  [3.5]   6.50  [1.1] 10.14 <0.001 
• Category Switching  12.00  [3.3] 10.37  [3.9]   6.50  [2.9]   7.10 <0.01 
  CLOX-I 13.94  [1.7] 13.38  [1.4] 11.43  [2.3]   4.83 <0.02 
Problem Solving      
  Matrix Reasoning b  58.71  [7.0] 52.00  [9.6] 45.25 [10.9]   6.69 <0.01 
Working Memory/ Attention      
  Digits Forward b 11.12  [2.4] 10.00  [2.0]   9.88  [1.1]   1.32 >0.25 
  Digits Backward b   7.88  [2.3]   5.88  [1.7]   4.50  [1.5]   8.12 <0.01 
  Reading Span Test   1.97  [0.6]   1.94  [0.7]   1.50  [0.5]   1.84 >0.15 
Memory      
  Paired Associates immediate c   9.63  [3.3]   8.63  [2.6]   6.88  [2.2]   2.39 >0.10 
  Paired Associates delayed c 10.10  [3.2]   9.25  [3.0]   8.25  [2.5]   1.00 >0.40 
  Auditory Recall index c 23.94  [03] 24.00  [0.0] 23.38  [0.9]   4.39 <0.05 
  ROF-II 19.41  [7.0] 16.44  [7.9] 12.50  [8.8]   2.03 <0.10 
Visuospatial Ability      
  ROF-I 33.81  [3.3] 30.88  [4.0] 31.38  [5.2]   1.83 >0.10 
  Line Orientation 27.06  [4.2] 20.38  [4.8] 22.75  [2.1]   8.44 <0.01 
  CLOX-II 15.00  [0.0] 14.50  [0.8] 14.43  [1.0]   2.83 <0.10 
 
 aDelis Kaplan Executive Functioning System standardised scores; b Wechsler Abbreviated Intelligence 
Scale standardised scores; c Wechsler Memory Scale- 3rd edition, standardised scores. Bold p values 
indicate where significant differences had been evident at time one (p<0.01). 
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Figure 11: Comparisions between the three groups of Parkinson’s disese patients on 
measures of cognitive functioning.   
 
As shown on Figure 11, at the one year follow-up the three groups previously 
identified by the cluster analyses maintained evidence for a continuum of impairment.  
For the 15 cognitive measures used, a significant difference was found between PD-
NCI and their matched controls for one measure of working memory, Reading span 
(t=3.20, df, 17) and for PD-UCI group compared to their matched controls one measure 
of verbal fluency ( t=2.25, df, 14) and one measure of visuospatial ability, (t=2.34, df, 
14).  But the PD-MCI group were significantly different from their controls on 
measures of executive function (Letter Fluency, t=3.96, df,14; Category Fluency , 
t=3.90, df, 14, and Category Switching (t=5.01, df, 14), problem solving (Matrix 
Reasoning (t=3.62, df, 16), and working memory (Digits Backward, t=3.13, df, 14 and 
Reading Span t=5.02, df,14).  No deficits were evident for any of the PD groups 
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compared to their matched controls for attention (Digits Forward) or Memory (Paired 
Associated-I & II, Auditory Recall and ROF-II).  Only the PD-UCI group showed 
evidence of impairment in visuospatial ability (Figure 12).   
Comparisons were made between scores at time one and time two using average 
z-scores based on time one control mean and SD.  Average scores were generated using 
14 of the 15 measures shown on Table 43.  One measure was excluded as there was no 
exact comparison at time one (Auditory Recall-truncated).  As can be seen on Figure 
13, PD from healthy controls (F=32.73, df=1, p<0.0001), and each PD group was 
significantly different from their matched controls (F=6.26, df=2, p<0.01).  A 
significant difference across the three PD groups was also evident (F=5.03, df=2, 
p<0.05).  However, there was no significant group by time interaction (F=2.25, df=1, 
p>0.10).   
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Figure 12: Comparison between Parkinson’s disease patients and matched controls on a 
truncated set of measures of cognitive functioning at time two.   
*p<0.05; ** p<0.01; ***p<0.001.   
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As can be seen on Figure 13, the PD-UCI patients appeared to improve over the 
one year follow-up period.  However, post hoc analyses indicated that this change was 
not significant. 
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Figure 13: Comparison between PD-NCI, PD-UCI and PD-MCI and their matched 
controls for average z-scores at time one versus time two.   
(z = 0 is mean at time one.)   
As can be seen in Figure 14, PD patients performed more poorly than healthy 
controls on the DRS-II.  There was an overall group difference for PD compared to 
healthy controls ( F=7.63, df=1, p<0.01) and across three PD groups (F=3.62, df= 2, 
p<0.05).  When compared to their matched controls, there was no significant difference 
for the PD-NCI (t=1.6, df=32, p>0.10) or the PD-UCI (t=1.3, df=14, p>0.20) group.  
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However, a significant difference was evident for the PD-MCI group compared to their 
matched control group (t=2.2, df=14, p<0.05).   
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Figure 14: Comparison between Parkinson’s disease patients and matched control using 
the Dementia Rating Scale ajusted for age and education.   
 
As shown in Figure 15 there was an over all group difference for PD patients 
and healthy controls using the Functional Activities Questionnaire (F=13.2, df=1, 
p<0.001).  Each of the PD groups were significantly different from their matched 
control group (PD-NCI t=-2.2, df=27, p<0.05; PD-UCI, t=-2.3, df=11, p<0.05 and PD-
MCI, t=-2.2, df=13, p<0.05).  However, there was no significant difference between the 
three PD groups (F=0.60, df=2, p<0.55).   
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Figure 15: Comparison between Parkinson’s diseae patients and matched healthy 
controls using the Functional Activities Questionnaire.   
(PD-NCI n= 15 v matched control n=13; PD-UCI n=7 v matched control n=7; PD-MCI n= 8 v 
matched control n=7.)   
 
4.5.6 Discussion   
The aim of this research was to identify the profile of PD patients using 
previously identified groupings based on cognitive performance.  The three groupings 
formed a continuum of cognitive impairment.  At one end of the continuum was a PD 
group that had little or no evidence cognitive impairment (PD-NCI), at the other was a 
group with evidence of impairment on most domains tested (PD-MCI).  A third, 
intermediate group had a more variable pattern of deficits showing evidence of severe 
impairment on some domains and no impairment on others-these were considered to 
have an uncertain level of cognitive impairment (PD-UCI).  Based on findings from the 
literature regarding Alzheimer’s Disease, we hypothesised that patients in the PD-MCI 
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would form a group with cognitive deficits more severe than those generally associated 
with PD or normal aging, and these patients would be more likely to show evidence of 
dementia (PDD) over time as depicted by the illustration below.   
 
PD-NCI   PD-UCI   PD-MCI   PDD 
 
Increasing cognitive impairment 
 
 
At the one year follow-up reported here, we used a set of tests from 5 cognitive 
domains (executive function, problem solving, working memory/attention, memory and 
visuospatial ability) that we previously had found to differentiate the PD groups.  
Significant differences between the three PD groups on measures of executive function, 
problem solving, working memory and general memory were still evident at the 1 year 
follow-up.  Impairments in each of these domains were greatest for the PD-MCI group.  
In terms of visuospatial ability, there was evidence of equivalent deficits for both the 
PD-UCI group and the PD-MCI group.  There were no differences between the groups 
for the measure of attention.  These findings were consistent with our time one results.   
As the groups differed in terms pre-morbid intelligence we also compared them 
to controls that were matched in terms of age and pre-morbid intelligence.  There was 
clear evidence of increasing impairment for the three groups, while the PD-NCI group 
differed from their matched controls on only 1 of 15 measures tested and the PD-UCI 
on only two out of the 15, the PD-MCI group on was impaired on 6/15 measures (3 out 
of the 5 cognitive domains tested).  There was consistent evidence of deficits in verbal 
fluency which has previously been suggested as an indicator of more global cognitive 
impairment and possibly predicative of later dementia(Jacobs et al., 1995).  However, 
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only one patient from the PD-MCI group had symptoms consistent with the DSM-IV 
criteria for possible dementia at the one year follow-up.  This finding may be 
conservative as 33% (4/12) of the PD-MCI group were not available for testing at time 
two and these patients tended to be older and perform more poorly on the MMSE.   
When performance at time one was compared with that at time two, using z-
scores based on the time one control mean and standard deviation, there were 
significant differences between the PD patients and healthy controls.  Each PD group 
was significantly different from their matched controls and a significant difference 
across the three PD groups was also evident.  However, there was no evidence of 
increasing deficits across time for any of the groups.  Indeed while the PD-NCI and 
PD-MCI group remained relatively stable over the one year follow-up the PD-UCI 
group appeared to improve.  This finding may in part be explained by the fact that only 
tests that significantly discriminated between the groups were used at time two.  For 
example, the PD-UCI group tended to do better than the other two PD groups on tests 
of memory and when this effect was removed from the overall time one scores the PD-
UCI groups overall score dropped.   
One question was whether the cognitive deficits detected would have an impact 
on the ability of the individual to function in every day living.  This is important as a 
diagnosis of dementia requires evidence of deficits in social or occupational functioning 
(DSM-IV).  In terms of functioning in activities of daily living PD patients performed 
more poorly than controls and there was evidence of increased problems for the PD-
MCI group.  The increased difficulties with every day functioning that was apparent for 
the PD groups is consistent with our hypothesis that the PD-MCI group represents a 
level of cognitive impairment that is indicative of pre-clinical dementia.  It could be 
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questioned whether the individuals in the PD-MCI group are simply more physically 
impaired.  However, the three PD groups were comparable with regard to motor 
impairments as measured by the UPDRS or H&Y stage.   
There is little information regarding the possible profile of cognitive deficits 
that may reflect pre-clinical dementia in PD with most research focusing on which 
deficit is most predictive of dementia.  However, deficits in executive function have 
previously been associated with increasing decline in cognitive performance and a 
potential indicator of pre-clinical dementia (Jacobs et al., 1995; Janvin, Aarsland, & 
Larsen, 2005; Montse, Pere, Carme, Francesc, & Eduardo, 2001).  In this current study 
there was little evidence of memory problems for any of the three PD groups.  While 
this finding is consistent with some research (Ross, 1996; Woods & Troster, 2003) the 
opposite finding has also been reported (Levy et al., 2002). This inconsistency likely 
reflects different characteristics of patient groups and the variety of tests that have been 
used to assess these deficits.  We also found a variable pattern of visuospatial deficits.  
Visuospatial deficits have been found to differentiate PD patients from healthy controls 
but have not been reported as predictive of pre-clinical dementia(Levy et al., 2002; 
Mahieux et al., 1998).  Consistent with previous research we found no evidence of 
deficits in attention (Mayeux et al., 1995; Woods & Troster, 2003).  Therefore, from 
this study and the current literature the cognitive profile associated with pre-clinical 
dementia appears to include executive function, problem solving and working memory 
deficits, with more variable outcomes associated with and visuospatial abilities.  Unlike 
Alzheimer’s disease general memory problems do not appear to be associated with pre-
clinical dementia in PD.  Moreover, attentional and planning skills appear to remain 
intact (Mayeux et al., 1995; McKinlay, Grace, Dalrymple-Alford, & Roger; Woods & 
Troster, 2003).   
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This study had a number of strengths.  A longitudinal design was used to 
investigate the cognitive profile of pre-clinical dementia in PD.  Further, a healthy 
control group was used to compare the PD groups and the study also used a broad 
selection of tests to assess any deficits.  We also investigated how deficits in cognitive 
functioning related to functional activities of daily living.  However, the study had a 
number of weaknesses; some of the more poorly performing patients were not available 
at this 1 year follow-up, and the number of patients in each of the sub-groups was less 
than ideal.  However, despite the loss of participants the overall pattern of deficits 
found at time one were consistent with the findings at time two.   
Conclusions 
The concept of PD-MCI could provide an important avenue for understanding 
cognitive deficits in PD.  Moreover, the concept of PD-MCI presents an opportunity to 
intervene and delay the onset of more severe cognitive problems that may result in later 
dementia.  However, to effectively intervene, a profile of both spared and impaired 
abilities needs to be identified.  The cognitive profile of the most impaired patients, 
those who may represent a pre-clinical dementia group, included deficits in executive 
function, problem solving and working memory.  There were also spared functions 
including attention and most aspects of memory.  Decreased functioning in activities of 
daily living was also associated with increasing cognitive problems.  Further follow-up 
of this group is necessary to monitor how the cognitive profile of these groups will 
evolve.  
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4.6 Identification of a Discrete Battery of Tests to Detect Patients in Stage of 
Pre-Clinical Dementia (PD-MCI)  
 262 
4.6.1 Overview   
The idea of MCI provides a useful way of conceptualising cognitive decline in 
PD and may be valuable in guiding appropriate treatment interventions (see Figure 16 
for a suggested decision tree for differential diagnosis of PD-MCI).  Unfortunately, 
there is currently no consensus regarding the cognitive profile that is indicative of 
preclinical dementia in PD or for the tests that should be used evaluate potential 
cognitive and neuropsychiatric problems.  This dearth of information limits the use of 
decisions trees, such as the one suggested below, to assist clinical judgement.   
Therefore, one aim of this study that had an immediate practical application 
was to develop a discrete group of non-invasive tests for use in clinical settings.  
Achieving this objective required the identification of the cognitive profile specific to 
PD.  Based on this profile the most sensitive and appropriate combination of measures 
could be selected for use in detecting the onset of cognitive decline (taking into 
account the possible neuropsychiatric problems that might accompany this disorder) 
in patients with PD.   
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4.6.2 Process for identification of cognitive profile   
There were a number of steps undertaken in this project to detect the cognitive 
profile in PD and the measures that might be most sensitive to cognitive impairments 
and decline (see Figure 17 for overview) these included:   
Review of Literature:  
• Firstly, a comprehensive search and critical review of the literature 
published between 1980 and 2006 was performed to assemble the most 
relevant evidence on cognitive performance for patients with PD.  The 
primary sources of literature were Medline and PsycINFO.  Citations were 
screened for relevance to cognitive deficit associated with PD.  Additional 
studies were found by hand-searching references lists for relevant articles. 
• The systematic process of review identified over one hundred and twenty 
five tests that had previously been used to assess cognitive performance in 
patients with PD4.  Many of these tests were conceptually similar, so the 
most appropriate of these were used5.  As the proposed test battery was 
intended to be used with patients longitudinally to track individual 
performance, tests which placed high demands on fine motor skills or 
speeded performance were also eliminated.   
                                                
4 One test of particular note, the Wisconsin Card Sorting test has been used extensively with PD 
patients. However, it has a lengthy administration time therefore, this test was replaced with a 
conceptually similar test that had a shorter administration time (ID/ED shift from the CANTAB).  
5 Some tests had been developed specifically for a particular experimental design and did not have 
wider applicability and therefore were not included. 
  265 
  
 
 
 
 
Figure 17: Overview of test selection based on findings from the PhD reseach.   
Comprehensive review of literature: 
Identified approximately 125 test previously 
used in context PD. 
A 
28 cognitive tests/subtests from eight different 
domains 
 
 
B 
14 Cognitive tests/subtests from 
six domains 
C 
10 cognitive tests/subtests from  
five domains 
Exclusions: 
1. Tests conceptually similar 
2. Tests requiring fine motor skills 
3. Timed performance 
Exclusions: 
1. Tests not sensitive  
2. Tests conceptually difficulty 
3. Tests not readily available    
 
Exclusions: 
 
1.Tests not sensitive to cognitive  
profile in PD. 
 
Inclusions: 
1. Conceptually similar to those sensitive, 
which had been excluded due to 
unavailability.  
Inclusion: 
Theoretically sensitive tests (tap into 3 fronto-
striatal non motor circuits: Dorsolateral, 
Orbitofrontal and Anterior cingulate)  
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• The selection of tests was further refined based on current theoretical 
understanding of cortical and sub-cortical changes associated with PD 
which could be expected to impact on cognitive and neuropsychiatric 
functioning.   
4.6.3 Step A - 28 cognitive tests/subtests from eight different domains   
• From the tests identified, 28 tests over 8 different domains (executive 
function, planning, problem solving, working memory, attention, speed of 
processing, memory/learning, visuospatial ability) were selected for 
further evaluation based on the criteria outlined above (see Table 44 
below).   
• Tests that did not differentiate between group or within group differences 
were excluded at this point.  There were some exceptions to this rule and 
these are outlined below.   
• Of the selected tests, 13 over five domains (executive functioning, problem 
solving, working memory, speed of processing, visuospatial ability) 
differentiated PD v healthy controls (see numbered tests on left hand of 
Table 43) eight of these also differentiated a continuum of cognitive 
decline for different sub-groups of patients (see numbered tests on right 
hand side of Table 43).   
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Table 44: Cognitive tests selected for initial analysis.   
Distinguished healthy 
control v PD 
Test 
s 
Distinguished sub-
groups of PD patients 
 Executive Functioning/Planning 
Verbal Fluency sub-tests: a 
 
 • Letter Fluency  1 
1 • Category Fluency   
2 • Category Switching  2 
3   CLOX-I 3 
   Key Search b  
    Zoo Map b  
 Color-Word Interference sub-tests:a  
4 • Inhibition  4 
5 • Switching  5 
   ID/ED- Phases completed c  
 Problem solving  
 Sorting sub-tests: a  
 • Card sorting   
 • Card sorting description  6 
6   Matrix reasoning d 7 
7   Stockings of Cambridge c (1) 8 
   Tower Test a (2)  
 Working Memory/ Attention  
   Digits Forward e  
   Digits Backward e  
   Letter number sequencing e  
8   Reading Span Test  
9    Spatial Span c 9 
 Speed of Processing  
 Verbal Fluency Test: a  
10 • Word naming   
11 • Color naming  10 
 Memory/Learning  
   Logical memory immediate e  
   Logical memory delayed e  
   Paired Associates immediate e  
   Paired Associates delayed e  
   Auditory Recall index e  
   ROF-II&III  
 Visuospatial ability  
12   ROF-I 11 
   Line Orientation 12 
13   CLOX-II 13 
 
(1)Number of towers completed in minimum moves; aDelis Kaplan Executive Functioning System 
standardised scores; b Behavioural Assessment of the Dysexecutive Syndrome profile scores;c Cambridge 
Neuropsychological Test Automated Battery;d Wechsler Abbreviated Intelligence Scale standardised 
scores; e Wechsler Memory Scale- 3rd edition, standardised scores.  Bolded numbers indicate tests able to 
discriminate between PD v Healthy controls and sub-groups of PD patients.   
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4.6.4 Step B - 14 cognitive tests/subtests from six domains   
• Using the information gained from both the between and within group 
comparisons and prior to commencement of the one year follow-up, a 
number of criteria were imposed to ensure that the battery of tests 
developed would be of use to a wide range of clinicians:   
• Tests were required to be readily available for use by clinicians.  
All CANTAB tasks were eliminated on this criterion (ID/ED shift, 
Stockings of Cambridge, Spatial Span Test).   
• Tests that posed problems for patients in terms of fine movements 
being required were excluded (ROF I, II and II, CLOX were 
eliminated on this criterion).   
• Tests that were conceptually difficult were eliminated (The Stroop 
task proved to be impossible for many of the people in the MCI 
group).   
This latter question was most important as it was intended that these tests 
would be useful not only for identifying patients who were more cognitively 
impaired, but also for following patients longitudinally as they became increasingly 
more impaired and demonstrated symptoms consistent with dementia.   
This process of elimination left four out of the original tests (Letter Fluency, 
Category Switching, Matrix Reasoning and Line Orientation).  Two measures that 
were excluded require special mention here these were the Stoop test and the Rey 
Osterrieth Figure Test.   
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The Stoop test was excluded because more impaired patients found this task 
difficult.  Further, a small number of patients in the early stages of dementia who had 
been tested in the course of this study were unable to complete the Stroop task.  
Therefore, the Stroop test was considered unsuitable for the purposes of this project as 
it was intended to follow patients long-term and to specifically include dementia 
groups to test the sensitivity and specificity of any identified test battery.   
The Rey Osterrieth Figure was found to be an excellent test of visuospatial 
ability and potentially of planning ability (this hypothesis is still being investigated).  
Unfortunately, the task required a degree of motor control and some patients found it 
impossible to complete; for this reason it was also excluded.   
Five other tests were retained for the following reasons:  
• Category Fluency as this is a necessary step prior to Category Fluency 
Switching, which had been found to be sensitive to cognitive decline in 
PD.   
• Paired Associates I&II was retained as a measure of memory ability.  
Although memory was unimpaired in PD patients, regardless of the their 
cognitive status, it was expected that as a quick and easy to administer 
memory/learning task, Paired Associates (or an equivalent list learning 
task such as the Rey Auditory Verbal Learning Test) would be useful for 
differentiating patients with PD-MCI from other dementias for which 
memory is a core feature.   
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• Digits Forward, and Backward were included as simple measures of 
attention which could be expected to be unimpaired for patients with PD 
without dementia.   
Table 45: Selection of tests suggested as sensitive for detecting the cognitive profile 
of Parkinson’s disease patients.   
Tests time one Tests time two 
Tests of Executive function/Verbal fluency a Tests of Verbal Fluency a 
• Letter Fluency • Letter Fluency 
• Category Fluency • Category Fluency 
• Category Switching • Category Switching 
General Memory/Learning General Memory/Learning 
Paired Associates I&II Paired Associates I&II 
Tests of Working Memory /Attention Tests of Working Memory /Attention 
Digits Forward Digits Forward 
Digits Backward Digits Backward 
 DOT-R 
Problem solving Problem solving 
Matrix Reasoning b Matrix Reasoning b 
 Tower task 
Visuospatial ability Visuospatial ability 
Line Orientation Line Orientation 
 VOSP Letter Recognition 
 VOSP Object Recognition 
 
aDelis Kaplan Executive Functioning System standardised scores; b Wechsler Abbreviated Intelligence 
Scale standardised scores;  
At the one year follow-up (time two), tests conceptually similar to those found 
to be sensitive at time one, but which had failed to meet the inclusion criteria for time 
two, were added these included:   
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• The VOSP Letter and Object Recognition as a measure of visuospatial 
ability that did not involve motor skills to replace ROF.   
• The DOT-R was included as a measure of working memory performance.  
Working memory had been found to be impaired at time one, but the most 
sensitive test for working memory performance was part of the CANTAB 
battery.  Tests from this battery were excluded as these are not in general 
use with clinicians.   
• A computerised version of the Tower of London task was added.  The 
CANTAB version had been found to be a sensitive measure of problem 
solving ability at time one but was eliminated at time two for the reasons 
outlined above.   
Initial findings indicated that the DOT-R, Tower of London task and VOSP 
recognition task were able to significantly differentiate the groups and were therefore 
added to the final test selection.   
4.6.5 Step C - 10 cognitive tests/subtests from five domains   
The final selection of tests was based on measures from time one and two that 
were most sensitive to cognitive decline in PD and met all the criteria outlined at step 
A and B.  In addition to the cognitive measures outlined above, tests appropriate for 
detecting neuropsychiatric problems were added (see Table 46).   
To this suggested test battery, measures suitable for gathering collateral 
information were also added.  The reason for this was twofold.  Firstly, given the 
previous findings it seemed pertinent to gather information regarding significant-other 
distress.  Moreover, information from an independent source was sought regarding 
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any deterioration in the ability of the PD patient to perform ADL’s.  Reliable 
information about the patients ability to complete ADLs is essential in order to 
differentiate those patients suffering from PD-MCI from those already in the early 
stages of dementia.   
Table 46: The final selection of tests for assessing the cognitive profile of patients 
with Parkinson’s disease without dementia.   
Final Test Selection 
Initial Screening /Background tests 
Beck Depression Inventory (BDI-II) 
Apathy Scale 
Fatigue Scale 
Modified Hoehn and Yahr 
Unified Parkinson’s disease Rating Scale (UPDRS) 
Neuropsychiatric Inventory (NPI) 
The Modified MMSE (3MS) 
Tests of Verbal Fluency 
Category Fluency 
Letter Fluency 
General Memory 
Paired Associates I&II 
Problem Solving 
Matrix Reasoning (WASI) 
Tower Task 
Tests of Working Memory/Attention 
Digits Forward 
Digits Backward 
Digit Ordering Test 
Visuoperceptual 
Judgement of Line Orientation 
VOSP 
 
 
4.6.6 Conclusion   
The suggested test battery would provide comprehensive information 
regarding current cognitive and neuropsychiatric and motor status and is sufficiently 
brief to incorporate as part of a routine follow-up procedure.  A number of the 
neuropsychiatric measures (BDI-II, Fatigue Scale, Apathy Scale) are suitable for 
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patients to complete in the waiting room prior to any consultation with their 
neurologist.   
It is acknowledged that any set of tests suggested here are preliminary only.  
Further confirmation of these tests would be required i.e., in terms of their sensitivity 
(further evaluation with new groups of PD patients) and specificity (evaluation of the 
final test selection with other patient groups such as Huntington’s disease, 
Alzheimer’s dementia etc).  Other confirmatory methods which identified structural 
changes in patients e.g. fMRI/MRI, EEG and eye-movements would also be useful for 
determining not only whether the suggested battery of tests were accurate but also 
further illuminating the cause of cognitive and neuropsychiatric problems in patients 
with PD.   
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Chapter 5 – Deficits in planning in Parkinson’s disease   
Abbreviations used in the text Chapter Five 
1) ANCOVAs = Analyses of covariance; 2) ANOVA = analysis of variance; 3) BDI-
II = Beck Depression Inventory; 4) CANTAB = Cambridge Neuropsychological Test 
Automated Battery; 5) CANTAB-TOL = Cambridge Neuropsychological Test 
Automated Battery - Tower subtest; 6) D-KEFS = Delis Kaplan Executive Function 
System; 7) D-KEFS-TOH = Delis Kaplan Executive Function System-Tower of 
Hanoi subtest; 8) DRS-II = Dementia Rating Scale-II; 9) DSM-IV = Diagnostic and 
Statistical Manual Fourth Edition; 10) H&Y = Hoehn and Yahr Staging Scale; 11) 
MMSE = Mini Mental Status Exam; 12) NART = National Adult Reading test; 13) 
PD = Parkinson’s disease; 14) TOH = Tower of Hanoi 15) TOL = Tower of London; 
16) TOL = Tower of London; 17) UPDRS = Unified Parkinson’s disease Rating 
Scale. 
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5.1 Overview   
Planning deficits have been associated with cognitive decline in Parkinson’s 
disease (PD).  However, in the initial analysis which measured cognitive performance 
for individuals with PD, as outlined in chapter 4, deficits in planning performance 
were found to be inconsistent.  Therefore, to more fully complete objective 1, which 
was to develop a cognitive profile for PD patients, we examined planning ability in 
more depth.   
Planning refers to the ability to look ahead through a series of possible steps, 
some of which may be counterintuitive, to reach a desired goal.  The ability to plan is 
an essential part of daily living, and difficulties with this skill may impact on an 
individual’s autonomy.  Planning deficits in PD have been previously reported to be 
evident, even in the early stages of the disease process (Cools, Stefanova, Barker, 
Robbins, & Owen, 2002; Culbertson, Moberg, Duda, Stern, & Weintraub, 2004; 
Morris et al., 1988; Owen et al., 1992).  The most common tasks used to measure 
planning ability in PD are the Tower of London (TOL) (Shallice, 1982) and the 
Tower of Hanoi (TOH).   
5.1.1 Difficulty with research in this area   
There are two main areas of difficulty with this area of research.  Firstly, the 
literature is inconsistent with regard to the presence or exact nature of any planning 
deficits in PD, possibly reflecting the variation of TOL and TOH tasks used.  Further, 
the TOL and TOH have been used interchangeably with PD patients, despite the fact 
that there is currently no evidence regarding the relative sensitivity of these two tower 
tasks.   
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Another area of difficulty relates to the complexity of different tower 
problems.  In the PD literature little attention has been paid to the selection of 
problems sets.  However, recent research has placed particular importance on the 
selection of tower problems as it has been suggested that different aspects of 
individual problem may increase or decrease the level of task complexity, and 
therefore planning demands (Berg & Byrd, 2002; Kaller, Unterrainer, Rahm, & 
Halsband, 2004; Ward & Allport, 1997).   
5.2 Current Research   
5.2.1 Manuscript 1 – Two Tower Tasks   
The first manuscript in this chapter was designed to investigate the relative 
sensitivity of two widely and interchangeably used measures, the TOL and the TOH, 
for the clinical assessment of planning deficits in PD.  It was found that patients were 
impaired on the measure of the TOL but not on the TOH.  Further investigation 
revealed that only a very small percentage of variance between the two tasks was 
shared.  On further analysis it was clear that the two tasks were not interchangeable 
and relied on different cognitive processes.  While performance on the TOL was 
dependent on inhibition and spatial working memory, performance on the TOH was 
dependent on intact spatial working memory.   
It was concluded that the lack of consistency in the findings between the two 
tower tasks could be related to a number of issues including:  
1. The actual differences in the tower structures.  
2. Insufficient attention to the difficulty of the problem set.  
3. Variation in how performance is measured.  
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Therefore, a study was designed to examine the effects these issues.   
5.2.2 Manuscript 2 – Problem Structure   
The second manuscript was designed to examine assess planning in PD 
patients using a computerised version the TOL task and a problem set that 
systematically manipulated the problem complexity.  Subtle aspects of the TOL task 
were hypothesised to impact on performance. These aspects include:   
1. Sub-goals required 
2. Search depth 
3. Sub optimal alternatives  
4. Counter intuitive moves 
5. Start position 
6. Goal position 
7. Nested problems 
At the most basic level, the number of moves can be considered an indicator 
of problem difficulty.  However, two problems may have the same number of moves 
but differ with respect to the number of alternative moves available.  This was 
outlined in the recent work by Berg and Byrd (2002) in their description of the 
“problem space” associated with the Tower of London Task.  The problem space 
defined by Berg and Byrd (2002) is the graphic representation of the moves possible 
under the rules of the task.  As can be seen in Figure 18, adapted from the work of 
Berg and Byrd (2002), for each segment of the circle there are 6 possible ball 
positions.   
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Figure 18: Problem space for the Tower of London. The various arrangements of balls 
in each of the 6 sections are identical, only the order of ball colors change.  Adapted 
from Berg W.K. & Byrd D.L. (2002).   
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Each of the segments on the circle are the same in that they have an identical 6 
possible ball positions, but differ in the arrangements of the ball colors (Berg & Byrd, 
2002).  There are 210 spatially unique problems for each permutation in the type of 
TOL task represented in Figure 18, ranging from 1-8 move problems, giving a total of 
1260 possible unique problem sets (see Berg & Byrd, 2002 for a complete discussion 
regarding the problem space).  With this graphical representation of the tower task it 
is easy to see that the difficulty of a particular problem may be influenced by more 
than just the number of moves required for its solution.  For example, problems with 
the same number of moves may have a different ‘search depth’ or sub-goal pattern.  A 
sub-goal refers to moves that are essential to the solution of a given problem, but do 
not place a ball into its goal position (Ward & Allport, 1997).  The search depth is 
defined as the number of sub-goal moves before the first ball can be moved into a 
goal space.  A longer search depth is considered to increase the difficulty of the 
problem as it requires more moves to be held in mind prior to being able to place the 
first ball in its goal position.  Not only may a problem vary according to the number 
of paths available for achieving an optimal solution, but there may also be ‘sub-
optimal alternatives’.  Sub-optimal alternatives refer to problems with one or more 
paths which take more than the minimum number of moves, but allow the first ball to 
be placed into its goal position within a number of moves equal to the optimal 
solution.   
Further, the presence and number of ‘counter-intuitive moves’ increases 
complexity.  Counter-intuitive moves are moves that do not lead directly to the end 
goal and in some cases may require a ball to first be removed from its goal state in 
order to perform the optimal solution.  Start position and finish positions may affect 
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the individuals’ performance.  For example, in the flat start position, where there is 
one ball on each peg, there is no obvious first move.  In contrast, a tower start position 
where all three balls on the tallest peg, the ordering of moves to obtain the finish 
position is more obvious (Berg & Byrd, 2002).  Further, the latter has only two 
possible start moves while the former has four (Berg & Byrd, 2002).  Moreover, a flat 
finish position provides an unclear final sequence, whereas a tower end gives a clear 
ordering for the sequence of final moves.   
The importance of the finish position or ‘goal hierarchy’ has been discussed in 
some depth by Kaller et al., (2004).  These authors suggest that a tower end position 
can be considered ‘unambiguous’ in relation to the final moves required, whereas a 
flat goal position can be considered ‘totally ambiguous’.  A goal position in between 
these two extremes may be considered ‘partially ambiguous’.  Finally, problems may 
be ‘nested’, referring to the situation where the optimal path for the first problem is 
contained entirely in the second.  The second problem differs only with regard to the 
additional moves at the start or finish.   
Results from our study indicated that number of moves alone could not be 
considered an accurate indicator of problem difficulty.  Instead planning performance 
was influenced by more subtle aspects of problems structure, including subgoaling 
patters and goal hierarchy.  Indeed, planning in PD patients was not impaired in 
general but only affected when the information provided by the problem states was 
ambiguous concerning the sequential order of subgoals.  However, patients with PD 
were more likely to find problems with increased search depth more difficult than 
healthy controls.   
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5.3 Planning Deficits in Parkinson’s Disease: A Comparison of Two Tower 
Task .  
(In review Journal of Clinical and Experimental Neuropsychology)
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5.3.1 Abstract   
Variations of the Tower of Hanoi (TOH) and Shallice’s Tower of London 
(TOL) have frequently been used to assess planning ability in patients with 
Parkinson’s disease (PD).  However, there is currently no evidence regarding the 
relative sensitivity of these two tower tasks with PD patients despite the fact that they 
are often regarded as interchangeable.  Forty patients with PD met the criteria for this 
study.  Each patient was individually matched to a healthy control in terms of age, sex 
and pre-morbid intelligence.  Planning ability was assessed using the CANTAB-TOL 
task and the D-KEFS-TOH.  To assess the relative contribution of different cognitive 
processes, participants also completed tests of working memory and inhibition.  The 
PD group was impaired on the CANTAB-TOL but not the D-KEFS-TOH.  Further, 
only 7%-24% of the variance between the two tasks was shared, suggesting that 
different cognitive processes were required for the tasks.  Regression analysis 
revealed that performance on the CANTAB-TOL was dependent on inhibition and 
spatial working memory, whereas performance on the D-KEFS-TOH was dependent 
on spatial working memory only.  The CANTAB- TOL and D-KEFS-TOH are not 
equally sensitive at detecting planning deficits in PD patients and should not be 
considered interchangeable measures of planning ability in clinical populations.   
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5.3.2 Introduction   
Variations of the Tower of Hanoi puzzle (TOH) and Tower of London task 
(TOL) have been employed to assess planning ability for patients with a variety of 
disorders including Parkinson’s disease (PD).  As Welsh, Satterlee-Cartmell and Stein 
(1999) have pointed out, these two tasks are generally considered to be 
interchangeable as they purport to measure the same cognitive processes including 
planning.  The ability to plan is an executive function in which the prefrontal cortex 
has pre-eminence.  Because fronto-striatal degeneration is known to occur during PD, 
planning deficits are a distinct possibility in patients with this disorder.  However, 
results of research that has examined planning deficits in PD patients are mixed, 
which may in part be due to the different versions of tasks that have been used to 
assess this skill.   
Multiple variations of tower tasks have been used to assess planning in PD 
(Culbertson, Moberg, Duda, Stern, & Weintraub, 2004; Leiguarda et al., 1997; Morris 
et al., 1988; Owen et al., 1992; Saint-Cyr, Taylor, & Lange, 1988).  For example, 
Culbertson et al. (2004) reported that a group of 65 PD patients (mean Hoehn & Yahr 
= 2.27) performed significantly worse, compared to controls, in terms of average total 
moves and rule and time violations.  This study used the Tower of London-Drexel 
which is similar in construction to Shallice’s TOL task (Shallice, 1982).  However, 
Morris et al. (1988) previously reported no difference in the average number of moves 
taken by his participants to complete the tower problems, although the PD patients 
took longer to think about or plan the solution.  The tower task used by Morris et al. 
(1988) was a computer variation of the TOL task, but used colored rectangular blocks 
instead of balls.  Their results were supported by Saint-Cyr et al. (1988) who reported 
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that non-medicated PD patients with mild symptoms showed no impairment in 
problem solving accuracy using a three-disk version of the Tower of Toronto (a 
variation of the TOH task).  Finally, Owen et al. (1992) examined outcomes for three 
sub-groups of PD patients, divided according to disease stage - early non medicated, 
mild to moderate stage medicated, and late stage medicated.  Owen et al. reported that 
PD patients spent longer planning solutions compared to controls.  Further, increased 
errors in execution of solutions were evident for patients in the later stages of the 
disease.  Owen et al. used a computerized tower task from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB-TOL).  The CANTAB-TOL 
consists of two sets of three colored balls, one in the top half of the screen and the 
other in the bottom half, that hang in pockets similar to snooker balls.  The participant 
is asked to make the arrangement of the colored balls in the bottom half of the screen 
match that in the top half using the minimum number of moves.   
Overall, results of studies which have assessed planning deficits in PD patients 
are inconsistent.  While variations in disease severity and medications may in part 
account for some of these findings, the lack of comparability between the different 
versions of tower tasks that have been used to assess planning in PD may also have 
contributed.   
The present study compared performance of a group of PD patients with 
matched controls to investigate the comparability of two versions of the tower task for 
assessing potential planning deficits in PD patients.  To this end, tower tasks from two 
well-established neuropsychological test batteries were used, the Cambridge 
Automated Neuropsychological Test Battery –tower task which is based on Shallice’s 
Tower of London (CANTAB-TOL) and the Delis-Kaplan Executive Function System 
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– tower task (D-KEFS-TOH) based on the Tower of Hanoi task.  If these two tower 
tasks are functionally equivalent as measures of planning, then a similar pattern of 
deficits should be revealed for both tasks and the level of shared variance should be 
high.   
The present study was also designed to investigate whether any planning 
deficits shown by the PD patients might be linked with specific cognitive processes.  
If the two tasks are not functionally equivalent then we could expect that different 
cognitive processes would be recruited in their solutions.  Measures of working 
memory and inhibition were selected to investigate this as these have previously been 
found to be important for the successful execution of the tower tasks (Welsh, 
Satterlee-Cartmell, & Stein, 1999). Planned correlation and regression analyses were 
conducted to determine whether the relationships between task performance and 
cognitive skills were the same for both tower tasks and whether differences between 
PD patients and controls might be attributed to deficits in working memory or 
inhibition.   
5.3.3 Methods   
This study is part of a broader project examining cognitive, neuropsychiatric 
and language outcomes for patients with PD and received approval from the 
Canterbury Ethics Committee.  Patients were on anti-parkinsonian medication and 
were tested while on optimal levels of medication (confirmed by patient report and 
also by observations made by the examiner).   
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Participants  
Parkinson’s disease group  
PD patients in the Canterbury region who could be identified at the time of 
this study who did not have a diagnosis of dementia were invited by letter to 
participate.  Patients were identified by two experienced neurologists and were 
required to meet the following inclusion criteria: 1) A diagnosis of idiopathic 
Parkinson’s disease confirmed by a neurologist who specialised in motor disorders; 2) 
Assessed as Hoehn and Yahr stage I-IV (stage 1, n=8; stage 1.5, n=6; stage 2, n= 7; 
stage 2.5, n=10; stage 3, n=7; stage 4, n=2) (Hoehn & Yahr, 1967); 3) Aged between 
50 and 80 years; 4) Adequate or corrected hearing and vision (self-report, checked by 
examiner); 5) Stable on PD medication; and 6) English as the primary spoken 
language.   
Patients were excluded for the following reasons: 1. currently involved in a 
therapeutic trial or; 2. a history of: a) moderate or severe head injury,b) stroke or other 
neurological impairment, c) a major medical illness, d) significant psychiatric illness 
requiring hospitalisation, e) suspicion of dementia symptoms (Mini Mental Status 
Examine (MMSE) <25, (Folstein, Folstein, & McHugh, 1975), f) diagnosis of a 
learning disability, 3. major depressive episode in the previous 6 months, 4.  pre-
morbid IQ estimated at <85 using National Adult Reading Test (NART Nelson & 
Willison, 1991), 5. currently taking medications known to have a significant effect on 
the central nervous system (other than medications prescribed for the control of PD 
symptoms) or 6. presence of depression.   
Of the 115 letters that were mailed, 6/115 (5.2%) of individuals with PD could 
not participate due to illness, 6/115 (5.2%) were deceased, 8/115 (6.9%) declined, 
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34/115 (29.6%) did not respond, and 21/115 (18.3%) did not meet the 
inclusion/exclusion criteria.  After exclusions, 40 participants with PD were avaliable 
for inclusion in this study.   
Controls  
Controls were recruited from a number of sources including a previously 
established data base, advertisements at local clubs (bowling, hiking and table tennis) 
and businesses.  All controls were given a brief outline of the study on first phone 
contact.  If they were still willing to participate they were then sent an information 
sheet.  In addition to adequate or corrected hearing and vision (self report, checked by 
the examiner) and being aged between 50 to 80 years of age, the same exclusion 
criteria listed above also applied to the control group.   
Procedure  
Assessments were carried out over two sessions which were scheduled at least 
one week apart.  Tests were presented in a fixed order with breaks taken as required.  
Written consent was obtained from participants at the start of the first testing session 
after the study had been explained.  Information pertinent to the inclusion/exclusion 
criteria was elicited from all participants during the first session using a semi-
structured interview.   
Demographic and Clinical information  
Severity of motor symptoms was assessed using the Unified Parkinson’s 
Disease Rating Scale (UPDRS) (Fahn & Elton, 1987) motor section and the Hoehn 
and Yahr (Hoehn & Yahr, 1967).  Premorbid IQ was assessed using the National 
Adult Reading Test (NART) and mood was rated using the Beck Depression 
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Inventory-II (BDI-II) (Beck, Steer, & Brown, 1996).  The Mini Mental Status Exam 
(MMSE) (Folstein, Folstein, & McHugh, 1975) and Dementia Rating Scale (Jurica, 
2001) provided information regarding current mental status.   
Cognitive Tests:  
Cambridge Neuropsychological Test Automated Battery (CANTAB):  
The CANTAB provides a computerized series of tasks using a touch sensitive 
screen.  Three tasks from the CANTAB were used and included: 1. Stockings of 
Cambridge (CANTAB-TOL), 2. Spatial Span, and 3. Spatial Working Memory.  
Further details regarding the different tasks and procedures may be found in Owen, 
Downes, Sahakian, Polkey, & Robbins (1990).   
Stockings of Cambridge (CANTAB-TOL ) is a computerised version of the 
Tower of London (Shallice, 1982).  For this task the participant was shown two 
displays of three colored balls.  The participant was required to re-arrange the balls in 
the bottom half of the screen to match the arrangement in the top half of the screen.  A 
total of 12 test problems were administered.  The minimum number of moves required 
to solve each problem varied from two to five moves (2x2 move, 2x3 move, 4x4 
move and 4x5 move).  If a participant was unable to solve three consecutive problems 
in the maximum allowable number of moves the task was discontinued.  Three 
outcome measures were generated from this task: Number of successfully completed 
problems, number of problems completed in the minimum number of moves, and total 
score.  This last score was generated by adding the average number of moves for the 
two, three, four and five move problems.  The maximum possible number of moves 
(two times the minimum number of moves plus one) was allocated to participants 
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who were unable to complete a given trial.  Total possible scores ranged from a 
minimum of 14 to a maximum of 31 moves.   
Spatial Span: The CANTAB spatial span task, a computerized version of the 
Corsi Block tapping task (Milner, 1971), was used to assess spatial working memory.  
In this task a random pattern of nine white boxes appeared on the screen.  Some of the 
boxes changed color for a brief period to indicate a sequence.  After a brief delay, the 
participant was required to touch the boxes in the same order that they had changed 
color.  Sequences varied in length from two to nine boxes.  If a participant failed to 
remember the sequence correctly another trial at that level was given.  If the 
participant failed on the second trial at that level, the task was discontinued.  Spatial 
span was determined by the longest sequence correctly remembered by the 
participant.   
Spatial Working Memory: For this task participants were required to find a 
blue token hidden in a group of randomly arranged boxes without looking in a box 
more than once.  Boxes were opened by touching each one so that it opened revealing 
its contents.  Once the token was found, the participant placed it in an empty column 
on the side of the screen.  A new token was then hidden in a different box and the 
participant searched again.  The process was repeated until all the boxes had been 
used to hide the token and the column at the side of the screen was filled.  There were 
four practice trials, each with three boxes and then the test trials which included four 
trials with four, six, and eight boxes.  Total number of boxes opened to complete all 
trials was used as a measure of spatial working memory performance with higher 
scores being indicative of poorer performance.   
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Daneman and Carpenter Reading Span Test (Daneman & Carpenter, 
1980)-This test was used to assess the participants verbal working memory (Waters & 
Caplan, 1996b) and involved the presentation of sets of two to six sentences, each 
consisting of eight to 13 words.  Each set of sentences had three trials with 60 
sentences in total.  Testing began with sequences of two sentences.  Participants were 
asked to read each sentence out loud, judge the veracity of the statement, and 
remember the last word in each sentence (e.g., the hamburger bit into the juicy man).  
At the end of each trial, which was signaled by a blank card, the participant was asked 
to recall as many of the last words as possible.  Spans ranged from 1.5-6.  The test 
was discontinued if the participant was unable to remember the last word from any of 
the sentences in a trial set.  The reading span was determined as the maximum number 
of sentences remembered with over 66% accuracy (two out of three trials correctly 
recalled).  A ½ point was given if the participant remembered one of the sequences in 
a given trial.   
Delis Kaplan Executive Functioning System (D-KEFS) (Delis, Kaplan, & 
Kramer, 2001): Two of the nine sub-tests were selected for use from this battery.  
Sub-tests were administered according to procedures outlined in the manual.  For each 
sub-test, raw scores were converted to age corrected scaled scores (mean=10 and 
SD=3).   
1. The D-KEFS-TOH consists of five discs which vary in diameter from large 
to small, and a board with three vertical pegs of equal size.  For each of the nine 
problems the participant was presented with a picture of the tower to be built and two 
to five discs (depending on the level of difficulty of the tower) on the board in a 
predetermined starting position.  Participants were asked to plan their moves prior to 
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starting while observing two rules: never place a larger disc on top of a smaller disc 
and only move one disc at a time.  The task was discontinued after failure to complete 
three consecutive problems in the allotted time.  Three scores were generated for this 
task, an age-adjusted total score, number of problems completed in minimum moves 
and total problems completed successfully.  Because there is no maximum number of 
allowable moves, the total number of moves was not used as an outcome measure for 
this task.  For the age-adjusted score, a raw score was first calculated that included 
bonus points which were allocated on the basis of the number of moves made and 
faster completion times.   
2. Color-Word Interference Test: This test measured the participants’ ability to 
inhibit automatic verbal responses.  Participants were required to respond to four 
separate conditions.  In the first condition, participants were presented with a page 
displaying rows of colored patches that they were required to name, and in the second 
condition they were given a page with rows of words that they were required to read.  
The third condition is the traditional “stroop effect” where the participants were 
presented with a page of words printed in dissonant ink colors and asked to name the 
color of the ink that the letters are printed in rather than reading the word.  In the 
fourth and final condition, the inhibition switching task, participants were presented 
with a page with rows of words again printed in dissonant ink colors, but in this 
condition some of the words were in boxes.  The participant was required to name the 
color of the ink for the words that were not in boxes but to read the word if the word 
was inside a box.  For each condition, participants were required to name the colors or 
read the words as quickly as possible without skipping any or making any mistakes.  
Time taken to complete each condition was recorded and then converted to a 
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standardized score according to procedures outlined in the manual.  The third and 
fourth conditions were used in this study as measures of inhibition.   
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5.3.5 Statistical Analysis   
t- tests were used to compare PD patients versus healthy controls on clinical 
characteristics and for each of the tower tasks.  Pearson’s correlation was then used to 
examine the relationship between the two tower tasks and clinical and demographic 
status and also different measures of working memory and inhibition.  Analysis of 
covariance (ANCOVA) was used for group comparisons to control for the effects of 
inhibition and, separately, working memory.  Correlations between performance on 
the tower tasks and measures of working memory and inhibition were computed 
separately for PD patients and controls.  Finally, multiple regression analysis was 
used to assess the influence of inhibition and working memory for performance on the 
CANTAB-TOL and separately for the D-KEFS-TOH.   
5.3.6 Results   
Patients were well matched to healthy controls in terms of age and pre-morbid 
IQ (Table 47), but differed in terms of symptoms consistent with low mood (as 
measured by the BDI-II) and current mental status (as measured by the MMSE and 
DRS-II), but no patient met the criteria for a depressive episode or dementia (DSM-IV 
criteria).   
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Table 47: Clinical and demographic characteristics, Parkinson’s disease group versus 
controls.   
 Parkinson’s disease (n=40) Control Group (n=40)   
 Mean SD Mean SD t-value p-value 
NART1 109.05 10.13 111.20 10.30 0.94 >0.30 
Education(yrs)2 13.94 2.56 13.76 2.57 -0.30 >0.75 
Age 66.15 6.65 66.58 5.47 0.31 >0.75 
MMSE3 28.65 1.42 29.58 0.71 3.67 <0.001* 
BDI-II4 7.59 4.34 4.13 3.39 -3.96 <0.001* 
DRS-II5 10.53 2.12 11.45 2.11 1.82 <0.10 
PD onset6 6.49 4.35     
UPDRS7 28.46 9.49     
1National Adult Reading Test used to estimate premorbid IQ, 2Total number of years of formal 
education, 3Mini Mental Status Exam,4Beck Depression Inventory-II;5Dementia Rating Scale-II; 
6Number of years since diagnosis of Parkinson’s disease, 7Unified Parkinson’s disease Rating Scale 
(motor score component); *Significant group difference. 
As shown in Table 48, the PD group performed more poorly than controls on 
the CANTAB-TOL, completing significantly fewer towers in the minimum number of 
moves and on average requiring more moves to solve the problems.  The PD group 
also solved fewer CANTAB-TOL tower problems, but this difference fell short of 
significance (p < 0.06).  By contrast, there were no differences between the groups on 
the D-KEFS-TOH (see Table 48).  Effect sizes for outcome measures on the CANTB-
TOL ranged from medium to large whereas those for the D-KEFS-TOH were all 
small.  The PD group also showed deficits for two of the three working memory tasks 
(spatial span and reading span) and on both measures of inhibition.   
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Table 48: Parkinson’s disease group compared to controls on two tower tasks and 
working memory tasks.   
 Controls 
Mean (SD) 
PD Patients 
Mean (SD) 
 
t-value 
 
p-value 
Cohens 
d 
CANTAB- TOL
1
      
  Number solved in min moves 8.1  (2.1) 6.6  (2.6) 2.81 <0.01* 0.60 
  Number correctly solved 10.3  (1.6) 9.4  (2.8) 1.80 <0.06 0.39 
  Total number of moves used 18.1  (2.7) 20.1  (4.1) 2.62 <0.02* -0.58 
D-KEFS TOH
3
      
  Number solved in min moves 4.2  (1.2) 4.1  (1.1) 0.50 >0.60 0.09 
  Number correctly solved 7.0  (1.7) 6.8  (1.5) 0.62 >0.50 0.13 
  Age adjusted scaled score 10.3  (3.1) 9.8  (2.6) 0.80 >0.40 0.17 
Working Memory Tasks      
  Spatial Span  5.2  (1.1) 4.6  (0.7) 2.78 <0.01* 0.65 
  Spatial Working Memory4 186.6  (19.9) 195.0  (18.1) 1.97 <0.06 -0.44 
  Daneman & Carpenter 2.5  (0.7) 1.7  (0.6) 5.73 <0.001* 1.23 
Inhibition Tasks
5
      
  Inhibition 11.6  (2.3) 9.1  (3.3) 3.87 <0.001* 0.88 
  Inhibition Switching  11.8  (2.3) 9.1  (3.7) 4.0 <0.001* 0.88 
 
1 Cambridge Automated Neuropsychological Test Battery- Stockings of Cambridge; 2 Total average 
number of moves made; 3 Delis-Kaplan Executive Function System Tower Task; 4 Total number of 
moves higher scores indicate greater impairment;5 Delis-Kaplan Executive Function System Color- 
Word Interference Test. . *significant group difference.
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To enable a direct comparison between the CANTAB-TOL and D-KEFS-
TOH, the total number of towers completed in minimum moves and total number of 
towers correctly solved were converted to percentage scores.  On average the PD 
patients solved only 55.2% of the CANTAB-TOL problems in the minimum number 
of moves while the matched controls solved 65.5%.  However, both groups solved a 
similar number of problems in the minimum number of moves for the D-KEFS-TOH, 
with the PD and healthy controls group solving 45.3% and 46.6% of problems 
respectively.  In terms of the average total number of towers correctly solved, PD 
patients solved 78.3% of CANTAB-TOL problems compared to 86.0% for controls, 
and 75.5% of D-KEFS-TOH problems compared to 78.1% for controls.   
Table 49 shows the relationship for PD patients between performance on the 
tower tasks and measures of clinical and demographic status.  For performance on the 
CANTAB-TOL, significant correlations were evident with age and current mental 
status (as measured by the MMSE and DRS-II).  There was also a significant positive 
correlation for the CANTAB-TOL problems completed in the minimum number of 
moves and pre-morbid IQ (see Table 49).  The only significant correlations between 
performance on the D-KEFS-TOH were found between the age-adjusted tower score 
pre-morbid IQ, and DRS-II, and between towers conducted in the minimum number 
of moves and DRS-II score.   
As can be seen in Table 50, only low-to-moderate correlations were found for 
PD patients on the two tower tasks (r=.27 to r=-.49), indicating that between 7-24% 
of variance in the tasks was shared.  In terms working memory measures, only spatial 
span showed a significant positive correlation with all outcome measures on 
CANTAB–TOL.  Spatial working memory was only significantly associated with the 
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number of towers solved in minimum moves, and the verbal working memory task 
was significantly associated only with the number of towers correctly solved (see 
Table 50).  Both measures of inhibition showed a moderate correlation with the 
CANTAB-TOL.  A stronger pattern was evident between performance on the D-
KEFS-TOH and measures of working memory with significant positive correlations 
evident for both spatial span and spatial working memory.  There were no significant 
correlations between verbal working memory and only one measure of inhibition was 
associated with the D-KEFS-TOH (see Table 50).   
The level of shared variance between the two tower tasks for healthy controls 
was similar to that for PD patients (r=.28 to r=-.61; 7-37% shared variance), but the 
pattern of performance across related tasks differed (see Table 51).  Among measures 
of working memory, only spatial working memory was significantly correlated with 
tower performance.  This finding was consistent across both tasks.  By contrast, there 
were no significant correlations with the spatial span task or verbal working memory 
for both the CANTAB-TOL and D-KEFS-TOH (see Table 51).  Inhibition was related 
to performance on the CANTAB-TOL but not with performance on any aspect of the 
D-KEFS-TOH.  
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Separate ANCOVAs were used to assess whether group differences observed 
for the CANTAB-TOL remained significant after controlling for working memory 
and inhibition.  Spatial working memory from the CANTAB was selected as a 
covariate because it was the only working memory measure to have a significant 
association with performance on the tower tasks for both controls and PD patients 
(see Tables 50 and 51).  Similarly, simple inhibition was chosen as a covariate for 
inhibition, because it was the measure of inhibition that most strongly correlated with 
tower performance for both the controls and PD patients (see Tables 50 and 51).  With 
spatial working memory as a covariate, group differences were still evident for the 
number of tower problems on the CANTAB-TOL solved in the minimum number of 
moves (F=4.64, df=77, p<0.05).  However, there were no longer significant group 
differences for the number of towers solved correctly or the total number of moves 
used (F= 1.50, df=77, p>0.25 and F=3.77, df=77, p<0.06 respectively).  With simple 
inhibition as a covariate there were no significant group differences for number of 
problems solved in the minimum number of moves (F=1.27, df=77, p > .30), total 
number of towers solved (F=0.04, df=77, p > .90) or total number of moves used 
(F=0.86, df=77, p > .40).   
Finally, regression analyses were conducted to test whether deficits shown by 
the PD patients on the CANTAB-TOL task were due to deficits in spatial working 
memory, inhibition, or both.  For these analyses, group (PD vs control) and spatial 
working memory (or simple inhibition) was entered at the first step, and simple 
inhibition (or spatial working memory) was entered at the second step.  When group 
and spatial working memory were entered in the first step, inhibition was significantly 
related to the number of towers solved in minimum moves (β = 0.39, R2 change = 
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0.12, p < 0.001), the number of towers correctly solved (β = 0.39, R2 change = 0.12, p 
< 0.001) and the total number of moves (β = -0.31, R2 change = 0.12, p <0.001).  
Conversely, spatial working memory was significantly related to all outcome 
measures when group and inhibition were entered on the first step (minimum number 
of moves, β = 0.30, R2 change = 0.08, p < 0.01, total number of towers solved, β = 
0.22, R2 change = 0.04, p < 0.05 and total number of moves β = -0.39, R2 change = 
0.08, p < 0.01).  This suggests that impairments in both spatial working memory and 
inhibition are necessary to account for the deficits in CANTAB-TOL performance 
observed in the PD patients relative to controls.   
For the D-KEFS-TOH simple inhibition was not significantly related to any of 
the outcome measures when entered at the second step (number of towers solved in 
minimum moves, β = 0.14, R2 change < 0.01, p < 0.25; total number of towers solved, 
β = 0.21, R2 change < 0.03, p < 0.10 and for the scaled score, β = 0.15 R2 change < 
0.02, p < 0.25).  However, when group and inhibition were entered in the first step, 
spatial working memory was significantly related to D-KEFS-TOH performance in 
terms of the number of towers solved in minimum moves (β = 0.51, R2 change = 0.23, 
p < 0.001), the number of towers correctly solved (β = 0.37, R2 change = 0.12, p < 
0.01) and the scaled score (β = 0.47, R2 change = 0.20, p < 0.001).  This suggests that 
spatial working memory is a stronger determiner of performance on the D-KEFS-
TOH than simple inhibition.   
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5.3.7 Discussion   
The main objective of this study was to compare two planning subtests of two 
well-established neuropsychological test batteries with respect to their sensitivity to 
detect planning impairments in patients with PD.  To this end, we used the tower tasks 
from the Cambridge Automated Neuropsychological Test Battery (CANTAB-TOL) 
and the Delis-Kaplan Executive Function System (D-KEFS-TOH).  In addition, 
measures of working memory and inhibition were also utilized.  Compared to 
matched controls, medicated PD patients without dementia were impaired on the 
CANTAB-TOL but not the D-KEFS-TOH.  PD patients also performed more poorly 
on measures of working memory and inhibition when compared to matched controls.  
Moderate correlations were obtained for PD patients between performance on the two 
tower tasks, and with measures of working memory and inhibition.  By contrast, for 
healthy controls there was little association between performance on the tower tasks 
and measures of inhibition, and only one of the three working memory tasks was 
significantly related to performance on either of the tower tasks.  Spatial working 
memory and inhibition was related to performance on the TOL task but the 
contribution of inhibition to the TOH was much weaker.  This finding was confirmed 
using regression analysis which showed that whereas performance on the CANTAB-
TOL task was dependent on inhibition and spatial working memory, performance on 
the D-KEFS-TOH was dependent on spatial working memory only.  These findings 
suggest that the CANTAB-TOL and the D-KEFS-TOH require different cognitive 
skills and should not be considered interchangeable measures of planning ability for 
use with PD patients.   
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These findings are consistent with previous research, using healthy younger 
participants, which reported that a significant amount of non-shared variance exists 
between the two tower tasks (Welsh, Satterlee-Cartmell, & Stein, 1999).  Further, 
previous research has also found evidence for the recruitment of different cognitive 
processes when solving the TOH compared to the TOL (Welsh, Satterlee-Cartmell, & 
Stein, 1999; Zook, Davalos, DeLosh, & Davis, 2004).  For example, Handley et al., 
(2002) reported that the TOH task correlated more highly with spatial memory 
capacity but not complex verbal working memory.  Consistent with this finding, in the 
present study, D-KEFS-TOH performance was only correlated with (visuo-) spatial 
but not verbal aspects of working memory.  Welsh, Satterlee-Cartmell and Stein 
(1999) found that working memory and inhibition was strongly related to 
performance on the TOL task but the contribution of inhibition to the TOH was much 
weaker.   
Apart from the obvious physical structures of the two tower tasks, there are a 
number of possible reasons why these two tasks might vary in relation to the 
recruitment of cognitive processes.  Firstly, the D-KEFS-TOH requires participants to 
plan for problems that require between 1-26 moves for perfect execution.  On the 
other hand, the CANTAB-TOL task problem set only requires 2-5 moves.  Although 
both tasks instruct the participant to plan their moves prior to engaging in the task, it 
is likely that for many of the moves for the D-KEFS-TOH participants engage in “on 
line planning”, that is they plan moves while they are engaged in the task rather than 
planning all the moves before beginning the task.  This is most likely because more 
complex problems in the TOH task are substantially based on recursive shuffling of 
discs (in contrast to the TOL) which would be difficult to plan out in full prior to 
beginning the task (Newell & Simon, 1972).  Secondly, there may be floor effects 
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associated with D-KEFS-TOH.  Although problems are graded, with easier problems 
being presented first and more difficult ones later, problems move rapidly from those 
that nearly all participants can solve in minimum moves to problems that only a few 
can solve, thus reducing the sensitivity of the task.  Further, only one problem is 
presented at each level of difficulty and there are no introductory problems.  By 
contrast the CANTAB-TOL presents a number of introductory problems and more 
than one problem at each level.   
On the other hand, the CANTAB-TOL uses the original set of problems as 
outlined by Shallice (1982), which are nested in that earlier problems may form part 
of later problems.  As a result, performance may depend to some extent on 
participants’ learning across the problem set and thus the CANTAB-TOL may not 
represent a test of pure planning ability.  It has previously been reported that PD 
patients have problems with learning, even in the early stages of the disease 
(Buytenhuijs et al., 1994), thus controls may benefit more from the nesting of 
CANTAB-TOL problems than PD patients.   
As Berg and Byrd (2002) point out, the lack of consistency in findings 
between different tower tasks could be related to a number of issues including: 1) The 
actual differences in the tower structure; 2) Insufficient attention to the difficulty of 
the problem set; and 3) Variation in performance measures.  Given these caveats it is 
difficult to make direct comparisons between the D-KEFS-TOH and the CANTAB-
TOL.  Further, it seems likely that both present potential confounds in terms of the 
problems sets that are used.  Nevertheless the CANTAB-TOL was the more sensitive 
task as despite these potential problems it was still able to detect significant 
differences between the PD group and controls, in contrast to the D-KEFS-TOH.
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Planning in Parkinson’s Disease: A Matter of Problem Structure?   
(In press journal Neuropsychologia avaliable on line August 2007) 
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5.4.1 Abstract   
Although the Tower of London (TOL) has been extensively used to assess 
planning ability in patients with Parkinson’s disease (PD), the reported presence or 
extent of any planning deficits has been inconsistent.  This may partly be due to the 
heterogeneity of the TOL tasks used and a failure to consider how structural problem 
parameters may affect task complexity.  In the present study, planning in PD patients 
was assessed by systematically manipulating TOL problem structure.  Results clearly 
disprove the identity assumption of problems with an equal number of minimum 
moves.  Instead, substantial parts of planning performance were related to more subtle 
aspects of problem structure, such as subgoaling patterns and goal hierarchy.  
Planning in PD patients was not impaired in general but was affected when the 
information provided by the problem states was ambiguous in terms of the sequential 
order of subgoals, but not by increases in search depth.   
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5.4.2 Introduction   
In addition to its well-known motor symptoms, Parkinson’s disease (PD) is 
associated with a number of cognitive deficits, including planning.  To plan 
successfully, an individual must look ahead through a series of possible steps, some of 
which may be counterintuitive, to reach a desired goal.  The ability to plan is an 
essential part of daily living, and difficulties with this skill may negatively affect 
autonomy and quality of life.  Planning deficits in PD have been found even in the 
early stages of the disease process (Culbertson, Moberg, Duda, Stern, & Weintraub, 
2004; Hodgson, Tiesman, Owen, & Kennard, 2002; Morris et al., 1988; Owen et al., 
1992), and may reflect the fronto-striatal circuit degeneration associated with this 
disorder (Owen, 2004a).  One of the most common tasks used to measure planning 
ability in PD is the Tower of London (TOL; Shallice, 1982).  However, the literature 
is inconsistent with regard to the presence or exact nature of any planning deficits in 
PD, possibly reflecting the variation of TOL tasks applied6.  Further, non-uniform 
procedures and problem sets have been used, making it difficult to compare results 
across studies.  To effectively assess planning deficits in PD a more systematic 
consideration of these issues is required (Taylor & Saint-Cyr, 1995).   
Recent research has emphasized the selection of specific tower problems 
because it has been suggested that different aspects of individual problems may 
increase or decrease the level of task complexity, and therefore the cognitive demands 
for planning (Berg & Byrd, 2002).  At the most basic level, the minimum number of 
moves can be viewed as an indication of how difficult a particular problem is.  
However, difficulty may be influenced by more than just the number of moves 
                                                
6For instance, Culbertson et al., (2004) reported a group of PD patients performing significantly worse 
than controls in terms of average number of moves, while Morris et al.,(1988) previously found no 
differences in accuracy but only for planning times. 
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required for solution.  For example, problems with the same number of moves may 
have a different search depth or subgoaling pattern.  A subgoal move refers to moves 
that are essential to the solution of a given problem, but do not place the ball into its 
goal position (Ward & Allport, 1997).  Search depth is defined as the number of 
subgoal moves before the first ball can be placed into a goal space(Spitz, Webster, & 
Borys, 1982).  In TOL problems, search depth is related to mainly two predominant 
subgoaling patterns (Kaller, Unterrainer, Rahm, & Halsband, 2004).  Specifically, 
optimal solutions of five-move problems either require (1) sequences of two initial 
subgoal moves followed by three goal moves; or (2) sequences of a subgoal move 
followed by a goal move, another subgoal move, and two final goal moves (Figure 
19-A).  As a result, five-move TOL problems feature search depths of either two or 
one initial subgoal moves, respectively.   
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Figure 19: (A) Structural Problem Parameters, (B) Factorial Design (Part I), (C) 
Factorial Design (Part II), (D) Experimental Problem Set.   
(A) Structural Problem Parameters.  Illustrations of goal hierarchy and search depth are exemplified 
on five-move TOL problems that were applied in Part II of the experiment. Four different types of 
problems were administered (P21-P24). In the TOL, two predominant subgoaling patterns are 
evident causing “search depths” of either one (P23, P24) or two initial subgoal moves (P21, P22). 
Goal hierarchy relates to the three possible configurations of the goal state: “tower” (P21), “partial 
tower” (P22, P23), and “flat” structures (P24) differentially predispose the consecutive order of the 
final goal moves and the associated subgoal sequences. Goal moves and subgoal moves are indicated 
by digits ‘1’ and ‘0’, respectively. Dashed circles around problem states denote goal moves.  (B) 
Factorial Design (Part I).  For the assessment of general planning ability, search depth was step-
wise increased in combination with the minimum number of moves (P11-P13). Goal hierarchy was 
kept unambiguous by using only goal states with “tower” structures. Problems featured only one 
optimal path to solution and no suboptimal alternatives.  (C) Factorial Design (Part II). In the 
second part, the influence of goal hierarchy and search depth on planning performance was 
systematically manipulated in a set of five-move problems (P21-P24) while controlling for other 
influences of problem structure. (D) Experimental Problem Set. Numbers in boxes at the bottom 
denote start state and goal state of presented problems in the notation suggested by Berg & Byrd 
(2002). 
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Goal hierarchy is another aspect of problem structure that affects task 
complexity (Ward & Allport, 1997).  Goal hierarchy is related to the ambiguity of 
information on subgoal ordering, that is, the degree to which the sequence of the final 
goal moves can be derived from the configuration of the goal state (Kaller, 
Unterrainer, Rahm, & Halsband, 2004).  For example, problems with “tower” goal 
states, where all three balls are stacked on a single rod, provide an unambiguous goal 
hierarchy because the ball at the bottom has to be placed in its goal position before the 
ball that is second from the bottom, and so on.  By contrast, no such information can 
be derived from “flat” goal states (Figure 19-A).  Problems may also vary concerning 
the number of optimal paths to solution which refer to the number of different 
possible solutions that allow the problems to be solved in the minimum number of 
moves (Newman & Pittman, in press; Unterrainer, Rahm, Halsband, & Kaller, 2005).  
In addition, there may also be suboptimal alternatives that take more than the 
minimum number of moves, but allow the first ball to be placed into its goal position 
within a number of moves equal to the optimal solution (Kaller, Unterrainer, Rahm, & 
Halsband, 2004).   
Given the variety of the aforementioned aspects of problem structure, it seems 
plausible to assume that systematic manipulations of TOL problem parameters will 
have differential effects on planning performance, in particular with respect to clinical 
populations that are known to have planning impairments.  The aims of the present 
study are hence twofold.  First, to test the widespread assumption of identical task 
complexity for problems with an equal number of minimum moves.  The apparent 
popularity of this assumption seems to be implicated to some extent by the large 
number of studies using minimum moves as the only indicator of problem difficulty, 
without any consideration of other structural problem parameters.  The second goal 
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was to test the hypothesis that planning ability of PD patients is more severely 
affected in problems that, irrespective of the minimum number of moves, have higher 
demands on active manipulation of spatial information within working memory and 
identification and implementation of organizational strategies (Cools, 2006; Owen, 
2004b).  Thus, in the present study the effects of systematic manipulations of problem 
structure were examined in terms of goal hierarchy and search depth.   
5.4.3 Methods   
Participants  
The study was approved by the local ethics committee and all participants 
gave written informed consent prior to participation.  Participants were recruited from 
a data base of PD patients and healthy controls.  Thirty non-demented and non-
depressed patients with idiopathic PD diagnosed by a neurologist who specialized in 
movement disorders were assessed (see Table 52 for inclusion/exclusion criteria).  All 
patients were on anti-Parkinsonian medication and were tested while on optimal 
levels.  Thirty healthy controls were individually matched in terms of age and pre-
morbid intelligence.   
Assessments were carried out at the University of Canterbury over two testing 
sessions.  Tests were presented in a fixed order with breaks taken as required.  
Planning ability was assessed using the TOL at the beginning of the second session7.   
                                                
7  Full information regarding tower structures used and the order of presentation can be found in 
appendix (XXVIII) 
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Table 52: Inclusion and exclusion criteria.   
The same criteria were also applied for the selection of healthy controls with the 
exception of issues related to diagnosis and medical treatment of Parkinson’s disease.   
Inclusion criteria: 
• Diagnosis of idiopathic Parkinson’s disease, assessed as between Hoehn and Yahr 
(1967) stage I-III 
• Aged between 50 and 80 years, English as the primary spoken language, adequate 
or corrected hearing and vision (self-report checked by examiner) 
Exclusion criteria: 
• History of moderate or severe head injury, stroke or other neurological impairment, 
major medical illness, psychiatric illness requiring hospitalisation 
• Currently involved in a therapeutic trial 
• Suspicion of dementia (MMSE<25), diagnosis of learning disability, pre-morbid 
IQ<85 (NART) 
• Acute depression or major depressive episode in the previous six months (BDI-
II>17; DSM IV) 
• Taking other than anti-Parkinsonian medication known to have significant effects 
on the central nervous system 
 
Demographic and Clinical Information  
Pre-morbid intelligence was estimated using the National Adult Reading Test 
(NART; Nelson & Willison, 1991).  Current cognitive status was examined by the 
Mini Mental Status Exam (MMSE, Folstein, Folstein, & McHugh, 1975) and the 
Dementia Rating Scale (DRS-2; Jurica, Leitten, & Mattis, 2001).  The Beck 
Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996) was applied as a 
measure of affective disturbances.  In addition to the Hoehn and Yahr (1967), severity 
of motor impairment was assessed the Unified Parkinson’s Disease Rating Scale 
(UPDRS; Fahn & Elton, 1987).  Demographic and clinical characteristics for PD 
patients vs healthy controls is shown in Table 53.   
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Table 53: Sample descriptions in terms of demographic and clinical information.   
 Controls 
Mean (SD) 
PD 
Mean (SD) 
 
t-value 
 
p-value 
  Age 66.43 (5.3) 65.77 (6.6) 0.43 > .65 
  EDU1 
  NART2 
13.78 (2.7) 
111.67 (10.8) 
14.08 (2.8) 
109.93 (10.8) 
0.42 
0.70 
> .65 
> .45 
  MMSE3 
  DRS-24 
29.70 (0.5) 
12.07 (2.6) 
28.90 (1.2) 
10.60 (1.8) 
3.44 
2.52 
< .01 
< .05 
  BDI-II5 3.33 (2.6) 8.60 (3.8) 5.29 < .001 
  PD-Ons6 
  PD-Dur7 
- 
- 
58.5 (8.8) 
7.3 (4.6) 
- 
- 
- 
- 
  H&Y8 
  UPDRS9 
- 
- 
2.30 (0.6) 
27.13 (7.5) 
- 
- 
- 
- 
1 Total years of education;2 National Adult Reading Test;3 Mini Mental Status Exam; 4 
Dementia Rating Scale;5 Beck Depression Rating Scale; 6 Age of onset  (in years); 7  
duration of disease (in years);8 Hohen & Yarh; 9 Unified Parkinson’s disease Rating 
Scale.  
Although there were significant differences between the two groups in terms 
of mood ratings (BDI-II) and cognitive status (MMSE, DRS-2), none of the PD 
patients showed any evidence of clinical depression or dementia (see Table 53).   
Planning Task and Instructions  
A computerized version of the TOL was used to assess planning ability.  Start 
and goal states were presented in the lower and upper half of the screen, respectively.  
Participants were instructed to transform the start state into the goal state while 
following three rules: (1) only one ball may be moved at a time; (2) a ball cannot be 
moved while another is lying on top of it; and (3) three balls may be placed on the 
tallest rod, two balls on the middle rod, and one ball on the shortest rod.  Participants 
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were instructed to solve each problem in the minimum number of moves (indicated on 
the screen).  To match the goal state, participants had to operate on the start state.  
Movements were executed on an ELO 17” touch sensitive screen.  Individual trials 
were initiated by the experimenter.  Before displaying the next problem, participants 
were prompted by the program to plan ahead first.  Prior to the experimental trials, 
participants were familiarized with the TOL and the handling of the touch screen in a 
practice phase using two- and three-move problems.   
Experimental Design  
The assessment of planning ability occurred in two parts.  The objective of 
Part I was to examine whether planning in PD was generally impaired even in highly 
structured and well-defined situations.  Therefore, the minimum number of moves 
was systematically increased from three to five moves while problems featured only a 
totally unambiguous goal hierarchy.  This enabled search depth, but no other 
confound, to be varied systematically (together with minimum number of moves) 
from zero to two initial subgoal moves before the first goal move (Figure 19-B).  In 
addition, problems had only one optimal path for solution but no suboptimal 
alternatives.   
A more complex scenario was examined in Part II by systematically varying 
search depth and goal hierarchy in a set of five-move problems (Figure 19-A and 19-
C).  In contrast to Part I, the applied problems also featured alternative paths leading 
to suboptimal solutions.  The minimum number of five moves for these TOL 
problems could only be achieved by one optimal path for solution.  The specific aim 
of Part II was to disentangle the contributions of two specific aspects of problem 
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structure, that is, search depth and goal hierarchy, to planning impairments in PD 
patients, while the minimum number of moves was kept constant.   
The factorial designs of both Part I and II are illustrated in Figure 19-B and 
19-C, respectively.  Due to general features of the TOL problem space, the 
combination of both search depth and goal hierarchy in Part II inevitably results in an 
imbalanced design since certain problem configurations simply do not exist.  Testing 
for possible interactions between goal hierarchy and search depth would therefore be 
unfeasible (Winer, 1962).  However, to allow for a factorial analysis of the interesting 
main effects and interactions with group, the composition of the two structural 
problem parameters was transformed into a hierarchical design by nesting the relative 
ambiguity of subgoal ordering ( i.e., goal hierarchy) under the levels of search depth 
(Figure 19-C).  The resulting problem set is shown in Figure 19-D.  Within Parts I and 
II, problems were presented block-wise using a fixed order within blocks.  Across 
blocks, different isoforms of problems were applied using pseudo-randomized 
permutation of ball colours.  More detailed information on the selection of structurally 
unique problems and the balancing of isoforms (Berg & Byrd, 2002) can be obtained 
from the corresponding authors.   
Measures  
For the analyses reported below, accuracy of problem solutions was recorded.  
The terms ‘performance’ and ‘accuracy’ are henceforth used interchangeably and 
refer to the percentage of problems correctly solved in the minimum number of 
moves.   
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5.4.4 Results 
Part I 
Performance in the first part of the experiment was almost at ceiling for both 
healthy controls and PD patients (Table 54).  A two-way repeated-measures ANOVA 
on accuracy revealed a significant main effect for the minimum number of moves 
[F(2,58)=6.81, p=.002, η2=.105], but no main effect for group [F(1,58)=.11, p=.742, 
η2=.002] or interaction between factors [F(2,58)=.55, p=.577, η2=.009].  Post-hoc 
pair-wise comparisons yielded significant differences between three-move problems 
and four- as well as five-move problems (p<.005) but performance in four- and five-
move problems proved to be equally difficult (p=.993).   
 
Table 54: Part I – Mean percent of Tower Of London problems correctly solved, 
listed separately for the Parkinson’s disease patients and healthy controls.   
Part I three moves four moves five moves 
Controls 100.0 % (0) 92.3 % (3.1) 94.4 % (3.2) 
PD 98.9 % (1.1) 93.4 % (3.7) 91.2 % (3.9) 
Numbers in parentheses denote the standard error of mean. 
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Part II 
As is evident from Figure 20, performance in five-move problems could be 
systematically attributed to the experimental manipulations of problem structure.  A 
three-way repeated-measures ANOVA on accuracy yielded significant main effects 
for search depth [F(1,58)=22.31, p<.001, η2=.278] and goal hierarchy [F(1,58)=9.12, 
p=.004, η2=.137] but not for group [F(1,58)=.53, p=.472, η2=.009].  In addition, the 
interaction between group and goal hierarchy was significant [F(2,58)=4.70, p=.034, 
η2=.075].  Post-hoc analyses confirmed a highly significant effect of goal hierarchy in 
the PD group (p<.001) but not for controls (p=.580).  That is, planning performance of 
PD patients was, in contrast to healthy controls, specifically affected by increased 
ambiguity of goal hierarchy.  None of the remaining interactions was found to reach 
statistical significance [all F(1,58)<.5, p>.5, η2<.01].   
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Figure 20: Part II – mean performance in percent, plotted separately for the 
Parkinson’s disease group versus healthy controls and according to the experimental 
manipulation of problem structure, that is, search depth and ambiguity of goal 
hierarchy.   
Note that in part II, all problems had an equal minimum number of five moves for optimal 
solution.  Error bars denote the standard error of mean.   
 
To preclude that a possibly existing interaction between search depth and 
group had been simply masked due to the interleaved shifting of goal hierarchy within 
the nested design, an additional two-way repeated-measures ANOVA was conducted 
on search depth (cells P22 and P23, Figure 19-C) and group.  That is, the effects of 
search depth and group were directly tested in those problems that featured a partially 
ambiguous goal hierarchy.  In line with the analysis reported above, results again 
revealed a significant main effect solely for search depth [F(1,58)=27.77, p<.001, 
η2=.324], but neither a main effect of group [F(1,58)=.07, p=.800, η2=.001] nor an 
interaction [F(1,58)=.84, p=.363, η2=.014].   
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5.4.5 Discussion   
The results of this study revealed that planning in PD patients was generally 
intact when the ambiguity of the planning situation was reduced to a minimum (Part 
I).  In such cases, PD patients correctly solved even five-move problems with an 
accuracy of greater than 90 percent.  However, it was also found that planning 
performance of PD patients substantially declined if the ambiguity of goal hierarchy 
was increased (Part II).  That is, compared to normal controls, PD patients exhibited a 
discernable planning deficit only in those problems with less predictable subgoal 
sequences.   
With respect to the first aim of this study, these results strongly challenge the 
wide-spread assumption that problems with an equal minimum number of moves also 
feature an identical level of task difficulty.  Instead, the present results suggest that 
problems with an equal minimum number of moves do not necessarily have to share 
identical task difficulty (within-level variability), nor does a gradual increase of 
minimum moves necessarily imply a correlated rise of task difficulty (between-level 
invariability).  This conclusion is supported by previous research on the psychometric 
properties of the TOL (Culbertson, Moberg, Duda, Stern, & Weintraub, 2004; Humes, 
Welsh, Retzlaff, & Cookson, 1997; Kafer & Hunter, 1997; Schnirman, Welsh, & 
Retzlaff, 1998) as well as by studies explicitly addressing the impact of problem 
structure on planning (Carder, Handley, & Perfect, 2004; Kaller, Unterrainer, Rahm, 
& Halsband, 2004; Newman & Pittman, in press; Unterrainer, Rahm, Halsband, & 
Kaller, 2005; Ward & Allport, 1997).   
With respect to the second aim of this study, planning performance of PD 
patients was indeed specifically associated with systematic manipulations of structural 
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problem parameters (Part II).  PD patients were not impaired in general but only 
affected when the information provided by the goal state was ambiguous with respect 
to the sequential order of subgoals.  PD patients were, however, no more liable to 
increases in search depth than healthy controls (Figure 20).  These results are 
particularly pertinent in the light of a recently proposed framework on the distinct 
roles that are played by the striatum and the prefrontal cortex in the flexibility and 
stability of cognitive representation, respectively (Cools, 2006).  Given a prevalence 
of dopamine depletion particularly in the dorsal striatum, PD patients with mild to 
moderate symptoms are supposed to exhibit a dissociable pattern of impaired active 
reorganization and manipulation of working memory contents, while maintenance of 
information is preserved (Owen, 2004).  These opposing predictions seem to be also 
reflected in the present results because a PD-specific deficit was observed for TOL 
problems with higher ambiguous goal hierarchy but not for increases in search depth.  
Goal hierarchy affects the “degrees of freedom” of the planning situation by more or 
less explicitly determining the sequential order of single steps on the solution path 
(Kaller, Unterrainer, Rahm, & Halsband, 2004; Ward & Allport, 1997).  Higher 
ambiguity of goal hierarchy should therefore be associated with increasing demands 
on cognitive flexibility, that is, the active implementation of organizational strategies 
in order to search and generate the optimal sequence of moves (Cools, 2006; Owen, 
2004).  Thus, in the absence of direct guidelines that are explicitly provided by the 
configuration of the goal states, PD patients would consequently be expected to 
exhibit less efficient planning abilities (see also Taylor & Saint-Cyr, 1995), as was 
observed in the present study.  In contrast, given a likely “anchoring” function of the 
first goal move and the chunking of subgoal-move sequences (Ward & Allport, 1997), 
increases of search depth might primarily relate to aspects of working memory 
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maintenance.  Because working memory is generally not affected in mild to moderate 
stages of the disease (Owen et al., 1992) PD patients would accordingly not be 
expected to show any specific planning deficits in problems with larger search depths, 
which is again consistent with the present results.  However, increases in search depth 
are, at least to some extent, also associated with higher demands on strategic look-
ahead (Spitz, Webster, & Borys, 1982) that, unlike the present study, might cause a 
PD-related decline in accuracy.  Likewise, accomplishing suboptimal alternatives 
might also increase demands on cognitive flexibility as misleading paths, if 
recognized, have to be circumvented by searching an optimal solution.  Present data8, 
however, do not suggest such an association.  Instead, participants did not necessarily 
become aware of when they had chosen a suboptimal path.  As the minimum number 
of moves was indicated, PD patients as well as healthy controls have most likely not 
planned ahead complete solutions but seemingly started instead to execute already 
after having found a partial solution path towards a first goal move, which in 
problems with suboptimal alternatives could have been also misleading.  Thus, it 
rather seems that increased problem difficulty due to suboptimal alternatives might be 
mainly related to other processes such as, for instance, to successfully inhibit a 
premature selection of inappropriate moves (Carder, Handley, & Perfect, 2004).  
Future research should therefore address these issues in particular.   
Taken together, systematic manipulations of TOL problem structure in the 
present study provided clear evidence that detection of planning deficits in PD 
                                                
8A comparison of five-move problems with an unambiguous goal hierarchy and search depths of two 
intermediate moves across Parts I and II (P13 and P21, see Fig. 1-B and 1-C) allows to estimate the 
impact of suboptimal alternatives on planning performance. Results revealed a highly significant effect 
of suboptimal alternatives [F(1,58)=90.48, p<.001, η2=.609] which was, however, entirely independent 
of group [F(1,58)=1.19, p=.280, η2=.020] or any interactions with group [F(1,58)=.18, p=.674, 
η2=.003].  
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patients is dependent on the cognitive demands of the specific problems employed in 
the task.  Given the wide-spread use of the TOL and other related disc-transfer tasks 
as assessment tools in clinical and research contexts, more attention should be paid to 
the effects of problem structure.   
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Chapter 6 – Higher Order Language Functioning in Parkinson’s disease   
Abbreviations used in the text Chapter Six 
1) BDI-II = Beck Depression Inventory; 2) DRS-II = Dementia Rating Scale-II; 3) 
DSM-IV = Diagnostic and Statistical Manual Fourth Edition; 4) H&Y = Hoehn and 
Yahr Staging Scale; 5) ID/ED = Inter Dimensional/Extra Dimensional Shift; 6) 
MMSE = Mini Mental Status Exam; 7) NART = National Adult Reading test 8) PD 
= Parkinson’s disease; 9) TLC-E = Test of Language Competence Expanded Edition 
- Level 2; 10) UPDRS = Unified Parkinson’s disease Rating Scale; 11) WASI = 
Wechsler Abbreviated Scale of Intelligence.  
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6 1 Overview   
Language deficits in Parkinson’s disease are traditionally associated with 
motor symptoms that affect both movement and speech.  However, deficits in higher 
order language have been associated with PD, with speed of processing and working 
memory being suggested as mediating any deficits.  Higher order language skills are 
necessary for everyday communication and enable the interpretation of covert 
meanings associated with inference and ambiguity.  These processes rely on intact 
prefrontal functioning that enable individuals to respond quickly and appropriately to 
novel situations (McNamara & Durso, 2003; Pearce, McDonald, & Coltheart, 1998).  
However, there is considerable debate as to the exact nature of the relationship 
between higher order language and other cognitive process mediated by the prefrontal 
cortex.  Currently little information exists as to whether any language deficits are a 
primary effect of the disorder or secondary to the cognitive deficits that commonly 
accompany PD.  Therefore, the present study had two major aims: First, to examine 
higher-order language functioning in patients with PD without dementia; and second, 
to examine the degree to which any language deficits might be mediated by cognitive 
deficits associated with the pre-frontal cortex, including working memory, 
information processing speed and attention.   
6.1.1 Difficulty with research in this area 
Assessing skills that resemble those that are used in everyday communication 
is difficult in the confines of a structured testing setting.  Only certain aspects of 
higher-order language can be assessed in a structured environment that is created 
during standardized neuropsychological testing, this study does not evaluate these 
deficits in an ecologically-valid way, that is, in situ.  Additional or different aspects of 
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language than that tested may be impaired in actual conversational interactions which 
are often rapid and unpredictable.   
6.2 Current Research   
6.2.1 Manuscript 1 – Higher Order Language   
This manuscript aimed to address the fifth objective of the thesis; the 
identification of the relative contribution of working memory and speed of processing 
on higher order language skills.  Overall, PD patients were impaired on aspects of 
higher-order language, working memory and speed of mental processing.  Measures 
of cognition were significantly correlated with language functioning.  Path analyses 
revealed that deficits in higher order language functioning were mediated by verbal 
working memory and speed of information processing.  Regression analyses found 
that speed of information processing was a stronger determiner of language 
performance than verbal working memory.  We found that higher-order language 
deficits are not a primary effect of PD, but can be explained in terms of deficits in 
speed of information processing associated with the disease.   
As a caveat to this manuscript, it is important to be aware that the particular 
analysis chosen has some disadvantages.  Path analysis provides a mathematical way 
to test the hypothesized relationships between variables.  The major advantage of 
using path analysis is that it permits the testing of hypothesized causal models 
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002; Shrout & Bolger, 2002).  
However, these causal models are specified based on the theory, and better causal 
paths may be possible.  Further, path analysis assumes that the relationships between 
the variables are linear, additive and causal.  In reality these assumptions are often 
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violated (MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002; Shrout & Bolger, 
2002).   
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6.3 The Effect of Attention, Working Memory and Speed of Information 
Processing on Higher Order Language Functioning in Parkinson’s disease   
(In review Journal of Brain and Language)
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6.3.1 Abstract   
Parkinson’s disease (PD) is traditionally associated with motor symptoms that 
affect both movement and speech.  However, impairments in cognition and aspects of 
higher-order language functioning may also accompany this disorder.  The present 
study investigated whether higher order language deficits in PD represented a primary 
deficit or were a secondary effect of deficits in cognition.  Forty patients with PD 
were compared to age and IQ-matched controls on measures of higher- order 
language functioning using the Test of Language Competence- Expanded (TLC-E).  
Measures of cognitive ability that were potentially related to higher order language, 
including working memory, speed of mental processing and attention, were also 
obtained.  Overall, PD patients were impaired on aspects of higher-order language, 
working memory and speed of mental processing.  Measures of cognition were 
significantly correlated with language functioning.  Path analyses revealed that 
deficits in higher order language functioning were mediated by verbal working 
memory and speed of information processing.  Regression analyses found that speed 
of information processing was a stronger determiner of language performance than 
verbal working memory.  Results suggest that higher-order language deficits are not a 
primary effect of PD, but can be explained in terms of deficits in speed of information 
processing associated with the disease.   
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6.3.2 Introduction   
Parkinson’s disease (PD) is a neurodegenerative disorder that largely affects 
the basal ganglia (Middleton & Strick, 2000a).  Classic symptoms of this disorder are 
motor deficits and include rigidity, bradykinesia, tremor and postural instability 
(Vaughan & Hardie, 2002).  It is thus not surprising that prior research on 
communication deficits in PD has generally studied those aspects of motor control 
which are related to speech production.  Yet more recently there has been a growing 
awareness that PD is not only associated with impairments in language production, 
but also a range of cognitive deficits that may impact on language ability, including 
comprehension and effective verbal expression (Grossman, Carvell, Stern, Gollomp, 
& Hurtig, 1992; Owen, 2004a).  Cognitive problems, similar to those associated with 
frontal lobe damage, are particularly implicated in the processing of complex 
information such as language (Royall et al., 2002).  However, the exact nature of any 
deficits in higher order language functioning associated with PD is not well defined, 
and there is considerable controversy regarding the role of the prefrontal cortex in any 
language deficits that have previously been reported for these patients.   
Specifically, such language-related deficits include reduced verbal fluency, 
difficulties with pragmatic language, processing of past tense verbs, and impairments 
in detecting and correcting syntax errors (McNamara & Durso, 2003; Monetta & Pell, 
2007; Ullman, 2001).  The most frequently-reported deficit involves the 
comprehension of sentences with complex or irregular grammatical structures (Bodis-
Wollner & Jo, 2006; Grossman, 1999; Grossman et al., 1991; Grossman, Carvell, 
Stern, Gollomp, & Hurtig, 1992; Grossman et al., 2003; Lieberman, Friedman, & 
Feldman, 1990; McNamara, Krueger, O'Quin, Clark, & Durso, 1996).  Impaired 
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sentence comprehension in PD has been associated with deficits in a number of tasks 
mediated by the prefrontal cortex including set switching, inhibition, working 
memory, attention and processing speed (Angwin, Chenery, Copland, Murdoch, & 
Silburn, 2005; Grossman et al., 2003; Grossman et al., 2002; Hochstadt, Nakano, 
Lieberman, & Friedman, 2006).  Indeed, Grossman and colleagues (1992) reported 
that working memory and attention accounted for over 97% of the variance in 
complex sentence comprehension for PD patients.  It is clear that a number of 
different skills, mediated by the prefrontal cortex, have been implicated with deficits 
in complex sentence comprehension.  However, few studies have investigated 
impairments in higher-order language among PD patients and the impact of such 
deficits on everyday communication.   
A range of higher-order language skills is necessary for everyday 
communication to enable the interpretation of covert meanings associated with 
inference and ambiguity.  In general terms, language may be viewed as three distinct 
but interdependent aspects of communication: 1) content (semantics or meaning); 2) 
form (grammatical structure of sentences); and 3) use (social context of verbal 
interactions).  Higher-order language requires intact functioning in all of these areas 
and is likely to rely on prefrontal skills that enable individuals to respond quickly and 
appropriately to novel situations.  For example, pragmatic deficits, which refer to the 
use of language in context, including the ability to turn take and to respond with the 
appropriate quantity of relevant information, are seen following damage to the 
prefrontal cortex (McNamara & Durso, 2003; Pearce, McDonald, & Coltheart, 1998), 
and have also been found in PD patients.  McNamara et al. (2003) examined 
pragmatic ability in 22 non-demented PD patients and reported significant deficits 
when compared to healthy controls, these deficits correlated with poorer performance 
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on tests of prefrontal ability.  Lewis et al. (1998) compared the higher-order language 
abilities of 20 non-demented PD patients (all Hoehn and Yahr stage 3) compared to 
healthy controls.  PD patients were significantly poorer at interpreting ambiguity, 
figurative language and sentence construction.  Furthermore, patients with lower 
levels of general cognitive functioning were more impaired than other PD patients.  
However, their study did not examine the relationship between deficits in higher order 
language and different measures of prefrontal functioning.   
It is evident from the existing literature that a range of cognitive and language 
deficits are associated with PD.  However, there is currently little information as to 
whether the language deficits are a primary effect of PD, or secondary to the cognitive 
deficits associated with the disease.  This question is particularly pertinent in terms of 
higher-order language functioning, which relies on a number of skills that are 
generally considered to be mediated by the pre-frontal cortex.  Therefore, the present 
study had two major aims: First, to examine higher-order language functioning in 
patients with PD without dementia; and second, to examine the degree to which any 
language deficits might be mediated by cognitive deficits associated with the pre-
frontal cortex, including working memory, information processing speed and 
attention.   
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6.3.3 Methods   
This study received approval from the Upper South B Regional Ethics 
Committee.  Parkinson’s patients in the Canterbury region, who could be identified at 
the time of this study and had not been diagnosed with dementia, were invited by 
letter to participate.  Participants were required to meet the following inclusion 
criteria: a) a diagnosis of idiopathic Parkinson’s disease, confirmed by a specialist 
neurologist b) assessed at the Hoehn & Yahr stage I-IV; c) aged between 50 and 80 
years; d) adequate or corrected hearing and vision (self report checked by examiner); 
e) stable on PD medication; f) English as the primary spoken language; g) no 
suspicion of dementia (MMSE ≥25).  The following exclusion criteria were applied: 
a) currently involved in a therapeutic trial; b) a history of: i) moderate or severe head 
injury, ii) stroke or other neurological impairment, iii) other major medical illness , iv) 
significant psychiatric illness requiring hospitalization, v) major depressive episode in 
the previous 6 months; c) diagnosis of, or special education for, a learning disability, 
d) pre-morbid IQ estimated at <85 using National Adult Reading Test (NART); e) 
currently taking medications known to have a significant effect on Central Nervous 
System (other than medications prescribed for the control of PD symptoms) and f) 
Beck Depression Inventory–II score of >16.   
Of the 115 letters that were mailed, 6/115 (5.2%) of individuals with PD could 
not participate due to illness, 6/115 (5.2%) were deceased, 8/115 (6.9%) declined, 
34/115 (29.6%) did not respond, and 21/115 (18.3%) did not meet the 
inclusion/exclusion criteria.  Forty participants with PD who met the 
exclusion/inclusion criteria were available to participate in the study.  All patients 
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were on antiparkinsonian medication and were tested while on optimal levels of 
medication (self-report and examiner observation).   
Controls:  
Controls were recruited from a number of sources including a previously 
established data base, advertisements at local clubs (bowling, hiking and table tennis) 
and businesses.  All controls were given a brief outline of the study on first phone 
contact.  If they were still willing to participate, an information sheet was mailed to 
them.  In addition to adequate or corrected hearing and vision (self report and checked 
by the examiner) and being aged between 50 to 80 years of age, the same exclusion 
criteria listed above also applied to the control group.   
Procedure  
Assessments were carried out at the University of Canterbury.  Written 
informed consent was obtained from all participants at beginning of testing after the 
study had been explained.   
Additional information pertinent to the inclusion/exclusion criteria was 
obtained from all participants using a semi-structured interview.  PD patients also 
underwent a clinical assessment that included the Hoehn & Yahr staging and the 
Unified Parkinson’s Disease Rating scale to assess motor impairment.  All tests were 
conducted according to standardized procedures:  
Clinical/Demographic Information  
1) National Adult Reading Test (NART) (Nelson & Willison, 1991) was used to 
estimate pre-morbid IQ.  This test is comprised of a list of 50 “irregular” words 
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printed in order of increasing difficulty.  Words were scored 0 for incorrect and 1 
for correct pronunciation (Lezak, 1995).  Raw scores were converted to an 
estimated IQ score according to instructions in the manual (Nelson & Willison, 
1991).   
2) Vocabulary was assessed using a sub-test from the Wechsler Abbreviated 
Scale of Intelligence (WASI) (Wechsler, 1999).  This test measured the 
participant’s expressive language skills and consists of 42 orally presented words 
for which the participant provided a verbal description.  Items were scored either 
0 for an incorrect description, 1 for a partially correct description, or 2 for a 
correct description.  Raw scores were converted to age corrected T-scores (mean 
of 50 and standard deviation of 10).   
3) Beck Depression Inventory-II. (BDI-II) was used to assess mood and 
consisted of 21 items.  Each question was rated 0-3 with higher scores indicating 
greater intensity of symptoms (Beck, Steer, & Brown, 1996).  The BDI-II has 
been validated for use with PD patients, with a cut off of 16/17 being 
recommended for detecting the presence of depression (Leentjens, 2004).   
4) The Mini Mental Status Exam (MMSE) provided information regarding 
current cognitive status of the participant and includes items that assess attention, 
orientation to time and place, short term memory and language.  Scores range 
from 0-30, with lower scores indicating greater impairment.  A variety of cut-offs 
have been suggested for this instrument, but scores below 23-24 have been 
reported as having high sensitivity and specificity for identifying individuals with 
dementia (O'Connor et al., 1989).  Participants were included if they scored ≥25 
(Folstein, Folstein, & McHugh, 1975).   
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5) To ensure that none of the patients included in the study met the criteria for 
dementia, the Dementia Rating scale (DRS-2) (Jurica, 2001) was used in addition 
to the MMSE.  This scale consists of 36 tasks and five subscales.  The five 
subscales provide information on specific abilities and include: 1. Attention; 2. 
Initiation/Preservation; 3. Construction ability; 4. Conceptualization; and 5. 
Memory.  Based on normative data, raw scores from each subscale were summed 
to provide an overall score (ranging from 0-144 with higher scores indicating 
better performance) A DRS-II score of 130 has previously been validated as 
appropriate for PD patients (Brown et al., 1999).  However, Green et al. (2002) 
noted that this may exclude some patients due to motor deficits.  Therefore, 
patients with a total raw score of <120 were excluded and those with raw scores 
between 120 and 130 were further assessed for dementia by a registered clinical 
psychologist using the Diagnostic and Statistical Manual of Mental Disorders-IV 
(DSM-IV) criteria.  Two patients scored below 130, but neither patient met the 
DSM-IV criteria for dementia.  A combined scaled score adjusted for age and 
education was then generated using a regression formula provided in the 
administration manual is used for comparisons between the groups (Jurica, 2001).   
Two additional measures were used for patients with PD to provide 
information regarding motor impairment.   
6) Unified Parkinson’s Disease Rating Scale (UPDRS) (Fahn & Elton, 1987) is 
a 42 item test covering 4 areas.  Section one assesses mentation, behavior and 
mood, section two assesses activities of daily living, section three severity of 
motor symptoms and section four complications of therapy.  For this study scores 
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from the motor section were used to provide information regarding severity of 
motor problems.   
7) The Hoehn and Yahr (H&Y) was used to rate the stage of the disease (Hoehn 
& Yahr, 1967).  A numeric rating of 0-5 is used to represent increasing severity of 
symptoms, where 0 indicates no sign of the disease and 5 indicates that the patient 
is wheel chair bound or bedridden unless aided.  The  modified version of this 
scale was used, which provides increments of 0.5 in the midranges.   
Language and Cognitive assessment:  
1. Test of Language Competence- Expanded Edition (TLC-E): The TLC-E 
Level two was used to assess higher order language functioning.  This test is 
comprised of four sub-tests, three related to comprehension and one to 
language formulation.  Explicit scoring instructions are provided in the test 
manual (Wig & Secord, 1989).  Five scores were generated from this test: A 
total score (maximum = 189), and four subtest scores that corresponded to the 
following areas of language competence:  
• Ambiguous Sentences: assessed the participant’s ability to recognize lexical 
and structural ambiguities of a sentence.  Participants were orally presented a 
sentence that had two alternative meanings.  The ambiguous sentence was then 
displayed in print.  For example, “I saw the girl take his picture”.  Participants 
were then asked to provide two correct meanings for the sentence.  A total of 
15 sentences were presented, two trial sentences and 13 test sentences.  A 
score of 0 was given for no correct responses, 1 for one correct response, and 
3 if the participant correctly identified both correct responses.  Possible scores 
ranged from 0-39.   
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• Listening Comprehension (making inferences).  The objective of this subtest 
was to assess the participants’ ability to identify inferences in a series of short 
paragraphs.  Participants were first read a scenario that was displayed in print.  
For example, “Eric had wanted a moped for the longest time.  He sure was 
grateful for his Uncle Fred.  Question: Eric was grateful for Uncle Fred 
because…” Participants were then read four statements, provided in print at 
the bottom of the page, and asked to select two plausible inferences for the 
scenario.  A total of 13 sentences were presented in this manner (one trial 
sentence and 12 test sentences).  A score of 0 was given for no correct 
responses, 1 for one correct response, and 3 if the participant correctly 
identified both correct responses.  Possible scores ranged from 0-36.   
• Oral Expression (recreating sentences).  This subtest was used to evaluate the 
ability to formulate a grammatically complete sentence incorporating three 
key words.  Participants were presented with a picture of a scene and read a 
sentence.  At the top of the picture were three words. The participant was 
required to create an appropriate sentence incorporating all three words.  Two 
trial sentences and 13 test sentences were presented.  All responses are 
recorded verbatim and are scored for inclusion of target words, 0 for one or no 
target words, 1 for any two words, and 3 points for all three words.  Sentences 
were also scored in terms semantic, syntactic and pragmatic accuracy.  Intact 
sentences were given a score of 3 points, sentences with minor deviations 1 
point and 0 points for major deviations which result in nonsensical, “bizarre”, 
or fragmented sentences.  Possible scores ranged from 0-78.   
• Figurative Language: This subtest is comprised of two parts and is designed to 
assess the ability to interpret metaphoric expressions.  In task A, participants 
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were verbally presented with a situation, e.g., “A boy talking about his 
girlfriend” and a figurative expression related to the situation “she is easily 
crushed”.  Both the description of the situation and the figurative expression 
were also presented in print.  Participants were then asked to provide an 
interpretation for the figurative expression which was recorded verbatim.  In 
task B, they were asked to match the figurative expression to one of four 
explanations.  The situation description, figurative expression and the four 
explanations were all presented in print.  The test consists of one trial and 12 
test items.  A score of 0 is given if the participant is unable to give an accurate 
interpretation or select the correct matching expression.  A score of 1 is given 
if the participant could give either an accurate interpretation or select the 
correct matching expression and 3 if they complete both task A and B 
correctly.  For each of the subtests, a discontinue rule of failure to respond to 
three consecutive items is used.  Possible scores range from 0-36.   
2. Attention: This skill was assessed using the sub-test of Digits Forward from 
the Wechsler Memory Scale-III (WMS-III) (Wechsler, 1997), in which 
participants were required to repeat an increasing string of verbally-presented 
digits (2-9 items).  Two trials were presented for each level of difficulty.  The 
test was discontinued if a participant was unable to correctly answer both of 
the trials at any given level.  Raw scores were then age adjusted using the 
procedures set out in the manual [mean 10, standard deviation, 3].   
3. Working Memory: The Daneman and Carpenter Reading Span test (Daneman 
& Carpenter, 1980) was used to assess verbal working memory (Waters & 
Caplan, 1996a).  This test involved the presentation of sets of 2 to 6 sentences, 
each consisting of 8 to 13 words.  Testing began with sequences of two 
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sentences with three trials.  Participants were asked to read the first sentence 
out loud, judge the veracity of the statement, and remember the last word in 
the sentence.  They then read the second sentence out loud, again judged the 
veracity of the statement and remembered the last word.  At the end of the 
trial, which was signified by a blank card, the participant was asked to recall 
as many of the last words as possible, but not starting with the last word 
presented unless that was the only word they could remember.  The participant 
then moved on to sequences of three, four, five and six sentences.  Each level 
of complexity had three trials, with a total of 60 sentences being presented.  
The reading span was the maximum number of words remembered with over 
65% accuracy (two out of three trials correctly recalled).  The test was 
discontinued if a participant is unable to remember the last word from any of 
the sentences in a trial set.   
4. Speed of Mental Processing: Word naming and Color naming from the Delis 
Kaplan Executive Function System (D-KEFS) (Delis, Kaplan, & Kramer, 
2001) were used to assess this skill.  For the color naming portion of this test, 
participants were presented with a page with rows of colored patches or words 
that they were required to name or read.  For both conditions, they were asked 
to name the colors or read the words as quickly as possible without skipping 
any or making any mistakes.  Time taken to identify the colored patches or 
words was recorded.  Raw scores were then converted to age-adjusted scores 
with a mean 10, standard deviation, 3, as specified in the manual.  Scores for 
color naming and word reading were then averaged to provide a single score 
for speed of mental processing.   
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6.3.4 Data analyses   
Differences in demographic and clinical characteristics were examined using t 
tests and χ2 as appropriate.  t tests were also used to compare PD patients and matched 
controls on measures of language, working memory, speed of mental processing and 
attention.  Total scores for language and each of the sub-tests were then converted to 
z-scores using the control mean and standard deviation so that comparisons could be 
made across these measures.  Pearson correlations were employed to assess the 
association between language, working memory, speed of mental processing, and 
attention.  Separate path analysis models were then used to test whether the 
relationship between PD and deficits in higher order language could be explained by 
working memory, speed of mental processing, and attention as mediating variables 
(Sobel’s z).  Finally, multiple regressions were used to assess the influence of 
measures of working memory and speed of mental processing on higher-order 
language functioning.   
6.3.5 Results   
Demographic and clinical characteristics  
Comparisons between patients with PD and their healthy controls on clinical 
and demographic characteristics are shown in Table 55.  Each of the 40 PD patients, 
included in the main study, was matched as closely as possible to a healthy control in 
terms of age and pre-morbid IQ using the NART.  Matching was confirmed by t tests 
(IQ: t = 0.94, df =78, p > .30; and age: t = 0.31 df = 78, p > .75).   
Patients with PD had significantly lower MMSE scores and were more likely 
to endorse symptoms associated with low mood (see Table 55).  Also, there were 
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significantly more males in the PD group (PD 26/40 [65%] v Control 13/40 [32.5%]) 
(χ2(df = 1) = 8.46, p < .01).  Motor scores for patients with PD varied from mild to 
severe as measured by the H&Y (see Table 55).   
Table 55: Clinical and demographic characterstics, Parkinson’s disease group versus 
controls.   
 
 Parkinson's disease (n=40) Control Group (n=40)   
  
 
 Mean SD Range Mean SD Range t-value p-level          
 
NART
1
 109.05 [10.13] 87-131 111.20 [10.30] 90-128 0.94 >0.30 
Education (yrs)
2
 13.94  [2.56] 11-22 13.76 [2.57] 8-20 -0.30 >0.75 
Vocubulary 56.60 [7.98] 39 - 70 59.13 [7.69] 43 - 73 1.44 >0.15
 
Age 66.15  [6.65] 52-77 66.58 [5.47] 52-76 0.31 >0.75 
MMSE
3
 28.65  [1.42] 25-30 29.58 [0.71] 28-30 3.67 <0.001 
BDI-II
4
 7.59  [4.34] 0-16 4.13 [3.39] 0-15 -3.96 <0.001 
PD Onset
5
 6.49  [4.35]     0.25-23 
UPDRS
6
 28.46  [9.49] 13-49 
H&Y Stage
7                  1              1.5              2               2.5              3                4 
  (n=8) (n=6) (n=7) (n=10) (n=7) (n=2) 
         
   
1National Adult Reading Test, 2Total number of years formal education, 3Mini Mental Status Exam, 
4Beck Depression Inventory, 5Number of years since diagnosis of Parkinson’s disease, 6Unified Parkinson’s 
Disease Rating Scale (motor score component); 7 Hoehn and Yahr.  
 
 
Results for tests of higher-order language functioning are shown in Table 56.  
There were significant differences between PD patients and matched controls.  PD 
patients performed more poorly in terms of their overall TCL-E score and for three 
out of the four subtests.  Deficits were also evident for tests of speed of mental 
processing and working memory, as measured by the combined color and word 
identification task and the Daneman and Carpenter Reading span task, respectively.  
However, there was no significant difference for measures of attention as assessed by 
the digits forward task or for ability to interpret ambiguous sentences.   
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Table 56: Comparisons between Parkinson's disease group and matched controls on 
measures of Language Functioning, Information Processing Speed, Working 
Memory and Attention.   
  
PD Patients 
 
Controls 
 
t 
 
p 
     
 
TLC-E Total1 
 
155.95 (19.12) 
 
167.28 (16.22) 
 
2.86 
 
<0.01 
     
Subtests:     
   Ambiguous Sentence   31.18  (6.47)   32.35   (5.63) 0.87 >0.35 
   Making Inferences   25.73  (4.87)   29.73   (4.64) 3.76 <0.001 
   Oral Expression   68.70  (8.22)   72.78   (6.07 2.52 <0.02 
   Figurative Language   30.25  (5.48)   33.10   (3.79) 2.71 <0.01 
     
Information Processing 
Speed 
   9.66   (1.87)   11.34   (1.47) 4.46  <0.0001 
Reading Span Task    1.66   (0.57)     2.46   (0.67) 5.73  <0.0001 
Digits Forward 
 
  10.23  (2.13)   10.95   (2.25) 1.48   >0.10 
1 Test of Language Competence – Expanded, total score.  
 
For descriptive purposes and to enable comparison between the different sub-
tests, raw scores were converted to z-scores using the control mean and standard 
deviation.  Figure 21 displays the comparison between PD and their matched controls 
using z-scores for total TCL-E score and each of the four sub-tests.  Parkinson’s 
patients did not differ from matched controls in terms of their understanding of 
sentences that contained ambiguity.  However, for three of the four sub-tests, PD 
patients were performing between 0.67-0.82 SD below the mean of the matched 
controls.   
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Figure 21: Comparisons between the matched control group and Parkinson’s disease 
patients for different aspects of higher order language using the Test of Language 
Competence – Expanded.   
Note:  *p<.05; **p<.01; ***p<.001.   
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Because we were interested in the relationship between language performance 
and cognitive processes, we first examined the correlations between language 
functioning and speed of processing, working memory, and attention.  Table 57 shows 
correlations for the combined sample (i.e., PD patients and controls).  Not 
surprisingly, there were significant positive correlations between all each of the 
different measures of cognition and higher order language functioning.  Significant 
negative correlations were also found between disease state (i.e., PD vs Control) and 
measures of cognition and higher-language functioning, confirming the deficits shown 
by PD patients in Figure 21 and Table 56.   
Next a series of path analyses were conducted to determine whether the 
language deficits observed in the PD patients might be a secondary effect of deficits 
in cognitive functioning.  Specifically, we tested whether working memory, 
information processing speed, and attention might mediate the relationship between 
disease state and higher-order language functioning evidenced in Table 57.  Because 
the TCL-E subtests were highly correlated, we used the total score as our measure of 
higher-order language functioning.   
Four basic steps were followed in the models described here (Shrout & 
Bolger, 2002).  First, the direct path in which the independent variable (in this case 
disease state) caused a change in another dependent variable (in this case higher order 
language) was calculated (represented by the solid arc in Figures 22 and 23).  We then 
tested the relationship between disease state and a potential mediating variable 
(attention, information processing speed and working memory).  Next, the 
relationship between the proposed mediating variable and higher order language was 
assessed.  Finally, we calculated the change in the relationship between disease state 
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and higher order language when the mediator was included.  The resulting effect is 
the indirect path and is signified by a dotted line in Figures 22 and 23.  To see 
whether the pattern of results reflected a significant change we used Sobel’s z-test 
(Baron & Kenny, 1986).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Path diagram where the intervening variable is Attention.   
 
As can be seen in Figure 22, there was no significant association between PD 
disease state and attention.  Further, although performance on measures of attention 
were significantly associated with language performance, there was no evidence of a 
significant mediating effect (Sobel’s z =1.37, p>0.15) and the relationship between 
disease state and higher order language remained significant even after attention was 
controlled for (see Table 53 for beta weights).   
Attention 
Language PD Control 
-.17  .36*** 
-.31** 
-.25* 
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Figure 23: Path diagram where the intervening variable is Working Memory and 
separately Information Processing Speed.   
 
Figure 23 shows that there was a significant change in the relationship 
between disease state and higher order language functioning with the inclusion of 
either working memory or information processing speed as a mediator (see Table 58 
for full results).  For both these models, the indirect pathway between disease state 
and higher order language functioning was no longer significant when the mediating 
variable was included, and the drop in association between the direct and indirect 
pathways was significant (Sobel’s z = 2.30, p< 0.05 and z = 3.1, p< 0.01 for working 
memory and information processing speed respectively).  Thus, results of the path 
analyses suggest that both working memory and speed of processing, but not 
attention, can explain the deficits in higher-order language functioning shown by the 
PD patients.   
-.15 -.10 
Speed of Processing 
Language PD /Control 
Working Memory 
Language PD /Control 
-.54*** .27* 
-.31** 
-.45*** .51***
-.31** 
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Table 58: Regression coefficients for mediating variables.9   
Variable ß t ß t ß t 
 Step 1 
(criterion: Lang) 
Step 2 
(criterion: PS) 
Step 3 
(criterion: Lang) 
Group -0.31 -2.86** -0.45 -4.46*** -0.10 -0.88 ns 
Information Processing 
Speed (PS) 
     0.47**  4.32 
       
  Step 2 
(criterion: WM) 
Step 3 
(criterion: Lang) 
Group    -0.54 -5.73*** -0.16 -1.27ns 
Working Memory (WM)      0.27  2.16* 
       
  Step 2 
(criterion: ATT ) 
Step 3 
(criterion: Lang) 
Group   -0.17 -1.48ns -0.25 -2.43* 
Attention (ATT) 
 
     0.36  3.57*** 
 
 
Because measures of working memory and processing speed were correlated 
(see Table 57), we conducted a final series of regressions to test whether one of these 
variables might be primarily responsible for the language deficits associated with PD.  
For these analyses, group (PD vs control) and verbal working memory (or information 
processing speed) was entered at the first step, and speed of processing (or verbal 
working memory) was entered at the second step.  When group and verbal working 
memory were entered in the first step, information processing speed was significantly 
related to the TCL-E (β=0.44, R2 change =0.15, p<0.001).  When information 
processing speed and group were entered on the first step, verbal working memory 
was not significantly related to the TCL-E (β=0.18, R2 change =0.02, p<0.15).  These 
results suggest that information processing speed is a stronger determiner of 
performance on the TCL-E than verbal working memory, and hence that the higher-
                                                
9 Full details for this analysis are contained in the appendix XXIX. 
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order language deficits associated with PD are best understood as being mediated by 
deficits in processing speed.   
6.3.6 Discussion   
The goal of this study was to assess higher order language functioning in 
patients with PD compared to healthy older adults, and to examine the degree to 
which deficits that were observed could be explained by processes associated with the 
pre–frontal cortex.  These processes included working memory, speed of information 
processing and attention. Patients with PD performed significantly more poorly on 
higher order language tasks than healthy controls.  Performance on higher order 
language tasks were significantly correlated with information processing speed, verbal 
working memory and attention.  These three pre-frontal skills accounted for 13% to 
26% of the variance on the TCL-E.  Whereas path analyses indicated that both verbal 
working memory and information processing speed mediated the relationship between 
disease status and higher-order language functioning, multiple regressions confirmed 
that information processing speed was a stronger determiner of language performance 
than verbal working memory.  Overall, these results suggest that the higher order 
language deficits in PD are secondary to deficits in information processing speed, for 
which the pre-frontal cortex plays a pre-eminent role.   
The comparisons between PD patients and matched controls in the present 
study are consistent with previous studies, which have documented deficits in speed 
of information processing and working memory in PD patients (Berry, Nicolson, 
Foster, Behrmann, & Sagar, 1999; Lewis et al., 2003; Lewis, Dove, Robbins, Barker, 
& Owen, 2003; Lewis, Slabosz, Robbins, Barker, & Owen, 2005; Pillon et al., 1989).  
Further, PD patients have consistently been reported as experiencing difficulty in 
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different components of language, particularly understanding complex sentences 
(Grossman et al., 2002; Hochstadt, Nakano, Lieberman, & Friedman, 2006). Deficits 
in working memory and speed of processing have previously been reported as 
affecting the accuracy of patients with PD with regard to understanding of complex 
sentences (Grossman et al., 2002; Hochstadt, Nakano, Lieberman, & Friedman, 
2006).   
Although relatively few studies have investigated outcomes for PD patients in 
terms of higher-order language functioning, Lewis et al. (1998) found that patients 
with PD exhibited deficits in understanding ambiguous and figurative language.  In 
this study patients did not show any difficulties in interpreting ambiguous sentences.  
However, patient characteristics may account for this apparent discrepancy.  Whereas 
Lewis et al.’s (1998) patients were assessed at H&Y stage III, the present study 
included patients across a wider range of severity (H&Y stage I-IV) to increase the 
generalizability of the findings.   
Attentional skills are required for performance of the skills associated with 
higher order language.  However, because PD patients have consistently been 
reported as having preserved attentional skills (Boller, Marcie, Starkstein, & Traykov, 
1998; Bradley, Welch, & Dick, 1989; Cooper, Sagar, Jordan, Harvey, & Sullivan, 
1991) it is not surprising that attention was not predictive of any deficits of higher 
order language.   
Results suggest that skills mediated by the pre-frontal cortex play a primary 
role in higher-order language.  Higher-order language functioning required in 
everyday communication is complex, with a considerable degree of novelty.  It would 
be expected that these types of language interactions would rely more heavily on 
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skills mediated by the prefrontal cortex because of their demands on attention, 
working memory and speed of information processing.   
The method of assessment used here enabled an examination skills which 
more closely resemble those that are used in everyday communication and their 
relationship with skills associated with the prefrontal cortex.  Nonetheless, it is 
pertinent to consider the limitations of this study.  Only non-demented patients with 
no illnesses apart from PD were included.  It is likely that higher order language 
deficits would be more severe in patients with greater cognitive decline. Further, 
although we endeavoured to obtain a representative sample patients were self-
selected. 
Higher-order language used in everyday communication requires the ability to 
understand meanings which extend beyond the actual words spoken.  Understanding 
of ambiguity and inference is also required.  Even subtle deficits in these areas of 
language may serve to increase isolation of PD patients from normal social interaction 
intensifying their reduced quality of life (Miller, Noble, Jones, & Burn, 2006 ).  It is 
also likely that these types of difficulties may cause frustration for caregivers who 
may not understand the changes in comprehension and interpretation that are 
occurring for the patient.  Understanding the exact nature of cognitive deficits, or 
intact skills, which could facilitate learning, could potentially provide a means of 
intervention to ease any language problems.  For example, education for professionals 
and caregivers regarding how to present information in an appropriate way to enhance 
communication could ease the frustration of caring for an individual who has 
difficulty communicating.  Patients could be instructed in the use of strategies to 
clarify misunderstandings.  Further, because effective communication appears to be 
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linked with intact cognition, professionals could screen for cognitive decline as a 
marker for communication problems and take steps to intervene early in the disease 
process.   
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Chapter 7 – Contribution to the field of Parkinson’s disease   
7.1 Opening Discussion   
Parkinson’s disease is one of the most common neurological disorders 
affecting people over the age of 50 years (de Rijk et al., 1997; Twelves, Perkins, & 
Counsell, 2003).  Historically, research in this field has focused on the overt motor 
impairments that characterise this disorder with tremor, rigidity, postural instability 
and bradykensia being the hallmark features (Braak & Braak, 2000).  While the 
etiology of PD remains unknown, neuropathalogical findings indicate that the loss of 
dopamine containing neurons in the substantia nigra and the nigrostriatal tract are 
primarily responsible for the characteristic motor symptoms (Braak & Braak, 2000).  
More recently, it has been recognised that in addition to the motor symptoms that 
accompany this disorder, cognitive and neuropsychiatric disturbances may also be a 
feature of the disease process (Brown & Marsden, 1990; Marsh, 2000).  However, the 
exact nature of any cognitive or neuropsychiatric problems remains undetermined.   
The finding that cognitive and neuropsychiatric disturbances are frequently 
co-morbid with the motor problem is not surprising.  Contemporary models of the 
basal ganglia suggest that these structures are involved in at least 5 parallel loops 
within the cerebral cortex.  Two of these loops are involved in motor functioning, 
with the remaining three loops implicated in cognition and behaviour (Alexander & 
Crutcher, 1990; Alexander, DeLong, & Strick, 1986).  Deficits associated with PD are 
thought to result from dysfunction in these loops, secondary to the depletion of 
dopamine containing neurons in the substantia nigra that project to the basal ganglia.  
The resultant degeneration in the fronto-striatal circuits is associated with a wide 
range of problems for individuals’ with PD, many of which are poorly defined.  
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Figure 24 below offers a way to conceptualise the relatively complex array of 
problems that may impact on the functional profile for individuals with PD.  
 
Figure 24: A schematic representation of the issues that influence the functional 
profile of patients with Parkinson’s disease.   
(Circles with the dark boarders indicate the issues addressed in this thesis).   
Both physical (i.e. motor functioning, non-motor functioning and medications 
effects), and non physical problems (i.e. cognitive and neuropsyciatric problems and 
caregiver distress), contribute to this profile.  While there is abundant literature 
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regarding the most common motor symptoms and effective assessment and treatment 
protocols for ameliorating these, there is still considerable debate regarding the typical 
cognitive and neuropsychiatric profile.  This in turn results in a lack of a consensus 
regarding the appropriate assessment for any cognitive and neuropsychiatric problems 
that might accompany this disorder.   
The general aims10 of this thesis were: 
a) To contribute to the understanding of neuropsychiatric problems for 
PD patients.   
b) To contribute to the understanding of cognitive deficits in PD by: 
i) Defining the aspects of executive function that are impaired or 
spared.   
ii) Exploring whether sub-groups of people with PD could be 
identified based on their cognitive profile.  It was specifically 
intended to identify people with PD who could be considered as 
suffering from MCI.   
iii) Examining aspects of planning ability in PD patients.   
iv) Examining deficits in complex language.   
c) To identify a discrete battery of tests that could be used to identify 
patients with PD who might be experiencing MCI.   
                                                
10 A full description of the objectives for the thesis can be found in Chapter One, pages 64-66. 
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7.2 (A) Neuropsychiatric problems   
Although neuropsychiatric problems have previously received little attention in 
the literature, there is increasing recognition that they are frequently co-morbid with 
motor problems associated with PD (Shulman, Taback, Bean, & Weiner, 2001).  
Further, these neuropsychiatric problems can have a significant impact on the quality 
of life for PD patients and in some cases may be more disruptive than the motor 
symptoms (Fernandez, Tabamo, David, & Friedman, 2001).  Therefore, to contribute 
to the understanding of neuropsychiatric problems for PD patients, this thesis assessed 
a range of possible problems (including depression, anxiety, fatigue, apathy, sleep 
difficulties and hallucinations) in order to establish a likely profile for patients with 
PD without dementia.  Moreover, the relationship between these neuropsychiatric 
problems and quality of life was also examined.  Further, as depression is one of the 
most frequently reported neuropsychiatric problems, commonly used scales of 
depression were assessed to identify which was most sensitive to symptoms consistent 
with low mood or depression in PD.   
Collateral information from a significant-other11 regarding the presence of these 
problems was also collected to determine whether these two sources of information 
were interchangeable.  As neuropsychiatric problems have been found to impact on 
the caregivers’ ability to cope, the levels of distress that significant others were 
experiencing and the relationship of this distress to problems experienced by the PD 
patient, were assessed.   
                                                
11 The significant other was a person volunteered by the patient who knew them well. In most cases this 
was a spouse. 
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7.2.1 Overview of Results   
Overall, neuropsychiatric problems were common for patients with PD, with over 
70% of patients experiencing at least one problem.  Fatigue, depression, apathy and 
sleep difficulties were the most commonly reported problems, whereas symptoms 
consistent with anxiety and the presence of hallucinations were relatively less 
common.  Neuropsychiatric problems were associated with non-tremor scores but not 
tremor scores, age, gender or disease duration.  Most importantly, in addition to motor 
deficits, neuropsychiatric problems contributed to a reduced quality of life for 
individuals with PD.   
The level of agreement regarding the presence of neuropsychiatric problems 
between significant others and patients with PD was low.  A maximum agreement 
level of approximately 40% was found for the presence of apathy, with a low of 7.7% 
agreement for the reported presence of symptoms consistent with anxiety.  These 
results suggest that the ratings of significant others and patients cannot be treated as 
interchangeable.  Interestingly, levels of stress reported by the significant-other were 
influenced by their perception of the presence of neuropsychiatric problems in the 
patient, not just the presence of these problems.   
In terms of the most sensitive screening measure of depression, there was a high 
level of agreement between the BDI-II and the GDS.  By contrast, the HADS 
identified significantly fewer of the patients as having possible or probable 
depression.  Given the prevalence of depression among patients with PD, it is 
recommended that either the BDI-II or the GDS be used as a routine screen for 
depression.  While some have argued that the BDI-II may identify too many false 
positives, this scale has the important advantage of being consistent with the criteria 
 359 
for a major depressive episode outlined in the DSM-IV.  Moreover, all self-report 
scales used for the detection of symptoms consistent with depression, are screening 
measures.  Therefore, patients identified as “at risk” would still require screening by a 
qualified clinician for a diagnosis to be made, negating the disadvantage of a high 
level of false positives.   
7.2.2 Summary   
In summary, as neuropsychiatric problems are frequent and affect quality of life 
for many patients with PD, patients should be routinely screened for these problems.  
Depression is one of the most common neuropsychiatric problems associated with PD 
and that both the BDI-II and GDS were equally sensitive at detecting symptoms of 
low mood or depression for this patient group.  However, the HADS or the UPDRS 
alone were not sensitive and had unacceptably high levels of false negatives.   
Significant-other reports provide valuable information regarding their own 
perception of the patient’s problems.  However, significant-other reports of 
neuropsychiatric problems cannot be considered interchangeable with self-reports as 
they are likely influenced by the significant-others own levels of stress which may be 
unrelated to the patient’s problems.  Research suggests that it is important to monitor 
significant- other stress as it may signal increased difficulties coping with the needs of 
a patient with PD.  Moreover caregiver-stress maybe manageable with appropriate 
intervention or education, providing potential benefits in terms of improved quality of 
life for both the carer and the patient.   
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7.3 (B) Cognitive deficits in PD   
Cognitive deficits commonly accompany PD, even in the absence of dementia.  
However, there is still considerable controversy regarding the exact profile of deficits 
associated with this disorder (Brown & Marsden, 1990; Lewis et al., 2005).  To 
contribute to the understanding of cognitive deficits that accompany PD in the 
absence of dementia, a comprehensive assessment across multiple domains 
(including, memory/learning, language, planning, visuospatial ability, working 
memory, problem solving, executive function, attention, and speed of processing) was 
conducted.  This project placed a particular emphasis on tests that were sensitive to 
executive dysfunction and its sub-components.  While deficits in individual aspects of 
executive functions have frequently been reported, there is little information regarding 
which aspects are impaired or spared for patients with PD.   
As part of examining the cognitive profile for PD, this project also examined 
the possibility that different sub-groups of patients might exist that were identifiable 
by their cognitive deficits.  This aspect of the research was particularly aimed at 
investigating areas of cognitive decline that might signal a period of decline consistent 
with preclinical dementia or “PD-MCI”.   
7.3.1 Overview of Results   
A major contribution of this research was that it assessed a single group of 
patients on tests that covered a broad range of cognitive domains in order to identify a 
cognitive profile for PD patients.  Evidence of impaired performance across different 
aspects of executive functioning and its sub-components (working memory, problem 
solving, planning and speed of processing) were found.  Deficits in visuospatial 
functioning, independent of executive functioning, were also apparent.  Interestingly, 
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patients with PD did not show a global decline on measures of executive functioning 
and there was evidence of relative sparing on most measures of planning and problem 
solving.   
In the initial analysis for the project, evidence for planning deficits was at best 
weak.  The only task where impairment was found was for a version of the Tower of 
London task.  Furthermore, there was no sign of impairment for the Tower of Hanoi 
task, often used interchangeably with the Tower of London task as a measure of 
planning ability.  It was hoped that the differences between these tasks would lead to a 
greater understanding of planning ability in PD patients.   
Therefore, the relative sensitivity of these two widely used measures of planning 
ability was investigated.  It was found that there was only a small percentage of 
shared variance between the two tasks.  Moreover, the performance relied on different 
cognitive processes, and while performance on the Tower of London was dependent 
on inhibition and spatial working memory, performance on the Tower of Hanoi was 
dependent on intact spatial working memory.  These results suggested that neither of 
the commonly used tower tasks were particularly good for detecting planning deficits 
per se.  Therefore, a new tower task was designed to systematically manipulate 
problem complexity to more accurately tap into the skills required for planning.  The 
results indicated that planning performance was generally intact, with impairments 
being evident only when the requirements of the task became more effortful.   
As part of the investigation into cognitive deficits in PD, this thesis also 
investigated whether higher order language deficits represented a primary deficit or 
were a secondary effect to deficits in cognition.  Overall, PD patients showed 
impairments on aspects of higher-order language, working memory and speed of 
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mental processing.  Measures of cognition were significantly correlated with language 
functioning.  Further, analysis revealed that the deficits in higher order language were 
mediated by verbal working memory and speed of information processing, with speed 
of information processing being a stronger determiner of performance.  It was 
therefore concluded that higher-order language deficits were not a primary effect of 
PD, but could be explained in terms of deficits in speed of information processing 
associated with the disease.   
All the initial analyses regarding cognitive performance (including higher order 
language and planning ability) were conducted comparing the patients with PD to 
matched healthy controls.  However, it was evident that the patients varied greatly 
with regard to their cognitive performance.  Moreover, this variance was not reliably 
associated with demographic or clinical characteristics.   
To address the issues outline above, an investigation into whether sub-groups 
of PD patients could be detected that differed in terms their cognitive performance 
was undertaken.  Sub-groups of PD patients were assessed in terms of between-group 
differences and also in comparison to individually-matched healthy controls in terms 
of their cognitive performance and ability to conduct activities of daily living.  Three 
sub-groups of patients were identified that formed a continuum of cognitive 
impairment from mild to severe.  Compared to their controls, one sub-group showed 
no or minimal cognitive impairment (PD-NCI), a second group showed a more 
variable pattern of severe and mild impairments (PD-UCI), and a third group had 
evidence of severe cognitive impairments across most of the cognitive domains tested.  
This latter group was labelled PD-Mild Cognitive Impairment (PD-MCI).  The PD-
UCI and PD-MCI groups were also significantly different from their controls with 
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respect to their ability to carry out functional activities of everyday living.  Results 
confirm that patients with PD are heterogeneous with regard to their cognitive 
presentation.  Further, the severity of cognitive deficits was not associated with other 
clinical and demographic characteristics such as motor impairments, age or disease 
duration.  Patients were followed-up at one year (time 2) and results were consistent 
with time one.   
7.3.2 Summary   
In this study we found evidence of impairment for a number of areas of 
cognitive performance including working memory, verbal fluency, response inhibition 
and problem solving.  However, there was limited evidence for deficits in the domains 
of attention, or planning.  Further investigation indicated that planning deficits were 
present, but only when the task became more effortful.  Deficits in aspects of 
language functioning were apparent, but these were secondary to other aspects of 
cognitive functioning i.e., speed of processing and working memory, with speed of 
processing being a stronger determiner of performance.   
From our initial analysis it was evident that not all patients with PD were 
showing evidence of cognitive impairment.  Indeed, three sub-groups of patients were 
identified that formed a continuum of cognitive impairment from mild to severe.  
These three groups also differed significantly from their controls with respect to their 
ability to carry out functional activities of everyday living.  Severity of cognitive 
deficits was not associated with other clinical and demographic characteristics such as 
motor impairments, age or disease duration.  Results from the one year follow-up 
confirmed the initial findings.   
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7.4 (C) Identification of a discrete battery of tests that could be used to identify 
patients with PD who might be experiencing MCI   
7.4.1 Summary   
The concept of PD-MCI provides a useful way of viewing cognitive decline in 
PD and could be used to guide appropriate treatment interventions.  Unfortunately, 
there is currently no generally agreed on set of tests to evaluate potential cognitive 
and neuropsychiatric problems for patients with PD.  Therefore, one aim of this study 
was to develop a discrete group of non-invasive tests that would have direct clinical 
application.  Based on our findings at time one and the preliminary findings of time 
two, we were able to develop a brief battery of tests.  The suggested test battery would 
provide comprehensive information regarding current cognitive and neuropsychiatric 
and motor status, and would be sufficiently brief to be incorporated as part of a 
routine follow-up procedure.   
7.5 Future directions   
An overall theme of this thesis has been to identify cognitive and 
neuropsychiatric strengths and deficits in people with PD.  As part of this, the 
combination of measures most sensitive and appropriate for detecting the onset of 
cognitive decline (taking into account the possible neuropsychiatric problems that 
might accompany this disorder) in patients with PD were identified.   
However, it is acknowledged that tests suggested here are preliminary only, 
and is intended to further evaluate these measures in terms of their sensitivity (i.e. 
further evaluation with new groups of PD patients) and specificity (i.e. evaluating the 
final test selection with other patient groups such as Huntington’s disease, 
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Alzheimer’s dementia etc), and also with other confirmatory methods e.g., 
fMRI/MRI, EEG and eye-movements.   
In addition, it is intended that the patients and their healthy controls will be 
followed up longitudinally.  This longitudinal follow-up will serve to identify/confirm 
the characteristics of the patients who will go on to develop dementia.  In this regard, 
it is expected that a greater percentage patients in the PD-MCI group will develop 
dementia than in the other two groups.  
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Appendices  
 401 
I - Ethnicity Questionnaire   
 402 
Ethnicity of participant (Today’s Date:                        ) 
       Name: 
 
Which ethnic group do you belong to? 
Mark the space or spaces which apply to you. 
 
ٱ New Zealand European 
 
ٱ Mäori (iwi:                                           ) 
 
ٱ Samoan 
 
ٱ Cook Island Mäori 
 
ٱ Tongan 
 
ٱ Niuean 
 
ٱ Chinese 
 
ٱ Indian 
 
ٱ OTHER  Please state: 
 
_________________________________________________ 
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II - Health Check-List And Background Information   
 404 
 
Health checklist and background for  Healthy controls____M / 
F 
 
Today’s Date:       
 
Full Name:       PD match: 
 
Date of birth:      GP: 
 
Satisfactory / corrected vision:  Yes / No  and hearing: Yes / No 
 
 
Current medications, including dose: 
 
 
 
 
 
 
Other Comments: 
 
 
Tick (and then underline) if any of the following exclusions (History or Current):     
○ Aged <49 and > 80 yrs 
○ Involved in any current therapeutic trial 
○ Moderate or severe head injury / stroke / other neurological     impairment 
(specify:       ) 
○ Neurosurgery 
○ Major medical illness (cardiovascular; diabetes req insulin; severe migraine; 
other:    ) 
○ Significant psychiatric illness requiring hospitalization (specify:              ) 
○ Major depression in last 6 months 
○ Dementia / hallucinations 
○ Indication of excess alcohol or substance abuse 
○ Medications known to have a significant effect on CNS other than anti-PD 
medication 
○ Diagnosis or special education for a learning disability 
Enter ID #_____________check below only after initial tests  
○ Mini-Mental Status score <24  
○ Pre-morbid IQ estimate < 85 
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Continued… 
 
Full Name:       PD match: 
 
Date of birth: 
 
GP: 
 
    Contact tel. Number (s):_____________________________________ 
 
1) What language do you and your family speak at home or at 
work?_____________________  
 
2) Years of education (in years post age 10/11, that is not counting primary 
school)?____________ 
 
3) Qualifications (indicate): 
  
   □  School qualification (For example: school certificate passes, sixth form 
qualification, higher   
                                              school qualification, University Bursary Entrance Exam). 
 
   □ Vocational qualification (For example: trade certificate, technicians certificate, 
apprenticeships,   
                                              national certificate, national diploma, advanced trade 
certificate bringing  
                                              certificate, pre vocational certificate). 
 
□ Higher qualification (For example: undergraduate diploma or certificate, New 
Zealand diploma or certificate, BA, BSc, MA, Ph.D., post-graduate diploma). 
 
   □ None of the above  
 
4) Which day(s) and time you are most likely to be free to take part in the 
study?_______________ 
 
5) Caffeine drinks (coffee, tea, chocolate, caffeinated soft drinks) 
Per day: None / Little (One cup or can per day) 
              Moderate (2 or 3) 
              Heavy (4 or more) 
6) Alcohol Daily average (ALAC guide: 
Per day: None / Little (less than moderate daily average)  
               Moderate (1/3 to 1 spirit;1-2.5 glass wine; or 2-5 glasses of beer; as a daily 
average)  
              Heavy (more than moderate daily average) 
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III - Instructions For The Tower Of London – Revised   
 407 
 
 
Tower of London Task 
 
 
 
 408 
 
Stage 1 
 
 
The participant will be shown a display with two sets of three coloured balls, one on 
the top half of the screen and one on the bottom half of the screen. 
 
 
The TOL Task Overview 
 
The participant must make the bottom half of the screen (marked start) look like the 
top half of the screen (marked with the word finish and is coloured blue to remind the 
participant what they are aiming for) 
 
The balls can be moved one at a time by touching the ball and then touching the 
position it is to be moved to.   
 
NOTE: When the touch screen is activated, the time from the appearance of a new 
arrangement on the screen until the first ball is touched is taken as the planning time. 
So it is very important to emphasise that the individual carefully plan their moves 
before they touch the first ball. 
   
 All information for the examiner is inside the brackets<> Bolded words in the boxes 
are to be read out by the examiner. 
 
 < IF AT ANY TIME THE PARTICIPANT APPEARS DISTRESSED OR 
UNABLE TO CONTINUE, ESCAPE BY PRESSING THE  apple  and T KEY 
TOGETHER> 
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Instructions: 
<1. Double click on tower of London icon which is on the desktop> 
<2. Go to file and open “new subject file. Enter subject details> 
<3. Go to Tower and open trial file> 
<4. Open TOL-Part 1> 
<5. Go to Tower and click on show trial file> 
 
< A grey screen will appear first. After instructions have been given press the space bar 
to reveal the problem.  After the participant has completed the problem press the space 
bar to display the grey screen and give the new instructions. This sequence is repeated 
for all problems>   
  
Introduction 
 
The next Task is a planning task.   
 
You might recall a similar task from last time. 
 
We have designed a NZ version which should work better than those  
designed overseas. 
 
 
 
Problems 1 and 2 (Grey screen will be visible) 
 
<Press the space bar to reveal the first TOL.  
For the first stage of testing the minimum number of moves required to solve the  
problem will appear in the right hand side of the screen.> 
 
 
For this task you will be shown a number of planning problems. 
On the screen there are two arrangements of coloured balls, one on  
the top half of the screen and one on the bottom. 
 
<point to the balls in the two arrangements> 
 
 
The tall peg holds up to three balls, but no more than three balls. 
The middle peg holds up to two balls.   
The short peg holds only one ball. <use model to demonstrate this> 
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You are to plan how to make the colour and position of the balls in 
the  
bottom half of the screen (the start < point>) look exactly like the top  
half (the finish < point>).  
The background of the top half is coloured blue to remind you which  
pattern you are copying.  That is, plan how you would change the 
start area here <point> to end up looking exactly like the finish area 
<point>. <point to the two halves of the screen> 
 
 
Before you touch the screen  <pause>  remember to plan your moves  
first.  The most important thing is to solve each problem in the  
minimum <pause>  number of moves. 
 
When you have finished planning, then you can move the balls.   
To move a ball all you have to do is touch the ball and then touch  
the position that you want the ball to move to.   
 
When you touch a ball you will hear a sound and the ball will flash. 
 If you change your mind about the ball you want to move just touch  
the ball again.   
 
On the side of the screen is a number < point>  This tells you the  
minimum moves that it takes to make the bottom pattern look 
exactly like the top.   
 
 
<Demonstrate the activating and deactivating of the balls 
then move ball to goal state> 
 
<There are a limited number of moves that the participant will be able to make before 
the problem will be discontinued (double the minimum + 1) in which case the screen 
will display the statement “Task end”> 
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Now the arrangement of the balls in the bottom half of the screen  
looks exactly like the top half. 
 
There are some simple rules to remember when you are planning  
your moves: 
1. You can only move one ball at a time <pause> 
2. You can only move the top ball on any peg <pause> 
3. You cannot place two balls in the same position <pause> 
4. You can move to an adjacent peg <pause; point> 
5. You can jump over the middle peg <pause; point> 
 
 
< Demonstrate rules on the model> 
 
 
We  will start with some 1 and 2 move problems so you can get used  
to the task, then we will move on to some three move problems 
 
 
<press space bar and grey screen will appear with the words  
   
 
“Please Remember 
To Plan ALL Your Moves Carefully 
Before Touching Any Ball” 
 
 
<IMPORTANT: Remember to emphasis that they must plan which moves they are 
going to make before they touch the screen> 
 
The next problem requires one move. Plan carefully how to make the  
bottom half look exactly the same as the top half, before you touch 
any  
of the balls. 
 
When you are ready, touch the ball you want to move and then touch 
the position you would like to move it to. 
 
< when they complete the problem or they run out of moves, press the space bar and a 
grey  
screen will appear.> 
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< To display the next problem the examiner must press the space bar> 
 
< If the participant seems confused or unsure the following prompts may be used:> 
 
Touch the ball you want to move 
 
Touch the position you would like to move the ball to 
 
You can jump over the middle peg 
 
If you change your mind touch the ball again and it will stop flashing 
 
Remember if you touch the ball twice you will not be able to move it  
 
 
 
<they will have activated and deactivated the ball without moving it> 
 
<If a participant seems to be impulsive prompt with> 
 
   
Remember to plan your moves carefully, before you touch any of the  
balls. 
Problems 3 and 4  
 
 
(grey screen should be visible at the start of each problem) 
 
<Problems 3 and 4 are two move problems. While the grey screen is visible introduce 
each by saying> 
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This is a two move problem.   
Remember to plan your moves first. 
The most important thing is to plan how to solve the problem in the  
minimum moves. 
Think carefully about ALL the moves that are required to make the  
bottom pattern look exactly like the top pattern. 
Don’t start moving any ball until you are certain you know which 
moves  
you are going to make. 
When you are certain you know all the moves you will have to make 
then start moving the balls. 
   
< press the space bar to reveal the problem> 
 
Movement Time (Important) 
< at the end of Phase 1  participants will be presented with a series of three towers that 
do not require any moves. For these towers participants will only be required to touch 
the ball they are instructed to touch> 
 
< Prepare the model with a red ball in the left hand peg, a blue ball on the middle peg 
and a green ball on the right had peg. For the first tower instruct the participant with> 
 
 
 
Now we are going to do something different. 
 
When the next tower appears I would like you to touch the red ball as  
quickly as you can. The red ball will be in this position <point to the 
model> 
 
<for the second tower instruct the participant with> 
 
For the next problem I would like you to touch the Blue ball as 
quickly  
as you can. The blue ball will be in this position <point to the model> 
 
<for the Third tower instruct the participant with> 
 
For the next problem I would like you to touch the green ball as 
quickly  
as you can. The green ball will be in this position <point to the model> 
 
Phase 2 
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1. <Go to Tower and open trial file> 
2. <Open TOL-Part 2> 
3. <Go to Tower and click on show trial file> 
 
 
Problems 5-16 
 
 <grey screen should be visible at the start of each problem.   
There are 12 three move problems> 
 
IMPORTANT: A participant will not continue to the next stage if they do not get 9/12 
problems solved correctly within “double the minimum +1”.  The examiner must 
count the number of problems correctly solved. 
 
< For the first two three move problems (problems 5 and 6 ) read the following 
instructions> 
 
These next problems are all three move problems. 
Remember to plan your moves first. 
The most important thing is to plan how to solve the problem in the  
minimum moves. 
Think carefully about ALL the moves that are required to make the  
bottom pattern look exactly like the top pattern 
Don’t start moving any ball until you are certain you know which 
moves  
you are going to make. 
When you are certain you know all the moves you will have to make  
then start moving the balls. 
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< for subsequent problems read the following> 
  
   
Remember to plan your moves first. 
The most important thing is to plan to solve the problem in the 
minimum  
moves.  
 
< If necessary prompt with the following> 
 
Think carefully about ALL the moves that are required to make the 
bottom pattern look exactly like the top pattern. 
 
 
 
Tower of London Phase 3 
. <Go to Tower and open trial file> 
2. <Open TOL-Part 3> 
3. <Go to Tower and click on show trial file> 
 
<There are 9 problems in this part of the task in the order of      
 ( 3,4,5,3,4,5,3,4,5 )  
 
 
< Bring up second TOL trial file.  A grey screen will be visible at this stage introduce 
the first problem by saying> 
 
For this next stage the problems will get a bit harder but the rules 
will  
be the same. 
Remember to first plan all of the moves required to solve the 
problem. 
The most important thing is to plan to solve the problem in the  
minimum moves. 
Think carefully about ALL the moves that are required to make the  
bottom pattern look exactly like the top pattern 
Don’t start moving any ball until you are certain you know which  
moves you are going to make 
When you are certain you know all the moves you will have to make  
then start moving the balls.  
This is a 3 Move problem 
 
 
<press space bar to show first problem> 
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< introduce problems 2-8 by saying one of the following statements order> 
 
Remember to plan your moves first. The most important thing is to  
plan to solve the problem in the minimum moves. 
This is a …. move problem. 
 
<If necessary use the following prompt> 
 
Think carefully about ALL the moves that are required to make the  
bottom pattern look exactly like the top pattern 
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 Movement Time (Important) 
 
< at the end of Phase 3  participants will be presented with a series of three towers that 
do not require any moves. For these towers participants will only be required to touch 
the ball they are instructed to touch> 
 
< Prepare the model with a green ball in the left hand peg, a red ball on the middle 
peg and a blue ball on the right had peg. For the first tower instruct the participant 
with> 
 
Now we are going to do something different. 
 
When the next tower appears I would like you to touch the green ball 
as  
quickly as you can. The green ball will be in this position <point to the 
model> 
 
<for the second tower instruct the participant with> 
 
For the next problem I would like you to touch the red ball as quickly 
as you can. The red ball will be in this position <point to the model> 
 
<for the Third tower instruct the participant with> 
 
For the next problem I would like you to touch the blue ball as 
quickly as you can. The blue ball will be in this position <point to the 
model> 
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IV - Gambling Task Instructions   
 419 
Decision Making Task Instructions 
(read these out loud to participant) 
 
• In front of you on the screen, there are 4 decks of cards A,B,C,D. 
• I want you to select one card at a time, by clicking on the card, from any deck you 
choose. 
• Each time you select a card, the computer will tell you that you have won some 
money. I don’t know how much money you will win. You will find out as we go 
along. Every time you win, the green bar gets bigger. 
• Every so often, however, when you click on a card, the computer tells you that 
you won some money, but then it says that you lost some money too.  I don’t 
know when you will lose, or how much you will lose. You will find out as we go 
along.  Every time you lose, the green bar gets smaller.  
• You are absolutely free to switch from one deck to the other at any time, and as 
often as you wish. 
• The goal of the game is to win as much money as possible and if you cant’ win, 
avoid losing money as much as possible. 
• You won’t know when the game will end. You must keep playing until the 
computer stops. 
• I am going to give you this $2000 credit, The green bar, to start the game. The red 
bar here is a reminder of how much money you borrowed to play the game, and 
how much money you have to pay back before we see how much you won or lost. 
• It is important to know that just like in a real card game, the computer does not 
change the order of the cards after the game starts.  You may not be able to figure 
out exactly when you will lose money, but the day is fair.  The computer does not 
make you lose at random, or make you lose money based on the last card you 
picked.  Also, each deck contains an equal number of cards of each colour, so the 
colour of the cards does not tell you which decks are better in this game.  So you 
must not try to figure out what the computer is doing.  All I can say is that some 
decks are worse than others.  You may find all of them bad, but some are worse 
than others.  No matter how much you find yourself losing, you can still win if 
you stay away from the worst decks. Please treat the play money in this game as 
real money, and any decision on what to do with it should be made as if you were 
using your own money.  
 
Permission to use this task was kindly provided by Antoine Bechara, Department of 
Neurology, Iowa.  
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V - Continuous Performance Task Instructions   
 
 421 
Continuous Performance Task Instructions 
 
 
 
 
 
 
 
 
 
Read out the following: 
 
 
“ The computer is going to display letters of the alphabet on the screen.  
Your task is to press the space bar here whenever a letter appears on the 
screen.  However, there is an exception to this - don’t press the space bar 
if an X is displayed.  Please respond as fast as you can, but also as 
accurately.  Accuracy is more important than speed.” 
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VI - Words Used For Daneman And Carpenter Reading Span Task - 
Study One   
 423 
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VII - Words Used For Daneman And Carpenter Reading Span Task 
- Study Two   
 425 
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VIII - Word Sequencing Test Instructions And Words Used In Study 
One   
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WORD SEQUENCING TEST  
Instructions and Word List Study One. 
 
1. Select 15 cards 
2. Instruct the participant to read each word aloud and to try to remember the 
order in which the words appeared. 
Say “ I want you to read each card out loud as I show them to you 
and I also want you to try to remember the order in which the words 
appeared”.  
3. Present one card in  a random order at the rate of one 3 seconds per word 
4. Following the word presentation, arrange the duplicate set of words on the 
table in front of the participant in a random two-dimensional array. 
5. Instruct the participant to place the words on the table in the same sequence in 
which they were originally presented by the examiner from the first word to 
the last word 
Say “ Now can you please place the words on the table in the same 
order in which they were originally shown to you from the 1
st
 word 
to the last.  If you are not sure give it your best guess” 
6. Allow as much time as needed. 
Word List 
1. Air 
2. Free 
3. Name 
4. Show 
5. Kind 
6. Keep 
7. Full 
8. Word 
9. Whole 
10. Job 
11. Turn 
12. Act 
13. Door 
14. Run 
15. True. 
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IX - Word Sequencing Test Instructions And Words Used In Study 
Two   
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WORD SEQUENCING TEST  
Instructions and Word List Study Two. 
 
Select 8 cards 
Instruct the participant to read each word aloud and to try to remember the order 
in which the words appeared. 
Say “ I want you to read each card out loud as I show them to you 
and I also want you to try to remember the order in which the words 
appeared”.  
Present one card in  a random order at the rate of one 3 seconds per word 
Following the word presentation, arrange the duplicate set of words on the table in 
front of the participant in a random two-dimensional array. 
Instruct the participant to place the words on the table in the same sequence in 
which they were originally presented by the examiner from the first word to the 
last word 
Say “ Now can you please place the words on the table in the same 
order in which they were originally shown to you from the 1
st
 word 
to the last.  If you are not sure give it your best guess” 
 
Allow as much time as needed. 
Word List 
1. Door 
2. Show 
3. True 
4. Name 
5. Turn 
6. Job 
7. Free 
8. Kind 
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X - The Fatigue Severity Scale   
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XI - Daily Sleep And Symptom Diary   
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Daily record to monitor your Parkinson’s disease symptoms 
We would like you to record your Parkinson’s symptoms for 
24 hours  
Prior to your next visit. 
 
 
Please use the hour slots on the facing page to help you keep 
track of your symptoms. 
 
Just fill in any details as and when you can. 
 
Try not to leave it too long in case you forget, but do not 
worry if you do not remember. 
 
 
Indicate the Following if you can: 
 
1. Note the time on each occasion you take/took your 
Parkinson’s medication(s). 
2. For each hourly interval record whether you were “on, 
off or asleep” 
 
ON- Means when you were free of many or most of your 
Parkinson’s symptoms (when the drugs seem to provide 
reasonable relief). For this, just write “On,” for that time or 
block of time. 
 
OFF- Means when you have many or most Parkinson’s 
symptoms from which you are normally free if the anti-
Parkinson drugs are working.  For this, just write “Off” and 
give a rough estimate of how long  (that is, the duration 
before any benefits come back). 
 
ASLEEP: for the hours you are asleep, enter asleep in this 
block of time 
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 Diary Hours 
Date:                                                         Day: 
     6.00am  
7.00  
8.00  
9.00  
10.00  
11.00  
12.00  
1.00  
2.00  
3.00  
4.00  
5.00  
6.00  
7.00  
8.00  
9.00  
10.00  
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XII - Letter From The Neurologists Inviting Participation In The 
Study   
 439 
 
 
 
 
 
Date 
 
 
 
Name 
Address 
 
 
Dear…………, 
 
We are doing some NEW research on language, memory and attention in people in  
Christchurch who have been diagnosed with Parkinson’s disease. We would very  
much like your help if you can.  Please look at the enclosed information sheet.  If you 
 are willing to have Audrey McKinlay contact you about this research, please either  
call her or place the reply slip in the pre-paid addressed envelope and then post that  
back to us. 
 
 
Thank you for your time. 
 
 
 
 
 
Professor Tim Anderson MD, FRACP  Dr John Fink FRACP 
Neurologist      Neurologist 
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XIII - Information Sheet For Parkinson’s Disease Patients For Study 
One   
 441 
 
 
 
 
 
 
Project Title: Thinking and language skills in people with Parkinson’s 
disease 
 
 
 
Name: 
 
Address: Date: 
 
 
 
 
 
                        
We would like to invite you to take part in a new research study, which 
is funded by the Canterbury Medical Research Foundation.  This study 
is being conducted by neurologists, Dr. Tim Anderson and Dr. John 
Fink, and psychologists Dr. Paul Barrett, Dr John Dalrymple-Alford and 
Audrey McKinlay.  This study will provide information on thinking 
(including attention and memory) and language in people with 
Parkinson’s Disease in the Canterbury region.  These responses will be 
compared with those obtained from people who do not have any 
neurological condition.   
 
This information sheet has either been given or forwarded to you by 
your neurologist or sent to you by your local Parkinson’s society. If you 
are interested in taking part in the study, please contact Audrey 
McKinlay (366 7001 Ext. 7885) or Dr. John Dalrymple-Alford (“John 
D-A” 364 2998 or 366 7002 Ext. 6382) who will be pleased to answer 
any questions you may have at this time.   
 
 
 
 
If you agree to participate in this research, please note that you are free 
to withdraw at any stage.  If you choose to withdraw, you do not need to 
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give a reason and this will not affect your future care or treatment.  You 
will continue your regular medication during the course of this study. 
 
The various tests follow standard procedures.  Past research has often 
missed detail that would improve the conclusions that can be made. We 
therefore ask you to attend on up to three separate visits.  This is 
necessary to minimise the length of each visit and allow for adequate 
breaks during each visit.  Most tests or subtests require a short period of 
concentration (5-10 minutes).  The first visit is at the Neurology 
Department at Christchurch Hospital. The next two are in the 
Psychology Department at the University of Canterbury.  These three 
visits are as follows: 
 
Visit 1. (about 2-3hrs, including breaks) 
This visit will gather some general information on your medical status, 
including the current condition of your Parkinson’s disease, and your 
general cognitive functioning (a short summary of your overall ability). 
This visit will help us to confirm whether you meet the scientific criteria 
for this study.  You will also be asked to take home some standard self-
report questionnaires to fill in and return (up to an hour; either by pre-
paid post or at to the next visit).  We may then invite you to return for 
the next two visits.  
 
Visit 2. (about 2-3 hours, including breaks) 
This visit will provide more specific information on memory, language 
and planning skills. You will also be asked to take home some new self-
report questionnaires to fill in and return at the next visit.  If you 
consent, we will also include a questionnaire for your spouse or 
caregiver to complete.   
 
Visit 3. (about 2-3 hours, including breaks) 
This final visit will include tests of language skills and other every day 
activities.  
 
Reimbursement 
All participants will be reimbursed $15 for each visit towards transport 
costs (or the cost of a taxi, if required, in the Christchurch region).  
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Confidentiality 
Please note that all information provided for this study will be treated in 
the utmost confidence.  All personal information will be securely stored, 
accessible only by the principal investigators of this study. Your identity 
will not be disclosed in any reports based on information from this 
study. We will on your consent notify your neurologist of your 
participation in this study, but will not disclose any information on your 
language and thinking skills unless requested in writing by you. 
 
Information regarding the findings of this study 
Although individual results will be kept strictly confidential, a summary 
of the findings from this research will be made available to all of the 
participants and we will be pleased to send you a copy on completion of 
the study.  The overall results gathered will be used for the purposes of 
this study and will contribute to the scientific knowledge on Parkinson’s 
disease.  They will also form part of a doctoral thesis by Audrey 
McKinlay.  The information obtained may be added to that obtained in 
future studies, because it is necessary to have large data-sets to improve 
our accuracy in describing the overall effects of Parkinson’s disease.  
 
Support Person 
You are invited to bring a partner/friend /family member or support 
person with you to any visit. An adjacent room will be available for 
them to wait if you desire.   
 
Significant Other 
If you consent, we would also like you to nominate a person who knows 
you well and could provide some information about your general 
demeanour and every day routines. If this person is also your support 
person, information could be collected when you attend one of the 
sessions. Otherwise, if you prefer, one of the researchers could visit 
them in their home. 
 
Participation 
Your participation in the study is entirely voluntary. You do not have to 
answer all the questions in the study and you are free to withdraw at any 
time for any reason. 
 
If you have any questions or concerns about any aspect of this study you 
are welcome to contact either Audrey McKinlay (366 7001 Ext. 7885) 
or Dr. John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 
6382).   
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If you have any queries of concerns about your rights as a participant in 
this study you may wish to contact a Health and Disability Advocate 
(03) 377 7501 or 0800 377 766 (outside of Christchurch). 
 
In the unlikely event of a physical injury as a result of your participation in this 
study, you will be covered by accident compensation legislation within its 
limitations.  If you have any questions about ACC please feel free to ask the 
researcher for more information before you take part in this study. 
This study has received ethical approval from the Canterbury Ethics 
Committee and we are committed to treating all of the study participants 
in a fair and ethical manner. 
  
We would greatly value your help. Thank you for considering this 
request. 
 
If you are interested in taking part in the study, please confirm with either 
of us  below. 
 
Audrey McKinlay (366 7001 Ext 7885) 
 
PhD Candidate 
Department of Psychology 
University of Canterbury 
 
 
 
John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).  
 
Senior Lecturer 
Department of Psychology 
University of Canterbury 
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XIV - Reply Slip For Study One   
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THINKING AND LANUGUAGE SKILLS IN PEOPLE 
WITH PAKINSON’S DISEASE 
 
 
REPLY SLIP 
 
 
 
 
 
 
 
I have read the information sheet and would be willing to be contacted  
regarding participation in the project “Thinking and language skills in  
people with Parkinson’s disease.” 
 
 
CONTACT DETAILS: 
 
Name:    
 
 
Telephone number :  
 
 
Most convenient contact time: 
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XV - Ethics Approval For Study One   
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XVI - Advertisement For Healthy Controls   
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Research Volunteers Wanted 
This project has been approved by the Canterbury Ethics Committee 
 
Healthy older people between the ages of 50-80 years are wanted as 
control participants for a study that examines thinking and language in 
people with Parkinson’s Disease. Evaluations of memory, attention, and 
language abilities will be assessed over three visits of 2-3 hours each. 
Participants will be reimbursed with a $20.00 petrol vouchers for each 
visit. 
If you are interested in taking part in this study please contact Audrey 
McKinlay (Clinical Psychologist) 3667001(Ext 7885). 
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XVII - Information Sheet For Healthy Controls   
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Information Sheet: For potential participants who are “Healthy 
Controls” in that they have not been diagnosed with any neurological 
disorder 
 
 
 
Project Title: Thinking and language skills in people with Parkinson’s 
disease 
 
 
 
Name: 
 
Address: Date: 
 
 
 
 
 
This information sheet is to summarise the nature of our study and 
follows our recent telephone contact through the Canterbury University 
Psychology Department’s list of research participants.  
 
We would like to invite you to take part in a new research study on the 
effects of Parkinson’s disease.  This study is being conducted by 
neurologists, Dr. Tim Anderson and Dr. John Fink, and psychologists 
Dr. Paul Barrett, Dr John Dalrymple-Alford and Audrey McKinlay.  
This study is funded by the Canterbury Medical Research Foundation. 
 
Parkinson’s disease is a neurological condition that affects about 100 or 
so people in every 100,000, but is more common in older people. This 
condition affects movement, but it may also affect thought (including 
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attention and memory) and language.  The study will provide 
information on thinking and language in people with Parkinson’s 
Disease in the Canterbury region. To understand these effects, we need 
to compare the abilities of Parkinson’s disease patients with that of 
“healthy controls” who do not have any neurological disorder.  This is 
why we are contacting you to ask for your help in this important work.  
If you agree to participate in this research, please note that you are free 
to withdraw at any stage.  If you choose to withdraw, you do not need to 
give a reason and this will not affect you in any way in the future.  
 
Audrey McKinlay {or named research assistant} will telephone you to 
see if you are interested in taking part in this study. She will be pleased 
to answer any questions you may have at this time.  Please feel free to 
take up to a month to decide if you would like to help.  Potential 
participants will be contacted from April 2003 through to April 2005. 
 
The various tests follow standard procedures.  Past research has often 
missed detail that would improve the conclusions that can be made. We 
therefore ask you to attend on up to three separate visits.  This is 
necessary to minimise the length of each visit and allow for adequate 
breaks during each visit.  Most tests or subtests require a short period of 
concentration (5-10 minutes).  The first visit is at the Neurology 
Department at Christchurch Hospital. The next two are in the 
Psychology Department at the University of Canterbury.  These three 
visits are as follows: 
 
Visit 1 (about 2-3 hrs, including breaks). 
This visit will gather some general information on your medical status 
and your general cognitive functioning (a short summary of your overall 
ability).  This visit will help us to confirm whether you meet the 
scientific criteria for this study.  You will also be asked to take home 
some standard self-report questionnaires to fill in and return (either by 
pre-paid post or at to the next visit).  We may then invite you to return 
for the next two visits.  
 
Visit 2. (about 2-3 hrs, including breaks). 
This visit will provide more specific information on memory, language 
and planning skills. You will also be asked to take home some new self-
report questionnaires to fill in and return at the next visit.  If you 
consent, we will also include a questionnaire for your spouse or a close 
friend to complete.   
 
Visit 3. (about 2-3 hrs, including breaks). 
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This final visit will include tests of language skills and other every day 
activities.  
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Reimbursement 
All participants will be reimbursed $15 for each visit towards transport 
costs (or the cost of a taxi, if required, in the Christchurch region).  
 
Confidentiality 
Please note that all information provided for this study will be treated in 
the utmost confidence.  All personal information will be securely stored, 
accessible only by the principal investigators of this study. Your identity 
will not be disclosed in any reports based on information from this 
study. 
  
Information regarding the findings of this study 
Although individual results will be kept strictly confidential, a summary 
of the findings from this research will be made available to all of the 
participants and we will be pleased to send you a copy on completion of 
the study.  The overall results gathered will be used for the purposes of 
this study and will contribute to the scientific knowledge on Parkinson’s 
disease.  They will also form part of a doctoral thesis by Audrey 
McKinlay.  This information will be added to that obtained in future 
studies, because larger data-sets will improve our accuracy on the 
overall effects of Parkinson’s disease. 
 
Support Person 
You are invited to bring a partner/friend /family member or support 
person with you to any visit. An adjacent room will be available for 
them to wait if you desire.  
 
Significant Other 
If you consent, we would also like you to nominate a person who knows 
you well and could provide some information about your general 
demeanour and every day routines. If this person is also your support 
person, information could be collected when you attend one of the 
sessions. Otherwise, if you prefer, one of the researchers could visit 
them in their home. 
 
Participation 
Your participation in the study is entirely voluntary. You do not have to 
answer all the questions in the study and you are free to withdraw at any 
time for any reason. 
 
If you have any questions or concerns about any aspect of this study you 
are welcome to contact either Audrey McKinlay (366 7001 Ext. 7885) 
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or Dr. John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 
6382).   
 
If you have any queries of concerns about your rights as a participant in 
this study you may wish to contact a Health and Disability Advocate 
(03) 377 7501 or 0800 377 766 (outside of Christchurch). 
 
In the unlikely event of a physical injury as a result of your participation in this 
study, you will be covered by accident compensation legislation within its 
limitations.  If you have any questions about ACC please feel free to ask the 
researcher for more information before you take part in this study. 
This study has received ethical approval from the Canterbury Ethics 
Committee and we are committed to treating all of the study participants 
in a fair and ethical manner. 
 
We would greatly value your help. Thank you for considering this 
request. 
 
If you are interested in taking part in the study, please confirm with 
either of us  below. 
 
 
  
Audrey McKinlay (366 7001 Ext 7885) 
 
PhD Candidate 
Department of Psychology 
University of Canterbury 
 
 
 
John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).  
 
Senior Lecturer 
Department of Psychology 
University of Canterbury 
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XVIII - Consent Form For Participants In Study One   
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Departments of Psychology and                         Departments of Neurology and              Department of Medicine, 
Electrical & Computer Engineering                     Medical Physics & Bioengineering,       Christchurch School of 
and Speech & Language Therapy                      Christchurch Hospital                             Medicine & Health Sciences 
University of Canterbury                                                       University of Otago 
 
Christchurch Brain Research Group 
 
Consent Form 
 
Project Title: Thinking and language skills in people with Parkinson’s disease 
 
I have been invited to take part in this study on thinking (including attention and 
memory) and language in people with Parkinson’s disease. An information sheet has 
been provided on the aims and purpose of the study.  I have read and understood the 
information it contained. I have been given an opportunity to discuss the study. I am 
satisfied with the answers that have been given. I have had time to consider whether 
to take part. 
 
I understand that: 
• Participation in the study is voluntary (my choice) 
• I am free to withdraw from the study at any time and this will in no way affect 
my future healthcare. 
• I am free to refuse to answer any questions that I do not want to answer. 
• This study has approval from the Canterbury Ethics Committee. 
• My participation in the study is confidential and no information that could 
identify me will be used in any reports that may be generated from this study. 
• The compensation provisions for this study are covered by accident 
compensation legislation within its limitations. 
 
I have been provided with information regarding who to contact if I have any 
concerns regarding the study. 
   (circle choice and cross out alternative below, as desired…)  
(PD patients only) My neurologist can be informed of my participation      YES 
NO/ NA 
(All participants) I would like to receive a copy of the results of this study      YES / 
NO 
(All participants) My name will be added to / remain on a research register held in 
confidence by the Christchurch Brain Research Group on the understanding that I can 
choose to withdraw from this register at any time if I so choose         YES / NO 
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I _________________________________________ (full name) hereby consent to 
take part in this study, entitled “Thinking and language skills in people with 
Parkinson’s disease”. 
                            
 
 
Signature:_______________________________ Date: _____________________
  
 
Researchers: John Dalrymple-Alford PhD, Tim Anderson MD, John Fink 
MD, Paul Barrett PhD, Audrey McKinlay MA, {RA name to 
be added} 
 
Contact phone number: Audrey McKinlay (366 7001 Ext. 7885) or Dr. John 
Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).   
Project explained by: 
_____________________________________________________ 
Project role: 
____________________________________________________________ 
Signature: _______________________________     
Date:________________________  
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XIX - Additional Statement For The Beck Depression Inventory   
 461 
Thinking and language skills in people with Parkinson’s disease 
 
 
 
Please note that both the BDI (most commonly used in PD studies) and 
the GDS (generally regarded as more suitable for older patient groups) 
will be provided, in order to verify their suitability, similarity or 
otherwise in PD patients and controls for this study. 
 
 
 
 
 
Additional Statement re the Beck Depression Inventory (the BDI) 
 
 
Please note that the additional Statement re the BDI is only given to anyone who fits 
the following standard criteria. A score of 14 (or above) on the Beck Depression 
Inventory is used as a conservative threshold for detecting mild depression (14-19; 
moderate: 20-28; severe: 29-63).  Symptoms indicative of depression are used simply 
for the purpose of specifying non-depressed individuals for the study (Note: a cut-off 
score of 17 is recommended by the BDI Manual for research purposes). 
 
We feel that it is important to give some cautious feedback to the participant if they 
show a score above 13 on the BDI.  Thus, ONLY in the event that one of the 
participants reveals a score of 14 or more on the BDI, the following statement will be 
given to the participant, for them to read, to fill in as they see fit, and sign (plus the 
researcher will give the participant a copy to retain). 
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Thinking and language skills in people with Parkinson’s disease 
 
 
Statement concerning the Beck Depression Inventory Score 
 
As part of a study looking at thinking and language in people with 
Parkinson’s disease, it was found that my Beck Depression Inventory Score 
(known as the BDI score) showed some indication of depressive symptoms. 
  
This Inventory gave an estimate of a mild / moderate / severe (Researcher to 
circle as appropriate) level of depressive symptoms in my case. 
 
I understand that this score is only indicative of depressive symptoms, but I 
have been advised by the Researcher that I should in the first instance contact my GP 
for further evaluation, should I choose. 
  
I agree / disagree (Participant to circle their preference and cross out word 
which they find inappropriate) that the Researcher should contact me as a follow-up 
reminder,  
 
and I agree / disagree (Participant to circle their preference and cross out word which 
they find inappropriate) that the Researcher may contact a friend, relative and/or GP 
or neurologist in confidence to provide me with further advice (Give name / contact 
here, if appropriate).  I understand that this contact would be made concerning my 
BDI score, and not any other score or information provided during this study. 
 
Name and phone of contact – provided by the participant:____________________ 
 
I, ________________________________ (print full name) fully understand the above 
statement, as amended by me, and understand that I will be given a signed copy of 
this statement.   
 
Date__________________________ 
 
 
Signature of Participant_______________________  
 
Signature of witness (normally, the researcher) __________________ 
 
Name of witness________________________________ 
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XX - Additional Statement For The Geriatric Depression Scale   
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Thinking and language skills in people with Parkinson’s disease 
 
 
Additional Statement re the Geriatric Depression Scale (GDS) 
 
 
Please note that the additional Statement re the Geriatric Depression Scale is only 
given to anyone who fits the following standard criteria. A score of 9 (or above) on 
the Geriatric Depression Scale is used as a conservative threshold for detecting mild 
depression (scale indicates normal, 5 +/- 4; mildly depressed 15 +/- 6; very depressed, 
23 +/- 5).  Symptoms indicative of depression are used simply for the purpose of 
specifying non-depressed individuals for the study. 
 
We feel that it is important to give some cautious feedback to the participant if they 
show a score above 9 on the GDS.  Thus, ONLY in the event that one of the 
participants reveals a score of 9 or more on the GDS, the following statement will be 
given to the participant, for them to read, to fill in as they see fit, and sign (plus the 
researcher will give the participant a copy to retain). 
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Thinking and language skills in people with Parkinson’s disease 
Statement concerning the Geriatric Depression Inventory Scale (GDS) 
 
As part of a study looking at thinking and language skills in 
people with Parkinson’s disease, it was found that my score on the 
Geriatric Depression Inventory Scale (GDS) showed some indication 
of depressive symptoms. 
  
This Inventory gave an estimate of a mild / moderate / severe 
(Researcher to circle as appropriate) level of depressive symptoms in my 
case. 
 
I understand that this score is only indicative of depressive 
symptoms, but I have been advised by the Researcher that I should in the 
first instance contact my GP for further evaluation, should I choose. 
  
I agree / disagree (Participant to circle their preference and cross 
out word which they find inappropriate) that the Researcher should 
contact me as a follow-up reminder,  
 
and I agree / disagree (Participant to circle their preference and cross out 
word which they find inappropriate) that the Researcher may contact a 
friend, relative and/or GP or neurologist in confidence to provide me with 
further advice (Give name / contact here, if appropriate).  I understand 
that this contact would be made concerning my GDS score, and not any 
other score or information provided during this study. 
 
Name and phone of contact – provided by the 
participant:____________________ 
I, ________________________________ (print full name) fully 
understand the above statement, as amended by me, and understand that I 
will be given a signed copy of this statement.   
Date__________________________ 
Signature of Participant_______________________   
Signature of witness (normally, the researcher) __________________ 
Name of witness_______________________________ 
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XXI - Consent To Obtain Information From Significant Other   
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Departments of Psychology and                       Departments of Neurology and                   Department of Medicine, 
Electrical & Computer Engineering                   Medical Physics & Bioengineering,             Christchurch School of 
and Speech & Language Therapy                    Christchurch Hospital                                  Medicine & Health Sciences 
University of Canterbury                                                          University of Otago 
 
Christchurch Brain Research Group 
 
Consent Form 
 
Project Title: Thinking and language skills in people with Parkinson’s disease 
 
I have been invited to take part in this study on thinking (including attention and 
memory) and language in people with Parkinson’s disease. An information sheet has 
been provided on the aims and purpose of the study.  I have read and understood the 
information it contained. I have been given an opportunity to discuss the study. I am 
satisfied with the answers that have been given. I have had time to consider whether 
to take part. 
 
I understand that: 
• Participation in the study is voluntary (my choice) 
• I am free to withdraw from the study at any time and this will in no way affect 
my future healthcare. 
• I am free to refuse to answer any questions that I do not want to answer. 
• This study has approval from the Canterbury Ethics Committee. 
• My participation in the study is confidential and no information that could 
identify me will be used in any reports that may be generated from this study. 
• The compensation provisions for this study are covered by accident 
compensation legislation within its limitations. 
 
I have been provided with information regarding who to contact if I have any 
concerns regarding the study. 
   (circle choice and cross out alternative below, as desired…)  
(PD patients only) My neurologist can be informed of my participation      YES / 
NO/ NA 
(All participants) I would like to receive a copy of the results of this study      YES / 
NO 
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(All participants) My name will be added to / remain on a research register held in 
confidence by the Christchurch Brain Research Group on the understanding that I can 
choose to withdraw from this register at any time if I so choose   
        YES / NO 
 
(continued) 
 
 
I _________________________________________ (full name) hereby consent to 
take part in this study, entitled “Thinking and language skills in people with 
Parkinson’s disease”. 
                            
 
 
Signature:_______________________________ Date: _____________________
  
 
Researchers: John Dalrymple-Alford PhD, Tim Anderson MD, John Fink 
MD, Paul Barrett PhD, Audrey McKinlay MA, {RA name to 
be added} 
 
Contact phone number: Audrey McKinlay (366 7001 Ext. 7885) or Dr. John 
Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).   
Project explained by: 
_____________________________________________________ 
Project role: 
____________________________________________________________ 
Signature: _______________________________     Date: 
________________________  
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XXII- Over View Of The Initial Findings Sent Out To Participants In 
Study One   
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XXIII - Information Sheet For Study Two   
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Van der Veer Institute  
for Parkinson’s and Brain Research 
and Department of Psychology 
University of Canterbury 
Private Bag 4800 
Christchurch 
New Zealand 
 
 
 
 
Information Sheet: For potential participants who are “Healthy Controls” 
in that they have not been diagnosed with any neurological disorder 
 
 
 
Project Title: Developing cognitive measures for Parkinson’s 
disease 
 
 
 
As discussed by phone we would like to invite you to take part in our 
research study “Developing cognitive (thinking and reasoning) measures 
for Parkinson’s disease”. We will be pleased to answer any questions you 
may have. This research is an extension of our main study that focused on 
thinking and language skills in people with Parkinson’s disease (PD). 
Based on our initial findings we now intend to develop new measures that 
may be more sensitive to the cognitive profile of PD patients. We are 
conducting this study in collaboration with neurologists, Dr. Tim 
Anderson and Dr. John Fink, and psychologist Dr. Paul Barrett.  This 
study is funded by the Canterbury Medical Research Foundation. 
 
To fully understand the effects of PD we need to compare the abilities of 
Parkinson’s disease patients with that of “healthy controls” that do not 
have any neurological disorder.  If you agree to continue to participate in 
this research, please note that you are free to withdraw at any stage.  If 
you choose to withdraw, you do not need to give a reason and this will 
not affect you in any way in the future. Please feel free to take up to a 
month to decide if you would like to take part. 
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The various tests follow standard procedures. We ask you to attend on 
two separate visits.  This is necessary to minimise the length of each visit 
and allow for adequate breaks during each visit.  As before most tests or 
subtests require a short period of concentration (5-15 minutes) Visits will 
take place at the Psychology Department at the University of Canterbury.  
These two visits are as follows: 
 
Visit 1. (About 2-2.5 hrs, including breaks) 
This visit will gather some general information on your medical status, 
including your general cognitive functioning (a short summary of your 
overall ability). You will also be asked to take home some standard self-
report questionnaires to fill in and return (up to 30 mins; either by pre-
paid post or at to the next visit).  If you consent, we will also include 
questionnaires for your spouse or caregiver to complete.  Information 
from a spouse or caregiver is collected to provide an additional 
perspective, regarding your daily functioning, from a person who knows 
you well.  
 
Visit 2. (About 2-3 hours, including breaks) 
While the first visit will focus on medical status and more general 
aspects of cognitive functioning, this visit will provide more specific 
information on memory (both short and long term).  Session 2 will also 
include measures of planning (ability to think ahead and organise) and 
decision making skills. 
 
Reimbursement 
All participants will be reimbursed $20 for each visit towards transport 
costs (or the cost of a taxi, if required, in the Christchurch region). We 
will reimburse petrol costs for participants who need to travel further 
distances. 
 
Confidentiality 
Please note that all information provided for this study will be treated in 
the utmost confidence.  All personal information will be securely stored, 
accessible only by the principal investigators of this study. Your identity 
will not be disclosed in any reports based on information from this 
study. 
 
Information regarding the findings of this study 
Although individual results will be kept strictly confidential, a summary 
of the findings from this research will be made available to all of the 
participants and we will be pleased to send you a copy once the study 
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and data analyses have been completed.  Results gathered will be used 
for the purposes of this study and will contribute to the scientific 
knowledge on Parkinson’s disease.  They will also form part of a 
doctoral thesis by Audrey McKinlay.  This information will be added to 
that obtained in future studies, because larger data-sets will improve our 
accuracy on the overall effects of Parkinson’s disease. 
 
Support Person 
You are invited to bring a partner/friend /family member or support 
person with you to any visit. A nearby room will be available for them 
to wait if you desire.  
 
Participation 
Your participation in the study is entirely voluntary. You do not have to 
answer all the questions in the study and you are free to withdraw at any 
time for any reason. 
 
If you have any questions or concerns about any aspect of this study you 
are welcome to contact either Audrey McKinlay (366 7001 Ext. 7885) 
or Dr. John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 
6382).   
 
If you have any queries of concerns about your rights as a participant in 
this study you may wish to contact a Health and Disability Advocate 
(03) 377 7501 or 0800 377 766 (outside of Christchurch). 
 
In the unlikely event of a physical injury as a result of your participation in this 
study, you may be covered by ACC under the Injury Prevention, Rehabilitation 
and Compensation Act.  ACC cover is not automatic and your case will need to be 
assessed by ACC according to the provisions of the 2001 Injury Prevention 
Rehabilitation and Compensation Act.  If your claim is accepted by ACC, you still 
might not get any compensation.  This depends on a number of factors such as 
whether you are an earner or non-earner.  ACC usually provides only partial 
reimbursement of costs and expenses and there may be no lump sum compensation 
payable.  There is no cover for mental injury unless it is a result of physical injury.  
If you have ACC cover, generally this will affect your right to sue the 
investigators.  If you have any questions about ACC, contact your nearest ACC 
office or the investigator.  
 
This study has received ethical approval from the Canterbury Ethics 
Committee and we are committed to treating all of the study participants 
in a fair and ethical manner. 
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We would greatly value your continued help. Thank you for considering 
this request. 
 
If you are interested in continuing to take part in the study, please confirm 
with either of us below. 
 
 
 
 
 
 
 
Audrey McKinlay (366 7001 Ext 7885) 
Clinical Psychologist 
PhD Candidate 
Department of Psychology 
University of Canterbury 
 
 
 
 
 
 
 
 
 
John Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).  
Associate Professor 
Department of Psychology 
University of Canterbury 
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XXIV - Ethics Approval For Study Two   
 480 
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XXV - Consent Form Used For Study Two   
 482 
Consent Form 
 
Project Title: Developing cognitive measures for Parkinson’s disease 
 
I have been invited to take part in this study on cognition (including thinking and 
reasoning) and planning and decision making in people with Parkinson’s disease. An 
information sheet has been provided on the aims and purpose of the study.  I have 
read and understood the information it contained. I have been given an opportunity to 
discuss the study. I am satisfied with the answers that have been given. I have had 
time to consider whether to take part. 
 
I understand that: 
• Participation in the study is voluntary (my choice) 
• I am free to withdraw from the study at any time and this will in no way affect 
my future healthcare. 
• I am free to refuse to answer any questions that I do not want to answer. 
• This study has approval from the Canterbury Ethics Committee. 
• My participation in the study is confidential and no information that could 
identify me will be used in any reports that may be generated from this study. 
• if any assessments raise concern about my health this will be conveyed to me 
and my General Practitioner 
•  
I have been provided with information regarding who to contact if I have any 
concerns regarding the study. 
(PD patients only) My neurologist can be informed of my participation  YES / NO 
(All participants) I would like to receive a copy of the results of this study   YES / NO 
 
I _________________________________________ consent to take part in this study 
                             (full name) 
 
Signature:_______________________________ Date: _____________________ 
 
Researchers: John Dalrymple-Alford PhD, Tim Anderson MD, John Fink 
MD, Paul Barrett PhD, Audrey McKinlay MA, Dip Clin psyc, 
Phillip Kavangh, research assistant. 
Contact phone number: Audrey McKinlay (366 7001 Ext. 7885) or Dr. John 
Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).   
Project explained by:___________________________________________________ 
Project role: __________________________________________________________ 
Signature: _______________________________Date: ________________________ 
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XXVI - Health Check List And Hallucination Questionnaire Used In 
Study Two   
 484 
Health checklist and background for Parkinson’s disease 
patients  
(to be completed by investigator) 
 
Today’s Date:       
 
Full Name:       Control match: 
 
Date of birth:      GP: 
 
Satisfactory / corrected vision:  Yes / No  and hearing: Yes / No 
 
 
Current medications, including dose: 
 
 
 
 
 
 
Other Comments: 
 
 
○ Major medical illness (cardiovascular; diabetes req insulin; severe migraine; 
other:                 ) 
○ Significant psychiatric illness requiring hospitalization (specify:             ) 
○ Major depression in last 6 months 
○ Dementia / hallucinations 
○ Medications known to have a significant effect on CNS other than anti-PD 
medication 
  
1) Which day(s) and time you are most likely to be free to take part in the 
study?_______________ 
 
2) Caffeine drinks (e.g. coffee, tea, chocolate, caffeinated soft drinks) 
Per day: None / Little (One cup or can per day) 
              Moderate (2 or 3) 
              Heavy (4 or more) 
3) Alcohol Daily average (ALAC guide: Male amount shown below; half of this for 
women) 
 
Per day: None / Little (less than moderate daily average)  
              Moderate (1/3 to 1 spirit;1-2.5 glass wine; or 2-5 glasses of beer; as a daily 
average)  
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              Heavy (more than moderate daily average 
 486 
Questions For Hallucinations 
(Asked by Researcher) 
 
 
Do you have any day-time sleepiness?   Yes/No 
If yes describe: 
 
 
Do you every have any sudden falls/faintness?  Yes/No 
If yes explain: 
 
 
Specific Questions if Hallucinations Pressent 
 Are they bought on by the medication?  Yes/No 
 Are they present when you are moving?  Yes/No 
 How frequently do you experience them?  Daily/Weekly/Monthly 
 How long do they last? 
 What do you make of these episodes? (do they retain insight i.e do they know 
that these episodes are strange or bizarre?) 
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XXVII - Consent Form To Obtain Information From A Significant 
Other - Study Two   
 488 
Consent to obtain additional information from my spouse, caregiver 
or “significant other” person 
 
Project Title: Developing Cognitive measures for Parkinson’s Disease 
 
I agree that the researchers involved with this study may seek to obtain additional 
relevant information from the person named below. I understand that the information 
sought will cover aspects of my general daily functioning, including questions relating 
to my planning and decision making.  
 
I have heard and understood an explanation of the reasons for wanting to obtain 
information from someone else about me.  I have had an opportunity to ask questions 
and am satisfied with the answers I have been given.  
I understand that: 
• I may withdraw my consent at any time and this will in no way affect 
my future health care. 
• Participation of the person I have nominated (below) is entirely 
voluntary (their choice). 
• The information provided by this person will be strictly confidential 
and no information that could identify me will be used in any reports 
that may be generated from this study. 
• That person is entirely free to refuse to answer any questions that they 
do not want to answer. 
• This study has approval from the Canterbury Ethics Committee. 
 
 
Signed:____________________________________    
Date:___________________________ 
 
Full name: 
__________________________________________________________________ 
                                                     (please print) 
 
 
Name of person 
nominated:_____________________________________________________ 
Relationship to 
participant:_____________________________________________________ 
 
Signed consent by nominated 
person______________________________________________ 
 
Researchers: John Dalrymple-Alford PhD, Tim Anderson MD, John Fink 
MD, Paul Barrett PhD, Audrey McKinlay MA, Dip Clin Psyc 
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Contact phone number: Audrey McKinlay (366 7001 Ext. 7885) or Dr. John 
Dalrymple-Alford (“John D-A” 364 2998 or 366 7002 Ext. 6382).   
This form explained to participant 
by:_________________________________________ 
Project role: 
____________________________________________________________ 
Signature: _______________________________     Date: 
________________________  
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XXVIII - Overview Of Problem Selection And Tower Structures   
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    12             25                  26             34   
16                    15                   13                 11      
16                    64                   63                61      
 
Problem type 1 
 
Isoforms 12:34* 
 22:64 
  32:54* 
  42:24 
 52:14 
  62:44 
 
 
3 Move Problems - Optimal Path (asterix indicate problems used) 
subgoaling pattern  111. Red circles indicate goal moves. 
Problem type 2 
 
Isoforms 16:11* 
 26:21 
  36:31* 
  46:41 
  56:51* 
  66:61 
 
 
 
Problem type 3 
 
Isoforms 16:61 
 26:31 
  36:21* 
  46:51 
  56:41* 
  66:11 
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   11             12                  25             24   
 
   14                   15                  22                21 
12                   25                  23                 21 
 14                    66                   65                  63 
Problem type 1 
 
Isoforms  11:24 
   21:14* 
   31:44 
   41:34 
   51:64* 
   61:54 
3 Move Problems - Optimal Path  (asterix indicate problems used) 
subgoaling pattern   011. Red circles indicate goal moves. 
 
    Problem type 4. 
 
    Isoforms  14:63* 
      24:33 
       34:23 
       44:53 
       54:43 
       64:13* 
 
Problem type 2 
 
Isoforms 12:21 
 22:11 
  32:41 
  42:31* 
 52:61 
  62:51* 
 
Problem type 3 
 
Isoforms 14:21 
 24:11 
  34:41 
  44:31 
  54:61* 
  64:51* 
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   14                    66                   65               52                 51 
4 Move Problems - Optimal Path (asterix indicate problems used) 
subgoaling pattern  0111. Red circles indicate goal moves. 
   Problem type 1 
 
   Isoforms 14:51* 
    24:41 
     34:11* 
     44:61 
     54:31* 
     65:21 
 
500  
     Problem type 1 
 
     Isoforms  12:31* 
        22:61* 
        32:51 
        42:21 
        52:11 
        62:41* 
 
   12             25                   26             34                   33               31 
  13                  14                    66                 65                 52               51        
 13                  14                     66                 65                52                53 
5 Move Problems - Optimal Path (asterix indicate problems used) 
subgoaling pattern  00111. Red circles indicate goal moves. 
 Problem type 2 
 
  Isoforms  13:51 
     23:41 
     33:11 
     43:61* 
     53:31 
     63:21* 
 Problem type 3 
 
 Isoforms  13:53 
    23:43* 
    33:13 
    43:63 
    53:33* 
    63:23 
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Problem type 1. 
 
Isoforms  14:54* 
   24:44 
   34:14* 
   44:64 
   54:34 
   64:24 
Problem type 2. 
 
Isoforms  15:55 
   25:45 
   35:15* 
   45:65 
   55:35 
   65:25* 
 
   14                   66                    65                 52                  53               54 
  15                   16                   64                 63                  62               55        
5 Move Problems - Optimal Path (asterix indicate problems used) 
subgoaling pattern  01011. Red circles indicate goal moves  
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   12             13                    14               66                 65               52                 51 
    12                    13                    14                 66                 65                 52              53 
   Problem type 1 
 
   Isoforms 12:51* 
    22:41 
     32:11 
     42:61 
    52:31 
     62:21* 
 
 
   Problem type 2 
 
    Isoforms  12:53 
       22:43* 
       32:13 
       42:63 
       52:33* 
       62:23 
6 Move Problems - Optimal Path ( asterix indicate problems used) 
subgoaling pattern  000111. Red circles indicate goal moves. 
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XXIX - Full Analysis For Regression Outcomes – Language And 
Parkinson’s Disease  
504 
Table 1: Results of regression analysis, where the Total Score on the PDQ-39 is used as the 
Dependent variable.  Results displayed show incremental change accounted for by each 
neuropsychiatric symptom (R2 change) after controlling for motor symptoms (tremor, non 
tremor scores). 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.06 1.97 4.29 0.46 >0.60     
Non Tremor 0.61 20.48 4.07 0.04 <0.001     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      59.17 0.71 0.46 <0.001 
Apathy        3.21 0.43 0.04 <0.10 
Fatigue       2.96 0.43 0.04 <0.10 
Depression      26.15 0.62 0.23 <0.001 
Sleep        1.71 0.41 0.02 >0.15 
Hallucinations        8.62 0.49 0.10 <0.001 
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Table 2: Results of a regression analysis, where ratings on the sub-scale “Mobility” from the 
PDQ-39, is used as the dependent variable.  Results displayed show incremental change 
accounted for by each neuropsychiatric symptom (R2 change) after controlling for motor 
symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor -0.10 -5.52 6.13 -0.90 >0.35     
Non Tremor 0.71 37.72 5.82 6.49 <0.0001     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      15.43 0.55 0.18 <0.001 
Apathy      0.00 0.48 0.00 >0.90 
Fatigue      2.39 0.51 0.26 >0.10 
Depression      7.19 0.55 0.07 <0.02 
Sleep      0.09 0.48 0.00 >0.77 
Hallucinations      2.92 0.51 0.03 <0.10 
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Table 3:Results of a regression analysis, where ratings on the sub-scale “Bodily Discomfort”  
from the PDQ-39, is used as the dependent variable.  Results displayed show incremental 
change accounted for by each neuropsychiatric symptom (R2 change) after controlling for 
motor symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.03 1.71 7.55 0.23 >0.80     
Non Tremor 0.39 20.26 7.16 2.83 <0.01     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      11.23 0.26 0.22 <0.01 
Apathy      0.10 0.17 0.00 >0.70 
Fatigue      3.28 0.22 0.06 <0.10 
Depression      4.53 0.24 0.08 <0.05 
Sleep      2.27 0.20 0.04 >0.10 
Hallucinations      7.66 0.28 0.12 <0.01 
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Table 4: Results of a regression analysis, where ratings on the sub-scale “Cognitive 
Impairment” from the PDQ-39, is used as the dependent variable.  Results displayed show 
incremental change accounted for by each neuropsychiatric symptom (R2 change) after 
controlling for motor symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.23 9.62 5.16 1.87 <0.10     
Non Tremor 0.48 18.69 4.88 3.83 <0.001     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      31.37 0.62 0.32 <0.0001 
Apathy      7.41 0.44 0.09 <0.01 
Fatigue      7.43 0.44 0.09 <0.01 
Depression      14.67 0.51 0.16 <0.001 
Sleep      0.08 0.34 0.00 >0.75 
Hallucinations      8.89 0.45 0.11 <0.01 
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Table 5: Results of a regression analysis, where ratings on the sub-scale “Social Support” 
from the PDQ-39, is used as the dependent variable.  Results displayed show incremental 
change accounted for by each neuropsychiatric symptom (R2 change) after controlling for 
motor symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.15 4.33 4.17 1.04 >0.30     
Non Tremor 0.36 9.93 3.95 2.51 <0.05     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      7.57 0.23 0.16 <0.01 
Apathy      0.89 0.19 0.02 >0.30 
Fatigue      2.66 0.22 0.05 >0.10 
Depression      3.58 0.24 0.06 <0.10 
Sleep      1.13 0.19 0.02 >0.25 
Hallucinations      0.43 0.18 0.01 >0.50 
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Table 6:  Results of a regression analysis, where ratings on the sub-scale “Communication 
difficulties” from the PDQ-39, is used as the dependent variable.  Results displayed show 
incremental change accounted for by each neuropsychiatric symptom (R2 change) after 
controlling for motor symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.07 3.68 7.13 0.52 >0.60     
Non Tremor 0.49 24.66 6.75 3.65 <0.001     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      7.20 0.30 0.14 <0.02 
Apathy      10.31 0.40 0.14 <0.01 
Fatigue      0.38 0.26 0.01 <0.50 
Depression      4.98 0.33 0.08 <0.05 
Sleep      3.37 0.31 0.05 <0.10 
Hallucinations      3.88 0.32 0.06 <0.06 
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Table 7: Results of a regression analysis, where ratings on the sub-scale “Activities of Daily 
Living” from the PDQ-39, is used as the dependent variable.  Results displayed show 
incremental change accounted for by each neuropsychiatric symptom (R2 change) after 
controlling for motor symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.14 6.74 5.73 1.18 >0.20     
Non Tremor 0.60 28.28 5.44 5.20 <0.0001     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      8.86 0.44 0.13 <0.01 
Apathy      7.02 0.50 0.08 <0.02 
Fatigue      5.42 0.49 0.06 <0.05 
Depression      5.18 0.48 0.06 <0.05 
Sleep      3.59 0.47 0.04 <0.10 
Hallucinations      6.13 0.49 0.07 <0.02 
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Table 8: Results of a regression analysis, where ratings on the sub-scale “Stigma” from the 
PDQ-39, is used as the dependent variable.  Results displayed show incremental change 
accounted for by each neuropsychiatric symptom (R2 change) after controlling for motor 
symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.14 7.36 7.62 0.97 >0.30     
Non Tremor 0.60 7.28 7.23 1.01 >0.30     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      10.29 0.25 0.20 <0.01 
Apathy      1.87 0.90 0.04 >0.15 
Fatigue      0.07 0.06 0.00 >0.75 
Depression      5.86 0.16 0.11 <0.02 
Sleep      0.91 0.07 0.02 >0.30 
Hallucinations      2.33 0.10 0.05 >0.10 
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Table 9: Results of a regression analysis, where ratings on the sub-scale “Emotion” from the 
PDQ-39, is used as the dependent variable.  Results displayed show incremental change 
accounted for by each neuropsychiatric symptom (R2 change) after controlling for motor 
symptoms (tremor, non tremor scores). 
 
 
Independent 
Variables 
Beta B Std. 
Err. 
Of B 
t p     
Tremor 0.03 1.36 6.36 0.21 >0.80     
Non Tremor 0.33 13.82 6.04 2.29 <0.05     
Variables 
Entered 
     F-
value 
R
2
 R
2
 
change 
p 
Anxiety      61.31 0.63 0.60 <0.0001 
Apathy      2.01 0.15 0.04 >0.15 
Fatigue      1.82 0.15 0.03 >0.15 
Depression      39.50 0.53 0.41 <0.0001 
Sleep      0.92 0.13 0.02 >0.30 
Hallucinations      9.59 0.27 0.16 <0.01 
 
 
